 
Official Title:  A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 
III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally 
Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease  
Study ID: [REMOVED] 
Document Date s: Protocol  Version 6: 02-April -2021  
Protocol  Version 4: 16-April -2019  
 
 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
2/Protocol BN40423 , Version 6PROTOCOL HISTORY
Protocol Associated Region -Specific Protocol s
Version Date Final Region Version Date Final
6 See electronic date 
stamp on title page  
5 5 November 2019   
4 16 April 2019   
1 18 September 2018 VHP 3 24 January 2019
European Union 2 13 December 2018
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
3/Protocol BN40423 , Version 6PROTOCOL A MENDMENT, VERSION 6:
RATIONA LE
Protocol BN40423 has been amended in accordance with the Urgent Safety Measure 
Dear Investigator Letter issued on 22 March 2021.  A pre -planned review of safety and 
efficacy data from Study BN40423, as well as available open- label data, was conducted 
by [CONTACT_3433] e BN40423 independent Data Monitoring Committee (iDMC).  Following review of 
the data, the iDMC has recommended that all dosing (120 mg every 8 weeks [Q8 W] and 
every 16 weeks [Q16 W] and placebo) in Study BN40423 be stopped.  This iDMC 
recommendation was not based on any new emergent safety concerns, but on a totality 
of evidence indicating that the treatment arms demonstrated unfavorable safety and 
efficacy trends compared to the placebo arm over time.
The iDMC has also made a recommendation for the ongoing patients in the Study 
BN40423 to be followed for safety and efficacy outcomes as per protocol, without study 
drug administration.  Study BN40955 (open -label extension [OLE]) is exploring similar
regimens (i.e, tominersen [RO7234292] 120 mg Q8 W and Q16 W); therefore, the 
Sponsor has made a decision to pause dosing in the OLE until further data assessments 
can be conducted.
Changes to the protocol, along with a rationale for each change, are summarized below:
Language has been added to indicate that no furthe r study treatment will be 
administered in this study as of [ADDRESS_1109569] etion (Sections 1.3, 
3.1.1, 4.5, and 4.6,andFigure 2 , and Appendices 1a and 1b ).
It has been clarified that neurologic examinations should be performed prior to 
lumbar puncture (LP), if there is no study treatment administration ( Section s3.1.1
and4.5.3, and Appendices 1a, 1b ,and 9).
Language has been added to clarify that patien ts will no longer be able to enter the 
OLE study (BN40955) after completion of this study (Section 3.1.1).
It has been clarified that all patients in the treatment period will discontinue study 
treatment and enter the early treatment termination (ETT) sche dule. The previous 
version of the protocol already described the ETT schedule for following of 
individuals, for safety and efficacy outcomes, who have discontinued the study drug 
but not withdrawn consent for continued study par ticipation (Sections 3.1.1, 4.2, and 
4.6, and Figure 1 and 2). Additional clarification on visits and assessments required 
on the ETT schedule has been provided (Section [IP_ADDRESS], and Figure 3, and 
Appendices 1a and 1b) .
The ETT visit window has been extended from 28 ( 7 days) f rom last dose to 
within 56 days of the decision to discontinue study treatment (i.e., from 22 March 
2021).  This extension has been made to facilitate scheduling of the ETT visit using 
the existing planned visit schedule (Section [IP_ADDRESS], and Appendices 1a and 1b).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
4/Protocol BN40423 , Version 6It has been clarified that following the iDMC recommendation to discontinue study 
treatment dosing in this study, the Sponsor will be unblinded to treatment 
assignment, to allow for data analyses to occur, in order to enhance the 
understanding of RO7234292 effects and to inform RO7234292 program next steps 
(Sections 3.1.2, 4.2, and [IP_ADDRESS]).
End of study and length of study have been adjusted, as a result of all patients 
moving to the ETT schedule (Section 3.2).
It has been clarified that patients should not perform any activity that is associated 
with a change in the ambient air pressure for at least [ADDRESS_1109570] lumbar 
procedure, irrespective if study treatment is administered or not (Section 4.5.5 , 
Appendices 1a and 1b).
As per protocol, individuals will have an LP at the ETT visit.  Additional safety 
assessments including lumbar puncture and laboratory tests have been added to 
the end of treatment (EoT) assessment for ETT to ensure complete and adequate 
collection of foll ow-up safety outcomes (Section 4.5.5, Appendices 1a and 1b).
Wording in Section 5.1.[ADDRESS_1109571] available risk data as per the RO7234292 Investigator’s Brochure 
Version 7.
Adverse event reporting pe riod has been clarified , as a result of all patients moving 
to ETT schedule and discontinuing study treatment (Sections 5.3.1 and [IP_ADDRESS]).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
5/Protocol BN40423 , Version 6TABLE OF CONTENTS
PROTOCOL AMENDMENT ACCEPTANCE FORM .......................................... 14
PROTOCOL SYNOPSIS .................................................................................... 15
1. BACKGROUND .......................................................................................... 28
1.1 Background on Huntington's Disease .................................... 28
1.2 Background on RO7234292 .................................................. 29
1.3 Study Rationale and Benefit Risk Assessment ..................... 31
2. OBJECTIVES AND EN DPOINTS ............................................................... 32
2.1 Efficacy Objectives ................................................................ 32
2.1.1 Primary Efficacy Objective ..................................................... 32
2.1.2 Secondary Efficacy Objective ................................................ 32
2.1.3 Exploratory Efficacy Objective ............................................... 33
2.2 Safety Objective .................................................................... 33
2.3 Pharmacokinetic Objectives .................................................. 34
2.4 Immunogenicity Objectives .................................................... 34
2.5 Biomarker Objectives ............................................................. 34
2.5.1 Primary Biomarker Objective ................................................. 34
2.5.2 Secondary Biomarker Objective ............................................ 35
2.5.3 Exploratory Biomarker Objective ........................................... 35
2.6 Health Status Utility Objective ............................................... 35
3. STUDY DESIGN ......................................................................................... 36
3.1 Description of the Study ......................................................... 36
3.1.1 Overview of Study Design ..................................................... 36
[IP_ADDRESS] Clarification of Existing Study Design for Early 
Treatment Termination (Applicable to all Patients 
from 22 March 2021) ............................................................. 40
[IP_ADDRESS] Study Design Overvie w for Patients Enrolled 
prior to Implementation of Protocol Version 4 ........................ 41
3.1.2 Independent Data Monitoring Committee .............................. 45
3.2 End of Study and Length of Study ......................................... 45
3.3 Rationale for Study Design .................................................... 45
3.3.1 Rationale for RO7234292 Dose and Schedule ...................... 45
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
6/Protocol BN40423 , Version 63.3.2 Rationale for Patient Population ............................................ 48
3.3.3 Rationale for Control Group ................................................... 48
3.3.4 Rationale for Biomarker Assessments ................................... 48
[IP_ADDRESS] Cerebrospi[INVESTIGATOR_116252] ............................................ 48
[IP_ADDRESS] Blood Biomarkers .................................................................. 49
[IP_ADDRESS] Genetic Testing to Determine CAG Repeat 
Length .................................................................................... 49
[IP_ADDRESS] Clinical Genotypi[INVESTIGATOR_007] ................................................................ 49
[IP_ADDRESS] Magnetic Resonance Imaging ............................................... 49
4. MATERIALS AND MET HODS .................................................................... 50
4.1 Patients.................................................................................. 50
4.1.1 Inclusion Criteria .................................................................... 50
4.1.2 Exclusion Criteria ................................................................... 52
4.2 Method of Treatment Assignment and Blinding ..................... 54
4.3 Study Treatment and Other Treatments Relevant 
to the Study Design ............................................................... 56
4.3.1 Study Treatment Formulation, Packaging, and 
Handling ................................................................................ 56
[IP_ADDRESS] RO7234292 ........................................................................... 56
[IP_ADDRESS] Placebo .................................................................................. 56
4.3.2 Study Treatment Dosage, Administration, and 
Compliance ............................................................................ 56
[IP_ADDRESS] RO72 [ADDRESS_1109572] Accountability ................... 57
4.3.4 Continued Access to RO7234292 ......................................... 57
4.4 Concomitant Therapy ............................................................ 58
4.4.1 Permitted Therapy ................................................................ .58
4.4.2 Prohibited Therapy ................................................................ 59
4.5 Study Assessments ............................................................... 59
4.5.1 Informed Consent Forms and Screening Log ........................ 59
4.5.2 Medical History, Concomitant Medication, and 
Demographic Data ................................................................ .60
4.5.3 Physical and Neurologic Examinations .................................. 61
4.5.4 Vital Signs .............................................................................. 61
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
7/Protocol BN40423 , Version 64.5.5 Collection of Cerebrospi[INVESTIGATOR_17106] (Lumbar 
Puncture Procedure) ............................................................. 61
4.5.6 Laboratory, Biomarker, and Other Biological 
Samples ................................................................................. 63
4.5.7 Magnetic Resonance Imaging ............................................... 65
4.5.8 Electrocardiograms ................................................................ 65
4.5.9 Patient -Reported, Clinician -Reported, Stud y 
Observer -Reported, and Performance Outcomes ................. 66
[IP_ADDRESS] Composite Unified Huntington's Disease Rating 
Scale ...................................................................................... 67
[IP_ADDRESS] Total Functional Capacity Scale ............................................ 67
[IP_ADDRESS] Total Motor Score .................................................................. 67
[IP_ADDRESS] Symbol Digit Modalities Test ................................................. 68
[IP_ADDRESS] Stroop W ord Reading Test .................................................... 68
[IP_ADDRESS] UHDRS Functional Assessment ............................................ 68
[IP_ADDRESS] Independence Scale .............................................................. 68
[IP_ADDRESS] HD Daily Activities Scale ....................................................... 68
[IP_ADDRESS] Clinical Global Impression Severity and Change 
Scales .................................................................................... 69
[IP_ADDRESS] Patient Global Impression Severity and Change 
Scales ................................................................
.................... 69
[IP_ADDRESS] Companion -Reported Global 
Impression Severity and Change Scales .............................. 69
[IP_ADDRESS] Montreal Cognitive Assessment ............................................ 70
[IP_ADDRESS] Work Productivity and Activity Impairment ............................. 70
[IP_ADDRESS] Apathy Evaluation Scale ................................
........................ 70
[IP_ADDRESS] Neuro -Qol Cognition Function Short Form, 
Version 2................................................................
............... 70
[IP_ADDRESS] HDSpeaking Difficulty Item ................................................... 70
[IP_ADDRESS] Symptoms of Major Depressive Disorder Scale .................... 71
[IP_ADDRESS] HD Companion -Reported Irritability and Angry 
Outbursts Scale ..................................................................... 71
[IP_ADDRESS] EuroQol 5 -Dimension, 5-Level Questionnaire ....................... 71
[IP_ADDRESS] Health Utilities Index Mark 2 and Mark 3 ............................... 71
[IP_ADDRESS] Columbia -Suicide Severity Rating Scale ............................... 72
[IP_ADDRESS] Optional Exit Interviews ......................................................... 72
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
8/Protocol BN40423 , Version [IP_ADDRESS] [COMPANY_002] HD Mobile Application:  Remote Testing 
(Smartphone and Wrist-Worn Wearable) ............................... 72
[IP_ADDRESS] [COMPANY_002] HD Mobile Application:  In -Clinic 
Assessments ......................................................................... 73
4.5.10 Optional Samples for Research Biosample 
Repository ............................................................................. 74
[IP_ADDRESS] Overview of the Research Biosample Repository .................. 74
[IP_ADDRESS] Approval by [CONTACT_33427] .................................................................. 74
[IP_ADDRESS] Sample Collection .................................................................. 74
[IP_ADDRESS] Confidentiality ........................................................................ 75
[IP_ADDRESS] Consent to Participate in the Research 
Biosample Repository ............................................................ 76
[IP_ADDRESS] Withdrawal from the Research Biosample 
Repository ............................................................................. 76
[IP_ADDRESS] Monitoring and Oversight ....................................................... 76
4.6 Treatment, Patient, Study, and Site 
Discontinuation ...................................................................... 77
4.6.1 Study Treatment Discontinuation ........................................... 77
4.6.2 Patient Discontinuation from Study ........................................ 78
4.6.3 Study Discontinuation ............................................................ 78
4.6.4 Site Discontinuation ............................................................... 78
5. ASSESSMENT OF SAF ETY....................................................................... 79
5.1 Safety Plan ............................................................................ 79
5.1.1 Known Risks Associated with Lumbar Puncture .................... 79
[IP_ADDRESS] Post Lumbar Puncture Syndrome ......................................... 80
[IP_ADDRESS] Spi[INVESTIGATOR_626839] .................................................................. 81
[IP_ADDRESS] Meningitis .............................................................................. 81
5.1.2 Potential Risks Associated with RO7234292 ......................... 81
[IP_ADDRESS] Neurologic Changes .............................................................. 81
[IP_ADDRESS] Elevations in CSF WBCs and Protein ................................
....83
[IP_ADDRESS] Thrombocytopenia ................................................................ .83
[IP_ADDRESS] Kidney Effects ........................................................................ 83
[IP_ADDRESS] Liver Effects ........................................................................... 84
[IP_ADDRESS] Hydrocephalus ....................................................................... 84
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
9/Protocol BN40423 , Version [IP_ADDRESS] Neuropsychiatric Changes ..................................................... 84
[IP_ADDRESS] Potential Risk due to Reduction of Target Protein 
HTT........................................................................................ 85
5.1.3 Management of Patients Who Experience 
Adverse Events ..................................................................... 86
[IP_ADDRESS] Dose Modifications ................................................................ 86
[IP_ADDRESS] Treatment Interruption ........................................................... 86
[IP_ADDRESS] Management Guidelines ........................................................ 86
5.2 Safety Parameters and Definitions ........................................ 89
5.2.1 Adverse Events ..................................................................... 89
5.2.2 Serious Adverse Events (Immediately Reportable 
to the Sponsor) ...................................................................... [ADDRESS_1109573] (Immediately 
Reportable to the Sponsor) .................................................... 90
5.3 Methods and Timing for Capturing and 
Assessing Safety Parameters ................................................ 91
5.3.1 Adverse Event Reporting Period ........................................... 91
5.3.2 Eliciting Adverse Event Information ....................................... 91
5.3.3 Assessment of Severity of Adverse Events ........................... 92
5.3.4 Assessment of Causality of Adverse Events ......................... 92
5.3.5 Procedures for Recording Adverse Events ............................ 93
[IP_ADDRESS] Injection Reactions ................................................................ 93
[IP_ADDRESS] Diagnosis versus Signs and Symptoms ................................ .93
[IP_ADDRESS] Adverse Events That Are Secondary to Other 
Events.................................................................................... 93
[IP_ADDRESS] Persistent or Recurrent Adverse Events ................................ 94
[IP_ADDRESS] Abnormal Laboratory Values ................................................. 95
[IP_ADDRESS] Abnormal Vital Sign Values ................................................... 95
[IP_ADDRESS] Abnormal Liver Function Tests .............................................. 96
[IP_ADDRESS] Deaths ................................................................................... 96
[IP_ADDRESS] Preexisting Medical Conditions .............................................. 97
[IP_ADDRESS] Lack of Efficacy or W orsening of Huntington's 
Disease .................................................................................. 97
[IP_ADDRESS] Hospi[INVESTIGATOR_26589] .......................... 97
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
10/Protocol BN40423 , Version [IP_ADDRESS] Reporting Requirements for Cases of Accidental 
Overdose or Medication Error ................................................ 98
[IP_ADDRESS] Patient -Reported or Observer -Reported Outcome 
Data ....................................................................................... 99
[IP_ADDRESS] Safety Biomarker Data ........................................................... [ADDRESS_1109574] ................... 100
[IP_ADDRESS] Events That Occur prior to Study Drug Initiation .................. 100
[IP_ADDRESS] Events That Occur after Study Drug Initiation ...................... 100
5.4.3 Reporting Requirements for Pregnancies ............................ 101
[IP_ADDRESS] Pregnancies in Female Patients .......................................... 101
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients ............... 101
[IP_ADDRESS] Abortions ............................................................................. 101
[IP_ADDRESS] Congenital Anomalies/Birth Defects .................................... [ADDRESS_1109575] of Study .......................................... 106
6.5 Summaries of Demographic and Baseline 
Characteristics ..................................................................... 106
6.6 Efficacy Analyses ................................................................ 106
6.6.1 Estimands ............................................................................ 107
6.6.2 Primary Efficacy Analysis .................................................... 108
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
11/Protocol BN40423 , Version 66.6.[ADDRESS_1109576] or Ethics Committee .................. 117
8.4 Confidentiality ...................................................................... 117
8.5 Financial Disclosure ............................................................ 118
9. STUDY DOCUMENTATI ON, MONITORING, AND
ADMINISTRATION ................................................................................... 118
9.1 Study Documentation .......................................................... 118
9.2 Protocol Deviations .............................................................. 119
9.3 Management of Study Quality ............................................. 119
9.4 Site Inspections ................................................................... 119
9.5 Administrative Structure ....................................................... 119
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
13/Protocol BN40423 , Version 6Appendix 2 Clinician -Reported Outcomes for Patients Enrolled after 
Implementation of Protocol Version 4 ....................................... 140
Appendix 3 Patient -Reported, Observer -Reported, and Performance 
Outcomes and [COMPANY_002] HD Mobile Application for Patients 
Enrolled aft er Implementation of Protocol Version 4................. 141
Appendix 4 Clinical Assessments Order and Duration for Patients 
Enrolled after Implementation of Protocol Version .................... 144
Appendix 5 Guidelines for Order of Assessments ....................................... 148
Appendix 6 Grading Scale for Adverse Events Relating to Laboratory 
Abnormalities for All Patients .................................................... 149
Appendix 7 [COMPANY_002] HD Mobile Application for Patients Enrolled after 
Implementation of Protocol Version 4:  Active Test ................... 152
Appendix 8 Diagnostic Confidence Level for All Patients ............................. 156
Appendix 9 Guidance for Neurolog ical Examination for All Patients ............ 157
Appendix 10 Schedule of Activities for Patients Enrolled before 
Implementation of Protocol Version 4 ....................................... 158
Appendix 11 Clinician -Reported Outcomes for Patients Enrolled before 
Implementation of Protocol Version 4 ....................................... 165
Appendix 12 Patient -Reported, Observer -Reported, and Performance 
Outcomes and [COMPANY_002] HD Mobile Application for Patients 
Enrolled before Implementation of Protocol Version 4.............. 166
Appendix 13 Clinical Assessments Order and Duration for Patients 
Enrolled before Implementation of Protocol Version 4 .............. 169
Appendix 14 [COMPANY_002] HD Mobile Application for Patients Enrolled before 
Implementation of Protocol Version 4:  Active Test ................... 173
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
14/Protocol BN40423 , Version 6PROTOCOL AMENDMENT ACCEPTA NCE FORM
TITLE: A RANDOMIZED, MULTICENTER, DOUBLE -BLIND, 
PLACEBO -CONTROLLED ,PHA SEIII CLINICA L 
STUDY TO EVA LUATE THE EFFICA CY AND 
SAFETY OF INTRA THECA LLY ADMINISTERED 
RO7234292 (RG6042) IN PA TIENTS WITH 
MANIFEST HUNTINGTON'S DISEA SE
PROTOCOL NUMBER: BN40423
VERSION NUMBER: [ADDRESS_1109577] NUMBER: 2018 -002987 -14
IND NUMBER: [ADDRESS_1109578] NUMBER [STUDY_ID_REMOVED]
TEST PRODUCT: RO7234292 
MEDICA L MONITOR: , M.D., Ph.D .
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
I agree to conduct the study  in accordance with the current protocol.
Principal Investigator's Name  (print)
Principal Investigator's Signature [CONTACT_33505].  Please return a copy of 
the signed form as instructed by [CONTACT_27860].

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
15/Protocol BN40423 , Version 6PROTOCOL SYNOPSIS
TITLE:A RANDOMIZED, MULTICENTER, DOUBLE -BLIND, PL ACEBO -
CONTROLLED, PHA SEIII CLINICA L STUDY TO EVA LUATE THE 
EFFIC ACY AND SA FETY OF INTRA THECA LLY A DMINISTERED 
RO7234292 (RG6042) IN PA TIENTS WITH MANIFEST 
HUNTINGTON'S DISEA SE
PROTOCOL NUMBER: BN40423
VERSION NUM BER: [ADDRESS_1109579] NUMBER: 2018- 002987 -14
IND NUMBER: [ADDRESS_1109580] NUMBER [STUDY_ID_REMOVED]
TEST PRODUCT: RO7234292
PHASE: Phase III
INDIC ATION: Huntington's disease
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
Objectives and Endpoints
This study will evaluate the efficacy , safety, pharmacokinetic (PK), and biomarker effects of 
RO7234292 compared with placebo in patients with manifest Huntington's disease ( HD).  
Specific objectives and corresponding endpoints for the study are outlined b elow.
Efficacy Objectives
Primary Efficacy  Objecti ve
The primary  efficacy  objective for this study is to evaluate the efficacy of RO7234292 compared 
withplacebo on the basis of the following endpoint:
Change from baseline in the c omposite Unified Huntington's Disease Rating Scale
(cUHDRS )score at Week 101 
Note:  The primary  efficacy  endpoint for the U.S. Food and Drug Administration (FDA) 
will be c hange from baseline in the Total Functional Capacity (TFC)score at Week 101 
Secondary Efficacy Objective
The secondary efficacy  objective for this study is to evaluate the efficacy of RO7234292 
compared withplacebo on the basis of the following endpoints:  
Change from baseline in scores for the following individual scales at Week 101: 
-TFC 
-Total Motor Score (TMS)
-Symbol Digit Modalities Test (SDMT)
-Stroop Word Reading Test (S WR)
Note:  For the U.S. FDA, the first secondary endpoint will be c hange from baseline in 
the cUHDRS score at Week 101 instead of TFC, as TFC will be the primary  endpoint.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
16/Protocol BN40423 , Version 6Change from baseline in the Clinical Global Impression, Severity Scale (CGI -S) score at 
Week 101
Proportion of patients with a decrease from baseline of 1 point on the TFC at W eek 101
Proportion of patients with a decline from baseline of 1.2 points on the cUHDRS at Week 
101
Proportion of patients with an unchanged or improved score on the Clinical Global 
Impression, Change Scale (CGI -C) score from baseline at Week101
Explorator y Efficacy Objective
The exploratory efficacy  objective for this study is to evaluate the efficacy  of RO7234292
compared withplacebo on the basis of the following endpoints:  
Change from baseline in the Apathy Evaluation Scale (AES) score at W eek101
Change from baseline in the Sy mptoms of Major Depressive Disorder Scale (SMDDS) 
score at Week101
Change from baseline in the Huntington's Disease Daily Activities Scale (HD -DAS) score at 
Week93
Change from baseline in the Patient Global Impression, Severity Scale (PGI -S) score at 
Week101
Change from baseline in the Quality of Life in Neurological Disorders ( Neuro -Qol) Cognition 
Function Short Form at Week 101
Change from baseline in the Huntington's Disease Speaking Difficulty Item Scale (HD -SDI) 
score at Week101
Change from baseline in the Huntington's Disease Companion -Reported Irritability and 
Angr y Outbursts Scale ( HD-CIAOS) score at Week101
Change from baseline in the in -clinic patient -reported EuroQol 5 -Dimension Questionnaire 
(5-level version; EQ -5D-5L) index -score and visual analogue scale (VAS) at W eek 101
Change f rom baseline in the sensor -based measures collected by [CONTACT_626891] ( app; smartphone and wrist- worn wearable) at Week 101
Safety O bjective
The safety  objective for this study is to evaluate the safety and tolerability of RO7234292 
compared with placebo on the basis of the following endpoints: 
Incidence and severity of adverse events, with severity determined according to the 
Adverse Event Severity Grading Scale
Change from baseline in Montreal Cognitive Assessment (MoCA)
Change from baseline in vital signs 
Change from baseline in ECG parameters
Change from baseline in clinical laboratory results
Proportion of patient s with suicidal ideation or behavior , as assessed by [CONTACT_174273] -Suicide 
Severity Rating Scale ( C-SSRS ) score at each visit, including detailed focus on any 
individual cases identified as having severe ideation or behavior during the study conduct
Pharmacokinetic Objectives
The PKobjective for this study is to characterize the RO7234292 PK profile in plasma and 
trough CSF on the basis of the following endpoint s:
Concentration of RO7234292 in plasma at specified timepoints
Trough concentration of RO7234292 in CSF at specified timepoints
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
17/Protocol BN40423 , Version 6The exploratory pharmacokinetic/pharmacodynamic (PK/PD) objective for this study is to 
evaluate potential relationships between drug exposure and the efficacy and safety of 
RO7234292 on the basis of the following endpoint s:
Relationship between plasma profiles and/or trough CSF concentration s ofPKparamet ers 
for RO7234292 and efficacy endpoints 
Relationship between plasma profiles and/or trough CSF concentration s ofPK parameters 
for RO7234292 and safety endpoints
Immunogenicity Objectives
The immunogenicity objective for this study is to evaluate the immune response to RO7234292
on the basis of the following endpoint s:
Incidence of anti-drug antibodies ( ADAs )at specified timepoints relative to the prevalence 
of ADAs at baseline
Titer and antibody subtype, determined if ADAs are identified
The exploratory immunogenicity objective for this study is to evaluate potential effects of ADAs 
on the basis of the following endpoint:
Relationship between ADA status and efficacy , safety, or PK endpoi nts
Biomarker Objectives
Primary Biomarker Objective
The primary  biomarker objective for this study is to evaluate the effects of RO7234292 
compared withplacebo on the basis of the following endpoint:
Change from baseline in CSF mHTT protein level at W eek101
Secondary Biomarker Objective
The secondary biomarker objective for this study is to evaluate the effects of RO7234292 
compared withplacebo on the basis of the following endpoints:
Change from baseline in whole and regional bra in volumes (caudate, whole brain, and 
ventricular), as determined by [CONTACT_803899] (MRI), at W eek 101
Change from baseline in CSF neurofilament light chain (NfL) protein level at W eek101
Explorator yBiomarker Objective
The exploratory biomarker objective for this study is to identify biomarkers that are predictive of 
response to RO7234292 (i.e., predictive biomarkers), are early surrogates of efficacy, are 
associated with progression to a more severe disease state (i.e., prognostic biomarkers), are 
associated with acquired resistance to RO7234292, are associated with susceptibility to 
developi[INVESTIGATOR_803856] 
(i.e., safety  biomarkers), can provide evidence of RO7234292 activity (i.e., PDbiomarkers), or 
can increase the knowledge and understanding of disease biology and drug safety, on the basis 
of the following endpoints:
Relationship between biomarkers in blood, plasma, and CSF and efficacy , safety, PK, 
immun ogenicit y, or other biomarker endpoints
Relationship between imaging biomarkers (e.g., putamen, cortical grey matter, cortical 
white matter volumes, resting state functional MRI signal )and efficacy , safety, PK, 
immunogenicity, or other biomarker endpoints
Health Status Utility Objective
The exploratory health status utility objective for this study is to evaluate health status utility 
scores of patients treated with RO7234292 on the basis of the following endpoint:
Change from baseline in p atient -and com panion -reported EQ -5D-5L Index and VAS scores 
at specified timepoints 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
18/Protocol BN40423 , Version 6Change from baseline in companion self -reported and proxy -reported Health Utilities Index 
Mark 2 ( HUI2) and Mark 3 (HUI3) scores at specified timepoints
Change from baseline in p atient -and companion -reported Work Productivity and Activity 
Impairment (WPAI) scores at specified timepoints 
Study Design
Description of Study
Study BN40423 is a Phase III,randomized, placebo -controlled, double -blind, multic enter clinical 
study to evaluate the efficacy , safety, PK, and biomarker effects ofintrathe cally administered 
RO7234292 in patients with manifest HD. 
Effective 22 March 2021, no further study treatment will be administered in this study.
Patients on the study will continue to be followe d for safety and efficacy outcomes until study 
completion .
Prospective patients will undergo screening assessments during a 4- week screening period.  A 
maximum of one re-screening will be allowed within 8 weeks of the initial screening failure for 
patients who fail the initial screening.   If re -screening is required, the CAG repeat length testing 
from the initial screening does not need to be repeated (historical values prior to screening will 
not be accepted).  The screening MRI and viral serology from the initial screening, including 
from other [COMPANY_002] RO7234292 studies, may  be acceptable as part of the re- screening 
assessments if performed within 12 weeks of the baseline visit.
Upon completion of the screening period, eligible patients will be randomly allo cated in a 
1:1:1 ratio to receive RO7234292 ever y 8weeks ( Q8W ; RO7234292 Q8 Warm), RO7234292 
every 16weeks ( Q16W; RO7234292 Q16W arm), or placebo Q8W (placebo arm) by [CONTACT_803900].  To maintain the study blind and integrity, patients in the RO7234292 Q16 Warm will 
also receive placebo (i.e., alternating doses of active drug and placebo).
During scheduled clinic visits, patients will undergo safety and tolerability evaluations that 
include neurologic examinations, vital signs, ECGs, clinical laboratory tests, MoCA, C -SSRS, 
neuroimaging assessments (neurologic safety sequences), and a review of any adverse events 
includin g related concomitant medications, as detailed in the schedule of activities.  Patients in 
Japan must be monitored in the hospi[INVESTIGATOR_803857] 24 hours after Day 1 study drug 
administration.  Discharge will be determined at the discretion of the p rincipal investigator.
In the case of a failed IT bolus dosing procedure or a failed CSF collection procedure (e.g., due 
to an inadequate establishment of access to the IT space ), a second attempt may occur up to 7 
days after the originally scheduled attem pt.  For this additional visit, safety and tolerability 
evaluations on the day of LP administration will be performed as detailed in the protocol, 
including neurological examination (predose and postdose , or pre -procedure if no study 
treatment is being adm inistered ), vital signs, and a review of adverse events and concomitant 
medication.  If the second attempt occurs more than [ADDRESS_1109581] attempt, local 
laborator y analysis of coagulation factors (INR and/or PT, aPTT) and platelets need to be 
cond ucted again and results reviewed prior to the LP attempt.
During the treatment period, a telephone safety follow -up call will be conducted for the months 
in which no clinic visits are scheduled to check for any change in patient status (i.e., adverse 
events, concomitant medications) since the patient’s last visit.  W here deemed appropriate, an 
unscheduled clinic visit should be arranged for safety follow -up; no dosing will occur at these 
unscheduled visits. A safety follow -uptelephone call will also be co nducted approximately [ADDRESS_1109582] in -clinic visit at Week 101.
Effective 22 March 2021, all patients will discontinue study treatment and will no longer be 
able to enter the OLE study (BN40955) after completing this study.
Forpatients enrolled in Study BN40423 who discontinue study treatment prematurely, but do 
not withdraw consent for continued participation in the study, an ETT schedule will apply .  
An independent Data Monitoring Committee (iDMC) and independent Data Coordinating Cen ter 
(iDCC) will be employed to monitor and evaluate patient safety throughout the study as well as 
to evaluate evidence of early efficacy.  
Clarification of Existing Study Design for Early Treatment Termination (Applicable to all 
Patients from 22 March 20 21)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
19/Protocol BN40423 , Version 6Following the iDMC recommendation and Sponsor’s decision to discontinue study treatment 
in this study, as of 22 March 2021, all patients will transition to the existing ETT schedule.
All patients who discontinue study treatment prematurely but do not w ithdraw consent for 
continued participation in the study, will return to the clinic for the following visits as part 
of the ETT schedule:
ETT visit to be performed within a maximum of 56 days of the decision to discontinue 
study treatment.
Follow -up study visits at Weeks 53 and 69 (if not already completed) for collection of 
clinical outcome data for the primary and secondary endpoints.  If the ETT visit falls 
within 30 days of either scheduled visits at Week 53 or Week 69, then only the E TT 
visit should be performed.
End-of-treatment (EoT) visit at Week 101 (EoT for ETT).
Therefore, after discontinuation of study treatment, patients will attend a minimum of two 
and up to four in -clinic visits depending on which visits have already been com pleted at the 
time of study drug discontinuation.
After discontinuation of study treatment, telephone safety follow -up calls will be conducted 
every 8 weeks between the clinic visits to check for any change in patient status (i.e., adverse 
events, concomit ant medications) since the patient’s last visit .  Where deemed appropriate, an 
unscheduled clinic visit should be arranged for safety follow -up.
For patients consented to version [ADDRESS_1109583] dose.
Study Design Overview for Patients Enrolled prior to Implementation of Protocol Version 4
All patients enrolled in Study BN40423 prior to implementation of the Version 4 protocol 
amendm ent will be prematurely discontinued by [CONTACT_803901]40955, once approval has been granted by [CONTACT_803902]/IRBs.  
Patients who choose to enroll in the OLE will complete an end- of-treatment visit in 
StudyBN40423, which can also serve as the inclusion visit for Study BN40955.  All patients 
who are prematurely disconti nued by  [CONTACT_803903]40955 will additionally undergo safety follow -up telephone call approximately [ADDRESS_1109584] meet the following criteria for study entry during screening (some will be 
reassessed at baseline prior to randomization and study drug dosing ):
Signed Informed Consent Form
Age [ADDRESS_1109585] dose administration
Manifest HD diagnosis, defined as a diagnostic confidence level ( DCL)score of 4 
Independence Scale (IS) score 70 
Genetically confirmed disease by [CONTACT_626896] a CAP score 400 (Zhang et al. 
2011), calculated as follows:
CAPAge(CAG repeat length 33.66)
Ability to read the words "red," "blue," and "green" in native language
Ability to walk unassisted without a cane or walker and move about without a wheelchair on 
a daily basis as determined at screening and baseline visit
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
20/Protocol BN40423 , Version 6-Long-distance (e.g. ,50meters) use of wheelchairs for convenience ortransfer is
permitted.
Body mass index 16 32 kg/m2; total body weight 40kg
Ability to undergo and tolerate MRI scans (e.g., no claustrophobia, no severe chorea or 
other condition that precludes MRI scans or renders scanning intolerable for the patient, no 
MRI- incompatible intrauterine devices, metalli c dental braces, or other metal implants)
Ability to tolerate blood draws and lumbar punctures
Creatinine c learance (CrCl ) 60mL/min (Cockcroft -Gault formula)
Ability and willingness, in the investigator's judgment, to comply with all aspects of the 
protocol including completion of interviews and questionnaires for the duration of the study 
Ability and willingness, in the investigator's judgment, to carry a sma rtphone, wear a digital 
monitoring device, and complete smartphone -based tasks
Stable medical, ps ychiatric, and neurological status for at least 12 weeks prior to screening 
and at the time of enrollment
Signed study companion consent for participation who fulfills all of the following criteria:
-Age 18 years
-Reliable and competent, in the investigator's judgment
-Sufficiently knowledgeable of the patient's condition to complete study companion 
assessments of the patient, and likely to remain sufficiently kn owledgeable throughout 
the study, in the investigator's judgment
-Able to comment on study participant's sy mptoms and functioning experience
-Able and willing to attend in person all clinical visits for completion of companion 
assessments and for input into the clinician -rated TFC scale
Note:  Companions must have no cognitive, behavioral or motor change, in the opi[INVESTIGATOR_8574], that would question the validity of the acquired observer -reported 
data.
All effort should be made to retain the study c ompanion; however, should this not be 
possible, a study companion should be replaced and new consent obtained. 
A study companion is required for all patients who enroll after implementation of 
Version 5 of the protocol. The companion is optional but highly recommended for 
patients who enrolled under Protocol Versions 1 4.
For women of childbearing potential:  agreement to remain abstinent (refrain from 
heterosexual intercourse) or use contraceptive measures, as defined below:
Women must remain abstinent or use two methods of contraception, including at least 
one method with a failure rate of  1% per year, during the treatment period and for 5 
months after the final dose of study drug. 
A woman is considered to be of childbeari ng potential if she is postmenarcheal, has 
not reached a postmenopausal state ( 12continuous months of amenorrhea with no 
identified cause other than menopause), and has not undergone surgical sterilization 
(removal of ovaries and/or uterus).  The defini tion of childbearing potential may be 
adapted for alignment with local guidelines or requirements.
Examples of contraceptive methods with a failure rate of 1%per year include 
bilateral tubal ligation, male sterilization, established proper use of hormo nal 
contraceptives that inhibit ovulation, hormone -releasing intrauterine devices, and 
copper intrauterine devices.   A vasectomized man must undergo a medical 
assessment that confirms the success of the surger y before he can be considered 
surgically steril e.
Hormonal contraceptive methods mu stbe supplemented by a barrier method.
The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinenc e 
(e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and withdrawal 
are not acceptable methods of contraception.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
21/Protocol BN40423 , Version 6For men:  agreement to remain abstinent (refrain from heterosexual intercourse) or use a 
condom, and agreement to refrain fr om donating sperm, as defined below:
With a female partner of childbearing potential or pregnant female partner, men must 
remain abstinent or use a condom during the treatment period and for 5months after 
the final dose of study  drug to avoid exposing the embryo.  Men must refrain from 
donating sperm during this same period.
The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and withdrawal 
are not acceptable methods of preventing drug exposure .
Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
History of attempted suicide or suicidal ideation with plan (i.e., active suicidal ideat ion) that 
required hospi[INVESTIGATOR_601316]/or change in level of care within 12 months prior to screening
Current suicidal ideation is demonstrated by [CONTACT_941] C -SSRS per judgment of the 
investigator.  If suicidal ideation is present, a risk assessment should be don e by [CONTACT_803904].  Mild passive suicidal ideation (i.e., occasional 
thoughts that life is not worth living or is hard) without history of att empts or 
hospi[INVESTIGATOR_601317] 12 months is generally acceptable for study participation, 
but final decision on participation should be made carefully and in consultation with an 
appropriately qualified mental health professional. 
Current active psychosis, confusional state, or violent behavior
Any serious medical condition or clinically significant laborator y, or vital sign abnormality or 
claustrophobia atscreening that, in the investigator's judgment, precludes the patient's safe 
participation in and completion of the study
History known to the investigator or presence of an abnormal ECG that is clinically 
significant in the investigator's opi[INVESTIGATOR_1649], including complete left bundle branch block, second -
or third -degree atrioventricular heart block, or evidence of prior m yocardial infarction
Lifetime clinical diagnosis of chronic migraines
Pregnant or breastfeeding, or intending to become pregnant during the study or within 
5months after the final dose of study drug
Women of childbearing potential m ust have a negative serum pregnancy test result at 
screening and a confirmatory urine pregnancy test prior to initiation of study drug.  
Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter
Positive for hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg) at screening
Known HIV infection
Current or previous use of an antisense oligonucleotide (including small interfering RNA)
Current or previous use of anti -psychotics prescribed for a primary independent psychoti c 
disorder (i.e., schizophrenia, schizoaffective disorder, bipolar disorder type I, severe with 
psychotic features), cholinesterase inhibitors, memantine, amantadine, or riluzole within 
12weeks from initiation of study treatment
Current use of antipsychotics for motor sy mptoms or mood stabilization (i.e., irritability or 
aggressive behavior) and/or tetrabenazine, valbenazine, or deutetrabenazine at a dose that 
has not been stable for at least 12 weeks prior to screening or is anticipated to chan ge 
between screening and treatment initiation
Current use of supplements (e.g., coenzy me Q10, vitamins, creatine) at a dose that has not 
been stable for at least 6 weeks prior to screening or is anticipated to change during the 
study
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
22/Protocol BN40423 , Version 6Current use of an a ntidepressant or benzodiazepi[INVESTIGATOR_16717] a dose that has not been stable for 
at least 12weeks prior to screening or is anticipated to change between screening and 
treatment initiation
Treatment with investigational therapy within 4 weeks or 5 drug-elimination half -lives prior to 
screening, whichever is longer
Antiplatelet or anticoagulant therapy within 14 days prior to screening or anticipated use 
during the study, including, but not limited to, aspi[INVESTIGATOR_248] (unless 81mg/day), clopi[INVESTIGATOR_7745], 
dipyridam ole, warfarin, da bigatran, rivaroxaban, and api[INVESTIGATOR_3822]
History of bleeding diathesis or coagulopathy
Platelet count less than the lower limit of normal   
Platelet counts between 125,000 and 150,000 mm 3are permissible as long as the 
investigator confirms there is no evidence of current bleeding diathesis or 
coagulopathy.  
History of gene therapy, cell transplantation, or any experimental brain surger y
Concurrent or planned concurrent participation in any interventional clinical study, including 
explicit pharmacological and n on-pharmacological interventions (e.g., lumbar puncture)
Observational studies (e.g., ENROLL -HD prospective study ) are acceptable. 
Drug (i.e., cannabis, opi[INVESTIGATOR_2480], stimulant, hallucinogen, designer) and/or alcohol abuse or 
psychological or physiological depe ndenc y within 12 months prior to screening, as per the 
investigator's judgment
Abuse is defined as a maladaptive pattern of use that leads to failure to fulfill major 
work or social obligations or use in situations where it leads to physical danger or lega l 
problems, and may  be the focus of clinical attention.  
Poor peripheral venous access
Scoliosis or spi[INVESTIGATOR_626841]7234292 up the neu raxis
An infection requiring oral or IV antibiotics within 14 days prior to screening and prior to 
randomization
Antiretroviral medications, including antiretroviral medication taken as prophylaxis within 
12months of study enrollment
Malignanc y within 5 years prior to screening, except basal or squamous cell carcinoma of 
the skin or carcinoma in situ of the cervix that has been successfully treated
Preexisting intra-axial or extra -axial lesion s(e.g., tumor, arterio -venous malformation , 
meningiom as) as assessed by a centrally read MRI scan during the screening period
End of Study
The end of this study is defined as the date when the last patient, last visit occurs.  The end of 
the study is expected to occur approximately 101weeks ( 25months) after the last patient is 
enrolled.  
Length of Study
The total length of the study, from screening of the first patient to the end of the study, is 
expected to be approximately [ADDRESS_1109586] patient to the end of the 
study, is now expected to be approximately 4 years .
Investigational Medicinal Products
The investigational medicinal products (IMPs) for this study are RO7234292 and RO7234 [ADDRESS_1109587] (Investigational Drug)
RO7234292 will be supplied by [CONTACT_319071], preservative -free liquid in a 20 -mL 
single -use vial containing 10 mL of 6.0 mg/mL RO7234292 drug product for IT injection . For a 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
23/Protocol BN40423 , Version 6120-mg dose (20 -mL dosing volume), two vials containing 10 mL of 6.0 mg/mL RO7234292 will 
be pooled by [CONTACT_803905] [ADDRESS_1109588].
For information on the formulation, preparation, and handling of RO7234292 placebo, refer to 
the pharmacy  manual.
Statistical Methods
Primary A nalysis
The primary  efficacy  endpoint is the change from baseline in cUHDRS score at W eek 101.  This 
is defined as the attribute "variable" of the primary  estimand.
Note :The primary  efficacy  endpoint for the U.S. FDA will be change from baseline in the TFC 
score at Week 101.  TFC will be analyzed the same way as the cUHDRS.
The primary  efficacy  analy sis for this study will compare each active treatment arm, RO7234292 
Q8Wand RO7234292 Q16W , against the placebo arm. To account for the multiple 
comparison, an appropriate procedure will be used to maintain the overall two -sided type I error 
at 5% (details will be given in the SAP). 
The analysis of the primary endpoint will be performed by [CONTACT_803906]
(ANCOVA).  The model will include the corresponding endpoint baseline score, CAG repeat 
length, baseline CAP score, and treatment as covariates; the final list of covariates will be 
defined in the SAP.  On the basis of this analy sis, least squares mean for the treatment 
differences at Week101 and corresponding 95% CIs will be derived.  
The robustness of the primary method of estimation described above may be explored by 
[CONTACT_803907]. These sensitivity analy ses will be described in the SAP.
Determination of Sample Size  
The planned sample size is adequate to capture meaningful clinical decline on both the TFC 
andcUHDRS and was estimated on the basis of data available from non- interventional studies 
(TRACK -HD, COHORT, ENROLL -HD) and a randomized placebo -controlled study (2CARE).  
Based on these data, using the anticipated trial population, a meta- analysis for the change from 
baseline at [ADDRESS_1109589] deviation of 1.78.  A conservative treatment discontinuation rate 
at Week 101 for patients receiving placebo or active is assumed to be 20% and 15%, 
respectively.  Using these assumptions, the simulation described in the protocol was performed 
to estimate the sample size.  
It was estimated that 267patients per arm will provide approximately 80% power, at a two -sided 
 0.025level, to detect a 40% slowing of clinical decline for RO7234292 as compared with 
placebo at [ADDRESS_1109590] translates into an expected average decline of 
~0.82 points at 101 weeks for the RO7234292 arms.  The minimal detectable difference wi th 
these assumptions is ~0.[ADDRESS_1109591] standards of integrity 
when an optional interim analy sis is executed.
If an interim analy sis is conducted, the Sponsor will remain blinded.  The interim analysis will be 
conducted by [CONTACT_294823].  Interactions between the iDMC and Sponsor 
will be carried out as specified in the iDMC Charter.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
24/Protocol BN40423 , Version 6The decision to conduct an interim analysis, along with the rationale, specification of the 
endpoint (e.g., clinical and/or biomarker endpoint), number of patients, and statistical details for 
each analysis, will be introduced via a future protocol amendment , which will be submitted to 
relevant health authorities at least [ADDRESS_1109592] of the interim analy sis.  The 
iDMC Charter will document potential recommendations the iDMC can make to the Sponsor as
a result of an interim analysis, and the iDMC Charter will be made available to relevant health 
authorities. 
If there is a potential for the study to be stopped for positive efficacy as a result of an interim 
analysis of efficacy data, the type I error rate will be controlled to ensure statistical validity is 
maintained.  Additional criteria for recommending that the study be stopped for positive efficacy 
willbe added to a future protocol amendment.  
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
25/Protocol BN40423 , Version 6LIST OF A BBREVI ATIONS AND DEFINITIONS OF TERMS
Abbreviation Definition
ADA anti-drug antibody
ANCOVA analysis of covariance
AES Apathy Evaluation Scale
app application
ASO antisense oligonucleotide
CAP CAGAge Product
CGI-C Clinical Global Impression Change
CGI-S Clinical Global Impression Severity
ClinRO clinician -reported outcome
CrCl creatinine clearance
CrGI -C Companion -Reported Global Impression Change
CrGI -S Companion -Reported Global Impression Severity
CSF cerebrospi[INVESTIGATOR_872] 
C-SSRS Columbia -Suicide Severity Rating Scale
CTCAE Common Terminology Criteria for Adverse Events
cUHDRS composite Unified Huntington's Disease Rating 
Scale
DCL diagnostic confidence level
EC Ethics Committee
eCRF electronic Case Report Form
EDC electronic data capture
EQ-5D-5L EuroQol 5 -Dimension, 5 -Level Questionnaire
EMA European Medicines Agency
FDA Food and Drug Administration
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HD Huntington's disease
HD-CIAOS Huntington's Disease Companion -Reported 
Irritability and Angry Outbursts Scale
HD-DAS Huntington's Disease Daily Activities Scale
HDID Huntington's Disease Identification Number
HD-SDI Huntington's Disease Speaking Difficulty Item
HIPAA Health Insurance Portability and Accountability Act
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
26/Protocol BN40423 , Version 6Abbreviation Definition
HRQoL health- related quality of life
HTT huntingtin (gene)
HTT huntingtin (protein)
HUI Health Utilities Index
HUI2 HUI Mark [ADDRESS_1109593]
IND Investigational New Drug (Application)
IRB Institutional Review Board
IS Independence Scale
IT intrathecal
ITT intent -to-treat (population)
IxRS interactive voice or web- based response system 
LP lumbar puncture
mHTT mutant huntingtin (protein)
MoCA Montreal Cognitive Assessment
MRI magnetic resonance imaging
NCI National Cancer Institute
NCI CTCAE National Cancer Institute Common Terminology 
Criteria for Adverse Events
Neuro- Qol Quality of Life in Neurological Disorders
NfL neurofilament light chain (protein)
NRS numeric rating scale
NSDR nonstudy drug related (reasons)
ObsRO observer -reported outcome
OLE open -label extension
PD pharmacodynamic
PerfO performance outcome
PGI-C Patient Global Impression Change
PGI-S Patient Global Impression Severity
PK pharmacokinetic
PRO patient -reported outcome
Q4W every 4 weeks
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
27/Protocol BN40423 , Version 6Abbreviation Definition
Q8W every [ADDRESS_1109594] study drug related (reasons)
SMDDS Symptoms of Major Depressive Disorder Scale
SWR Stroop Word Reading
TFC Total Functional Capacity Scale
TMS Total Motor Score
UHDRS Unified Huntington's Disease Rating Scale
VAS visual analog uescale
WES whole exome sequencing
WGS whole genome sequencing
WPAI Work Productivity and Activity Impairment
wtHTT wild-type huntingtin (protein)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
28/Protocol BN40423 , Version 61. BACKGROUND
1.1 BACKGROUND ON HUNTINGTON'S DISEA SE
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused 
by [CONTACT_803908] 1 of the Huntingtin HTT gene on chromosome 4, 
which encodes for a mutant huntingtin (mHTT) protein.  Based upon non clinical and 
clinical evidence, mHTT is considered the primary driver of HD pathophysiology 
(WildandTabrizi 2017 ).  Individuals who carry at least [ADDRESS_1109595] motor onset is 
approximately 10 20 years, with pneumonia, heart failure, or other complications
frequently cited as the cause of d eath (Sorensen and Fenger 1992 ).  Individuals with 
end-stage disease have complete physical disability and profound body wasting.  
The estimated prevalence of HD in North America, northwestern Europe, and Australia 
ranges from 5.96 to 13.17 cases per 100,000 ( Baig et al. 2016 ).  Although genetic 
testing can be used to identify individuals who will develop the disease, the diagnosis of 
HD is clinical through neurologic examination of the motor system.  The clinical 
diagnosis of HD is made when the patient e xhibits " unequivocal presence of an 
otherwise unexplained extrapyramidal movement disorder " (e.g.,chorea, dystonia, 
bradykinesia, rigidity )or "motor onset" (Huntington Study Group 1996 ;
Hogarth etal.2005 ).  Motor onset is typi[INVESTIGATOR_803858] 15 -item motor 
examination of the Unified Huntington's Disease Rating Scale (UHDRS ).  After 
completion of the examination, a certified motor rater assigns a diagnostic confidence 
level (DCL) score.  Scores range from 0 to 4, with 0 representing n o impairment and 
4representing unequivocal motor signs of HD ( 99% confidence).  Among the 
considerable clinical phenotypic heterogeneity of the disease, motor onset is one of the 
more robust and consistently -agreed -upon disease features .  Behavioral features, 
including emotional disorders and personality changes, do not have a uniform 
presentation, are epi[INVESTIGATOR_616633], and do not usually progress steadily over time 
(Ross et al. 2014).  
Individuals with HD can be categorized as having either premanif est disease (diagnosed 
prior to motor onset) or manifest disease (diagnosed on the basis of motor onset).  The 
premanifest disease period can be subdivided into presymptomatic and prodromal
periods.  During the presympt omatic period, from birth to young adulthood , individuals 
are not clinically distinguishable from control s.  During the prodromal period, which can 
last many years before threshold clinical motor diagnosis, subtle motor changes and 
variable cognitive and behavioral changes appear but are no t sufficient to make the 
clinical diagnosis of HD. 
Themanifest disease period can be subdivided into five stages based on functional 
capacity ( Ross et al. 2014) .  Stage [ADDRESS_1109596] level of capacity and is 
characterized by [CONTACT_803909].  
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
29/Protocol BN40423 , Version 6Stage 5 represents severe disability and dependence on full -time care (Shoulson and 
Fahn 1979).  The fiveclinical stages are defined by [CONTACT_803910] (TFC) Scale, with S tage 1 corresponding to TFC scores of 1113, 
Stage 2 to scores of 710, Stage 3 to scores of 36, Stage 4 to scores of 12,and 
Stage 5 to a score of 0 (Shoulson et al. 197 9).  
Currently approved treatments aim to reduce the burden of symptoms, maximize 
function, and improve the patient 's quality of life (Nance et al. 2011).  Tetrabenazine and 
deutetrabenazine target abnormal involuntary movements (i.e., chorea) associated with 
HD, and these symptomatic therapi[INVESTIGATOR_159358] a challenging benefit risk profile.  These 
drugs have been linked to many significant adverse events, including parkinsonism, 
akathisia, sedation, and depression and suicidal thoughts.  T hey are contraindicated in 
patients who are actively suicidal and in patients with untreate d or inadequately treated 
depression.  Additionally, they may prolong the corrected QT interval (QTc) , and caution 
is advised when used in combination with other drugs or medical conditions that 
potentially prolong the QTc.
Other medications are utilized in HD to address particular symptoms, such as 
antidepressants (for depression, agitation, irritability), anticonvulsants (for irritability, 
impulsive behavior), anxiolytics (for anxiety), cognitive -enhancing agents (for cognitive 
disturbances) ,and neurole ptics (for chorea) (Paulson and Albin 2011).  
To date, there are no approved treatments able to slow or stop the clinical progression
ofHD.  
1.2 BACKGROUND ON RO7234292
Neuropathological abnormalities in HD appear to be the consequence of a toxic 
gain offunction of the mHTT protein ( Wexler et al. 1987; W alker2007; 
Moumné etal.2013).  Therefore, a therapy that reduces synthesis of the toxic mHTT
protein should directly target the primary disease mechanism.  As the genetic origin of 
HD is localized to just one gene, inhibiting the expression of this HTT gene is a 
promising therapeutic option (Stanek et al. 2013) .
RO7234292 ( RG6042 ) was originally developed by [CONTACT_81801], Inc. and was 
formerlyknown as ISIS443139 and IONIS -HTTRx .  This antisense 
oligonucleotide (ASO) is being developed to reduce the synthesis of all forms of the HTT
protein by [CONTACT_803911] -type and the mutant alleles and 
directing its catalytic degradation through the action of ribonuclease H1, an endo genous 
enzyme present in most mammalian cells (Crooke and Bennett 1996; Cerritelli and 
Crouch 2009), including cells of interest in the CNS (e.g., neurons and neuroglia).  
Reduction of theHTT gene mRNA, which in turn limits translation of the wild-type an d 
mutant huntingtin protein ,could potentially inhibit all downstream toxic effects and lead 
to asustained reversal in HD symptoms.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
30/Protocol BN40423 , Version 6Pharmacology data support selective targeting of HTT mRNA transcripts from both 
alleles as a potentially safe and effective mechanism for the treatment of HD .  Using 
ASOs targeting human HTT mRNA in rodents and non -human primates, s ignificant 
reduction of mutant HTT mRNA transcripts , wild -type HTT mRNA transcripts ,and mH TT
protein has been achieved throughout most brain regio ns (Kordasiewicz et al. 2012).  
Furthermore , transient delivery of these ASOs in transgenic mouse models of HD
delayed disease progression andmediated a sustained reversal of disease phenotype 
that persisted longer than HTT mRNA knockdown ( Kordasiewicz et al. 2012 ;Stanek et 
al. 2013 ).  
Nonclinical proof -of-concept studies with ASOs targeting mutant HTT have been 
conducted in three models of HD, including YAC128 mice expressing the full -length 
mutant human HTT transgene with a 128 CAG repeat expansion, bacterial artificial 
chromosome (BAC)HDmice expressing the full -length mutant human HTT genomic 
sequence with 97 CAG/CAA repeats, and R6/2 mice expressing exon 1 of the mutant 
human HTT gene with 110135CAG repeats.  These studies demonstrate that ASOs 
targeting human HTT mRNA improve motor function and protect against human HTT
transgene expression in YAC128 mice; i mprove motor function, hypoactivity ,and stress 
response in BACHD mice ; and p reserve striatal volume and increase survival in R6/2 
mice.
Thepharmacokinetics and toxicity of intrathecal (IT) administration of RO7234292 , an 
ASO that targets human HTT mRNA, were assessed in cynomolgus monkeys for 
13weeks (biweekly for the first month and then monthly ther eafter) at dose levels up to 
50mg/dose (5bolus administrations, for a total dose o f 250 mg) and chronically for 
9months, up to 35 mg/dose ([ADDRESS_1109597] rations for a total dose of 
350mg).  The drug was safe and well tolerated in these studies.
In a first -in-human, Phase I/IIa dou ble-blind, placebo -controlled, dose -escalation study 
(Clinicaltrials.gov Identifier [STUDY_ID_REMOVED]) (ISIS 443139 -CS1) four doses of RO7234292 
(ranging from 10 mg to 120 mg) were welltolerated and achieved significant 
dose- dependent lowering of cerebrospi[INVESTIGATOR_872] ( CSF) mHTT protein when administered 
intrathecally every 4 weeks (Q4 W; monthly ) to [ADDRESS_1109598] HD .  
Exploratory analyses identified a relationship between lowering of mHTT protein and 
improvement in some clinical measures.  Taken together, these data support further 
clinical testing to demonstrate definitive clinical benefit of mHTT protein reduction in the 
CNS. The data from this study also supported the initiation of Study ISIS 443139 -CS2 
(Study BN40697; Clinicaltrials.gov Ident ifier [STUDY_ID_REMOVED]) , a 15-month, Phase II ,
open -label extension (OLE) study for patients who participated in Study ISIS 443139-
CS1.  
Preliminary data from an analysis conducted when all individuals in Study BN40697 had 
reached 9 months of treatment show edthat a 12 0mg every -8-week (Q8 W; every 
2months) dosing regimen of RO7234292 achieve da 47% median CSF mHTT lowering 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
31/Protocol BN40423 , Version 6at trough (i.e., sample taken immediately before the next dose) and the 120 mg Q4 W 
dosing regimen achieve d a66% median lowering at trough .  Both results exceed the 
20%40% target for CSF mHTT lowering at trough and steady state based upon efficacy 
data from nonclinical models, and exceed the result of approximately 40% median 
lowering observed in the completed Phase I/IIa study. Details on the most recent 
information from nonclinical and clinical studies can be found in the RO7234292
Investigator's Brochure .
1.3 STUDY RA TIONA LE A ND BENEFIT RISK A SSESSMENT
Presently, there are no therapi[INVESTIGATOR_626842] , 
which is relentless until patients experience premature death.  The ASO RO7234292 is 
designed to target the cause of HD and offers the potential to meet this unmet medical 
need.  
To date, nonclinical and clinical data support further investigation of RO [ADDRESS_1109599] HD.  Building on the completed Phase I/IIa study and the ongoing 
Phase II OLE study, this Phase III, double- blind, placebo -controlled study (BN40423) will 
collect longer -term clinical efficacy and safety data to definitively evaluate the benefit 
and potential risks of RO7234292 when administered by [CONTACT_626905] Q8Wor every 
16weeks ( Q16W; every 4 months ) over a 25- month (2- year) period to patients wit h 
manifest HD.   
Review of safety and tolerability 9 -month data for RO7234292 from the Phase II OLE 
suggests that, relative to the Q4 W treatment regimen, the Q8 W treatment regimen may 
be more suitable for chronic IT dosing, as evidenced by [CONTACT_803912].  This is supported by [CONTACT_803913], 
decreased proportion of patients with moderate adverse events, and fewer adverse 
events considered possibly related to study drug in the Q8 W regimen compar ed to the 
Q4W regimen (for details see the RO7234292 Investigator’s Brochure).
There have been no acute safety concerns meriting a change to the ongoing Phase II 
OLE study protocol (BN40697).  However, given the [ADDRESS_1109600] the dose rationale.   As a 
result, the results from OLE Study BN40697 justify a change in Study BN40423 to 
explore less frequent dosing regimens by [CONTACT_626908] Q8 W RO7234292 and placebo 
arms, and replacing the Q4 W arm with a Q16 W arm.
The existing dose rationale tests a mo re frequent dosing regimen (i.e ., 120 mg Q8 W), 
which from present dat ais anticipated to maintain trough CSF mHT T reduction of at 
least ~40%, and a less frequent regimen (i.e., 120 mg Q16 W), which is still anticipated to 
lower mHTT acutely, but will allow greater recovery of HTT levels between doses.  From 
present data, trough CSF mHTT reduction of ~25% are pred icted to be maintained in a 
120-mg Q16 W paradigm.  
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
32/Protocol BN40423 , Version 6A pre -planned review of safety and efficacy data from Study BN40423, as well as 
available open -label data , was conducted by [CONTACT_626886]40423 independent Data Monitoring 
Committee (iDMC). Following review of the data, the iDMC recommended that all 
dosing (120 mg Q8W and Q16W and placebo) in Study BN40423 be stopped. This 
iDMC recommendation was not based on any new emergent safety concerns, but on a 
totality of evidence indicating that the treatment arms demo nstrated unfavorable safety 
and efficacy trends compared to the placebo arm over time. The iDMC also made a 
recommendation for the ongoing patients in the Study BN40423 to be followed for 
safety and efficacy outcomes as per protocol, without study drug ad ministration.
As a result of iDMC’s recommendation and Sponsor’s decision, effective [ADDRESS_1109601] udy 
completion (see Section [IP_ADDRESS], Appendix 1a, and Appendix 1b).
The known potential risks related to lumbar punctures are elaborated, along with 
mitigation measures, in Section 5.1.  
2. OBJECTIVES A ND ENDPO INTS
This study will evaluate the efficacy, safety, pharmacokine tic (PK), and biomarker effects
of RO7234292 compared with placebo in patients with manifest HD .  Specific objectives 
and corresponding endpoints for the study are outlined below.
2.1 EFFICA CY OBJECTIVES
2.1.1 Primary  Efficacy  Objective
The primary efficacy objectiv e for this study is to evaluate the efficacy of RO7234292
compared withplacebo on the basis of the following endpoint:
Change from baseline in the composite Unified Huntington's Disease Rating Scale
(cUHDRS
)score at Week 101 
Note:  The primary efficacy endpoint for the U.S. Food and Drug Administration 
(FDA) will be c hange from baseline in the TFC score at Week 101.
2.1.2 Secondary  Efficacy Objective
The secondary efficacy objective for this study is to evaluate the efficacy of RO7234292 
compared withplaceb oon the basis of the following endpoints:  
Change from baseline in scores for the following individual scales at Week 101: 
-TFC
-Total Motor Score (TMS)
-Symbol Digit Modalities Test (SDMT)
-Stroop Word Reading (SW R)Test
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
33/Protocol BN40423 , Version 6Note:  For the U.S. FDA, the first secondary endpoint will be c hange from 
baseline in the cUHDRS score at Week 101 instead of TFC, as TFC will be the 
primary endpoint.
Change from baseline in the Clinical Global Impression, Severity Scale (CGI -S) 
score at Week 101
Proportion of patients with a decrease from baseline of 1 point on the TFC at 
Week101
Proportion of patients with a decline from baseline of 1.2 points on the cUHDRS at 
Week 101
Proportion of patients with an unchanged or improved score on the Clinical Global 
Impression, Ch ange Scale (CGI -C) score from baseline at Week101
2.1.3 Exploratory  Efficacy  Objective
The exploratory efficacy objective for this study is to evaluate the efficacy of RO7234292
compared withplacebo on the basis of the following endpoints:  
Change from baseline in the Apathy Evaluation Scale (AES) score at W eek101
Change from baseline in the Symptoms of Major Depressive Disorder Scale 
(SMDDS) score at W eek101
Change from baseline in the Huntington's Disease Daily Activities Scale (HD -DAS) 
score at Week93
Change from baseline in the Patient Global Impression, Severity Scale (PGI -S) 
score at Week101
Change from baseline in the Quality of Life in Neurological Disorders ( Neuro -Qol) 
Cognition Function Short Form at Week101
Change from baseline in the Hunt ington's Disease Speaking Difficulty Item Scale 
(HD-SDI) score at Week101
Change from baseline in the Huntington's Disease Companion -Reported Irritability 
and Angry Outbursts Scale ( HD-CIAOS) score at W eek101
Change from baseline in the in -clinic patient -reported EuroQol 5 -Dimension 
Questionnaire (5 -level version; EQ -5D-5L) index -score and visual analogue scale 
(VAS) at Week 101
Change from baseline in the sensor -based measures collected by [CONTACT_626913] (app; smartphone and wrist -worn w earable) at Week 101
2.2 SAFETY OBJECTIVE
The safety objective for this study is to evaluate the safety and tolerability of RO7234292 
compared with placebo on the basis of the following endpoints: 
Incidence and severity of adverse events, with severity determined according to the 
Adverse Event Severity Grading Scale (see Table 4 )
Change from baseline in Montreal Cognitive Assessment (Mo CA)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
34/Protocol BN40423 , Version 6Change from baseline in vital signs 
Change from baseline in ECG parameters
Change from baseline in clinical laboratory results
Proportion of patient s with suicidal ideation or behavior , as assessed by 
[CONTACT_174273] -Suicide Severity Rating Scale ( C-SSRS) score at each visit, including 
detailed focus on any individual cases identified as having severe ideation or 
behavior during the study conduct
2.3 PHA RMA COKINETIC OBJE CTIV ES
The PKobjective for this study is to characterize the RO72 [ZIP_CODE] PK profile in plasm a 
and trough CSF on the basis of the following endpoint s:
Concentration of RO7234292 in plasma at specified timepoints
Trough concentration of RO7234292 in CSF at specified timepoints
The exploratory pharmacokinetic/pharmacodynamic (PK/PD) objective for t his study is to 
evaluate potential relationships between drug exposure and the efficacy and safety of 
RO7234292 on the basis of the following endpoint s:
Relationship between plasma profiles and/or trough CSF concentrations of
PKparameters for RO7234292 and efficacy endpoints 
Relationship between plasma profiles and/or trough CSF concentrations of PK 
parameters for RO7234292 and safety endpoints
2.4 IMMUNOGENICITY OBJEC TIVE S
The immunogenicity objective for this study is to evaluate the immune response to 
RO7234292 on the basis of the following endpoint s:
Incidence of anti-drug antibodies ( ADAs )at specified timepoints relative to the 
prevalence of ADAs at baseline
Titer and antibody subtype, determined if ADAs are identified
The exploratory immunogenicit y objective for this study is to evaluate potential effects of 
ADAs on the basis of the following endpoint:
Relationship between ADA status and efficacy, safety, or PK endpoints
2.5 BIOMA RKER OBJECTIVE S
2.5.1 Primary  Biomarker Objective
The primary biomarker objective for this study is to evaluate the effects of RO7234292 
compared withplacebo on the basis of the following endpoint:
Change from baseline in CSF mHTT protein level at Week101
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
35/Protocol BN40423 , Version 62.5.2 Secondary  Biomarker Objective
The secondary biomarker objective for t his study is to evaluate the effects of 
RO7234292 compared withplacebo on the basis of the following endpoints:
Change from baseline in whole and regional brain volumes (caudate, whole brain, 
and ventricular), as determined by [CONTACT_803899] (MRI), at 
Week101
Change from baseline in CSF neurofilament light chain (NfL) protein level at 
Week101
2.5.3 Exploratory  Biomarker Objective
The exploratory biomarker objective for this study is to identify biomarkers that are 
predictive of response to RO7234292 (i.e., predictive biomarkers), are early surrogates 
of efficacy, are associated with progression to a more severe disease state 
(i.e., prognostic biomarkers), are associated with acquired resistance to RO7234292 , are 
associated with s usceptibility to developi[INVESTIGATOR_803859] (i.e., safety biomarkers), can provide evidence 
of RO7234292 activity (i.e., PDbiomarkers), or can increase the knowledge and 
understanding of disease biology and drug safety, on the basis of the following 
endpoint s:
Relationship between biomarkers in blood, plasma, and CSF (listed in Section 4.5.6 )
and efficacy, safety, PK, immunogenicity, or other biomarker endpoints
Relationship between imaging biomarkers (e.g., putamen, cortical grey matter, 
cortical white matter volumes, resting state functional MRI signal ) (see 
Section 4.5.7 ) and efficacy, safety, PK, immunogenicity, or other biomarker 
endpoints
2.6 HEA LTH STA TUS UTILIT Y OBJECTIVE
The exploratory health status utility objective for this study is to evaluate health status 
utility scores of patients treated with RO7234292 on the basis of the following endpoint:
Change from baseline in p atient -and companion -reported EQ -5D-5L Index and 
VAS scores at specified timepoints 
Change from baseline in companion self -reported and proxy -reported Health Utilities 
Index Mark 2 ( HUI2) and Mark 3 (HUI3) scores at specified timepoints
Change from baseline in p atient -and companion -reported Work Productivity and 
Activity Impairment (WPAI) scores at specified timepoints 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
36/Protocol BN40423 , Version 63. STUDY DESIGN
3.[ADDRESS_1109602] HD. 
Effective 22 March 2021, no further study treatment will be administered in this study.
Patients on the study will continue to be followed for safety and efficacy outcomes until 
study completion (see Section [IP_ADDRESS], Appendix 1a, and Appendix 1b).
Prospective patients will undergo screening assessments during a 4 -week screening 
period.  A maximum of one re-screening will be allowed within 8 weeks of the initial 
screening failure for patients who fail the initial screening (see Section 4.5.1 ). If 
re-screening is required, the CAG repeat length testing from the initial screening does 
not need to be repeated (historical values prior to screening will not be accepted) . The 
screening MRI and viral serology from the initial screening, including from other [COMPANY_002]
RO7234292 studies, may be acceptable as part of the re -screening assessments if 
performed within 12 weeks of the baseline visit.
Upon completion of the screening period, eligible patients will be randomly allocated in a 
1:1:1 ratio to receive RO7234292 Q8W (RO7234292 Q8Warm), RO7234292 Q16W
(RO7234292 Q16Warm), or placebo Q8W(placebo arm) by [CONTACT_626918], as described in 
Table 1 .  To maintain the study blind and integrity, patients in the RO7234292 Q16W
arm will also receive placebo (i.e., alternating doses of act ive drug and placebo).
Table 1Treatment Regimen s after Implementation of Protocol Version 4
Arm Treatment Regimen
RO7234292 Q8 W arm RO7234292 loading dose:  120 mg at Days 1 and 29 (2 doses)
RO7234292:  120 mg Q8 W from Week 13 to W eek 93 (11 doses)
RO7234292 Q16W  arm RO7234292 loading dose:  120 mg at Days 1 and 29 (2 doses)
RO7234292:  120 mg Q16W  from  Week 21 to W eek 85 (5 doses)
Placebo:  Q16W  from  Week 13 to W eek 93 (6 doses)
Placebo arm Placebo:  at Days 1 and 29 (2 doses) and Q8W  from  Week 13 to 
Week 93 (11 doses)
Q8Wevery 8 weeks; Q16W every 16 weeks.
Note: Effective 22 March 2021, no further study treatment will be administered in this 
study.
During scheduled clinic visits, patients will undergo safety and tolerability evaluations
that include neurologic examinations, vital signs, ECGs, clinical laboratory tests, MoCA, 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
37/Protocol BN40423 , Version 6C-SSRS, neuroimaging assessments (neurologic safety sequences), and a review of 
any adverse events including related concomitant medications, as detailed 
in Appendix 1a.  Patients in Japan must be monitored in the hospi[INVESTIGATOR_803857] 
24 hour s after Day1study drug administration.  Discharge will be determined at the 
discretion of the principal investigator.
Inthe case of a failed IT bolus dosing procedure or a failed CSF collection procedure 
(e.g.,due to an inadequate establishment of access to the IT space ), a second attempt 
may occur up to 7 days after the originally scheduled attempt .  For this additional visit ,
safety and tolerability evaluations on the day of LP administration will be performed as 
detailed in Appendix 1aand Appendix 1b, including neurological examination (predose 
and postdose, or pre -procedure if no study treatment is being administered ), vital signs, 
and a review of adverse event s and concomitant medicatio n. If the second attempt 
occurs more than 3days after the first attempt, local laboratory analysis of coagulation 
factors (INR and/or PT, aPTT) and p latele ts need to be conducted again and results 
reviewed prior to the LP attempt (see Appendix 1a).
During the treatment period, a telephone safety follow -up call will be conducted for the 
months in which no clinic visits are scheduled to check for any change in patient status 
(i.e., adver se events, concomitant medications) since the patient’s last visit
(see Appendix 1a).  Where deemed appropriate, an unscheduled clinic visit should be 
arranged for safety follow -up; no dosing will occur at these unscheduled visits. Asafety 
follow -up telephone call will also be conducted approximately [ADDRESS_1109603] 
in-clinic visit at Week 101. 
Effective 22 March 2021, all patients will discontinue study treatment and will no 
longer be able to enter the OLE study (BN40955) after completing this study.
For patients enrolled in Study BN40423 who discontinue study treatment prematurely ,
but do not withdraw consent for continued partici pation in the study ,an ETT schedule 
will apply ( Section [IP_ADDRESS]) .
An iDMC and independent Data Coordinating Center (iDCC) will be employed to monitor 
and evaluate patient safety throughout the study as well as to evaluate evidence of early 
efficacy (see Se ction 3.1.2 ).  
The Sponsor may choose to conduct one or more interim analyses during the study 
(further details are given in Section 6.12).
Figure 1and Figure 2present the study schema andoverview of the dosing schedule
respectively, for patients enrolled in Study BN40423 after implementation of Protocol 
Version 4.  A schedule of activities is provided in Appendix 1a.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
38/Protocol BN40423 , Version 6Figure 1Study Sche ma for Patients Enrolled after Implementation of Protocol Version 4
EoTend of treatment; ETTearly treatment termination; HDHuntington disease; Q8W every 8 weeks ; Q16W every 16 weeks .
aPatients in the RO7234292 Q16 Warm will receive placebo at alternating visits to keep the double blind, as shown in Figure 2and Appendix 1a
NOTE :  Effective 22 March 2021, all patients will be discontinued from study treatment and follow the ETT schedule (see Section [IP_ADDRESS] ).  

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
39/Protocol BN40423 , Version 6Figure 2Dosing Schem a for Patients Enrolled after Implementation of Protocol Version 4
EoTend of treatment; Q8W every 8 weeks ; Q16 Wevery 16 weeks .
Notes :Red, solid arrows indicate study drug administration, while black, dotted arrows indicate placebo administration.  Patients i n the 
RO7234292 Q8 W arm will receive a loading dose of RO7234292 on Days 1 and 29 (loading period), followed by [CONTACT_803914] Q8 W. 
Patients in the RO7234292 Q16 W arm will receive a loading dose of RO7234292 on Days 1 and 29 (loading period), followed by [CONTACT_803915] 
Q8W doses of placebo and active study drug.
NOTE: Effective March 22, 2021, no furt her study treatment will be administered in this study .  Effective 22 March 2021, all patients will be 
discontinued from study treatment and follow the ETT schedule (see Section [IP_ADDRESS] ).  

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
40/Protocol BN40423 , Version [IP_ADDRESS] Clarification of Existing Study Design for Early  Treatment 
Termination (A pplicable to all Patients from 22 March 2021)
Following the iDMC recommendation and Sponsor’s decision to discontin ue study 
treatment in this study, as of 22 March 2021, all patients will transition to the existing 
ETT schedule, outlined below and in Appendix 1b.
All patients who discontinue study treatment prematurely but do not withdraw consent 
for continued participation in the study ,will return to the clinic for the following visits 
as part of the ETT schedule:
 ETT visit to be performed within a maximum of 56 days of the decision to
discontinue study treatment .
 Follow -up study visits at Weeks 53 and 69 (if not already completed) for collection
of clinical outcome data for the primary and secondary endpoints (see Sections
2.1.1, 2.1.2, 2.2, and Appendix 1b).  If the ETT visit falls within 30 days of
either scheduled visits at Week 53 or Week 69, then only the ETT visit should be
performed.
 End-of-treatment (EoT) visit at Week 101 (EoT for ETT).
Therefore, after discontinuation of study treatment, patients will attend a minimum of 
two and up to four in -clinic visits depending on which visit shave already been 
completed at the time of study drug discontinuation as shown in Figure 3.
After discontinuation of study treatment, t elephone safety follow -up calls will be 
conducted every 8 weeks between the clinic visits to check for any change in patient 
status (i.e., adverse e vents, concomitant medications) since the patient’s last visit (see 
Appendix 1b).  Where deemed appropriate, an unscheduled clinic visit should be 
arranged for safety follow -up.
For patients consented to version [ADDRESS_1109604] dose.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
42/Protocol BN40423 , Version 6Table 2 Treatment Regimens prior to Implementation of Protoc ol 
Version 4
Arm Treatment Regimen
RO7234292 Q4 W arm –RO7234292:  120 mg Q4 W from Week 1 to W eek 97 (25 doses)
RO7234292 Q8Warm –RO7234292 loading dose:  120 mg at Days 1 and 29 (2 doses)
–Placebo:  Q8 W from Week 9 to W eek 97 (12 doses)
–RO7234292:  120 mg Q8W from Week 13 to W eek 93 
(11doses)
Placebo arm –Placebo:  Q4 W from Week 1 to W eek 97 (25 doses)
Q4Wevery 4 weeks; Q8W every 8 weeks.
Figure 4and Figure 5present study schema and overviews of the dosing schedule, 
respectively.  A schedule of activities is provided in Appendix 10, with additio nal 
assessments described in Appendix 11, Appendix 12, Appendix 13, and Appendix 14.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
43/Protocol BN40423 , Version 6Figure 4Study Schema for Patients Enrolled prior to Implementation of Protocol Version 4
EoTend of treatment; HD Huntington disease; Q4 Wevery 4 weeks; Q8 Wevery 8 weeks.
Notes:  All patients who enroll prior to implementation of Protocol Version 4 will be prematurely discontinued from treatment by [CONTACT_803916]- label extension study (BN40955).  These patients will complete an EoT visi t in Study BN40423, which can also serve 
as the screening visit for Study BN40955.  All patients who are prematurely discontinued by [CONTACT_803917]40955 will additionally undergo a safety follow -up telephone call approxim ately [ADDRESS_1109605] dose and a 5-month postdose
safety follow -up visit.  Patients in the Q8 W arm will remain in the Q8 W arm of the OLE study (BN40955).  Patients in the placebo arm or Q4 Warms 
will be randomly allocated to the Q8 W or Q16 W arms in Study BN40955.

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
44/Protocol BN40423 , Version 6Figure 5Dosing Schema for Patients Enrolled prior to Implementation of Protocol Version 4
EoTend of treatment; Q4W every 4 weeks; Q8 Wevery 8 weeks.
Notes:  Red, solid arrows indicate study drug administration, while black, dotted arrows indicate placebo administration.  Pa tients in the 
RO7234292 Q8 W arm will receive a loading dose of RO7234292 on Days 1 and 29 (loading period), followed by [CONTACT_803918]. 

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
45/Protocol BN40423 , Version 63.1.[ADDRESS_1109606], and abnormalities from neuroimaging assessme nts;vital signs; ECG
assessments ; laboratory parameters; and any other relevant safety information will be 
reviewed on a regular basis by [CONTACT_803919].   This information may 
also include MRI data and exploratory CSF biomarkers, for exam ple NfL and Tau.
These reviews will occur approximately every 6 months or at the discretion of the iDMC. 
The iDMC will also undertake evaluation of any interim analys is. Specific operational 
details ,such as the committee's composition, frequency and timing of meetings, and 
members' roles and responsibilities ,will be detailed in an iDMC Charter.
As a result of the iDMC's recommendation and the Sponsor’s decision to permanently 
stop study treatment, the Sponsor will be unblinded to treatment assignment .  
Following the unblinding, t he Sponsor will also monitor and evaluate patient safety 
outcomes .
3.[ADDRESS_1109607] visit occurs.  The 
end of the study is expected to oc cur approximately 101weeks ( 25months) after the last 
patient is enrolled.  
The total length of the study, from screening of the first patient to the end of the study, is 
expected to be approximately [ADDRESS_1109608] that brain tissue lowering 
of mHTT protein in the range of 30% 60% is associated with beneficial effects on the 
disease phenotype, which corresponds to a trough CSF lowering range of 2 0%40%
based on a non- human primate PK/PD model.  
Because of this uncertainty, two active dosing regimens and a placebo arm will be used 
in this study:  RO7234292 Q8W (RO72342 92 Q8W arm), RO7234292 Q16W
(RO7234292 Q16Warm), and placebo Q8W(placebo arm) by [CONTACT_626918].  To maintain 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
46/Protocol BN40423 , Version 6the study blind and integrity, patients in the RO7234292 Q16Warm will also receive 
placebo (i.e., alternating doses of active drug and placebo).
The 120 -mg dose has been chosen for the Q8Wdosing group based on the following:
In the chronic toxicology study in cynomolgus monkeys, the no -observed -adverse-
effect level was determined to beat least 35 mg/dose (the highest dose tested) .  
Conservativel y correcting for differences in CSF volume between cynomolgus 
monkeys ( 15 mL) and humans ( 150 mL) with a scaling factor of 10, the human 
equivalent dose corresponds to 350 mg, representing a 3 -fold safety margin to the 
proposed 120 -mg clinical dose.  
Both the 90 -mg and 120 -mg RO7234292 Q4 W groups in the Phase I/IIa study 
(ISIS 443139 -CS1) resulted in a median CSF mHTT protein reduction of 
approximately 40%, with individual cases reaching approximately 60% reduction at 
trough, well above the described pre clinical threshold for efficacy.  The 120 -mg dose 
group exhibited a more consistent decline compared with the 90 -mg dose group. 
In the same Phase I/IIa study, 120 mg of RO7234292 administered intrathecally 
Q4W for four doses was safe and well tolerated c ompared with placebo.  See 
additional details in the RO7234292 Investigator's Brochure. 
In approximately 70% of patients (23 of 34 patients) assigned to receive 
RO7234292 in the Phase I/IIa study , CSF mHTT protein was declining at the last 
trough measurement (either Day 113 or 141), suggesting sustained reduction of 
CSF mHTT protein up to 2 months postdose (last timepoint assessed). 
In the 120 -mg RO7234292 group in the Phase I/IIa study, CSF mHTT protein levels 
were reduced by [CONTACT_2669] 35% in all five cases for which a Day 141 sample was 
collected (i.e., [ADDRESS_1109609] dose ), in line with the observed Q8 W OLE data. 
Data from the ongoing Phase II OLE Study BN40697 (ISIS 443139 -CS2) showed 
that 120 -mg doses administered in Q4 W and Q8W  regimens achieved 66% and 
47% median reductions of CSF mHTT from baseline at trough, respectively, after 9 
months.  Both results exceed the 20% 40% target for CSF mHTT lowering at trough 
and steady state based upon efficacy data from nonclinical models, and exceed the 
result of approximately 40% median lowering observed in the completed Phase I/IIa 
study.  The observed effects on CSF mHTT lowering in the OLE after administration 
of three or four doses of 120 mg were also approximately 40%, consistent with 
results from the Phase I/IIa study (ISIS 443139 -CS1).
Review of safety and tolerability data for RO7234292 from the Phase II OLE 
suggest that relative to the Q4 W treatment regimen, the Q8 W treatment regimen 
may be more suitable for chronic IT dosing.  This is supported by [CONTACT_803920], decreased proportion of patients with moderate 
adverse events, and fewer adverse events considered possibly related to study drug 
in the Q8 W regimen compared to the Q4W  regimen (for details see the RO7234292 
Investigator’s Brochure).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
47/Protocol BN40423 , Version 6The 120 -mg dose has been chosen for the Q16 W dosing group based on the following: 
The nonclinical PK/PD model and updated clinical PK /PD model predicted the 
observed Q8W 9-month reductions.  From these model s, a Q16 W regimen is 
predicted to result in median CSF HTT trough lowering of 20
%25%, within the 
range of the 20% 40% target for CSF mHTT lowering at trough and steady state. 
Model predicted a cute lowering forthe120-mg Q16W  regimen is around 35%40%
CSF mHTT reduction, above observed threshold for efficacy based upon nonclinical 
models. 
Maintenance of trough lowering is not a necessary feature of this less frequent arm 
to test the primary hypothesis.   The hypothesis of this 120 -mg Q16 W arm (acute 
lowering, followed by [CONTACT_626921]) is supported by [CONTACT_803921] -mediated lowering of HTT protein is associated with 
sustained phenotypic benefit in the BACHD model ( Kordasiewicz et al. 2012).  
Efficacy in this model is sustained for 6 months even after a complete recovery of 
target mRNA and prot ein. 
Testing the less frequent regimen is of high interest to mitigate potential unknown 
long-term complications associated with a more frequent IT dosing of [ADDRESS_1109610] 
concentrations when administered systemically (Schoch and Miller 2017).  Therefore, 
the IT drug delivery method will be used in this trial, as presently no alternatives exist.  
A 25-month (2 -year) study treatment length has been chosen because the 
signal -to-noise characteristics of the primary endpoint cUHDRS (TFC for U.S. FDA) as 
investigated in prospective observational cohort studies and in placebo groups of prior 
clinical trials suggest that this length is optimal for trial efficacy .  A treatment duration of 
25 months will also enable demonstration of sustained, durable benefit on slowing
clinical progression as presumed to be achiev able with RO7234292 (which is proposed 
to be administered as a chronic treatment to slow clinical progression).  S tudies with a 
shorter treatment duration, such as 18 months, would require a dramatically larger 
sample size (i.e., 50%) under the 30% slowing of clinical progression assumption .This 
would result in a potential risk of signal dilution due to inherent variability of a larger 
number of sites and clinical raters, resulting in a potential increased risk of type II error.  
In summary, a [ADDRESS_1109611] the hypothesis of clinical efficacy ,as a function of 
more versus less frequent dosing, while mitigating theoretical risks of long -term IT 
dosing of 120 mg and of non -allele specific lowering of HTT.  The 25- month duration is 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
48/Protocol BN40423 , Version 6also considered appropriate for providing evidence of the benefit risk profile of
RO7234292 and longer -term tolerability of IT administration.
3.3.[ADDRESS_1109612] HD ( DCL score of 4[i.e., motor abnormalities 99% likely to be 
due to HD] ) who are ambulatory without assistance, verbal, and possess a CAGAge 
Product (CAP) score of 400(Zhang et al. 2011; see Section 4.1.1 ) and an 
Independence Scale (IS) score of [ADDRESS_1109613] disease where disabilit y might be more plausibly 
reversed or slowed in response to a therapeutic intervention compared with patients with 
more advanced disease (Penney et al. 1990).   This definition also corresponds to the 
patients most commonly recruited at present for clinical trials aiming to slow clinical 
progression.  Such cohorts are known to have a longitudinal decline in clinical measures 
(Paulsen et al. 2014) over a timeframe appropriate for clinical trials .
3.3.3 Rationale for Control Group
Patients will be randomly allocated to receive active treatment (RO7234292 Q8Wor 
Q16W) or placebo in this double -blind study because there are no disease -modifying 
standard -of-care treatments for patients with HD.  The placebo arm will be compared 
with th e RO7234292 treatment arms to enable a robust assessment of the primary 
endpoint and the benefit -risk profile.  As each patient completes the study or is 
prematurely discontinued by [CONTACT_14547] a consequence of the changes to the study 
through Protocol Version 4, they will be given the option of receiving RO7234292 in an 
OLE study (BN40955), provided they meet eligibility criteria and the data from the 
ongoing RO7234292 program support continued development.  Approval of 
Study BN40955 must also be granted by [CONTACT_803922]/IRB.   
3.3.4 Rationale for Biomarker A ssessments
[IP_ADDRESS] Cerebrospi[INVESTIGATOR_803860].  A toxic gain-of-function mechanism of mHTT
protein is widely considered to be the primary driver of disease pathophysiology in HD 
(WildandTabrizi 2017 ).  mHTT protein in human CSF is associated with disease stage 
and severity and with biomarkers of neuronal dama ge, including CSF NfL and CSF tau 
levels ( Wildet al. 2015).  NfL levels in CSF predict progressive MRI measures of brain 
atrophy, as well as progressive clinical decline in patients ( Wildand Tabrizi 2017 ).  
Longitudinal analysis of mHTT, NfL, tau,and o ther biomarkers related to HD, 
neurodegeneration, and inflammation in CSF may extend the current understanding of 
HD pathophysiology and progression and provide further data on how these putatively 
prognostic and potentially predictive biomarkers will respond to disease -modifying 
treatment.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
49/Protocol BN40423 , Version [IP_ADDRESS] Blood Biomarkers
NfL levels in blood correlate with NfL levels in CSF and could serve as prognostic blood 
biomarkers of disease onset and progression in HD ( Wildand Tabrizi 2017 ;
Johnson etal.2018 ).  Longitudinal analysis of NfL and other biomarkers related to HD, 
neurodegeneration, and inflammation in blood may facilitate understanding of HD 
pathophysiology and progression.
[IP_ADDRESS] Genetic Testing to Determ ine CA G Repeat Length
HD is caused by [CONTACT_803923] 1 of the HTT gene located on chromosome 4,
resulting in a polyglutamine (CAG) expansion in the huntingtin protein.  Above 35 CAG 
repeats, the age of HD onset is inversely correlated with the length of the expansion 
(Duyao et al. 1993).  CAG repeat length will be determined by [CONTACT_803924] .  
[IP_ADDRESS] Clinical Genoty pi[INVESTIGATOR_601322], it only 
accounts for approximately 50% of th e variance.  Identification of other genetic modifiers 
of disease severity and disease progression in HD could provide important insights, as 
has been recently shown in the Genetic Modifiers of Huntington's Disease Consortium 
(2015 ), where relatively commo n single nucleotide polymorphisms in the HD population 
were found to be associated with either an accelerated or delayed age of motor onset.  
Ablood sample will be collected to detect individual single nucleotide polymorphi sms, 
including SNP analysis of t he huntingt in gene, toexplore, for example, their influence on 
progression rates, age of onset, disease severity, or response to treatment.  
[IP_ADDRESS] Magnetic Resonance Imaging
MRI is a non -invasive method to assess structure and function of the human brain and 
can provide insights into pathophysiological mechanisms of neurologic and 
neuropsychiatric disease. Several MRI techniques have shown sensitivity to detect 
abnormal structure and function within brains of individuals suffering from HD.   Structural 
MRI wil l be used to assess brain volume, diffusion -weighted MRI will be used to examine 
structural brain connectivity , and resting -state f unctional MRI will be employed to identify 
functional connectivity. All of the measure s will be assessed at the whole- brain and
regional level s. The acquisition parameters of each sequence, structure, and length of 
each MRI session and image processing algorithms will be outlined in a separate MRI 
manual.
Structural Magnetic Resonance Imaging
Numerous structural MRI studies ha ve demonstrated wide -spread brain atrophy ,
including whole -brain, caudate, and ventricular changes in patients with premanifest and 
manifest HD ( Douaud et al. 2006
; Harrington et al. 2016 ).  Brain volume correlates with 
cognitive function (Peinemann et al. 2005 ).  Further, whole- brain, caudate, and 
ventricular volumes can predict and track progressive clinical decline in patients with HD 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
50/Protocol BN40423 , Version 6and can also be associate dwith molecular biomarkers of neurodegeneration, 
such asNfL (Tabrizi etal. 2012 ). 
Diffusion Magnetic Resonance Imaging
Widespread changes in basal ganglia cortical structural connectivity have also been 
observed in patients with HD ( Novak et al. 2015), including associations between 
striatum -sensorimotor cortex connections and UHDRS motor scale and TMS
(Bohanna et al. 2011), suggesting that the clinical phenotype in manifest HD may be a 
result of altered structural connectivity.
Resting -State Functional Magnetic Resonance Imaging
Resting- state functional MRI studies have generated evidence for functional connectivity 
alterations and their correlation to several clinical and cognitive measures in patients 
with HD ( Werneretal.2014 ; Dogan et al. 2015 ; Liuetal.2016 ; Espi[INVESTIGATOR_601323].2018 ), 
implying that disrupted functional integrity of distinct b rain networks may underlie clinical 
progression in HD.
4. MATERI ALS AND METHOD S
4.[ADDRESS_1109614] meet the following criteria for study entry during screening (some will be 
reassessed at baseline prior to randomization and study drug dosing ):
Signed Informed Consent Form
Age [ADDRESS_1109615] dose administration
Manifest HD diagnosis, defined as a DCL score of 4 (see Appendix 8)
Independence Scale (IS) score 70 
Genetically confirmed disease by [CONTACT_626896] a CAP score 400 (Zhang 
et al. 2011), calculated as follows:
CAPAge(CAG repeat length 33.66)
Ability to read the words "red," "blue," and "green" in native language
Ability to walk unassisted without a cane or walker and move about without a 
wheelchair on a daily basis as determined at screening and baseline visit
-Long-distance (e.g. ,50meters) use of wheelchairs for convenience or
transfer ispermitted.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
51/Protocol BN40423 , Version 6Body mass index 16 32 kg/m2; total body weight 40kg
Ability to undergo and tolerate MRI scans (e.g., no claustropho bia, no severe chorea 
or other condition that precludes MRI scans or renders scanning intolerable for the 
patient, no MRI -incompatible intrauterine devices, metallic dental braces, or other 
metal implants)
Ability to tolerate blood draws and lumbar punctures
Creatinine c learance (CrCl )60 mL/min (Cockcroft -Gault formula)
Ability and willingness, in the investigator's judgment, to comply with all aspects of 
the protocol including completion of interviews and questionnaires for the duration of 
the st udy 
Ability and willingness, in the investigator's judgment, to carry a smartphone, wear a 
digital monitoring device, and complete smartphone -based tasks
Stable medical, psychiatric, and neurological status for at least 12 weeks prior to 
screening and at the time of enrollment
Signed study companion consent for participation who fulfills all of the following 
criteria:
-Age 18 years
-Reliable and competent, in the investigator's judgment
-Sufficiently knowledgeable of the patient's condition to complete stud y 
companion assessments of the patient, and likely to remain sufficiently 
knowledgeable throughout the study, in the investigator's judgment
-Able to comment on study participant's symptoms and functioning experience, 
as required per Appendix 1
-Ableand willing to attend in person all clinical visits for completion of 
companion assessments and for input into the clinician -rated TFC s cale
Note:  Companions must have no cognitive, behavioral or motor change, in the 
opi[INVESTIGATOR_871], that would question the validity of the acquired 
observer -reported data.
All effort should be made to retain the study companion; however, should this 
not be possible, a study companion should be replaced and new consent 
obtained.
A study companion is required for all patients who enroll after implementation of 
Version 5 of the protocol. The companion is optional but highly recommended 
for patients who enrolled under Pr otocol Versions 1 4.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
52/Protocol BN40423 , Version 6For women of childbearing potential:  agreement to remain abstinent (refrain from 
heterosexual intercourse) or use contraceptive measures, as defined below:
Women must remain abstinent or use twomethods of contraception, including 
at least one method with a failure rate of 1% per year, during the treatment 
period and for 5 months after the final dose of study drug. 
A woman is considered to be of childbearing potential if she is postmenarcheal,
has not reached a postmenopausal state ( 12continuous months of 
amenorrhea with no identified cause other than menopause), and has not 
undergone surgical sterilization (removal of ovaries and/or uterus).   The 
definition of childbearing potential may be adapted for alignment with local 
guidelines or requirements.
Examples of contraceptive methods with a failure rate of 1%per year include 
bilateral tubal ligation, male sterilization, established proper use of hormonal 
contraceptives that inhibit ovulati on, hormone -releasing intrauterine devices, 
and copper intrauterine devices.   A vasectomized man must undergo a medical 
assessment that confirms the success of the surgery before he can be 
considered surgically sterile. 
Hormonal contraceptive methods must be supplemented by a barrier method.
The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptoth ermal, or postovulation 
methods) and withdrawal are not acceptable methods of contraception.
For men:  agreement to remain abstinent (refrain from heterosexual intercourse) or 
use a condom, and agreement to refrain from donating sperm, as defined below:
With a female partner of childbearing potential or pregnant female partner, men 
must remain abstinent or use a condom during the treatment period and for 
5months after the final dose of study drug to avoid exposing the embryo.  Men 
must refrain from donati ng sperm during this same period.
The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptotherma l, or postovulation 
methods) and withdrawal are not acceptable methods of preventing drug 
exposure .
4.1.2 Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
History of attempted suicide or suicidal ideation wit h plan (i.e., active suicidal 
ideation) that required hospi[INVESTIGATOR_601316]/or change in level of care within 12 months 
prior to screening
Current suicidal ideation is demonstrated by [CONTACT_941] C -SSRS per judgment of the 
investigator.  If suicidal ideation is prese nt, a risk assessment should be done 
by [CONTACT_803925]7234292 F.Hoffmann -La [COMPANY_002] Ltd
53/Protocol BN40423 , Version 6safe for the patient to participate in the study.  Mild passive suicidal ideation 
(i.e., occasional thoughts that life is not worth living or is hard) without history of 
attempts or hospi[INVESTIGATOR_601317] 12 months is generally acceptable for 
study participation, but final decision on participation should be made carefully 
and in consultation with an appropriately qualified mental hea lth professional. 
Current active psychosis, confusional state, or violent behavior
Any serious medical condition or clinically significant laboratory, or vital sign 
abnormality or claustrophobia at screening that, in the investigator's judgment,
precludes the patient's safe participation in and completion of the study
History known to the investigator or presence of an abnormal ECG that is clinically 
significant in the investigator 's opi[INVESTIGATOR_1649], including complete left bundle branch block, 
second- or third- degree atrioventricular heart block, or evidence of prior myocardial 
infarction
Lifetime clinical diagnosis of chronic migraines
Pregnant or breastfeeding, or intending to become pregnant during the study or 
within [ADDRESS_1109616] prior to initiation of 
study drug.   
Presence of an implanted shunt for the drainage of CSF or an implanted CNS
catheter
Positive for hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg) at 
screening
Known HIV infection
Current or previous use of an antisense oligonucleotide (including small interfering 
RNA)
Current or previous use of anti -psychotics prescribed for a primary independent 
psychotic disorder (i.e., schizophrenia, schizoaffective disorder, bipolar disorder 
type I, severe with psychotic features), cholinesterase inhibitors, memantine, 
amantadine, o
r riluzole within 12 weeks from initiation of study treatment
Current use of antipsychotics for motor symptoms or mood stabilization 
(i.e., irritability or aggressive behavior) and/or tetrabenazine, valbenazine, or 
deutetrabenazine at a dose that has not b een stable for at least 12 weeks prior to 
screening or is anticipated to change between screening and treatment initiation
Current use of supplements (e.g., coenzyme Q10, vitamins, creatine) at a dose that 
has not been stable for at least 6 weeks prior to screening or is anticipated to 
change during the study
Current use of an a ntidepressant or benzodiazepi[INVESTIGATOR_16717] a dose that has not been 
stable for at least 12weeks prior to screening or is anticipated to change between 
screening and treatment initiation
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
54/Protocol BN40423 , Version 6Treatment with investigational therapy within 4 weeks or 5 drug-elimination half -lives 
prior to screening, whichever is longer
Antiplatelet or anticoagulant therapy within 14 days prior to screening or anticipated 
use during the study, including, but not l imited to, aspi[INVESTIGATOR_248] ( unless 81mg/day ), 
clopi[INVESTIGATOR_7745], dipyridamole, warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]
History of bleeding diathesis or coagulopathy
Platelet count less than the lower limit of normal   
Platelet counts between 125,000 and 150,0 00 mm3are permissible as long as 
the investigator confirms there is no evidence of current bleeding diathesis or 
coagulopathy.  
History of gene therapy, cell transplantation, or any experimental brain surgery
Concurrent or planned participation in any in terventional clinical study, including 
explicit pharmacological and non -pharmacological interventions
Observational studies (e.g., ENROLL -HD prospective study) are acceptable. 
Drug (i.e., cannabis, opi[INVESTIGATOR_2480], stimulant, hallucinogen, designer) and/or alcohol abuse 
or psychological or physiological dependency within 12 months prior to screening, 
as per the investigator's judgment
Abuse is defined as a maladaptive pattern of use that leads to failure to fulfill 
major work or social obligations or use in situati ons where it leads to physical 
danger or legal problems, and may be the focus of clinical attention.  
Poor peripheral venous access
Scoliosis or spi[INVESTIGATOR_803861]7234292 up the 
neuraxis
An infection requiring oral or IV antibiotics within 14 days prior to screening and prior 
to randomization
Antiretroviral medications, including antiretroviral medication taken as prophylaxis
within 12 months of study enrollment
Malignancy within 5 years prior to screening, except basal or squamous cell
carcinoma of the skin or carcinoma in situ of the cervix that has been successfully 
treated
Preexisting intra-axial or extra -axial lesion s(e.g., tumor, arterio -venous 
malformation , meningiomas ) as assessed by a centrally read MRI scan during the 
screening period
4.[ADDRESS_1109617] after the entire cohort has been discontinued from 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
55/Protocol BN40423 , Version 6Study BN40423.  Patients will receive either the Q8 W regimen or Q16 W regimen in 
Study BN40955.  These patients will not be included in the primary analysis for Study 
BN40423.
Patients enrolled after implementation of Protocol Version 4 will be randomly allocated to 
receive 120 mg of RO7234292 Q8W, 120 mg of RO7234292 Q16W, or placebo Q8W.  
An independent interactive voice or web -based response system (IxRS) provider will 
conduct randomization and hold the treatment assignment code.
Effective 22 March 2021 ,all patients will be discontinued from study treatment and 
will follow the ETT schedule of a ssessments, outlined in Appendix 1b.  Patients who do 
not con sent to version 6 of the protocol should be discontinued from the study.
Study site personnel and patients will remain blinded to treatment assignment during the 
study.  Following the Sponsor ’sdecision to permanently discontinue study treatment, 
the Sponsor will become unblinded to treatment assignment. Other individuals who 
require access to patient treatment assignments to fulfill their job roles during theclinical 
trialinclude the unblinding group , clinical supply chain managers, sample handling staff, 
operational assay group personnel, IxRS service provider, iDMC members, and iDCC 
members.
While PK and ADA samples must be collected from patients assigned to the placebo 
arm to maintain the blinding of treatment assignment, PK and ADA assay results for 
these patients are generally not needed for the safe conduct or proper interpretation of 
this study.  Laboratories responsible for performing study drug PK and ADA assays will 
be unblinded to patient t reatment assignment in order to identify appropriate samples for 
analysis .  PK samples from patients assigned to the placebo arm will not be analyzed for 
study drug PK concentration except by [CONTACT_32236] (e.g., to evaluate a possible error in 
dosing).  Baselin e ADA samples will be analyzed for all patients.  Post -baseline ADA 
samples from patients assigned to the placebo arm will not be analyzed for ADAs except 
by [CONTACT_32236].
If unblinding is necessary for a medical emergency (e.g., in the case of a serious 
advers e event for which patient management might be affected by [CONTACT_123514]), the investigator will be able to break the treatment code by 
[CONTACT_123517].  The investigator is not required to contact [CONTACT_803926]; however, the treatment code should not be broken 
except in emergency situations.
If the investigator wishes to know the identity of the study drug for any reason other than 
a medical emergency, he or she should contact [CONTACT_803927].  The 
investigator should document and provide an explanation for any non -emergency 
unblinding.  If the Medical Monitor agrees to patient unblinding, t he investigator will be 
able to break the treatment code by [CONTACT_123517].
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
56/Protocol BN40423 , Version 6As per health authority reporting requirements, the Sponsor's Drug Safety representative 
will break the treatment code for all serious, unexpected suspected adverse reactions 
(see Section 5.7) that are considered by [CONTACT_123518].  The patient may continue to receive treatment .  The investigator andpatient
will remain blinded to treatment assignment .  Following the Sponsor’s decision to 
permanently discontinue study treatment, the Sponsor will become unblinded to 
treatment assignment including the Sponsor’s Drug Safety representative and 
personnel who must have access to patient treatment assignments to fulfill their r oles 
(as defined above).
4.3 STUDY TRE ATMENT A ND OTHER TRE ATMENTS REL EVANT 
TO THE STUDY DESIGN
The investigational medicinal products (IMPs) for this study are RO7234292 and 
RO7234292 placebo. 
4.3.1 Study Treatment Formulation, Packaging, and Handling
[IP_ADDRESS] RO7234292
RO7234292 will be supplied by [CONTACT_319071], preservative -free liquid in a 
20-mL single -use vial containing 10 mL of 6.0 mg/mL RO7234292 drug product for 
ITinjection. For a 120- mg dose (20 -mL dosing volume), two vials containing 10 mL of 
6.0mg/mL RO7234292 will be pooled by [CONTACT_626925] 20 mL of study drug.
For information on the formulation, preparation, and handling of RO7234292, refer to the 
pharmacy manual.
[IP_ADDRESS] Placebo
RO7234292 placebo will be sup plied by [CONTACT_14547] a sterile, preservative -free liquid 
in a 20-mL single -use vial containing [ADDRESS_1109618].
For information on the formulation, preparation, and handling of RO7234292 placebo, 
refer to the pharmacy man ual.
4.3.2 Study Treatment Dosage, A dministration, and Compliance
The treatment regimens are summarized in Section 3.1.
Any dose modification should be note d on the Study Drug Administration electronic 
Case Report Form (eCRF) .  Cases of accidental overdose or medication error, along
with any associated adverse events, should be reported as described in Section [IP_ADDRESS]
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
57/Protocol BN40423 , Version 6Guidelines for treatment interruption or discontinuation for patients who experience 
adverse events are provided in Section 5.1.3 .
[IP_ADDRESS] RO7234292 and Placebo
Each dose of RO7234292 (120 mg) and placebo will be administered as a single 
ITbolus injection of [ADDRESS_1109619] A ccountability
All IMPs required for completion of this study (RO7234292 or placebo ) will be provided 
by [CONTACT_1034].  The study site will acknowledge receipt of IMPs supplied by [CONTACT_429], using the IxRS to confirm the shipment condition and content.  Any damaged 
shipments will be replaced.
IMPs will either be disposed of at the study site according to the study site's institutional 
standard operating procedure or be returned to the Sponsor with the appropriate 
documentation.  The site's method of destroying Sponsor -supplied IMPs must be agreed 
to by [CONTACT_1034].  The site must obtain written authorization from the Sponsor before 
any Sponsor -supplied IMP is destroyed, and IMP destruction must be documented on 
the app ropriate form.
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by 
[CONTACT_25729].
4.3.4 Continued A ccess to RO7234292
The Sponsor will offer continued access to [COMPANY_002] IMP (RO7234292 ) free of charge to 
eligible patients in accordance with the [COMPANY_002] Global Policy on Continued Access to 
Investigational Medicinal Product , as outlined below.
A patient will be eligible to receive [COMPANY_002] IMP (RO7234292) after completing the study i f 
allof the following conditions are met:
The patient has a life- threatening or severe medical condition and requires 
continued [COMPANY_002] IMP treatment for his or her well -being
There are no appropriate alternative treatments available to the patient
The pati ent and his or her doctor comply with and satisfy any legal or regulatory 
requirements that apply to them
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
58/Protocol BN40423 , Version 6A patient will notbe eligible to receive [COMPANY_002] IMP (RO7234292 ) after completing the 
study if anyof the following conditions are met:
The [COMPANY_002] IMP is commercially marketed in the patient's country and is reasonably 
accessible to the patient (e.g., is covered by [CONTACT_102]'s insurance or wouldn't 
otherwise create a financial hardship for the patient)
The Sponsor has discontinued development of the IM P or data suggest that the IMP 
is not effective for HD
The Sponsor has reasonable safety concerns regarding the IMP as treatment for 
HD
Provision of the [COMPANY_002] IMP is not permitted under the laws and regulations of the 
patient's country
The [COMPANY_002] Global Policy on Continued Access to Investigational Medicinal Product is 
available at the following web site:
http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
4.4 CONCOMITA NT THERA PY
Concomitant HD therapy should constitute the optimal sup portive care for the individual 
according to the investigator's own best clinical judgment.   Concomitant therapy consists 
of any medication (e.g., prescription drugs, over -the-counter drugs, vaccines, herbal or 
homeopathic remedies, nutritional supplements ) used by a patient in addition to 
protocol -mandated treatment from screening to the end -of-treatment visit for patients 
who enter OLE Study BN40955 or the safety follow -up visit for patients who do not enroll 
in the OLE study .  Allsuch medications should be reported to the investigator and 
recorded on the Concomitant Medications eCRF.
4.4.1 Permitted Therapy  
Patients are permitted to use the following therapi[INVESTIGATOR_226]:
Contraceptive agents
Supplements (e.g., coenzyme Q10, vit amins, creatine) if the dose has been stable 
for at least 6 weeks prior to screening and the dose is not anticipated to change 
during the study
Antipsychotics only if prescribed for motor symptoms or for mood stabilization (i.e., 
irritability or aggressive ness) and/or tetrabenazine/deutetrabenazine/valbenazine if 
the dose has been stable for at least 12 weeks prior to screening and the dose is 
not anticipated to change between screening and the start of study treatment 
If clinically indicated, dose changes or medication stoppi[INVESTIGATOR_803862].
Antidepressant or benzodiazepi[INVESTIGATOR_803863] 12 weeks 
prior to s creening and the dose is not anticipated to change betwe en screening and 
the start of study treatment 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
59/Protocol BN40423 , Version 6If clinically indicated, dose changes or medication stoppi[INVESTIGATOR_803862].
Anti-epi[INVESTIGATOR_803864], pain, restless legs, or insomnia
Aspi[INVESTIGATOR_110247] 81 mg/day
Local anesthesia for the lumbar puncture procedure , depending on institutional 
guidelines   
Sedation may not be used for lumbar puncture.
4.4.2 Prohibited Therapy
Use of the following concomitant therapi[INVESTIGATOR_204721]:
Experimental agents or marketed HD agents at experimental doses that are being 
tested for the treatment of HD, including, but not limited to, cholinesterase inhibitors, 
memantine, amantadine, and riluzole  
Antiplatelet or anti coagulant therapy , including, but not limited to, aspi[INVESTIGATOR_248] (unless 
81mg/day), clopid ogrel, dipyridamole, warfarin, dabigatran, rivaroxaban, and 
api[INVESTIGATOR_3822]
Sedation for lumbar puncture or IT bolus procedures in the study
Depending on institutional guidelines, local anesthes ia is permissible for the 
lumbar puncture procedure
Use of anti -anxiety medication is discouraged during scheduled MRI scans in the 
study. Anti-anxiety medication used to prevent movement disorder to allow 
successful MRI scan is not permitted in this stud y, as movement disorder too severe 
to scan under drug -free conditions is an overall study exclusionary criterion .
4.5 STUDY ASSESSMENTS 
The schedule of activities to be performed during the study and guidance on the order
these assessments can be performed areprovided in Appendix 1aand Appendix 1b,
and Appendix 5, respectively .  All activities should be performed and documented for 
each patient.   
Patients will be closely monitored for safety and tolerability throughout the study.  
Patients should be a ssessed for toxicity prior to each dose; dosing will occur only if the 
clinical assessment and local laboratory test values are acceptable. Effective 22March 
2021, patients will be discontinued from study treatment but will continue to be 
followed for safety and efficacy outcomes as outlined in Section [IP_ADDRESS], Appendix 1a
and Appendix 1b.
4.5.[ADDRESS_1109620] be obtained before 
performing any study -related procedures (including screening evaluati ons).  Informed 
Consent Forms for patients and study companions will be maintained at the study site , 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
60/Protocol BN40423 , Version 6regardless of whether the patient is subsequently enrolled.   If a patient's capacity to 
consent is in question, the investigator should consult an appropriately qualified 
colleague who will independently assess capacity.  This additional assessment should 
also be documented.  If the patient’s capacity is confirmed , the investigator may proceed 
with signing of the Informed Consent Form.
All screening evaluations must be completed and reviewed to confirm that patients meet 
eligibility criteria before enrollment.  The investigator will maintain a screening log to 
record details of all patients screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
A maximum of one re-screening will be allowed within 8 weeks of the initial screening 
failure for patients who fail the initial scree ning (e.g., as a consequence of abnormal 
laboratory values or general medical status not meeting inclusion or exclusion criteria).  
If re-screening is required, CAG repeat length testing from the initial screening does not 
need to be repeated (historical v alues will not be accepted) . Thescreening MRI and 
viral serology from the initial screening, including f romother [COMPANY_002] RO7234292 studies, 
may be acceptable as part of the re -screening assessments if performed within 12
weeks of the baseline visit.
4.5.2 Medic al History , Concomitant Medication, and Demographic 
Data
Medical history, including clinically significant diseases, surg eries, HD history (including 
past hospi[INVESTIGATOR_602] [i.e., number, duration, and reason] )over the last 2 years , 
reproductive status, sm oking history, and use of alcohol and drugs of abuse will be 
recorded at baseline.  Alcohol and/or drug abuse is defined as a maladaptive pattern of 
use that leads to failure to fulfill major work or social obligations or use in situations 
where it leads t o physical danger or legal problems, and may be the focus of clinical 
attention.  Daily use of any drug (i.e., cannabinoid, opi[INVESTIGATOR_2480], stimulant, hallucinogen, 
designer) or daily alcohol use that meets criteria for either abuse or psychological or 
physiologic al dependence is not permitted and is exclusionary.  Occasional use that 
does not meet the criteria for abuse is permissible in this study.  
In addition, all medications (e.g .,prescription drugs, over -the-counter drugs, vaccines, 
herbal or homeopathic remedies, nutritional supplements) used by [CONTACT_803928] -of-treatment visit for patients who enter OLE Study BN40955 or the 
safety follow -up visit for patients who do not enroll in the OLE study will be recorded.  At 
the time of each study drug administration and telephone safety follow -up calls , an
interval medical history should be obtained and any changes in medications and any 
physician visits for HD or general medical care should be recorded.
Demographic data will include age, sex , self -reported race/ethnicity , and education level 
based on the International Standard Classification of Education scale.   Demographic
data and social status data ( e.g., relationship to patient and employment status) will also 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
61/Protocol BN40423 , Version 6be collected for the study c ompanion. Race/ethnicity is recorded because of the 
potential contribution of this variable to differences in observed pharmacokinetics, 
pharmacodynamics, toxicity, and/or response to treatment. 
A unique HD i dentification number (HDID ) will be collected from patients who already 
have an HDID.  For patients without an HDID, the number will be created via a web 
portal (see Section 8.4).
4.5.3 Physical and Neurologic Examinations
A complete physical examination, performed at screening and other specified visits 
(see Appendix 1), should include an evaluation of the head, eyes, ears, nose, and 
throat, and the cardiovascular, dermatologic, musculoskeletal, respi[INVESTIGATOR_696], 
gastrointestinal, and neurologic systems ;genitourinary examinations may be performed 
if clinically indicated.  The physical examinations s hould be conducted in the same 
manner on each occasion to ensure comparability to previous examinations , including 
weight.  Height will be measured at screening and baseline only.
A neurologic examination , including fundoscopy , performed at screening and a t every
clinical visit, should include assessment of mental status, level of consciousness, cranial 
nerve function, motor function, sensory function, reflexes, gait, and coordination (see
Appendix 9).  Theneurologic examination should be conducted in the same manner on 
each occasion to ensure comparability to previous examinations.  Neurologic 
examinations should be performed before and a fter treatment on each dosing day or 
before the lumbar puncture ,if there is no study treatment administration .  Weight 
should also be measured at each visit .
Any abnormality identified at baseline ( Week 1) should be recorded on the General 
Medical History and Baseline Conditions eCRF.  Changes from baseline abnormalities 
should be recorded in patient notes.  New or worsened clinically significant abnormalities 
(i.e., beyond expected variation ;normal age -related change ;or HD -related clinical 
progression ) should be recorded as adverse events on the Adverse Event eCRF.  
4.5.4 Vital Signs
Vital signs will include measurements of respi[INVESTIGATOR_697], pulse, temperature, and 
systolic and diastolic blood pressure while the patient is in a seated position after resting 
for approximately 5 minutes.  All data should be recorded on the appropriate eCRF.
4.5.5 Collection of Cerebrospi[INVESTIGATOR_17106] (Lumbar Puncture 
Procedure)
Within 72 hours prior to performing each scheduled lumbar puncture, local laboratory 
analysis of coagulation factors (INR and/or PT, aPTT) and platelets must be conducted 
and the results reviewed.  The lumbar puncture should be performed at approximately 
the same time at each visit (ideally in the morning between 8:00 a.m. and 12:00 noon or 
in the early afternoon between 12:00 noon and 3:00 p.m.) to minimize potential diurnal 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
62/Protocol BN40423 , Version 6variation of CSF parameters.  CSF fluid (20 mL) is to be collected for analyses using a 
lumbar puncture collection kit.  If there are difficulties in collecting [ADDRESS_1109621] lumbar puncture syndrome.  
Sedation may not be used.  Depending on institutional guidelines, local anesthesia 
should be used for the procedure.  Spi[INVESTIGATOR_803865], but ultrasound is not required.  Ultrasound 
may be used if attempts at lumbar puncture without imaging are unsuccessful, if it is 
local practice to use ultrasound, or if institutional guidelines dictate use of ultrasound 
with each lumbar puncture.  Fluoroscopy guidance can also be used, if local institutional 
guidelines dictate and local ECs and HA shave approved the use of the technique, but it 
is not required.  W here fluoroscopy is used, patients should also be informed and 
consent obtained .
For details on the lumbar puncture and IT bolus dosing procedure, please refer to the LP 
procedure and CSF collection guidelines and instructional video.   Effective
22March 2021, no further study treatment will be administered.
When applicable, study treatme nt administration will occur via a lumbar puncture using 
a needle inserted into the L3/L4 space, although placement at a different level (either in 
the space above or the space below) is allowed if patient anatomy or clinical judgment 
dictates.  The left lateral position is mandatory in the first instance for the procedure for 
consistency of procedure practice across sites and within patients , unless patient -
specific factors require use of the upright, sitting position or the physician/operator has 
pre-existing experience using LP/intrathecal bolus dosing in the sitting position and 
prefers the use of the upright sitting position, as guided by [CONTACT_102] , his or her 
judgment .  Whichever position is used, once access is established to the IT space, th e 
entire IT bolus procedure should be completed in the same position, to limit the risk of 
the needle losing position while the spi[INVESTIGATOR_803866].   Subsequent LP 
administrations should occur using the same position.
Patients will be discouraged fro m resting supi[INVESTIGATOR_803867] a minimum and, if 
feasible, walking briskly for approximately [ADDRESS_1109622] dose 
neurological examination can occur (if study treatment was administered) .  Patients 
should not perform any activity that is associated with a change in the ambient air 
pressure for at least 24hours post-LP procedure (e.g., air travel, scuba diving, or hot air 
balloons).
Lumbar punctures will be performed as specified in the schedule of activities 
(see Appendix 1), with the last CSF sample obtained at the Week 101 end -of-treatment 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
63/Protocol BN40423 , Version 6visit.  After discontinuation of study treatment, LPs will be performed at the ETT and 
EoT for ETT visits (see Appendix 1aand Appendix 1b).  No study drug will be 
administered at these visit s.
4.5.6 Laboratory , Biomarker, and Other Biological Samples
Samples for the following laboratory tests will be sent to the study site's local laboratory 
for analysis:
Coagulation:  INR and/or PT, aPTT, and platelet count
Urine pregnancy test
Urine pregnancy tests will be performed for women of childbearing potential at 
specified visits.  If aurine pregnancy test is positive, it must be confirmed by a 
serum pregnancy test (analyzed at a central laboratory).
CSF for safety:  cell count (RBCs and WBCs), glucose, and protein
The following samples will be sent to a central laboratory:
Hematology:  WBC count, RBC count, platelet count, hemoglobin, hematocrit, and 
differential count (neutrophils, eosinophils, basophils, monocytes, lymphocytes)
Serum chemistry panel:  bicarbonate or total carbon dioxide (if considered standard 
of care for the region), sodium, potassium, chloride, glucose, BUN or urea, 
creatinine, total protein, albumin, phosphorus, calcium, total and direct bilirubin, 
ALP, ALT, AST, uric acid, gamma -glutamyl trans ferase, and CPK
Thyroid panel:  thyroid -stimulating hormone and free thyroxine (also known as T4) 
levels
Viral serology:  HBsAg and HCV antibody (or viral RNA if HCV antibody assay is 
positive )
Serum pregnancy test
Serum pregnancy tests will be performed f or women of childbearing potential at 
screening.  At subsequent visits, it will be performed to confirm a positive urine 
pregnancy test (if applicable).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
64/Protocol BN40423 , Version 6Urinalysis, including dipstick (pH, specific gravity, glucose, protein, ketones, blood) 
and microscopi c examination for all abnormal dipstick results (sediment, RBCs, 
WBCs, casts, crystals, epi[INVESTIGATOR_1663], bacteria)
CSF and blood (plasma) samples for PK analyses and metabolite identification
Blood (plasma) samples for immunogenicity analyses
Blood sample for determination of CAG repeat length in HTT for patient eligibility 
Blood sample for clinical genotypi[INVESTIGATOR_803868]
CSF samples for analysis of mHTT ,NfL,and tau levels to evaluate the effects of 
RO7234292 compared with placebo (primary and secondary biomarker endpoints) 
Blood, plasma, and CSF samples for exploratory research on biomarkers and 
biomarker assay development
Exploratory biomarker research may include, but will not be limited to, total HTT protein, 
and other proteins related to HD, neuro degeneration, and inflammation.  Research may 
involve extraction of DNA and analysis of mutations, single nucleotide polymorphisms, 
and other genetic variations.  Rese arch will not be aimed at distinguishing germline 
mutations from somatic mutations .  
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.
Unless the patient gives specific consent for his or her leftover samples to be stored for 
optional exploratory research (see Section 4.5.10 ), biological samples will be destroyed 
when the final Clinical Study Report has been completed, with the following exception s:
Blood, plasma, and CSF samples collected for biomarker research and biomarker 
assay development will be destroyed no later than 10years after the final Clinical
Study Report has been completed .
Blood , plasma ,and CSF samples collected for PK or immunogenicity analysis may
be needed for additional immunogenicity characterization and for PK or 
immunogenicity assay development and validation; therefore, these samples will be 
destroyed no later than 5years after the final Clinical Study Report has been 
completed .
When a patient withdraws from the study, samples collected prior to the date of 
withdrawal may still be analyzed, unless the patient specifically requests that the 
samples be destroyed or local laws req uire destruction of the samples.  However, if 
samples have been tested prior to withdrawal, results from those tests will remain as 
part of the overall research data. 
Data arising from sample analysis , including data on mutations, will be subject to the 
confidentiality standards described in Section 8.4.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
65/Protocol BN40423 , Version 6Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by [CONTACT_2371] .  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication.
4.5.[ADDRESS_1109623] 
thecapability to perform a resting -state functional MRI or diffusion -weighted 
MRI. Forthese cases ,the Medical Monitor should be consulted; approval to continue 
without these scans would be required.
The MRI should be performed using a 3- Tesla (3T) magnet.  The acquisition parameters 
of each sequence, structure, and length of each MRI session, as well as image 
processing algorithms, will be outl ined in a separate MRI manual.   MRI scans will be 
managed by a central laboratory to monitor and ensure the integrity and quality of the 
acquired data.  The screening MRI will be evaluated by [CONTACT_803929].  Local neuroradiologists will still be responsible for assessing 
MRI-related ongoing safety monitoring. During central review, the Sponsor and/or site 
staff will be notified of any unexpected findings requir ingclinical follow -up.  
MRI should take place as earl y as possible within the screening window but may take 
place at any time during screening.  The MRI safety and efficacy screening scan will 
need to pass the central laboratory image QC and the results must be available before 
the patient can be enrolled in the study.   
After patient enrollment at specified timepoints, the MRI must be scheduled to occur 
before the lumbar puncture (see Appendix 1).  The MRI scan should be performed 
714days prior to the lumbar puncture to allow time for re -scanning if the quality of the 
initial MRI is inadequate. If the re -scan cannot be performed prior to the lumbar 
puncture, then it can b e conducted the day after the lumbar puncture , as long as there 
are no post-lumbar puncture contraindication sand it occurs within 2 weeks of the 
original scan.
4.5.8 Electrocardiograms
Triplicate ECG recording will be obtained at specified timepoints , within approximately 
5minutes of each other , as outlined in the schedule of activities (see Appendix 1), and 
may be obtained at unscheduled timepoints as clinically indicated.   For patients in 
Japan, additional triplicate ECG monitoring will be performed at 2 (± 30 minutes), 
4(±30minutes), and 6 (± 30 minutes) hours following the first administration of study 
drug (Day 1).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
66/Protocol BN40423 , Version 6The ECG recordings must be perfor med using a standard high -quality, high -fidelity 
digital electrocardiograph machine equipped with computer -based interval 
measurements.  Lead placement should be as consistent as possible.  ECG recording 
must be performed after the patient has been resting in a supi[INVESTIGATOR_21683] 
10minutes.  All ECGs are to be obtained prior to other invasive procedures scheduled at 
that same time (e.g., blood draws) and should not be obtained within 30 minutes after 
any meal.  Circumstances that may induce chang es in heart rate, including 
environmental distractions (e.g., television, radio, conversation) should be avoided 
during the pre -ECG resting period and during ECG recording. All data should be 
recorded on the appropriate eCRF.
The ECG recordings may be electronically transferred to a central vendor.  The
investigator must review, sign, and date all ECG tracings.  Paper copi[INVESTIGATOR_626856]'s permanent study file at the site.  
4.5.9 Patient -Reported, Clinician -Reported, Study
Observer -Reported, and Performance Outcomes
Patient -reported outcome (PRO) , clinician -reported outcome ( ClinRO ), 
observer -reported outcome (ObsRO), and performance outcome (PerfO) data will be
collected in the clinic to document the change from baseline over time.  To enable valid 
acquisition of all study companion related assessments, including the study companion 
input to the T FC s cale, study companions are required to attend in person all study visits
when the TFC rating occurs .  Additionally, PRO, Obs RO, and PerfO data will be 
collected remotely.  The instruments, translated into the local language as appropriate,
will be completed in their entirety at specified timepoints during the study.  To ensure 
instrument validity and that data standards meet health authority requirements, 
instruments will be self -administered or administered by a trained rater (as appropriate) .  
In-clinic data should be collected prior to the performance of the lumbar puncture 
procedure .
Patients , clinicians, and study companions will use an electronic device to capture 
outcome data during clinic visits , and scoring of ClinRO and PerfO measures will be 
supervised during acquisition and entry into a tablet to ensure instructions are given and 
appropriately followed.  Pape r must not be used to capture clinical outcome data, unless 
it is for performance outcome measures (e.g., SWR, SDMT ,and MoCA). Performance
measure outcomes must be completed in ink and not pencil.
Patients will use a smartphone andwrist-worn wea rable to capture outcome data 
remotely and at specified visits (see Section [IP_ADDRESS] ).  Study companions will use an 
electronic device to capture data remotel y and at specified visits.  The electronic device s
and/or instructions for completing the questionnaires electronically will be provided to 
patients and study companions by [CONTACT_6624].  Study companion device data will be 
transmitted to a centralized datab ase maintained by [CONTACT_40893].  The 
patient device data will be transmitted to a centralized database maintained by [CONTACT_445428]7234292 F.Hoffmann -La [COMPANY_002] Ltd
67/Protocol BN40423 , Version 6Sponsor.  The data will be available for access by [CONTACT_108897].  If the 
device is lost, a replacement w ill be sent.  All devices are encrypted and password 
protected.  See Appendix 1for the schedule of activities, and Appendix 2and
Appendix 3for a summary of timing and duration of each PRO, ClinRO, ObsRO, and 
PerfO assessment. Appendix 4shows the order and approximate timing of 
assessments at each clinic visit , while Appendix 5provides guidelines for the order of 
assessments .  Appendix 10through Appendix 14show relevant information for patients 
who enrolled in Study BN40423 before implementation of Protocol Version 4.
[IP_ADDRESS] Composite Unified Huntington's Disease Rating Scale
The cUHDRS i s a composite motor, cognitive, and global functional clinical outcome 
measure in patients with HD comprised of an equally weighted sum of Z scores of the 
TFC, the TMS, the SDMT, and the S WR scores from the UHDRS (Huntington Study 
Group 1996). It is a mul tidomain measure of clinical decline that tracks underlying 
progressive brain changes and is related to changes in daily functional ability 
(Schobel et al. 2017).  
The formula for cUHDRS scoring was originally developed for use in HD Stages 1 and 2 
(TFC 7 13) but has since been updated to encompass early HD Stage 3. This led to an 
update to the reference population (using ENROLL -HD data) from TFC 713to 
TFC513 (in both cases, a lower age cutoff of 20 years was used to limit the number of 
individuals included with juvenile -onset HD). The cUHDRS is scored using the following 
formula: 
       =     −8.8
2.8 −    −34.4
17.4 +     −25.2
12.4 +     −58
21.2 [PHONE_13048].9.2 Total Functional Capacity  Scale 
The TFC is a validated measure of global patient function in HD.   The TFC represents 
the investigator's assessment of the patient's capacity to perform a range of activities of 
basic daily living, including working, chores, managing finances, eating, dres sing, and 
bathing.  The 5 -item assessment is based on a brief interview with the patient and the 
study companion.  The TFC score ranges from 0 to 13, with a higher score representing 
better functioning.  A 1-point change in TFC score is a clinically meanin gful change in 
patient function (e.g., a 1 -point decline may indicate the loss of ability to work in a normal 
capacity) (Huntington Study Group 1996).  The TFC takes approximately 10 minutes to 
administer and will be completed at clinic visits.  Information for the TFC will be acquired 
from both the patient and companion , and input of the companion to the rating will be 
recorded electronically .  
[IP_ADDRESS] Total Motor Score
The TMS is a holistic measure of motor function in HD that is linked to both functional 
capaci ty based on the TFC score, independence, and driving status 
(Beglinger etal.2012; Schobel et al. 2017).  
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
68/Protocol BN40423 , Version 6The TMS score is the sum of the individual motor ratings obtained from administration of 
the 31 -item motor assessment portion of the UHDRS by [CONTACT_093].  The score 
ranges from 0 to 124, with a higher score representing more severe impairment.  The 
TMS takes approximately 15 minutes to administer and will be completed at clinic visits.
[IP_ADDRESS] Symbol Digit Modalities Test
The SDMT is used to assess attention, visuoperceptual processing, working memory, 
and psychomotor speed.  It has been shown to have strong reliability and validity 
(Smith 1982 ).  The patient pairs abstract symbols with specific numbers according to a 
translation key.  The test measures the number of items correctly paired (maximum 
of110 correct pairs) in 90 seconds.  The SDMT will be administered at clinic visits and 
can be completed in less than 5 minutes.  It will also be administered at specified 
timepoints indicated in Appendix 7on the [COMPANY_002] HD mobile app (via electronic SDMT).
[IP_ADDRESS] Stroop Word Reading Test 
The S WR Test is a measure of attention, processing, and psychomot or speed and 
depends upon quick verbal motor output.  Patients are presented with a page of color 
names (i.e., "BLUE," "RED," or "GREEN") printed in black ink and are asked to read 
aloud as many words as possible within a given amount of time (in 45 second s).  The 
number of words read correctly is counted, with a higher score indicating better cognitive 
performance.  It will also be administered at specified timepoints indicated in Appendix 7
on the [COMPANY_002] HD mobile app (via electronic S WR).    
[IP_ADDRESS] UHDRS Functional Assessment
The UHDRS Functional Assessment is a checklist of 25 common daily tasks.  The 
investigator indicates if the patient can perform the task by [CONTACT_91959] a score of 1 to all "yes" 
replies.  The checklist is then summed, and scores can range from 0 (inability to do any 
task) to 25 (ability to do all tasks on the checklist).  The UHDRS FA can be completed in 
15minutes.  
[IP_ADDRESS] Independence S cale
A patient's IS score is a measure of disease progression in functional disability and will 
be completed to evaluate a patient's degree of independence at screening and at 
specified timepoints.  It is a subscale of the UHDRS. The scale consists of 19 discr ete 
levels ranging from 10 to 100 (by 5), in which a score of 100 indicates no special care is 
needed and a score of 10 indicates the patients is fed by [CONTACT_803930]. 
[IP_ADDRESS] HD Daily  Activities Scale
The HD -DAS assesses patients' daily functi on.  Following a semi -structured interview 
with the patient and study companion, the patient's ability level to perform daily tasks 
such as eating or using a telephone will be recorded.  Each item is scored on a [ADDRESS_1109624].
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
69/Protocol BN40423 , Version [IP_ADDRESS] Clinical Global Impression Severity  and Change Scales
The CGI -S is a single- item measure of current global severity and is completed by [CONTACT_626929].  The CGI -S is assessed using an 11 -point numeric 
rating scale (NRS), where higher scores indicate greater severity.  The CGI -S can be 
completed in approximately 2 minutes.
The CGI -C is a single- item measure of change in global status (since starting the study) 
and is completed by [CONTACT_803931].  The CGI -C has seven 
response options:  "very much worse," "much worse," "minimally worse," "no change," 
"minimally improved," "much improved," and "very much improved."  The CGI -C can be 
completed in approximately 2 m inutes.  To assess the relevance of this change, a 
follow -up question with dichotomous response options ("yes" or "no") asks if the change 
has had a meaningful impact on the patient’s well -being.
[IP_ADDRESS] Patient Global Impression Severity  and Change Scales
The PG I-S is a single
-item measure of current global severity and is completed by [CONTACT_803932].  The PGI -S can be completed in approximately 
2minutes.  The PGI -S is assessed using an 11- point NRS, where higher scores indicate 
greater s
everity.  
The PGI -C is a single- item measure of change in global status (since starting the study) 
and is completed by [CONTACT_803933] -baseline visits.  The PGI -C has seven 
response options:  "very much worse," "much worse," "minimally worse ," "no change," 
"minimally improved," "much improved," and "very much improved." To assess the 
relevance of this change, a follow -up question with dichotomous response options ("yes" 
or "no") asks if the change has had a meaningful impact on the patient's well-being.  The 
PGI-C can be completed in approximately 2minutes.
[IP_ADDRESS] Companion -Reported Global Impression Severity and Change 
Scales
The Companion -Reported Global Impression Severity ( CrGI -S) is a single -item measure 
of current global severity and is compl eted by [CONTACT_283769] (about the patient) at 
specified clinic visits.  The CrGI -Scan be completed in approximately 2minutes.  The 
CrGI -S is assessed using an 11 -point NRS, where higher scores indicate greater 
severity.  
The Companion -Reported Global Imp ression Change ( CrGI -C) is a single- item measure 
of change in global status (since starting the study) and is completed by [CONTACT_283769] 
(about the patient) at specified post -baseline visits.  The CrGI -C has seven response 
options:  "very much worse," "muc h worse," "minimally worse," "no change," "minimally 
improved," "much improved," and "very much improved." To assess the relevance of this 
change, a follow -up question with dichotomous response options ("yes" or "no") asks if 
the change has had a meaningfu
l impact on the patient's well -being.  The CrGI -C can be 
completed in approximately 2minutes.  
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
70/Protocol BN40423 , Version [IP_ADDRESS] Montreal Cognitive Assessment
The MoCA is a patient -completed assessment used to detect cognitive impairment.  It 
contains a series of basic assessments, inclu ding attention and visuospatial tasks.  The 
total score ranges from 0 30, where lower scores indicate greater impairment.  It will be 
used in this study to characterize patients at screening and longitudinally to assess 
cognitive status at regular intervals throughout the study.  It takes approximately 
10minutes to administer.
[IP_ADDRESS] Work Productivity and A ctivity Impairment
The W PAI contains [ADDRESS_1109625] of disease on employment status 
(yes/no), hours missed due to disease, hours missed d ue to other reasons, hours 
worked, and impact on productivity and on daily activities (both using an 11- point NRS, 
where higher scores indicate greater impact).  The W PAI takes approximately 5 minutes 
to complete.  The WPAI will be completed by [CONTACT_102] (about him/herself) and by [CONTACT_803934] (about him/herself).  It will be completed at specified timepoints 
remotely by [CONTACT_803935].
[IP_ADDRESS] Apathy Evaluation Scale 
The AES is an 18-item assessment of apathy, including overt behavior, cognitive 
aspects of motivation, and emotional responsivity.  Each item is scored on a 4 -point 
Likert scale, from 1 ("Not at all") to 4 ("A lot").  A total score is created by [CONTACT_10621] 
18 items (scores range from 18 to 72; 3 items are reverse scored), with higher scores 
indicating greater apathy.  The AES takes approximately 10 minutes to complete and will 
be completed by [CONTACT_803936].
[IP_ADDRESS] Neuro -Qol Cogniti on Function Short Form, Version 2
The Neuro -Qol Cognition Function Short Form contains 8 items (including "trouble 
concentrating" and difficulty "learning new tasks or instructions"), each assessed using a 
5-point Likert scale, where lower scores indicate greater difficulty (4 items) or greater 
frequency (4 items).  The raw sum score is converted to a T -score distribution 
(mean 50, standard deviation 10).  The Neuro -Qol Cognition Function Short Form 
takes approximately 5 minutes to complete and will be completed by [CONTACT_803937].
[IP_ADDRESS] HDSpeaking Difficulty Item
The HD -SDI includes a single question assessing difficulty speaking over the past 
7days.  It is assessed using a 5 -point Likert scale, where higher scores indicate a 
greater frequency of difficulty.  The HD -SDI can be completed in less than 1 minute and 
will be completed at specified timepoints remotely by [CONTACT_803938].
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
71/Protocol BN40423 , Version [IP_ADDRESS] Symptoms of Major Depressive Disorder Scale 
The SMDDS is a newly developed, valid, and reliable self -report assessment of 
depression ( McCarrier et al. 2016 ).  It contains 16 items, measuring concepts such as 
sadness, irritability, worry, and sleep disturbance.  Each item is assessed on a 5 -point 
Likert scale, from "Not at all" to "Extr emely" (9 items) and from "Never" to "Always" 
(7items).  Item scores from 15 of the items (the least severe of the two eating items is 
not included) are summed to create a 0 60 score, where higher scores indicate more 
severe depressive symptomatology.  The SMDDS takes approximately 10 minutes to 
complete and will be completed by [CONTACT_803939].
The patient should be referred for immediate psychiatric evaluation in any event of 
suspected active suicidal intent, significant suicidal behavior, or clinical finding 
suggesting that the patient is dangerous to himself or herself.
[IP_ADDRESS] HD Companion -Reported Irritability  and Angry Outbursts Scale 
The HD -CIAOS is a study companion -reported assessment of the patient's irritability and 
angry outbur sts over the past 7 days and will be completed at specified timepoints 
remotely by [CONTACT_803940] .  It consists of three items: frequency 
of irritable behavior (6 -point Likert scale: "Not at all" to "Always"), frequency of angry 
outbursts (number of occurrences), and severity of the worst outburst (4 -point Likert 
scale "Mild" to "Very severe").  The HD -CIAOS takes about 2 minutes to complete.
[IP_ADDRESS] EuroQol 5 -Dimension , 5-Level Questionnaire
The EQ-5D-5L is a validated self -report health status questionnaire used to calculate a 
health status utility score for use in health economic analyses ( EuroQol Group 1990 ; 
Brooks 1996 ; Herdman et al. 2011 ; Janssen et al. 2013 ).  There are two components to 
the EQ -5D-5L:  a 5-item health state profi le that assesses mobility, self -care, usual 
activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures 
health state.  Published weighting systems allow for creation of a single composite score 
of the patient's health sta tus (Index score) from the 5-item scores (i.e., does not include 
the VAS).  The EQ -5D-5L takes approximately 5minutes to complete.  The Index score 
will be used in this study for informing pharmacoeconomic evaluations. The VAS score 
will be used to asses s health -related quality of life ( HRQoL) . The EQ -5D-5L will be 
completed both by [CONTACT_102] (about him/her self) and by [CONTACT_601370] (about 
him/herself )at baseline and at specified post -baseline clinic visits on anelectronic 
device.  In addition, it will be completed remotely at specified timepoints by [CONTACT_803941] .
[IP_ADDRESS] Health Utilities Index Mark 2 and Mark 3
The HUIis a multi -attribute system of health status (Feeny et al. 1995).  The HUI2 and 
HUI3 questionnaire (commonly referred to as HUI2/3) contains 15 items with Likert -type 
response options.  From these items, two scores can be produced:  HUI2 (7 items) and 
HUI3 (8 items).  Both scores are health utility indexes, where 0 death, and 1 perfect 
health.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
72/Protocol BN40423 , Version 6The HUI2/3 will be completed by [CONTACT_283769], both about him/herself and as a proxy 
report of the patient’s HRQoL.  The HUI2/3 will be completed at specified ti mepoints at 
clinic visits and remotely on an electronic device.
[IP_ADDRESS] Columbia- Suicide Severity Rating Scale
The C -SSRS is a structured tool to assess suicidal ideation and behavior.  
Four constructs are measured:  severity of ideation, intensity of ideation, be havior, and 
lethality of actual suicide attempts.  Binary (yes/no) data are collected for 10 categories, 
and composite endpoints based on the categories are followed over time to monitor 
patient safety ( Posner et al. 2011).  It maps to the Columbia -Classif ication Algorithm for 
Suicide Assessment and meets the criteria listed in the U.S. FDA draft guidance for 
assessment of suicidality in clinical trials ( FDA 2012 ).  The C -SSRS will be used to 
assess eligibility for the study (full version at baseline, requi ring approximately 20 
minutes to administer) and to monitor the patients throughout the study at clinic visits 
(follow -up version, requiring approximately 5 minutes to administer, assuming absence 
of suicidal ideation and no change in clinical status from previous administration).
The patient should be referred for immediate psychiatric evaluation in any event of 
suspected active suicidal intent, significant suicidal behavior, or clinical finding 
suggesting that the patient is dangerous to himself or hersel f.
[IP_ADDRESS] Optional Exit Interviews
Optional exit interviews will be conducted witha subset of patients (up to 60patients ) at 
select sites within approximately 1 week after the end -of-treatment visit.  The 
semi -structured interviews will be conducted by [CONTACT_803942]- clinic videotaped session.   The
interviews will enable patients to provide details about changes they observe in their
symptoms, as well as any impacts on daily life.
Interviews will be transcribed verbatim ,and themes emerging from these transcripts will 
be interpreted in relation to changes in patients' clinical outcome assessment scores . All 
participants in this optional study interview will be asked which arm they thought the y 
were assigned to (120 mg Q8W, 120 mg Q16W, or placebo).  Of note, patients andstaff
will remain blind to patient treatment assignment during the study . Following 
theSponsor ’sdecision to permanently discontinue study treatment, the Sponsor will 
become unblinded to treatment assignment, as outlined in Section 4.2.
Additional consent for this optional portion of the study will be included in the relevant 
Informed Consent Form.
[IP_ADDRESS] [COMPANY_002] HD Mobile A pplication:  Remote Testing (Smartphone 
and Wrist -Worn Wear able)
Smartphones and wrist -worn wearables have high -quality sensors that enable the 
remote, non -invasive, frequent ,and preci se measurement of motor and non -motor 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
73/Protocol BN40423 , Version 6symptoms (Maetzler et al. 2013; Andrzejewski et al. 2016; Adams et al. 2017; Lipsmeier 
et al. 2018) .  Each patient will receive a preconfigured smartphone and wrist -worn 
wearable with installed software for the [COMPANY_002] HD mobile app assessments.  The 
devices and software will monitor motor symptoms, non -motor symptoms, and activities 
associated wit h routine daily living throughout the course of the study.  Additional details 
are available in the [COMPANY_002] HD mobile app (Smartphone) manual.
Patients will be provided with devices and trained on their use during screening.  
Patients will also have in -clinic assessments of the digital platform that are supervised as 
indicated in Appendix 7.  Outside of the clinic, patients will be instructed to conduct an 
"active test" every day at approximately the same time (ideally in the morning, after 
breakfast).  The active test consists of a short, preconfigured schedule of tasks that 
assess motor symptoms (upper and lower body movements, upper limb d exterity, voice) 
and non- motor symptoms (processing speed, voice).  Testing will usually last 
approximately 5 minutes in total on a typi[INVESTIGATOR_626857].  Not all tests are daily.  
Additional information on the tasks and schedule is specified in Appendix 7.  
For "passive monitoring," patients will be instructed to carry the smartphone in a manner 
convenient to them (e.g., in a pocket or in a Sponsor -provided pouch) and wear the 
wrist-worn wearable throughout the day as they go about their daily routines.  
Companions will receive their own independent electronic device at screening, which is 
different from the patient smartphone.  
Patients will be encouraged to adhere to the daily schedule of tasks as much as 
possible; however, patients will not be excluded from the study for poor adherence, nor 
will missing a daily test be considered a protocol deviation. 
Device sensor data will be recorded continuously, throughout the active tests and 
passive monitoring.  Sound will only be recorded during selected active test tasks.  Data 
will be encrypted and uploaded to secure servers when the smartphone is connected 
toWi-Fi.  Patients will be asked to charge the d evices overnight.  If patients have a W i-Fi 
network at home, they will be encouraged to connect their smartphone to enable data 
transfer.  If no W i-Fi network is available, the sensor data will be transferred during clinic 
visits or after the devices have been returned.
[COMPANY_002] HD mobile app "baseline" data will consist of all data collected prior to and 
including the baseline visit (up to 28 days).  Baseline data will be collected for at least 
the 7 days up to and including Day 1. 
[IP_ADDRESS] [COMPANY_002] HD Mobile Application:  In -Clinic Assessments
Patients will be instructed to bring the smartphone and wearable to every clinic visit to 
check adherence and technical status of the devices.  At specified clinic visits, patients 
will be asked to conduct the "active test" tasks under the supervision of trained site staff , 
as shown in Appendix 7.  
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
74/Protocol BN40423 , Version 6The smartphone and wearable must be returned to the c linic in cases where the patient 
does not meet eligibility criteria, at the end of the study, or upon early termination from 
the study.  At the time of study completion or early termination, patients will be asked to 
complete a pen -and-paper satisfaction s urvey about their experience using the 
smartphone and wrist -worn wearable.
4.5.10 Optional Samples for Research Biosample Repository
[IP_ADDRESS] Overview  of the Research Biosample Repository
The Research Biosample Repository (RBR) is a centrally administered group of facilit ies 
used for the long- term storage of human biological specimens, including body fluids, 
solid tissues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides).  The 
collection, storage, and analysis of RBR samples will facilitate the rational design of new 
pharmaceutical agents and the development of diagnostic tests, which may allow for 
individualized drug therapy for patients in the future.
Samples for the RBR will be collected from patients who give specific consent to 
participate in this optional research.  RBR samples will be used to achieve the following 
objectives:
To study the association of biomarkers with efficacy or disease progression
To identify safety biomarkers that are associated with susceptibility to developi[INVESTIGATOR_803869] l ead to improved adverse event monitoring or investigation
To increase knowledge and understanding of disease biology and drug safety
To study drug response, including drug effects and the processes of drug absorption 
and disposition
To develop biomarker or diagnostic assays and establish the performance 
characteristics of these assays
[IP_ADDRESS] Approval by [CONTACT_204815], storage, and analysis of RBR samples is contingent upon the review and 
approval of the exploratory research and the RBR portion of the Informed Consent Form 
by [CONTACT_25733]'s IRB/EC and, if applicable, an appropriate regulatory body.  If a site has not 
been granted approval for RBR sampling, this section of the protocol (Section 4.5.10 )
will not be applicable at that site.
[IP_ADDRESS] Sample Collection
The following samples will be stored in the RBR and used for research purposes, 
including, but not limited to, re search on biomarkers related to RO7234292, the HTT 
protein, HD or other diseases , or drug safety:
Blood and serum samples collected at baseline and at W eeks 37, 69, and 101
Leftover blood, plasma, and CSF samples and any derivatives thereof 
(e.g.,proteins, peptides )
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
75/Protocol BN40423 , Version 6The above samples may be sent to one or more laboratories for analysis of germline or 
somatic mutations via whole genome sequencing (WGS), whole exome sequencing 
(WES), or other genomic analysis methods.  Genomics is in creasingly infor ming 
researcher s'understanding of disease pathobiology.  W GS and W ES provide a 
comprehensive characterization of the genome and exome, respectively, and, along with 
clinical data collected in this study, may increase the opportunity for developi[INVESTIGATOR_397988] a drug or develop adverse events.
Data generated from RBR samples will be analyzed in the context of this study but will 
also b e explored in aggregate with data from other studies.  The availability of a larger 
dataset will assist in identification and characterization of important biomarkers and 
pathways to support future drug development.
For sampling procedures, storage conditi ons, and shipment instructions, see the 
laboratory manual.  
RBR samples are to be stored until they are no longer needed or until they are 
exhausted.  However, the RBR storage period will be in accordance with the 
IRB/EC -approved Informed Consent Form and applicable laws (e.g., health authority 
requirements).
[IP_ADDRESS] Confidentiality
RBR samples and associated data will be labeled with a unique patient identification 
number.
Patient medical information associated with RBR samples is confidential and may be 
disclosed to third parties only as permitted by [CONTACT_25734] (or separate 
authorization for use and disclosure of personal health information) signed by [CONTACT_4677], unless permitted or required by [CONTACT_2371].
Given the complexity and exploratory nat ure of the analyses of RBR samples, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by [CONTACT_2371].  The aggregate results of any conducted research will 
be available in accordance with the effecti ve Sponsor policy on study data publication.
Data generated from RBR samples must be available for inspection upon request by 
[CONTACT_25735], and Sponsor monitors, 
representatives, and collaborators, as appropriate .
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of the RBR data will become and remain the exclusive and unburdened property 
of the Sponsor, except where agreed otherwise.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
76/Protocol BN40423 , Version [IP_ADDRESS] Consent to Participate in the Researc h Biosample Repository
The Informed Consent Form will contain a separate section that addresses participation 
in the RBR.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential hazards of participation in the RBR.  Patients will be 
told that they are free to refuse to participate and may withdraw their consent at any time 
and for any reason during the storage period.  A separate, specific signature [CONTACT_20030] a patient's agreement to pr ovide optional RBR samples.  Patients 
who decline to participate will not provide a separate signature.
The investigator should document whether or not the patient has given consent to 
participate and (if applicable) the date(s) of consent, by [CONTACT_12550] t he RBR Research 
Sample Informed Consent eCRF.
In the event of an RBR participant's death or loss of competence, the participant's 
samples and data will continue to be used as part of the RBR research.
[IP_ADDRESS] Withdrawal from the Research Biosample Repository
Patients who give consent to provide RBR samples have the right to withdraw their 
consent at any time for any reason.  After withdrawal of consent, any remaining samples 
will be destroyed or will no longer be linked to the patient.  However, if RBR samples 
have been tested prior to withdrawal of consent, results from those tests will remain as 
part of the overall research data.  If a patient wishes to withdraw consent to the testing of 
his or her RBR samples during the study , the investigator must inform the Med ical 
Monitor in writing of the patient's wishes through use of the appropriate RBR Subject 
Withdrawal Form and must enter the date of withdrawal on the RBR Research Sample 
Withdrawal of Informed Consent eCRF.  
Ifa patient wishes to withdraw consent to th e testing of his or her RBR samples after 
closure of the site, the investigator must inform the Sponsor by [CONTACT_70146]:
global_rcr -[EMAIL_1377]
A patient's withdrawal from this study does not, by [CONTACT_5071], constitute withdrawal of consent 
for testing of RBR samples.  Likewise, a patient's withdrawal of consent for testing of 
RBR samples does not constitute withdrawal from this study.
[IP_ADDRESS] Monitoring and Oversight
RBR samples will be tracked in a manner consistent with Good Clinical Practice by a 
quality -controlled, auditable, and appropriately validated laboratory information 
management system, to ensure compliance with data confidentiality as well as 
adherence to authorized use of samples as specified in this protocol and in the Informed 
Consent Form.  Sponsor monitors and auditors will have direct access to appropriate 
parts of records relating to patient participation in the RBR for the purposes of verifying 
the data provided to the Sponsor.  The site will permit monitoring, audits, IRB/EC review, 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
77/Protocol BN40423 , Version 6and health authority inspections by [CONTACT_123544].
4.6 TREA TMENT, PA TIENT, STUDY, AND SITE DISC ONTINUA TION
Due to the Sponsor’s decision to discontinue the [ADDRESS_1109626] this with a 120- mg Q16 W dosing regimen in Protocol Version 4, all patients who 
enrolled prior to implementation of Protocol Version 4 will be prematurely discontinued 
from the study by [CONTACT_803943] -of-treatment visit prior to entry 
into Study BN40955. 
Effective 22 March 2021, all patients will be discontinued from study treatment.
Patients who discontinue study treatment and do not withdraw con sent for continued 
participation in the study will follow the existing ETT schedule of a ssessments, 
outlined in Appendix 1aand Appendix 1b.  Patients who do not consent to version 6 of 
the protocol should be discontinued from the study.
An excessive rate of withdrawals (either study treatment discontinuation or withdrawal 
from the study) can render the study results non -interpretable.  Therefore, all efforts 
should be taken to motivate patients to comply with all study -specific procedures and to 
be followed until the end of the [ADDRESS_1109627] the patient 
in the patient's medical records and source documents.
4.6.[ADDRESS_1109628] permanently discontinue study treatment if they experience any of the 
following:
Any medical condition that the investigator or Sponsor determines may jeopardize 
the patient's safety if he or she continues to receive study treatment
Investigator or Sponsor determination that treatment discontinuation is in the best 
interest of the patient
Pregnancy
Loss of capacity to consent, if legal guardian consent is not possible
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF.  Patients who discontinue study treatment prematurely will not be
replaced.
All patients who dis continue study treatment prematurely but do not withdraw consent for 
continued participation in the study will return to the clinic for study visits at W eeks 53 
and 69 (if not already completed) for collection of clinical outcome data for the primary 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
78/Protocol BN40423 , Version 6and secondary endpoints (see Sections 2.1.1 , 2.1.2 , 2.2,and Appendix 1b).  If the early 
treatment termination visit falls within 30 days of either scheduled visits at Week 53 or 
Week 69, then only early treatment termination will be considered.  Patients will also 
attend the scheduled end -of-treatment (EoTfor E TT) visit at Week 101. Further 
clarification on the ETT schedule is pro vided in Section [IP_ADDRESS] and Appendix 1b.
4.6.[ADDRESS_1109629] the right to voluntarily withdraw from the study at any time for any reason.  
In addition, the investigator has the right to withdraw a pati ent from the study at any time.  
Reasons for withdrawal from the study may include, but are not limited to, the following:
Patient withdrawal of consent
Study termination or site closure
Every effort should be made to obtain information on patients who wi thdraw from the 
study but have not withdrawn consent.  The primary reason for withdrawal from the 
study should be documented on the appropriate eCRF.  If a patient requests to be 
withdrawn from the study, this request must be documented in the source docum ents 
and signed by [CONTACT_093].  Patients who withdraw from the study will not be
replaced.
4.6.3 Study Discontinuation
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following:
The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to patients
Patient enrollment is unsatisfactory
The Sponsor will notify the investigator if the Sponsor decides to discontinue the study .  
4.6.4 Site Discontinuation
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following:
Excessively slow recruitment
Poor protocol adherence
Inaccurate or incomplete data recording
Non-compliance with the International Council for Harmonisation (ICH) guideline for 
Good Clinical Practice
No study activity (i.e., all patients have completed the study and all obligations have 
been fulfilled)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
79/Protocol BN40423 , Version 65. ASSESSMENT OF SA FETY
5.1 SAFETY PLA N
RO7234292 is not approved and clinical development is ongoing.  The safety plan for 
patients in this study is based on clinical experience with RO7234292 in completed and 
ongoing studies.  The known safety risks for the lumbar puncture procedure and 
RO7234292 are ou tlined below in Sections 5.1.1 and 5.1.2 , respectively .  Please refer to 
the RO7234292 Investigator's Brochure for a complete summary of safety information.
Several measures will be taken to ensure the safety of patients participating in this 
study , including the eligibility criteria .  Patients wil l undergo safety monitoring during the 
study, including assessment of the incidence and severity of adverse events .  Guidelines 
for managing adverse events, including criteria for treatment interruption or 
discontinuation, are provided below .
5.1.[ADDRESS_1109630]lumbar puncture syndrome, spi[INVESTIGATOR_626858], and meningitis (see 
Sections [IP_ADDRESS] through [IP_ADDRESS] ) are potential risks associated with lumbar puncture. 
In the completed Phase I/IIa study, the most commonly reported adverse event s across 
all treatment groups (RO7234292, n 34; placebo, n 12) were procedural pain (54% of 
patients ) and post lumbar puncture syndrome (37% of patients ).
In the recently completed Phase II OLE study BN40697, potential LP procedure -
associated selected AEs were reported with similar incidence across the cohorts despi[INVESTIGATOR_626859] (16 patients [69.6%] in the Q4W cohort and 
17patients [73.9%] in the Q8W cohort).  Overall, the most frequently reported event 
was procedural pain (41.3%).  In the ongoing Phase III study BN40423, patients 
enrolled under Protocol Versions 1 3 (receiving Q4W blinded treatment) were 
discontinued following discontinuation of the Q4W dosing.  These patients ’ treatment 
assignments are now unblinded and hereby [CONTACT_626934] (ODC).  
In the ODC, potential LP procedure associated selected AEs were reported with similar 
incidence across the three cohorts (17 patients [47.2%] in the placebo cohort, 
14patients [40%] in the Q4W cohorts, and 17 patients [47.2%] in the Q8W cohort).  
Overall, the events reported with highest incidence were procedural pain and post -LP 
syndrome (14% each).
As of [ADDRESS_1109631] 2020, in the ongoing Study BN40955, potential LP procedure 
associated selected AEs were reported in 30 pa tients [22.9%] in the Q8W cohort and 
11patients [15.1%] in the Q16W cohort.  Overall the most frequently reported event 
was procedural pain (9.2% in the Q8W cohort and 4.1% in the Q16W cohort).
Many of the complications associated with lumbar puncture canbe avoided by [CONTACT_803944] a 24G atraumatic needle with a stylet, adherence to procedural 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
80/Protocol BN40423 , Version 6guidelines (see lumbar puncture manual and instructional video), and careful 
assessment of th e patient, including neurologic examination with fundoscopy both prior 
to and post lumbar puncture procedure.  Lumbar puncture should be avoided when a 
contraindication is present.
CSF leakage is more likely with larger bore needles.  To minimize this risk,a 
24G atraumatic needle will be used.  Training for use of the 24G atraumatic needle in 
this study will be provided prior to initiation of lumbar puncture, as will a review of 
extension tubing use and the need to gently aspi[INVESTIGATOR_626861].  If 
headache with characteristics of low -pressure syndrome is present after the procedure
and persists despi[INVESTIGATOR_31740] -of-care treatment , a blood patch should be considered .  
Formation of a subarachnoid epi[INVESTIGATOR_626863] (i.e. ,when a skin plug is introduced into the 
arachnoid space )can be avoided by [CONTACT_2363] a needle with stylet, which is mandatory.  
Rarely ,brain herniation can occur in the setting of lumbar puncture and increased 
intracranial pressure.  
There are specific contraindications to performing lumbar puncture.  T hese include 
unstable cardiorespi[INVESTIGATOR_82219], where positioning patient for lumbar puncture may not 
be tolerated, signs of cerebral herniation or incipi[INVESTIGATOR_626864], signs of 
increased intracranial pressure, or focal neurological findings on e xamination.  In those 
patients, lumbar puncture (and IT treatment administration) should not be performed and 
appropriate diagnostic work -up should be initiated.  On a case -by-case basis and 
following discussion with the Medical Monitor, such pa tients may be able to resume 
treatment.  P revious lumbar surgery is an exclusion criterion for this study.    
In the setting of H D, for the purposes of lumbar puncture and ITbolus injection of
RO7234292 , moderate to severe truncal chorea may also be prohibitive.  
[IP_ADDRESS] PostLumbar Puncture Sy ndrome
RO7234292 isdelivered directly to the CNS by [CONTACT_803945].  
Postlumbar puncture syndrome (e.g., headaches, nausea, vomiting, infection, 
hemorrhage, nerve irritation pain) can occur with IT administration.  Experience to date 
with post lumbar puncture syndrome, as reported in the completed Phase I/IIa study, 
includes headache, which occurred after 10% of procedures and was transient and mild 
in the vast majority of patients.   
In the recently completed Phase II OLE Study BN40697, post -LP syndrome events 
(such as post -LP syndrome, headache, migraine, nausea, vomiting or procedural 
headache) occurring within 5 days of LP were reported in 9 patients (39.1%) in the 
Q4W cohort and 13 patients (56.5%) in the Q8W coh ort.
In Study BN40423 ODC, post -LP syndrome events (post -LP syndrome, headache, 
migraine, nausea, vomiting or procedural headache) occurring within 5 days of LP were 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
81/Protocol BN40423 , Version 6reported in 14 patients (38.9%) in the placebo cohort, 8 patients (22.9%) in the Q4W 
cohor t and 14 patients (38.9%) in the Q8W cohort.
As [ADDRESS_1109632] -LP syndrome events (such as 
post-LP syndrome, headache, migraine, nausea, vomiting or procedural headache) 
occurring within 5 days of LP were reported in 7 patients (5.3%) in the Q8W cohort 
and 2 patients (2.7%) in the Q16W cohort. 
The majority of these events were mild or moderate and non -serious.  No events led to 
treatment interruption or discontinuation.
Patients should walk post lumbar procedure (see Sect ion4.3.2.1 ).However , if a patient 
develops a headache after the lumbar puncture with characteristic features, which 
makes walking intolerable, the patient should be encouraged to first sit down and if the 
headache persists then the patient should lie in a comfortable position, which is most 
likely in the supi[INVESTIGATOR_803870].  Supportive 
treatment may include rehydration, consumption of caffeinated drinks, simple 
analgesics, opi[INVESTIGATOR_2438], and antiemetics.  If these conservative measures fail, more specific 
measures may be indicated.
[IP_ADDRESS] Spi[INVESTIGATOR_626866]lumbar puncture spi[INVESTIGATOR_626867] a very rare but important potential risk that 
can present as persistent back pain, radicular pain, new sensory or motor symptoms, 
sphincter disturbance, or meningism.  Prompt MRI scanning should be performed if 
suspi[INVESTIGATOR_626868].  Patients with susceptibility to bleeding, patients 
with coagulopathy, and patient sreceiving anticoagulant therapy are at an increased risk 
of spi[INVESTIGATOR_626869] (see Section 4.1.2 ).  
Management of spi[INVESTIGATOR_626870].
[IP_ADDRESS] Meningitis
Meningitis is a rare potential risk of lumbar puncture.  Pa tients may present with 
headache, meningism, photophobia, neck stiffness, and pyrexia.  Guidelines for 
management of patients with suspected meningitis are provided in Table [ADDRESS_1109633] 2020 , including the completed Phase I/IIa study and its
Phase II OLE Study (BN40697 ), Study BN40423 (ODC), and the ongoing Study 
BN40955.  
[IP_ADDRESS] Neurologic Changes
In cynomolgus monkeys, acute, transient deficits in lower spi[INVESTIGATOR_154531] (patellar reflex 
in particular) were typi[INVESTIGATOR_218206] 2 to 8 hours following dosing, in the 13- week and in 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
82/Protocol BN40423 , Version 6the chronic toxicity studies.  The transient changes in patellar reflex were observed in all 
treatment groups, including controls, with a slightly higher incidence in the high -dose 
groups.  These findings were fully reversibl e within 24 hours following dosing.  No other 
treatment -related changes in general sensory and motor function parameters nor 
changes in the cerebral reflexes were observed.
In the Phase I/IIa MAD study (ISIS 443139 -CS1), no adverse trends in neurological 
examinations were detected and only a few drug -related neurological adverse events 
were observed in 2 patients.   See the RO7234292 Investigator’s Brochure for more 
information.
In the other completed and ongoing studies, among events associated with peripheral 
nervous system, 2 cases of asymptomatic lumbar radiculopathy that were characterized 
by [CONTACT_626937] (SAE) of radiculopathy and hyporeflexia (suspected unexpected serious 
adverse reaction [S[LOCATION_003]R] case) have been observed in the Phase II OLE study 
BN40697 at the Q4W 120 mg cohort.  In Study BN40423 ODC, one case of lumbar 
radiculopathy (post traumatic, considered not related to study drug by [CONTACT_093]) 
was reported in the Q8W cohort.  In Study BN40955, no treatment emergent 
radiculopathy cases have been reported. 
Among reflex change events in Study BN40697, areflexia and reflexes abnor mal were 
reported in [ADDRESS_1109634] been reported in Study 
BN40423 ODC.  For details, see the RO7234292 Investigator’s Brochure.
Among events associated with the central nervous system in Study BN40697, 
dysarthria was reported in 2 patients in the Q4W cohort; coordination abnormal was 
reported in 1 patient in the Q4W cohort; pleocytosis was reported in 1 patient in the 
Q4W arm; and ataxia was reported in 1 patient each in the Q4W and Q8W cohorts, 
respectively.  An SAE of cerebrovascular accid ent was reported in 1 patient in the Q4W 
cohort, which was considered by [CONTACT_803946].  SAEs of hemiparesis, myelitis, and neuritis (S[LOCATION_003]R cases) were reported 
in another patient in the Q4W cohort.  I n Study BN40423 ODC, ataxia (S[LOCATION_003]R case) 
and dysarthria were reported in 1 patient each in the Q4W cohort.  In Study BN40955, 
treatment -emergent event of ataxia was reported in 1 patient each in the Q8W and 
Q16W cohorts, respectively, pleocytosis was repor ted in 1 patient in the Q8W cohort, 
and two neurological S[LOCATION_003]R cases were reported in 2 patients in the Q8W cohort (1 
patient each for arachnoiditis and aseptic meningitis).  For details see the RO7234292 
Investigator’s Brochure.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
83/Protocol BN40423 , Version 6Following LP administrati on and post -LP mobilization, neurologic examinations should 
beconducted .  In addition, patients should be observed in clinic for any complications or 
complaints post -LP and intrathecal bolus injection of RO7234292.
[IP_ADDRESS] Elevations in CSF WBCs and Protein
The C SF W BC elevations were also observed in the chronic non- human primate study 
with slight increases over time.  Increases were mild, and there was no apparent dose 
dependency.
CSF protein and WBC increases have been observed in the RO7234292 program. 
In Stu dy BN40697, one patient was diagnosed with chemical meningitis (S[LOCATION_003]R case) 
in the Q4W cohort.  As of 4 October 20 20, in the ongoing Study BN40955, one patient 
experienced aseptic meningitis (clinically not infectious) and one patient experienced 
arachnoiditis, in the Q8W cohort.  
For details on CSF proteins and WBC laboratory values and non -serious AEs of CSF 
WBC and protein increases, please refer to the RO7234292 Investigator’s Brochure.
[IP_ADDRESS] Thrombocytopenia
Reductions in platelet count have been o bserved after systemic administration of some 
2'-MOE chimeric ASOs to clinical trial subjects.  However, no clinically significant 
reductions in platelet counts have been observed in clinical studies for RO7234292 to 
date.  Inone 13- week and one 9-month I T toxicity studies of RO7234292 in the 
cynomolgus monkey, there were no effects on hematology or coagulation parameters.
No clinically significant reduction in platelet counts has been observed in the completed 
and ongoing studies in the RO7234292 program to date.
Platelet counts will be monitored at each study visit prior to lumbar puncture.  See 
Table 3 for patient stoppi[INVESTIGATOR_626871].
[IP_ADDRESS] Kidney  Effects
Reductions in renal function have been observed after administration of some 2' -MOE 
containing chimeric ASOs to clinical trial subjects.  In the [ADDRESS_1109635] article related 
histologic findings in the visceral organs or effects on clinical chemistries.
No clinically significant reduction in kidney function was observed in the completed 
RO7234292 Phase l/IIa study. Among the other completed and ongoing studies, in the 
recently co mpleted Phase II OLE study BN40697, one case of moderate and non-serious
proteinuria was reported in the Q4W cohort, which resolved without any intervention, 
was considered by [CONTACT_343500], and the patient 
continued study drug administration. Noother clinically significant kidney abnormality 
has been observed.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
84/Protocol BN40423 , Version 6Kidney function will be monitored at each study visit.  Guidelines for management of 
patients who develop decreased re nal function are provided in Table 3 .
[IP_ADDRESS] Liver Effects
Elevations in liver enzymes have been observed after administration of some 2' -MOE 
chimeric ASOs to clinical trial subjects. However, no clinically significant elevation in liv er 
enzymes have been observed in the clinical studies for RO7234292 to date.
In the 13 -week and 9- month toxicity studies of RO7234292 in cynomolgus monkeys, 
there were no drug related histologic findings in the visceral organs, including the liver, 
or effe cts on clinical chemistry test levels. No clinically significant elevations in liver 
enzymes were observed in the completed RO7234292 Phase I/IIa study. Among the 
other completed and ongoing studies, in the recently completed Phase II OLE study 
BN40697, one mild AE of hepatic enzyme increase was reported in 1 patient in the 
Q4W cohort, which resolved without any intervention and was considered by [CONTACT_626938]7234292. No other clinically significant hepatic 
abnormality has been observ ed.
Liver enzymes will be monitored at each study visit.  Guidelines for management of 
patients who develop decreased liver function are provided in Table 3 .
[IP_ADDRESS] Hydrocephalus
Hydrocephalus is included as a warning in the labelling of one marketed IT -administered 
2'-MOE chimeric ASO.  
Ventricular volume expansion has been described in the RO7234292 Investigator’s 
Brochure and is being monitored in all RO7234292 studies.
An SAE of hydrocephalus following chemical meningitis was reported in a patient who 
has undergone shunting in the Q4W cohort of the recently completed Phase II OLE 
Study BN40697.  In ongoing blinded Study BN40423, 1 patient with symptomatic 
communicating hydrocephalus has been shunted (S[LOCATION_003]R case) and 1 patient with a 
medical history of hydrocephalus had an event of hydrocephalus (verbatim: worsening 
hydrocephalus) that was considered by [CONTACT_626939]. 
For details and description of non -serious AEs, refer to the RO7234292 Investigator’s 
Brochure; for management guidelines ,see Section [IP_ADDRESS] .
[IP_ADDRESS] Neuropsy chiatric Changes
RO7234292 is directly administered to the CNS , with limited clinical experience.
Nonclinical studies in animals did not show any adverse effects on the CNS.  Though a 
single case of completed suicide has occurred in the ongoing Phase II OLE study 
(BN40697), when weighing all available details of the case, the investigator has 
concluded that this event was not related to RO7234292.  Patients should be closely 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
85/Protocol BN40423 , Version 6monitored for sign s and symptoms of neuropsychiatric changes in addition to routine 
monitoring with the Columbia- Suicide Severity Rating Scale (C -SSRS) and the Montreal 
Cognitive Assessment battery.
[IP_ADDRESS] Potential Risk due to Reduction of Target Protein HTT
By [CONTACT_626940], RO7234292 lowers levels of both 
mHTT protein and normal wild -type huntingtin (wtHTT) protein in all patients, regardless 
of genetic variations.  The ASO modality provides partial, transient, reversible ,and 
titratable HTT l owering.  Partial HTT lowering is safe and well tolerated in normal rodents 
and non- human primates, as shown in multiple studies using ASOs and non -reversible 
approaches.  Furthermore, no safety signals of concern emerged during the completed
Phase I/IIa s tudy of RO7234292 in adults with HD (see RO7234292 Investigator's 
Brochure ), in which partial lowering was achieved.
Transgenic mice expressing human mHTT develop progressive HD -like phenotypes that 
recapi[INVESTIGATOR_626872].  ASO -mediated mHTT lowering provides 
therapeutic benefits and often restores normal functioning in transgenic and fully 
humanized animal models of HD, with generally similar results regardless of whether 
wtHTT is also lowered. Moreover, no detrimental effects of partia l wtHTT lowering in 
animal models have been reported in multiple studies using ASOs and non -reversible 
approaches.
Still, the c urrent understanding of the diverse cellular functions of HTT suggests potential 
theoretical risks associated with reducing total HTT levels in people with HD. More than 
two decades of research findings implicate HTT in a wide array of cellular functions, 
including microtubule- based transport, F- actin -based trafficking, Rab -based trafficking, 
brain- derived neurotrophic factor transport, ciliogenesis, transcription, chromatin 
modification, post -transcriptional gene- expression regulation, neurogenesis, 
synaptogenesis, synaptic plasticity, signaling pathways, cell stress responses, cell 
survival, selective macro -autophagy and DNA damage repair, as detailed in a recent 
review article (Liu and Zeitlin 2017).
Although functional HTT (mutant or wild-type) is es sential for embryogenesis, 
near-complete genetic ablation of HTT has little or no reported neurological effect in 
normal adult animals. However, complete ablat ion of wtHTT protein expression 
throughout life results in a worsening motor phenotype and, in male transgenic mice, 
age-dependent emergence of brain atrophy and decreased testicular size (Van 
Raamsdonk et al. 2005).  In co ntrast, decreases in mHTT protein expression ameliorate 
disease, and increases in mHTT protein exacerbate disease in animal models of HD, 
regardless of concomitant changes in wtHTT protein levels.
No clinically significant new neurologic events were observ ed in the completed 
Phase l/IIastudy.   As a precaution, a full neurologic examination will be conducted at 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
86/Protocol BN40423 , Version 6each study visit (on dosing days before and after dosing), and additional monitoring of 
cognition will be conducted throughout the study using the M oCA.
5.1.3 Management of Patients Who Experience A dverse Events
[IP_ADDRESS] Dose Modifications
No dose modifications are permitted in this study, whether by [CONTACT_626941] (i.e., all 
participants w ill receive 20 mL of blinded study drug per injection on a Q8W  basis).
[IP_ADDRESS] Treatment Interruption
Study drug may be temporarily suspended in patients who experience toxicity 
considered to be related to study drug.  If study drug has been withheld for 60days , 
from the date of the first missed dose, because of signs of persistent drug -induced 
toxicity or if the scheduled dose has been missed, the investigator should consult the 
Medical Monitor to determine if discontinuation from study drug is warranted.   Study drug
may be suspended for reasons other than toxicity (e.g., surgical procedures) with 
Medical Monitor approval.  The investigator and the Medical Monitor will determine the 
acceptable length of treatment interruption.
[IP_ADDRESS] Management Guidelines
Guidelines fo r management of specific adverse events are outlined in Table 3.  
Additional guidelines are provided in the subsections below.
Initial cl inical laboratory tests with results meeting criteria for withholding study drug must 
be repeated on new specimens as soon as possible , and results must be available prior 
to administering the next dose of study drug. In general, patients who do not reach the 
stoppi[INVESTIGATOR_626873] ;however ,the investig ator and Sponsor should confer 
as to whether additional close monitoring of the patient is indicated.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
87/Protocol BN40423 , Version 6Table 3Guidelines for Management of Patients Who Experience A dverse 
Events
Event Action to Be Taken
Elevations in CSF WBC 
count or proteins or 
suspected meningitis, 
radiculitis, arachnoiditis , 
hydrocephalus , or other 
acute neurologic sy mptomsWithhold study drug if diagnosis of meningitis, radiculitis,
arachnoiditis , hydrocephalus, or acute neurologic symptoms is 
suspected and initiate appropriate diagnostic work -up as 
indicated. 
Clinical signs and sy mptoms of hydrocephalus (e.g. ,new 
onset of per sistent or worsening gait disturbance , change 
in level of consciousness /cognition , change sin continence , 
or a combination of all three signs) are required for 
diagnosis of suspected hydrocephalus.  
Clinical signs and sy mptoms of meningitis (e.g., headache, stiff 
neck, fever) plus confirmatory WBCcount are required for 
diagn osis of suspected me ningitis ; and clinical signs and 
symptoms are required for diagnosis of radiculitis ,arachnoiditis , 
or acute neurologic sy mptoms .  Isolated lo w-level (e.g., 5 50/L
WBC count) elevations in CSF WBC count without clinical 
symptoms does not meet criteria for diagnosis of suspected 
meningitis.  
The Medical Monitor should be consulted in all cases where 
CSF WBC count elevations above 10/ Lare present, or a 
change from baseline in CSF proteins greater than twice 
baseline or where there is uncertainty to discuss next steps of 
patient management in the study.
If diagnosis of suspected meningitis, radiculitis, arachnoiditis , 
hydrocephalus, or other acute neurologic symptoms is refuted, 
the study drug may be resumed after consultation with the 
Medical Monitor.
In the event meningitis, radiculitis, arachnoiditis , hydrocephalus, 
or acute neurologic symptomdiagnosis is confirmed, standard -
of-care therapi[INVESTIGATOR_803871].
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
88/Protocol BN40423 , Version 6Table 3Guidelines for Management of Patients Who Experience A dverse 
Events (cont.)
Thrombocy topenia Ifplatelet count is 100,000/mm3:
oMonitor platelet count weekly
If platelet count is 75,000/mm3and 50,000/mm3in the 
absence of major bleeding or clinically relevant non -major 
bleeding :
oWithhold study  drug until the platelet count has recovered 
to 100,000/mm3.  
oThe suitability of the patient for continued dosing and 
frequency of monitoring should be discusse d with the 
Medical Monitor . 
If platelet count is 50,000/mm3:
oPermanently discontinue study drug . 
oMonitor platelet count s daily until two successive values 
show improvement .  Then monitor ever y 2[ADDRESS_1109636] of care should be considered for 
patients whose platelet count is 25,000/mm3.
Decreased renal function Withhold study  drug in the event of a persistent (2 weeks) 
decrease in eGFR or CrCl or increase in creatinine, as defined
below:
o eGFR or CrCl (using Cockcroft -Gault) 60mL/min
o Creatinine level increase of 2.0 above baseline
Study drug may be resumed when follow -up test results show 
that the patient no longer meets the dose interruption criteria.
Elevated liver enzy mes ALT or AST is 3ULN:
o Monitor weekly until ALT and AST return to 1.2ULN.
o Further investigation into the liver enzy me elevations may 
include hepatitis serologies and other diagnostic tests at 
the discretion of the investigator in consultation with the 
Medical Monitor.
Withhold study drug i n the event ofliver enzy mes that meet the 
following criteria without an alternative explanation (as 
discussed with the Medical Monitor):
o ALT or AST 5ULN 
o ALT or AST 3ULN, combined with total 
bilirubin 2ULN or INR 1.[ADDRESS_1109637] 3ULN coinciding with new appearance of
fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash , and/ or concomitant eosinophilia.
o Discontinue study drug permanently if levels do not return 
to baseline after 30 days.
CrClcreatinine clearance; CSF cerebrospi[INVESTIGATOR_872]; eGFR estim ated glomerular filtration rate; 
ULNupper limit of normal.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
89/Protocol BN40423 , Version 65.[ADDRESS_1109638], regardless of causal attribution.  An adverse event can 
therefore be any of the following:
Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product
Any new disease or exacerbation of an existing disease (a worsening in the 
character, fr equency, or severity of a known condition) (see Sections [IP_ADDRESS] and 
[IP_ADDRESS] for more information)
Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline
Any deterioration in a laboratory value or other clinical test (e.g., ECG, X -ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug
Adverse events that are related to a protocol -mandated intervention, including those 
that occur prior to assignment of study treatment (e.g., scree ning invasive 
procedures such as biopsies)
5.2.2 Serious A dverse Events (Immediately  Reportable to the 
Sponsor)
A serious adverse event is any adverse event that meets any of the following criteria:
Is fatal (i.e., the adverse event actually causes or leads to death)
Is life threatening (i.e., the adverse event, in the view of the investigator, places the 
patient at immediate risk of death)
This does not include any adverse event that, had it occurred in a more severe 
form or was allowed to continue, might have caused death.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
90/Protocol BN40423 , Version 6Requires or prolongs inpatient hospi[INVESTIGATOR_059] (see Section [IP_ADDRESS] )
Results in persistent or significant disability/incapacity (i.e., the adverse event 
results in substantial disruption of the patient's ability to conduct normal life 
functions)
Is a congenit al anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug
Is a significant medical event in the investigator's judgment (e.g., may jeopardize the 
patient or may require medical/surgical intervention to prevent one of the outcomes 
listed above)
The terms "severe" and "serious" are notsynonymous.  Severity refers to the intensity of 
an adverse event (e.g., rated as mild, moderate, or severe, or according to National 
Cancer Institute Common Terminology Criteria for Adverse Events [NC I CTCAE]; see
Section 5.3.3 ); the event itself may be of relatively minor medical significance (such as 
severe headache without any further findings) .
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.
Serious adverse events are required to be reported by [CONTACT_25741] (i.e., no more than 24 hours after learning of the e vent; see Section 5.4.2 for 
reporting instructions).
5.2.[ADDRESS_1109639] (Immediately  Reportable to 
the Sponsor)
Adverse events of spe cial interest are required to be reported by [CONTACT_33473] (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 for reporting instructions).  Adverse events of special interest for this study 
are as follows:
Cases of potential drug- induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, as defined by [CONTACT_25742]'s 
Law (see Section [IP_ADDRESS] )
Suspected transmission of an infectious agent by [CONTACT_5257], as defined below :
Any organis m, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non -pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a patient exposed to a medicinal product.  This term applies only
when a contamination of the study drug is suspected.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
91/Protocol BN40423 , Version 65.3 METHODS A ND TIMING F OR CA PTURING A ND ASSESSING 
SAFETY PARAMETERS
The investigator is r esponsible for ensuring that all adverse events (see Section 5.2.1 for 
definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Sections 5.45.6.
For each adverse event recorded on the Adverse Event eCRF, the investigator will make 
an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see 
Section 5.3.3 ), and causality (see Section 5.3.4 ).  
5.3.[ADDRESS_1109640].  All 
adverse events, whether reported by [CONTACT_25743], will be 
recorded in the patient's medical record and on the Adverse Event eCRF.
After informed consent has be en obtained but prior to initiation of study drug , only 
serious adverse events caused by a protocol -mandated intervention (e.g., invasive 
procedures such as biopsies, discontinuation of medications) should be reported 
(see Section 5.4.2 for instructions for reporting serious adverse events).
After initiation of study drug, all adverse events will be reported until [ADDRESS_1109641] dose in the OLE study 
(BN40955), at which time reporting will occur per the new study requirements .  For 
patients consented to version [ADDRESS_1109642] dose of study drug or until the EoT for ETT Week 101 visit (whichever is 
longer).  For patients consented to version [ADDRESS_1109643] dose.
Instructions for reporting adverse ev ents that occur after the adverse event reporting 
period are provided in Section 5.6.
5.3.2 Eliciting A dverse Ev ent Information
A consistent methodology of non-directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non -directive 
questions include the following:
"How have you felt since your last clinic visit?"
"Have you had any new or changed health problems since you were last here?" 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
92/Protocol BN40423 , Version 65.3.3 Assessment of Severity  of A dverse Events
The adverse event severity grading scale indicated in Table 4 will be used for assessing 
adverse event severity.  Laboratory values determined as an adverse event should be 
graded as per Appendix 6, which is based on the NCI CTCAE ( v5.0).
Table 4Adverse Event Severity Grading Scale
Severity Description
Mild Discomfort noticed, but no disruption of normal daily activity
Moderate Discomfort sufficient to reduce or affect normal daily activity
Severe Incapacitating with inability to work or to perform normal daily activity
Note:  Regardless of severity, some events may  also meet seriousness criteria.  
Refer to definition of a serious adverse event (see Section 5.2.2 ).
5.3.4 Assessment of Causality  of Adverse Events
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an 
adverse event is considered to be related to the study drug, indicating "yes" or "no" 
accordingly.  The following guidance should be taken into consideration (see also
Table 5 ):
Temporal relationship of event onset to the initiation of study drug
Course of the event, with special consideration of the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable)
Known association of the event with the study drug or with similar treatments
Known association of the event with the disease under study
Prese nce of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event
Presence of non -treatment -related factors that are known to be associated with the 
occurrence of the event
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
93/Protocol BN40423 , Version 6Table 5Causal A ttribution Guidance
Is the adverse event suspected to be caused by [CONTACT_25745], evidence, 
science -based rationales, and clinical judgment?
YES There is a plausible temporal relationship between the onset of the adverse event and 
administration of the study drug, and the adverse event cannot be readily explained by 
[CONTACT_102]'s clinical state, intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the 
adverse event follows a known pattern of response to the study drug; and/or the 
adverse event abates or resolves upon discontinuation of the study drug or dose 
reduction and, if applicable, reappears upon re -challenge.
NO An adverse event will be considered related, unless it fulfills the criteria specified below .  
Evidenc e exists that the adverse event has an etiology other than the study drug 
(e.g., preexisting medical condition, underlying disease, intercurrent illness, 
orconcomitant medication); and/or the adverse event has no plausible temporal 
relationship to adminis tration of the study drug (e.g., cancer diagnosed 2 days after 
firstdose of study drug).
5.3.[ADDRESS_1109644] medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF.  Avoid colloquialisms and abbreviations.
Only one adverse event term should be recorded in the event field on the Adverse Event 
eCRF.
[IP_ADDRESS] Injection Reactions
Adverse events that occur during or within 24 hours after study drug administration 
should be captured as individual signs and symptoms on the Adverse Event eCRF 
rather than an overall diagnosis (e.g., record dyspnea and hypotension as separate 
events rather than a diagnosis of IT bolus -related reaction or anaphylactic reaction.
[IP_ADDRESS] Diagnosis versus Signs and S ymptoms
For adverse events other than injectio nreactions (see Section [IP_ADDRESS] ), a diagnosis (if
known) should be recorded on the Adverse Event eCRF r ather than individual signs and 
symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and 
elevated transaminases).  However, if a constellation of signs and/or symptoms cannot 
be medically characterized as a single diagnosis or syndrome at the time of reporting, 
each individual event should be recorded on the Adverse Event eCRF.  If a diagnosis is 
subsequently established, all previously reported adverse events based on signs and 
symptoms should be nullified and replaced by [CONTACT_335578], with a starting date that corresponds to the starting date of the first 
symptom of the eventual diagnosis.
[IP_ADDRESS] Adverse Events That A re Secondary  to Other Events
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by [CONTACT_5252], with the exception of 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
94/Protocol BN40423 , Version 6severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time from the initi ating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:
If vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF.
If vomiting results in se vere dehydration, both events should be reported separately 
on the eCRF.
If a severe gastrointestinal hemorrhage leads to renal failure, both events should be 
reported separately on the eCRF.
If dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF.
If neutropenia is accompanied by [CONTACT_25747], both events should be reported 
separately on the eCRF.
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.
[IP_ADDRESS] Persistent or Recurrent A dverse Events
A persistent adverse event is one that extends continuously, without resolution, between 
patient evaluation timepoints.  Such events should only be recorded once on the 
Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the event is first reported.  If a persistent adverse event becomes 
more severe, the most extreme severity should also be recorded on the Adverse Event 
eCRF.  If th e event becomes serious, it should be reported to the Sponsor immediately 
(i.e., no more than 24 hours after learning that the event became serious; see 
Section 5.4.2 for reporting instructions).  The Adverse Event eCRF should be updated 
by[CONTACT_25748] "non -serious" to "serious," providing the date that the event 
became serious, and completing all data fields related to serious adverse event s.
A recurrent adverse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Adverse Event eCRF.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
95/Protocol BN40423 , Version [IP_ADDRESS] Abnormal Laboratory Values
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it meets any of the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modificati on, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy
Is clinically significant in the investigator's judgment 
It is the investigat or's responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., ALP and bilirubin 5 ULN associated with cholestasis), only the diagnosis 
(i.e., cholestasis) should be recorded on the Adverse Event eCRF.
If a clinically significant laboratory abnormality is not a sign of a dis ease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating whether the test result is above or below the normal range 
(e.g., "elevated potassium," as opposed to "abnormal potassium").  If the l aboratory 
abnormality can be characterized by a precise clinical term per standard definitions, the 
clinical term should be recorded as the adverse event.  For example, an elevated serum 
potassium level of 7.0 mEq/L should be recorded as "hyperkalemia."
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section [IP_ADDRESS] for 
details on recording persistent adverse events).
[IP_ADDRESS] Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event if it meets any of the following criter ia:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention or a change in concomitant therapy
Is clinically significant in the investigator's judgment 
It is the investigator's responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be clas sified as an adverse event.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
96/Protocol BN40423 , Version 6If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on 
the Adverse Event eCRF.
Observations of the same cl inically significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section [IP_ADDRESS] for 
detai ls on recording persistent adverse events).
[IP_ADDRESS] Abnormal Liver Function Tests
The finding of an elevated ALT or AST ( 3ULN) in combination with either an elevated 
total bilirubin ( 2ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as 
defined by [CONTACT_25742]'s Law).  Therefore, investigators must report as an adverse event the 
occurrence of either of the following:
Treatment -emergent ALT or AST 3ULN in c ombination with total bilirubin 
2ULN
Treatment -emergent ALT or AST 3ULN in combination with clinical jaundice
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section [IP_ADDRESS]) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event), either as a serious adverse event or an adverse event of special interest (see 
Section 5.4.2 ).
[IP_ADDRESS] Deaths
All deaths that occur during the protocol -specified adve rse event reporting period (see 
Section 5.3.1 ), regardless of relationship to study drug, must be recorded on the 
Adverse Event eCRF and immediately reported to the Sponsor (see Section 5.4.2 ).This 
includes death attributed to progression of HD .
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of death is un known and cannot be ascertained at the time of 
reporting, "unexplained death" should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), "unexplained death" should 
be replaced by [CONTACT_25749].  The term "sudden death" should not be 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death").
If the death is attributed solely to progression of HD, "Huntington's disease progression" 
should be recorded on the Adverse Event eCRF.   
Deaths that occur after the adverse event reporting period should be rep orted as 
described in Section 5.6.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
97/Protocol BN40423 , Version [IP_ADDRESS] Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  W hen 
recording such events on the Adverse Event eCRF, it is important to convey the concept 
that the preexisting condition has changed by [CONTACT_9672] 
(e.g., "more frequent headaches").
[IP_ADDRESS] Lack of Efficacy  or Worsening of Huntington's Disease
Events that are clearly consistent with the expected pattern of progression of the 
underlyi ng disease should not be recorded as adverse events.  These data will be 
captured as efficacy assessment data only.  If there is any uncertainty as to whether an 
event is due to disease progression, it should be reported as an adverse event.
[IP_ADDRESS] Hospi[INVESTIGATOR_5186] n or Prolonged Hospi[INVESTIGATOR_430702] (i.e., inpatient admission to a hospi[INVESTIGATOR_307]) 
or prolonged hospi[INVESTIGATOR_25676] a serious adverse 
event (per the definition of serious adverse even t inSection 5.2.2 ), except as outlined 
below.  
An event that leads to hospi[INVESTIGATOR_26664] a serious adverse event:
Hospi[INVESTIGATOR_25678]
Planned hospi[INVESTIGATOR_33402]
Hospi[INVESTIGATOR_272] a preexisting condition, provided that all of the following criteria 
are met:
The hospi[INVESTIGATOR_803872] p rior to the study or was scheduled during the 
study when elective surgery became necessary because of the expected 
normal progression of the disease .
The patient has not experienced an adverse event .
An event that leads to hospi[INVESTIGATOR_33405] a serious adverse event, but should be reported as an adverse event 
instead:
Hospi[INVESTIGATOR_803873]7234292 F.Hoffmann -La [COMPANY_002] Ltd
98/Protocol BN40423 , Version [IP_ADDRESS] Reporting Requirements for Cases of A ccidental Overdose or 
Medication Error
Accidental overdose and medication error (hereafter collectively referred to as "special
situations"), are defined as follows:
Accidental overdose:  accidental administrati on of a drug in a quantity that is higher 
than the assigned dose
Medication error:  accidental deviation in the administration of a drug 
In some cases, a medication error may be intercepted prior to administration of 
the drug.
Special situations are not in themselves adverse events, but may result in adverse 
events.  Each adverse event associated with a special situation should be recorded 
separately on the Adverse Event eCRF.  If the associated adverse event fulfills 
seriousnes s criteria, the event should be reported to the Sponsor immediately 
(i.e., nomore than 24 hours after learning of the event; see Section 5.4.2 ).  Fo r 
RO7234292 or placebo, adverse events associated with special situations should be 
recorded as described below for each situation:
Accidental overdose:  Enter the adverse event term.  Check the "Accidental 
overdose" and "Medication error" boxes.
Medicatio n error that does not qualify as an overdose:  Enter the adverse event 
term.  Check the "Medication error" box.
Medication error that qualifies as an overdose:  Enter the adverse event term.  
Check the "Accidental overdose" and "Medication error" boxes.
In addition, all special situations associated with RO7234292 or placebo, regardless of 
whether they result in an adverse event, should be recorded on the Adverse Event 
eCRF as described below:
Accidental overdose:  Enter the drug name [INVESTIGATOR_1238] "accidental overdose" as the event 
term.  Check the "Accidental overdose" and "Medication error" boxes.
Medication error that does not qualify as an overdose:  Enter the name [CONTACT_26865] a description of the error (e.g., wrong dose administered, wrong 
dosing schedule, incorrect route of administration, wrong drug, expi[INVESTIGATOR_26669]) as the event term.  Check the "Medication error" box.
Medication error that qualifies as an overdose:  Enter the drug name [INVESTIGATOR_1238] "accidental 
overdose" as the event term.  Check the "Accidental overdose" and "Medication 
error" boxes.  Enter a description of the error in the additional case details.
Intercepted medication error:  Enter the drug name [INVESTIGATOR_1238] "intercepted medication 
error" as the event term.  Check the "Medication error" box.  Enter a description of 
the error in the additional case details.
As an example, an accidental overdose that resulted in a headache would require two
entries on the Adverse Event eCRF, one entry to report the accidental overdose and one
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
99/Protocol BN40423 , Version 6entry to report the headache.  The "Accidental overdose" and "Medication error" boxes 
would need to be checked on both eCRF pages.
[IP_ADDRESS] Patient -Reported or Observer -Reported Outcome Data
Adverse event reports will not be derived by [CONTACT_803947] ,ObsRO ,or digital 
wearable device (HD mobile app) data, and safety analyses will not be performed using 
PRO or ObsRO or digital wearable device data.  Sites are not expected to review the 
PRO or ObsRO or digital wearable device data for adverse events.
[IP_ADDRESS] Safety  Biomarker Data
Adverse event reports will not be derived from safety biomarker data by [CONTACT_1034], 
and safety biomarker data will not be included in the formal safety analyses for this 
study.  In addition, safety biomarker data will not inform decisions o n patient 
management.
5.[ADDRESS_1109645] repo rt 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than [ADDRESS_1109646] report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study drug:
Serious adverse events (defined in Section 5.2.2 ; see Section 5.4.2 for details on 
reporting requirements)
Adverse events of special interest (defined in Section 5.2.3 ; see Section 5.4.2 for 
details on reporting requirements)
Pregnancies (see Section 5.4.3 for details on reporting requirements)
The investigator must report new significant follow -up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information).  New significant information includes the following:
New signs or symptoms or a change in the diagnosis
Significant new diagnostic test results
Change in causality based on new information
Change in the event's outcome, including recovery
Additional narrative information on the clinical course of the event
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
100/Protocol BN40423 , Version 65.4.[ADDRESS_1109647] Information for All Sites
Medical Monitor: , M.D., Ph.D .
Telephone No.:
Mobile Telephone No.:
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will
access the [COMPANY_002] Medical Emergency List, escalate emergency medical calls, provide 
medical translation service (if necessary), connect the investigator with a [COMPANY_002] Medical 
Responsible (listed above and/or on the [COMPANY_002] Medical Emergen cy List), and track all 
calls.  The Emergency Medical Call Center Help Desk will be available [ADDRESS_1109648]
[IP_ADDRESS] Events That Occur prior to Study  Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol -mandated intervention should be reported.  
The paper Clinical Trial Serious Adverse Event/Adverse Event of Special Interest 
Reporting Form provided to investigators should be completed and submitted to the 
Sponsor or it s designee immediately (i.e., no more than 24 hours after learning of the 
event), either by [CONTACT_249177].
[IP_ADDRESS] Events That Occur after Study  Drug Initiation
After ini tiation of study drug, serious adverse events and adverse events of special 
interest will be reported until 5 months after the final dose of study drug or until the EoT 
for ETT Week 101 visit (whichever is longer) .Investigators should record all case 
details that can be gathered immediately (i.e., within 24 hours after learning of the event) 
on the Adverse Event eCRF and submit the report via the electronic data capture (EDC) 
system.  A report will be generated and sent to [COMPANY_002] Safety Risk Management by [CONTACT_40835].
In the event that the EDC system is unavailable, the paper Clinical Trial Serious Adverse 
Event/Adverse Event of Special Interest Reporting Form provided to investigators should 
be completed and submitted to the Sponsor or its designee imme diately (i.e., no more 
than 24 hours after learning of the event), either by [CONTACT_123565].  Once the 
EDC system is available, all information will need to be ent ered and submitted via the 
EDC system.  
Instructions for reporting serious adverse events that occur 5 months after the final 
dose of study treatment are provided in Section 5.6.

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
101/Protocol BN40423 , Version 65.4.3 Reporting Requirements for Pregnancies
[IP_ADDRESS] Pregnancies in Female Patients
Female patients of childbearing potential will be instructed to immediately inform the 
investigator if they become pregn ant during the study or within 5 months after the final
dose of study drug .  A paper Clinical Trial Pregnancy Reporting Form should be 
completed and submitted to the Sponsor or its designee immediately (i.e., no more than 
24 hours after learning of the pre gnancy), either by [CONTACT_123565].  Pregnancy 
should not be recorded on the Adverse Event eCRF .  The investigator should 
discontinue study drug and counsel the pat ient, discussing the risks of the pregnancy 
and the possible effects on the fetus.  Monitoring of the patient should continue until 
conclusion of the pregnancy.  Any serious adverse events associated with the 
pregnancy (e.g., an event in the fetus, an event in the mother during or after the 
pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the 
Adverse Event eCRF.  In addition, the investigator will submit a Clinical Trial Pregnancy 
Reporting Form when updated information on the course and outcome of the pregnancy 
becomes available.  
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients
Male patients will be instructed through the Informed Consent Form to immediately 
inform the investigator if their partner becomes pregnant durin g the study or within 
5months after the final dose of study drug .  A paper Clinical Trial Pregnancy Reporting 
Form should be completed and submitted to the Sponsor or its designee immediately 
(i.e., no more than 24 hours after learning of the pregnancy), either by [CONTACT_162492].  Attempts should be made to collect and report details of the course and 
outcome of any pregnancy in the partner of a male patient expose d to study drug.  W hen 
permitted by [CONTACT_779], the pregnant partner would need to sign an Authorization for Use 
and Disclosure of Pregnancy Health Information to allow for follow -up on her pregnancy.  
If the authorization has been signed, the investigator s hould submit a Clinical Trial 
Pregnancy Reporting Form when updated information on the course and outcome of the 
pregnancy becomes available.  An investigator who is contact[CONTACT_249179], to support an informed decision in cooperation with the 
treating physician and/or obstetrician.
[IP_ADDRESS] Abortions
Aspontaneous abortion should be classified as a serious adverse event (as the Sponsor 
considers abortions to be medically significant), recorded on the Adverse Event eCRF, 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event; see Section 5.4.2 ).  
If a therapeutic or elective abortion was performed because of an underlying maternal or 
embryofetal toxicity, the toxicity should be classified as a serious adverse event, 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
102/Protocol BN40423 , Version 6recorded on the Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2 ).A therapeutic or 
elective abortion performed for reasons other than an underlying maternal or 
embryofetal toxicity is not considered an adverse event.
All abortions should be reported as pregnancy outcomes on the paper Clinical Trial 
Pregnancy Reporting Form.
[IP_ADDRESS] Congenital A nomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
drug or the female partner of a male patient exposed to study drug should be classified 
as a serious adver se event, recorded on the Adverse Event eCRF, and reported to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 ).
5.[ADDRESS_1109649] to 
follow -up, or the patient withdraws consent.  Every effort should be made to follow all 
serious adverse events considered to be related to study drug or trial -related procedures 
until a final outcome can be reported.
During the study period, resol ution of adverse events (with dates) should be documented 
on the Adverse Event eCRF and in the patient's medical record to facilitate source data 
verification.
All pregnancies reported during the study should be followed until pregnancy outcome.
5.5.[ADDRESS_1109650], and pregnancies, the 
Sponsor or a designee may follow up by [CONTACT_756], fax, email, and/or a monitoring visit 
to obtain additional case details and outcome information (e.g., from hospi [INVESTIGATOR_123444], consultant reports, autopsy reports) in order to perform an independent 
medical assessment of the reported case.
5.6 ADVERSE EVENTS THA T OCCUR AFTER THE A DVERSE 
EVENT REPORTING PERI OD
The Sponsor should be notified if the investigator becomes aware of any serious 
adverse event that occurs after the end of the adverse event reporting period (defined as 
greater than 5 months after the final dose of study drug), if the event is believed to be 
related to prior study drug treatment.  These e vents should be reported through use of 
the Adverse Event eCRF.  However, if the EDC system is not available, the investigator 
should report these events directly to the Sponsor or its designee, either by [CONTACT_803948]7234292 F.Hoffmann -La [COMPANY_002] Ltd
103/Protocol BN40423 , Version 6scanning and emailing the paper Clinic al Trial Serious Adverse Event/Adverse Event of 
Special Interest Reporting Form using the fax number or email address provided to 
investigators.
5.[ADDRESS_1109651] experience to identify and expeditiously 
communicate possible new safety findings to investigators, IRBs, ECs, and applicable 
health authorities based on applicable legislation.
To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events using the following reference document:
RO7234292 Investigator's Brochure
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by [CONTACT_25753].
6. STATISTICA L CONSIDER ATIONS AND ANAL YSIS PLAN
All patients enrolled prior to Version 4 of the protocol will not be included for any efficacy 
analysis.  The safety data coll ected for these patients up to and including the end of 
treatment visit in Protocol BN40423 will be analyzed separately.  
The primary efficacy analysis will be conducted at the end of the study (see Section 3.2).  
Treatment assignments will be unblinded to the Sponsor at the end of the study after the 
data have been cleaned andverified and the database has been locked.
Details of the planned statistical analyses mentioned below will be fully specified in a 
separate Statistical Analysis Plan ( SAP) , which will be finalized prior to the locking and 
unblinding of the study database.
Unless otherwise specified, all the p- values considered in Section 6are two -sided.
6.1 ANAL YSIS POPULA TIONS
The intent -to-treat (ITT) population will consist of all patients enrolled after 
implementation of Pr otocol Version [ADDRESS_1109652] therapy from that intended will be summarized in the 
group according to their planned randomized treatment.  The ITT population will be the 
primary population for all analyses of primary and secondary efficacy variables.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
104/Protocol BN40423 , Version 6The safety population for the trial will consist of all patients who enroll after 
implementation of Version 4 of the protocol and also receive any study treatment.  The 
safety population will be th e primary population for all safety analys es.  For the purpose 
of all safety analyses, it will be assessed whether patients received a treatment different 
from the one they were randomized to at any time during the course of the study.  In 
case the number and duration of such “treatment switches” warrants it, the safety 
population may be redefined by [CONTACT_803949], as opposed to which treatment they were randomized to.
The PK population will include all patients randomized after implementation of Protocol 
Version [ADDRESS_1109653] one dose, and had sufficient sampling to permit PK 
evaluation.
6.2 DETERMINA TION OF SA MPLE SIZE
The planned sample size is adequate to capture meaningful clinical decline on both the 
TFC and cUHDRS and was estimated on the basis of data available from 
non-interventional studies (TRACK -HD, COHORT, ENROLL -HD) and a randomized 
placebo -controlled study (2CARE).  Based on these data, using the anticipated trial 
population, a meta -analysis for the change from baseline at [ADDRESS_1109654] 
deviation of 1.78.  A conservative treatment discontinuation rate at W eek 101 for 
patients receiving placebo or ac tive is assumed to be 20% and 15%, respectively.  Using 
these assumptions, the simulation described below was performed to estimate the 
sample size.  
Description of Simulations to Derive the Sample Size
The design used for the simulation was simplified to consider only 2 treatment arms 
(placebo and active) and 2 postbaseline timepoints ( Week 49 and Week 101).  These 
simplifications are justifiable given that:
The overall alpha level 5% will be split to 2.5% ,such that each active treatment will 
be tested a gainst placebo independently. Within each testing chain, a hierarchical 
procedure will be used to test the primary endpoint and secondary endpoints (see 
Section 6.3).
The difference on the derived sample size for considering more than two 
postbaseline timepoints would be minimal. 
The following algorithm was run and repeated 500,000 times:
1.Generate change from baseline values in TFC a t Week 49 and Week 101 for 
Nactive patients according to the following bivariate normal distribution: 
  _  49
 _  101 =    = 0.47
0.82  , = 1.56 1.8
1.8 1.78   
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
105/Protocol BN40423 , Version 6where y_wk49 and y_wk101 is the change from baseline in TFC, respectively, at 
Week 49 and Week 101 , is the assumed true change at those two timepoints, 
and ∑ is the variance- covariance matrix.  Subsequently:
set to missing, due to study drug related (SDR) reasons, both values at 
Week 49 and Week 101 for 5% of the N patients.  Set to missing, due to 
nonstudy drug related (NSDR) reasons, both values at Week 49 and 
Week 101 for additional 2.5% of the N active patients.
set to missing, due to SDR reasons, only the value at W eek 101 for 
additional 5% of the N active patients.  Set to missing, due to NSDR
reasons, only the value at Week 101 for additional 2.5% of the N active 
patients.
2.Generate change from baseline values in TFC at W eek 49 and Week 101 for 
Nplacebo patients according to the following bivariate normal distribution: 
  _  49
 _  101 =    = 0.79
1.36  , = 1.56 1.8
1.8 1.78   
where y_wk49 and y_wk101 is the change from baseline in TFC, respectively, at 
Week 49 and Week 101, is the assumed true change at those two timepoints, 
and ∑ is the variance- covariance matrix.  Subsequently:
set to missing both values at W eek 49 and Week 101 for 10% of the 
Nplacebo patients
set to missing only the value at Week 101 for additional 10% of the 
Nplacebo patients
Given how missing data will be imputed, it is not relevant to differentiate missing 
data into SDR v ersus NSDR reasons for placebo patients.
3.Apply multiple imputations and derive [ADDRESS_1109655] to compare active versus placebo at W eek 101 for each completed 
dataset and pool the result (Rubin 1987) to derive an estimate of the treatment 
effect, including a p -value.
Across the 500,000 simulations, the power achieved, with the N patients per arm was 
calculated by [CONTACT_803950] p -value (in above Step 4) was below 2.5% 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
106/Protocol BN40423 , Version 6by 500,000.  The above procedure was repeated by [CONTACT_803951] N until the 
calculated power was close to 80%.
It was estimated that 267patients per arm will provide approximately 80% power, at a 
two-sided  0.025level, to detect a 40% slowing of clinical decline for RO7234292 as 
compared with placebo at [ADDRESS_1109656] translates into an expected 
average decline of ~0.82 points at 101 weeks for the RO7234292 arms.  The minimal 
detectable difference with these assumptions is ~0.[ADDRESS_1109657] MENT 
The overall alpha level 5% will be split to 2.5% for testing each active treatment against 
placebo . A hierarchical approach will be used for multiple adjustments that accounts for 
multiple endpoints (the primary and secondary endpoints).  
Within each test ing chain (RO7234292 Q8W  and RO7234292 Q16W ), the endpoint will 
be tested only if the preceding endpoint is significant at the alpha level 2.5% .  Details of 
the order for secondary endpoints will be detailed in the SAP. 
6.[ADDRESS_1109658] OF STUDY
The n umber sof patients who enroll in the study , discontinue from the study , and
complete the study will be summarized overall and by [CONTACT_2939].  Reasons for 
premature study withdrawal will be listed and summarized.  Enrollment and major 
protocol deviations will be listed and evaluated for their potential effects on the 
interpretation of study results.
6.5 SUMMA RIES OF DEMOGRA PHIC AND BA SELINE 
CHA RACTERISTICS
Demographic and baseline characteristics (including age, sex, CAG repeat length, CAP, 
HD stage, education ) will be summarized using means, standard deviations, medians, 
and ranges for continuous variables and proportions for categorical variables, as 
appropriate.  Summaries will be presented overall and by [CONTACT_1570].
6.6 EFFICA CY ANAL YSES
To ensure the tre atment groups under comparison are concurrent and that treatment 
regimens are comparable across the entire dosing period of the 25 -month study, for all 
efficacy analyses, patients enrolled prior to implementation of Protocol Version 4 will not 
be included and will be offered the option to enroll into Study BN40955 before reaching 
the primary endpoint assessment in the current study.    
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
107/Protocol BN40423 , Version 66.6.1 Estimands
Following the very recent estimand framework outlined in the ICH -E9 draft addendum
(FDA 2017) , the attributes of the estimand for the primary endpoint are defined as 
follows:
Population: ITT population (see Section 6.1)
Variable:   Change from baseline in cUHDRS score at Week 101  
–Note: cUHDRS scale will be replaced by [CONTACT_803952] .
Intercurrent events (ICEs) : 
–Treatment discontinued for study drug related reasons (e.g., treatment -related 
adverse event or lack of efficacy):
–After treatment discontinuation, t he actual off -treatment values will be 
used in the analysis. 
–Treatment discontinued for NSDR reasons (e.g., lost to follow -up): 
–After treatmen t discontinuation, imputed hypothetical values as if patient s 
had continued receiving study drug will be used in the analysis. In this 
instance, any data collected after treatment discontinuation will not be 
included in the analysis. 
Population level summary:   Difference in mean change from baseline at Week 101 
between each active arm and the placebo arm 
The primary estimand is a combination of a treatment -policy strategy and a hypothetical 
strategy (FDA 2017) to account for the different assumptions for each type of ICE. 
The Sponsor will emphasize to investigators the importance of collecting data for the 
primary endpoint through Week 101 , even if patients discontinue study drug but do not 
withdraw study consent, as well as the importance of providing detail ed reasons for 
treatment discontinuation . The primary estimator ,described by [CONTACT_803953] 6.6.2 , will be applied on the dataset produced after multiple imputation of any 
missing value.  In principle,
missing data as well as off -treatment data from patients who discontinued treatment 
for NSDR reasons will be imputed from patients with available data fro m the same 
treatment arm collected while on treatment
missing data from patients who discontinued treatment for SDR reasons will be 
imputed from: 
-patients with available data from the placebo arm collected either while on 
treatment or off treatment and
-patients with available data from the same treatment arm collected while off 
treatment
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
108/Protocol BN40423 , Version 6Multiple imputation of missing data values will be performed as follows:
1.Imputation step:  Missing data values will be imputed "m" times leading to "m" 
complete datase ts.  
2.Analysis step:  Each of the resulting "m" datasets will be analyzed using the 
statistical model described in Section 6.6.2 , whic h will provide an estimate of 
treatment difference.  
3.Pooling step:  The results from the "m" datasets will be combined (Rubin 1987) 
leading to an overall estimate of the treatment effect and associated 95% confidence 
intervals and p- values.
Full details of the algorithm for multiple imputation (e.g., which reference population to 
use for each missing data pattern ,number of imputed datasets, method for imputation , 
etc.)will be provided in the SAP.
A supplementary estimand may be considered (and will be d efined in the SAP). 
6.6.2 Primary  Efficacy  Analysis
The primary efficacy endpoint is the change from baseline in cUHDRS score at 
Week101.  This is defined as the attribute "variable" of the primary estimand in Section 
6.6.1 .
Note: The primary efficacy endpoint for the U.S. FDA will be change from baseline in 
the TFC score at W eek 101. TFC will be analy zed the same way as the cUHDRS.
The primary efficacy analysis for this study will compare each active treatment arm, 
RO7234292 Q8Wand RO7234292 Q16W, against the placebo arm.  
To account for the multiple comparison, an appropriate procedure will be used to 
maintain the overall two- sided type I error at 5% (details will be given in the SAP). 
The analysis of the primary endpoint will be performed by [CONTACT_803954] (ANCOVA ).  The model will include the corresponding endpoint baseline 
score, CAG repeat length, baseline CAP score (defined in Section 4.1.1 ), and treatment 
as covariates .  On the basis of this analysis, least squares mean for the treatment 
differences at Week101 and correspond ing 95% CIs will be derived.  
The robustness of the primary method of estimation described above may be explored 
by [CONTACT_803955]. These sensitivity analyses wil l be described in the SAP.
6.6.3 Secondary  Efficacy Analy ses
The secondary efficacy endpoints are identified in Section 2.1.2 .
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
109/Protocol BN40423 , Version 6Similar hypotheses as for th e primary efficacy endpoint will be tested for the secondary 
continuous efficacy endpoints. 
Categorical endpoints, such as CGI -C and the proportion of progressors, will be 
analyzed by [CONTACT_803956] (categorical), CAG 
repeat length, and CAP score as covariates .   
Methods for controlling type I error in the testing of the secondary endpoints will be 
described in the SAP. 
6.6.4 Subgroup A nalyses
The results of selected efficacy variables will be summarized within subgroup s using 
descriptive statistics.  The following variables will be used to define subgroups:
Sex (male vs. female)
Age at baseline (45 vs. 45years )
CAG repeat length (43 vs. 43)
Stage at baseline (I, II, III)
–Stage III will be considered only if there are enough patients.
Additional exploratory analyses of efficacy results may be performed using an ANCOVA 
model, similar to the primary analysis, based on change from baseline for the variable of 
interest, with baseline score (not for analysis by [CONTACT_803957]), CAP score, CAG repeat 
length (not for analysis by [CONTACT_803958]), treatment, subgroup, and treatment -by-
subgroup interaction as covariates .
6.6.5 Exploratory  Efficacy  Analysis
The exploratory efficacy endpoints are identified in Section 2.1.3 .
The exploratory endpoints will be summarized using tables, listings, and graphs, as 
appropriate.  Additional statistical modeling may be considered (e.g., ANCOVA, logistic 
regression).
6.6.[ADDRESS_1109659] to important 
baseline characteris tics (e.g., gender, CAG, age, IS, International Standard 
Classification of Education ).  The objective for use and exact algorithm for selecting 
historical controls will be specified in the SAP.  If implemented, the actual selection will 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
110/Protocol BN40423 , Version 6be made before data base lock and unblinding of treatment allocation and will be 
documented and stored in the Sponsor's database.   
Whether the Sponsor will decide to use those the historical controls, the exact algorithm 
for borrowing and for deriving an overall treatment effect will be described in the SAP 
before unblinding.
Additionally, given that some of the patients who will be enrolled in this study may have 
been part of ENROLL -HD, the Sponsor may explore a within -patient comparison for the 
rate of decline in cUHDRS or TFC score, beforetreatment with RO7234292 (prior to 
randomization, using ENROLL -HD registry data) and after treatment with RO7234292
(after randomization, using study data), for patients who were randomized to the active 
arm and had follow -up in ENROLL- HD of at least 1 year's duration prior to randomization
into this study.
6.7 SAFETY ANAL YSES
The safetypopulation (see Section 6.1) will be the primary population for all analyses of 
safety da ta.  Incorrect treatment assignments (patients who received a treatment 
different than their planned randomized treatment) will be summarized and the impact on 
the safety assessment will be discussed.
For all safety analyses, patients enrolled prior to im plementation of the Version 4 of the 
protocol will be summarized separately.
All verbatim adverse event terms will be mapped to MedDRA thesaurus terms.  The 
adverse event severity grading scale indicated in Table 4 will be used for assessing 
adverse event severity.  Laboratory values determined as an adverse event should be 
graded as per Appendix 6, which is based on the NCI CTCAE (v5.0).
All safety data , including adverse events, laboratory tests, CSSR- S,MoCA, ECG, and 
vital signs will be reported in individual listings and summarized by [CONTACT_626898]. For continuous variables, both the original 
value as well as the change from baseline will be reported. 
The in cidence of adverse events will be summarized on the basis of body systems and 
dictionary preferred terms. The incidence of adverse events by [CONTACT_803959] s will be provided. 
The iDMC will review safety data throughout the study. Analyses required for the iDMC 
data review will be performed as described in the iDMC Charter.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
111/Protocol BN40423 , Version 66.8 PHA RMA COKINETIC ANAL YSES
For all patients in the PK population (Section 6.1),CSF and plasma concentrations of 
RO7234292 will be presented descriptively, including arithmetic and geometric means, 
median, range, standard deviations, and coefficients of variation.   Nonlinear 
mixed -effects modeling will be used to analyze the concentration time data for
RO7234292 in CSF and plasma following IT administration .A covariate analysis will be 
conducted to evaluate the effect of covariates such as body weight, age ,and sex on 
RO7234292 exposure.   
Population and individual estimates of primary PK parameters (e.g., clearance, 
distribution volume) and secondary PK p arameters (e.g.,area under the plasma 
concentration time curve, average trough plasma concentration) will be computed and 
used to explore exposure- response relationship on primary and key secondary
endpoints, as well as safety measures.  The data from thi s study may be pooled with 
data from other studies conducted with RO7234292 to support the population PK/PD 
modeling .
Details of this mixed- effects modeling and exploration of exposure -response analysis 
and results will be described and reported in a docum ent separat efrom the Clinical 
Study Report.
6.[ADDRESS_1109660] one ADA 
assessment.  Patients will be grouped according to treatment received or, if no treatment 
is received prior to study discontinuation, according to treatment assigned.
The numbers and proportions of ADA -positive patients and ADA -negative patients at 
baseline (baseline prevalence) will be summarized by [CONTACT_1570]. For those who 
are ADA -positive, titers will be estimated as well as antibody subtype.   In addition, t he 
numbers and proportions of ADA -positive patients and ADA -negative patients at 
baseline (baseline prevalence) and after drug administration (post -baseline incidence) 
will be summarized for patients on active treatment only. When determining 
post-baseline incidence, patients are considered to be ADA positive if they are ADA 
negative or have missing data at baseline but develop an ADA response following study 
drug exposure (treatment -induced ADA response), or if they are ADA positive at 
baseline and the titer of one or more post -baseline samples is at least is at least 4 -fold 
greater than the titer of the baseline sample (treatment -enhanced ADA response).  
Patients are considered to be AD A negative if they are ADA negative or have missing 
data at baseline and all post -baseline samples are negative, or if they are ADA positive 
at baseline but do not have any post -baseline samples with a titer that is at least 4-fold 
greater than the titer o f the baseline sample (treatment unaffected). 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
112/Protocol BN40423 , Version 6The relationship between ADA status and safety, efficacy, PK, and biomarker endpoints 
will be analyzed and reported via descriptive statistics.
6.[ADDRESS_1109661] s model repeat measurement model will be used to model the change in 
each primary and secondary biomarker endpoint, adjusting for the baseline endpoint, 
CAG repeat length, CAP score, treatment, visit, and treatment -by-visit interaction (the 
final list of covariates and details of the model will be specified in the SAP).
6.[ADDRESS_1109662] an interim analysis, along with the rationale, specification of the 
endpoint (e.g., clinical and/or biomarker endpoint), number of patients, and statistical 
details for each analysis, wil l be introduced via a future protocol amendment , which will 
be submitted to relevant health authorities at least [ADDRESS_1109663] of the 
interim analysis.  The iDMC Charter will document potential recommendations the iDMC 
can make to the Spons or as a result of an interim analysis, and the iDMC Charter will be 
made available to relevant health authorities. 
If there is a potential for the study to be stopped for positive efficacy as a result of an 
interim analysis of efficacy data, the type I error rate will be controlled to ensure 
statistical validity is maintained.  Additional criteria for recommending that the study be 
stopped for positive efficacy willbe added to a future protocol amendment .  
7. DATA COLLECTION A ND MANAGEMENT
7.1 DATA QUA LITY ASSURA NCE
The Sponsor will be responsible for data management of this study, including quality 
checking of the data.  Data entered manually will be collected via EDC through use of 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
113/Protocol BN40423 , Version 6eCRFs.  Sites will be responsible for data entry into the EDC system.  In t he event of 
discrepant data, the Sponsor will request data clarification from the sites, which the sites 
will resolve electronically in the EDC system.
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be perf ormed on the data.  Central laboratory data electronic data 
from clinic visits (see Section 7.3)and electronic data obtained from the [COMPANY_002] HD 
mobile app (see Section 7.4) will be sent directly to the Sponsor, using the Sponsor's 
standard procedures to handle and process the electronic transfer of these data.
eCRFs and correction documentation will be maintained in the EDC system's audit trail.  
System backups for data stored by [CONTACT_40892]'s standard procedures.
7.[ADDRESS_1109664] that is attributable, secure, and accurate, 
in compliance with U.S. FDA regulations for electronic records (21 CFR Part 11).   The 
data will be transmitted to a centralized database maintained by [CONTACT_307191].
Theelectronic data will be available for view access only, via a secure vendor web 
portal. Only identified and trained users may view the data, and their actions will 
become part of the audit trail.  The Sponsor will have view access only.  System 
backups for data stored by [CONTACT_398150]'s standard procedures.
Once the study is comp lete, the data, audit trail, and trial and system documentation will 
be archived.  The investigator will receive patient data for the site in both human -and 
machine
-readable formats on an archival -quality compact disc that must be kept with the 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
114/Protocol BN40423 , Version 6study reco rds as source data.  Acknowledgement of receipt of the compact disc is 
required.  In addition, the Sponsor will receive all data in a machine -readable format on a 
compact disc.
7.4 ELECTRONIC DA TA OBTA INED BY [CONTACT_626950] L 
MONITORING PLA TFORM
During "ac tive tests" and "passive monitoring," the smartphone and wrist -worn wearable 
record movement and location data.  Data on the technical status and connectivity of the 
devices is also recorded.  Patients can choose to pause location data recording.  
Nopatient identifiable information is stored on the devices.  For selected "active test" 
tasks, touch and sound is also recorded.  Video is not recorded.
[COMPANY_002] HD mobile app (smartphone and wrist -worn wearable) sensor data are encrypted 
and uploaded to secure ser vers whenever the smart phone is connected to Wi-Fi . All 
sensor data will be managed by [CONTACT_626951].  This includes, but is not limited, to the analysis of 
sensor data together with protocol -specified assessments and activities associated with 
routine daily living.   The data will not be analyzed for efficacy until study end, unless they 
are chosen to be a part of a pre -specified interim analysis along with other clinical and/or 
biomar ker endpoints.
7.5 SOURCE DA TA DOCUMENT ATION
Study monitors will perform ongoing source data verification and review to confirm that 
critical protocol data (i.e., source data) entered into the eCRFs by [CONTACT_77038], complete, and veri fiable from source documents. 
Source documents (paper or electronic) are those in which patient data are recorded 
and documented for the first time.  They include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, mem oranda, PROs , evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_70069], 
microfiche, photographic negatives, microfilm or magnetic media, X -rays, patient files, 
and records kept at pharmacies, laboratories, and medico- technical departments 
involved in a clinical trial.
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in t he Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Source documents that are required to verify the validity and completenes s of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section 7.7.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
115/Protocol BN40423 , Version 6To facilitate source data verification and review, the investigators and institutions must 
provide the Sponsor direct access to applicable source documents and reports for 
trial-related monitoring, Sponsor audits, and IRB/EC review.  The study site must also 
allow inspection by [CONTACT_25756].
7.6 USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into a study site's computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with health 
authority requirements pertaining to computerized systems used in clinical research.  An 
acceptable computerized data collection system allows preservation of the original entry 
of data.  If original data are modified, the system should maintain a viewable audit trail 
that shows the original data as well as the reason for the change, name [CONTACT_33508], and date of the change.
7.[ADDRESS_1109665] of this study and the distribution of 
IMP, including eCRFs, electronic or paper PRO, ClinRO, ObsRO (if applicable), and 
PerfO data (if applicable ), Informed Consent Forms, laboratory test results, and 
medication inventory records, must be retained by [CONTACT_079] [INVESTIGATOR_8178] [ADDRESS_1109666] to local regulations.  
No records may be disposed of without the written approval of the Sponsor.  W ritten 
notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another location.
[COMPANY_002] will retain study data for 25 years after the final Clinical Study Report has been 
completed or for the length of time required by [CONTACT_109851], whichever is longer.
8. ETHICA L CONSIDERA TIONS
8.1 COMPLIA NCE WITH LA WSAND REGULATIONS
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the applicable laws 
and regulations of the count ry in which the research is conducted, whichever affords the 
greater protection to the individual.  The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management:  Definitions and Standards for 
Expedited Reporting). Studies conducted in the [LOCATION_002] or under a U.S. 
Investigational New Drug (IND) Application will comply with U.S. FDA regulations and 
applicable local, state, and federal laws.  Studies conducted in the European Union or 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
116/Protocol BN40423 , Version 6European Economic Area will comply with the E.U. Clinical Trial Directive (2001/20/EC ) 
and applicable local, regional, and national laws.
8.2 INFORMED CONSENT
The Sponsor's sample Informed Consent Form (and ancillary sample Informed Consent 
Forms) will be provided to each site.  If appli cable, it will be provided in a certified 
translation of the local language.  The Sponsor or its designee must review and approve 
any proposed deviations from the Sponsor's sample Informed Consent Forms or any 
alternate consent forms proposed by [CONTACT_779] (collectively, the "Consent Forms") before 
IRB/EC submission.  The final IRB/EC approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes according to local requirements.
If applicable, the Informed Consent Form will co ntain separate sections for any optional 
procedures.  The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential risks associated with each optional procedure.  
Patients will be told that they are free to re fuse to participate and may withdraw their 
consent at any time for any reason.  A separate, specific signature [CONTACT_33509] a patient's agreement to participate in optional procedures.  Patients who 
decline to participate will not provide a separate signature.
The Consent Forms must be signed and dated by [CONTACT_803960] h er 
participation in the stu dy. Thestudy companion must also sign and date a consent form 
prior to participation in the study.  The case history or clinical records for each patient 
shall document the informed consent process and that written informed consent was 
obtained prior to participation in the study.
The Consent Forms should be revised whenever there are changes to study procedures 
or when new informat ion becomes available that may affect the willingness of the patient 
to participate.  The final revised IRB/EC -approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes.
Patients must be re -consented to the most curren t version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 
IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent Forms, the case history or clinical rec ords for each patient shall document the 
informed consent process and that written informed consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.   If the patient 
should lose capacity to consent during the st udy (i.e., after enrollment), as judged by [CONTACT_1275], a legally authorized representative may sign on behalf of the patient.
A copy of each signed Consent Form must be provided to the patient or the patient's 
legally authorized representative.  All signed and dated Consent Forms must remain in 
each patient's study file or in the site file and must be available for verification by [CONTACT_33483].
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
117/Protocol BN40423 , Version 6For sites in the [LOCATION_002], each Consent Form may also include patient authorization 
to allow use and disclosure of personal health information in compliance with the U.S. 
Health Insurance Portability and Accountability Act (HIPAA) of 1996.  If the site utilizes a 
separate Authorization Form for patient authorization for use and disclosure of p ersonal 
health information under the HIPAA regulations, the review, approval, and other 
processes outlined above apply except that IRB review and approval may not be 
required per study site policies.
8.[ADDRESS_1109667] be submitted to the IRB/EC by [CONTACT_9532] [INVESTIGATOR_25684]/EC before the study is initiated.  
Inaddit ion, any patient recruitment materials must be approved by [CONTACT_1201]/EC. 
The Principal Investigator [INVESTIGATOR_25685]/EC annually or more frequently in accordance with the 
requirements, poli cies, and procedures established by [CONTACT_1201]/EC.  Investigators are 
also responsible for promptly informing the IRB/EC of any protocol amendments (see
Section 9.7).
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IN D saf ety reports 
or other safety -related communications from the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by [CONTACT_11577]/EC, and 
archived in the site's study file. 
8.[ADDRESS_1109668] parties only as permitted by [CONTACT_25734] (or separate 
authorizatio n for use and disclosure of personal health information) signed by [CONTACT_4677], unless permitted or required by [CONTACT_2371].
Medical information may be given to a patient's personal physician or other appropriate 
medical personnel responsible for the patient's welfa re, for treatment purposes.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by [CONTACT_2371].  The aggregate results o f any conducted research will 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
118/Protocol BN40423 , Version 6be available in accordance with the effective Sponsor policy on study data publication 
(see Section 9.6).
Data generated by [CONTACT_25757], Sponsor monitors, 
representatives, and collaborators, and the IRB/EC for each study site, as appropriate.
Study data may be submitted to government or other health research databases or 
shared with researchers, government agencies, companies, or other groups that are not 
participating in this study.  These data may be combined with or linked to other data and 
used for research purposes, to advance science and public health, or for analysis, 
development, and commercialization of products to treat and diagnose disease. Linking 
of data will be facilitated by [CONTACT_601379] (see Section 4.5.2 ).The HDID is a unique 
coded identifier for persons participating in studies in HD.  This HDID will stay the same 
for a person throughout all trials.  The use of the unique identifier will assure that people 
are only enrolled once in large observational studies like Enroll -HD, REGISTRY, 
COHORT, PREDICT, and TRACK -HD and will also allow approved comparison and 
combination of data between studies.  The HDID is a 9-digit number created by a secure 
one-way algorithm, based on unchanging information (date of birth, birth name, place of 
birth and mother’s maiden name). The identifying data are used for the split second 
needed by [CONTACT_803961]. For patients without a 
pre-existing HDID number in the source notes, the investigator should store the original 
data and the newly generated HDID in the patient’s source documents and in the 
investigat or file.   The HDID can be generated within the web portals of the observational 
studies or in the specially defined portal for the HDID generation under: 
https://hdid.enroll -hd.org. Inaddition, redacted clinical study reports and other summary 
reports wi ll be provided upon request.
8.5 FINA NCIA L DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or di sclosure statements to the appropriate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study (see definition of end of 
study in Sectio n3.2).
9. STUDY DOCUMENTATION, MONITORING, A ND 
ADMINISTRA TION
9.[ADDRESS_1109669] of 
the study to be fully documented, including, but not limited to, the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/EC and 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
119/Protocol BN40423 , Version 6governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, including an audit trail containing a complete record of all changes to 
data.
9.[ADDRESS_1109670] on patient safety and 
data integrity to the Sponsor and to the IRB/EC in accordance with established IRB/EC 
policies and procedures.  The Sponsor will review all prot ocol deviations and assess 
whether any represent a serious breach of Good Clinical Practice guidelines and require 
reporting to health authorities.  As per the Sponsor's standard operating procedures, 
prospective requests to deviate from the protocol, incl uding requests to waive protocol 
eligibility criteria, are not allowed.
9.3 MANAGEMENT OF STUDY QUA LITY
The Sponsor will implement a system to manage the quality of the study, focusing on 
processes and data that are essential to ensuring patient safety and dat a integrity.  The 
Sponsor will identify potential risks associated with critical trial processes and data and 
will implement plans for evaluating and controlling these risks.  Risk evaluation and 
control will include the selection of risk -based parameters (e.g., adverse event rate, 
protocol deviation rate) and the establishment of quality tolerance limits for these 
parameters.  Detection of deviations from quality tolerance limits will trigger an 
evaluation to determine if action is needed.  Details on the establishment and monitoring 
of quality tolerance limits will be provided in a Quality Tolerance Limit Management Plan.
9.4 SITE INSPECTIONS
Site visits will be conducted by [CONTACT_26833], patients' me dical records, and eCRFs.  The investigator will 
permit national and local health authorities; Sponsor monitors, representatives, and 
collaborators; and the IRBs/ECs to inspect facilities and records relevant to this study.
9.5 ADMINISTRA TIVE STRUC TURE
This tr ial will be sponsored and managed by F. Hoffmann -La [COMPANY_002] Ltd.  The Sponsor 
will provide clinical operations management, data management, and medical monitoring.
Approximately 110sites globally , which may include The Republic of China, will
participate to enroll approximately 801patients after implementation of Version 4 of the 
protocol .  Enrollment will occur through an IxRS.   
Central facilities will be used for certain study assessments throughout the study 
(e.g., specified laboratory tests, biomarker and PK analyses), as specified in 
Section 4.5.6 .  Accredited local laboratories will be used for routine monitoring; local 
laboratory ranges will be collected.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
120/Protocol BN40423 , Version 6An iDMC will be employed to monitor and evaluate patient safety throughout the study.  
9.6 DISSEMINA TION OF DA TA AN D PROTECTION OF TRA DE 
SECRETS
Regardless of the outcome of a trial, the Sponsor is dedicated to openly providing 
information on the trial to healthcare professionals and to the public, at scientific 
congresses, in clinical trial registries, and in peer -reviewed journals. The Sponsor will 
comply with all requirements for publication of study results.  Study data may be shared 
with others who are not participating in this study (see Section 8.4for details) and 
redacted Clinical Study Reports and other summary reports will be made available upon 
request, provided the requirements of [COMPANY_002]'s global policy on data sharing have been 
met.  For more information, refer to the [COMPANY_002] Global Policy on Sharing of Clinical Trials
Data at the following web site:
www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.pdf
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in patients involving an IMP for which a marketing authorization application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial results within [ADDRESS_1109671] editorial a nd ethical practice, the Sponsor will generally 
support publication of multicenter trials only in their entirety and not as individual center 
data.  In this case, a coordinating investigator [INVESTIGATOR_12992].
Authorship will be determ ined by [CONTACT_14346].  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by [CONTACT_26834].
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
121/Protocol BN40423 , Version 69.7 PROTOCOL A MENDMENTS
Any protocol amendments will be prepared by [CONTACT_1034].  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact [CONTACT_3031]).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
122/Protocol BN40423 , Version 610. REFERENCES
Andrzejewski KL, Dowling AV, Stamler D, et al. Wearable sensors in Huntington 
disease: a pi[INVESTIGATOR_799]. J Huntington's Dis 2016; 5.2:199 206.
Adams JL, Dinesh K, Xiong M,et al. Multiple wearable sensors in parkinson and 
Huntington disease individuals: a pi[INVESTIGATOR_626876]. Digit 
Biomark 2017:1:52 63
Baig SS, Strong M, Quarrell OW . The global prevalence ofHuntington's disease: a 
systematic review and discussion. Neurodegener Dis Manag 2016;6:331 43.
Beglinger LJ, Prest L, Mills JA, et al. Clinical predictors of driving status in Huntington's 
disease. Mov Disord 2012;27:1146 52.
Bohanna I, Georgiou -Karistianis N, Sritharan A, et al. Diffusion tensor im aging in 
Huntington's disease reveals distinct patterns of white matter degeneration 
associated with motor cognitive deficits. Brain Imaging Behav 2011;5:171 80.
Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53 72.
Cerritelli SM, Crouch RJ. Ribonuclease H: the enzymes in eukaryotes. FEBS J 
2009;276:1494 505.
Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Annu Rev 
Pharmacol Toxicol 1996;36:107 29.
Dogan I, Eickhoff CR, Fox PT, et al. Functional connectivi ty modeling of consistent 
cortico -striatal degeneration in Huntington's disease. Neuroimage Clin 
2015;7:640 52.
Douaud G, Gaura V, Ribeiro MJ, et al. Distribution of grey matter atrophy in Huntington's 
disease patients: a combined ROI -based and voxel -based morphometric study. 
Neuroimage 2006;32:1562 75.
Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age of 
onset in Huntington's disease. Nat Genet 1993;4:387 92.
Espi[INVESTIGATOR_601333], Turner JA, Vergara VM, et al. Whole-brain connectivity in a large study of 
Huntington's disease gene mutation carriers and healthy controls . Brain Connect 
2018 ;8:166 78. 
EuroQol Group. EuroQol a new facility for the measurement of health- related quality of 
life. Health Policy 1990;16:199 208.
[FDA] Food and Drug Administration.  Guidance for industry: suicidal ideation and 
behavior: prospective assessment of occurrence in clinical trials [resource on the 
Internet] 2012 [cited 28 February 2018]. Available from: 
https://www.fda.gov/drugs/guidancecom plianceregulatoryinformation/guidances/uc
m315156.htm.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
123/Protocol BN40423 , Version 6[FDA] Food and Drug Administration. E9(R1) statistical principles for clinical trials: 
addendum: estimands and sensitivity analysis in clinical trials. [resource on the 
Internet] 2017 [cited [ADDRESS_1109672] 2 018]. Available from: 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM582738.pdf .
Feeny D, Furlong W, Boyle M, et al. Multi -attribute health status classification systems . 
Health utilities index. Pharmacoeconomics 1995;7:490 502.
Genetic Modifiers of Huntington's Disease Consortium. Identification of genetic factors 
that modify clinical onset of Huntington's disease. Cell 2015;162:516 26.
Harrington DL, Long JD, Durgerian S, et al. Cross -sectional and longitudinal m ultimodal 
structural imaging in prodromal Huntington's disease. Mov Disord 
2016;31:1664 75.
Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new 
five-level version of EQ -5D (EQ -5D-5L). Qual Life Res 2011;20:1727 36.
Hogarth P, Kayson E, Kieburtz K, et al. Interrater agreement in the assessment of motor 
manifestations of Huntington's disease. Mov Disord 2005;20:293 7.
Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and 
consistency. Mov Disord 1996 ;11:136 42.
Janssen MF, Pi[INVESTIGATOR_19370], Golicki D, et al. Measurement properties of the EQ -5D-5L 
compared to the EQ -5D-3L across eight patient groups: a multi -country study. 
Qual Life Res 2013;22:1717 27.
Johnson EB, By[CONTACT_597684], Gregory S, et al. Neurofilament light protein in blood predicts 
regional atrophy in Huntington disease. Neurology 2018;90:e717 23.
Kordasiewicz HB, Stanek LM, W ancewicz EV, et al. Sustained therapeutic reversal of 
Huntington's disease by [CONTACT_626957]. Neuron 
2012;74:1031 44.
Lipsmeier F, Taylor KI, Kilchenmann T, et al. Evaluation of smartphone- based tsting to 
generate exploratory outcome measures in a phase 1 Parkinson' s disease clinical 
trial. Mov Diso rd 2018. doi : 10.1002/mds.[ZIP_CODE]. Epub ahead of print.
Liu JP, Zeitlin SO. Is huntingtin dispensable in the adult brain? J Huntingtons 
Dis2017;6:1 17.
Liu W , Yang J, Chen K, et al. Resting -state fMRI reveals potential neural correlates of 
impaired cognition in Huntington's disease. Parkinsonism Relat Disord
2016;27:41 6.
Maet zler W , Domingos J, Srulijes K, et al. Quantitative wearable sensors for objective 
assessment of Parkinson's disease. Mov Disord 2013;28:1628 37.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
124/Protocol BN40423 , Version 6McCarrier KP, Deal LS, Abraham L, et al. Patient -centered research to support the 
development of the Symptoms of Major Depressive Disorder Scale (SMDDS): 
initial qualitative research. Patient 2016;9:117 34.
Moumné L, Be tuing S, Caboche J. Multiple aspects of gene dysregulation in 
Huntington's disease. Front Neurol 2013;4:127.
Nance M, Paulsen JS, Rosenblatt A, et al. A physician's guide to the management of 
Huntington's disease, 3rdedition. Huntington's Disease Society of America, 2011. 
Novak MJ, Seunarine KK, Gibbard CR, et al. Basal ganglia -cortical structural 
connectivity in Huntington's disease. Hum Brain Mapp 2015;36:1728 40.
Paulsen JS, Long JD, Ross CA, et al. Prediction of manifest Huntington's disease with 
clinical and imaging measures: a prospective observational study. 
Lancet Neurol 2014;13:1193 201.
Paulson HL, Albin RL. Huntington’s disease: clinical features and routes to therapy. In: 
Lo DC, Hughes RE, editors. Neurobiology of Huntington's disease: appl ications to 
drug discovery. Boca Raton (FL): CRC Press/Taylor & Francis; 2011: Chapter 1.
Peinemann A, Schuller S, Pohl C, et al. Executive dysfunction in early stages of 
Huntington's disease is associated with striatal and insular atrophy: a 
neuropsycholo gical and voxel -based morphometric study. J Neurol Sci 
2005;239:11 9.
Penney JB, Young AB, Shoulson I, et al. Huntington’s disease in Venezuela: 7 years of 
follow -up on symptomatic and asymptomatic individuals.  Movement Disorders 
1990;5:93 9.
Posner K, Br own GK, Stanley B, et al. The Columbia -Suicide Severity Rating Scale: 
initial validity and internal consistency findings from three multisite studies with 
adolescents and adults. Am J Psychiatry 2011;168:1266 77.
Ross CA, Pantelyat A, Kogan J, et al. Determinants of functional disability in 
Huntington's disease: role of cognitive and motor dysfunction. Mov Disord 
2014;29:1351 8.
Rubin DB. Multiple Imputation for Nonresponse in Surveys. [LOCATION_001]: John W iley and 
Sons. 1987.
Schobel SA, Palermo G, Auinger P, et al. Motor, cognitive, and functional declines 
contribute to a single progressive factor in early HD.
Neurology 2017 ;89:2495 2502.
Schoch KM, Miller TM. Antisense oligonucleotides: translation from mouse models to 
human neurodegenerative diseases. Ne uron 2017;94:1056 70.
Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. 
Neurology 1979;29:1 3.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
125/Protocol BN40423 , Version 6Smith, A. Symbol Digit Modalities Test (SDMT). Manual (rev.). Los Angeles: Western 
Psychological Services, 1982.
Sorensen SA, Fenger K. Causes of death in patients with Huntington's disease and in 
unaffected first degree relatives. J Med Genet 1992;29:911 4.
Stanek LM, Yang W, Angus S, et al. Antisense oligonucleotide -mediated correction of 
transcriptional dysregulat ion is correlated with behavioral benefits in the YAC128 
mouse model of Huntington's disease. J Huntingtons Dis 2013;2:217 28.
Tabrizi SJ, Reilmann R, Roos RAC, et al. Potential endpoints for clinical trials in 
premanifest and early Huntington's disease in the TRACK -HD study: analysis of 
24month observational data. Lancet Neurol 2012;11:42 53.
Van Raamsdonk JM, Pearson J, Rogers DA, et al. Loss of wild -type huntingtin 
influences motor dysfunction and survival in the YAC128 mouse model of 
Huntington disease . Hum Mol Genet 2005;14:1379 92.
Walker FO. Huntington's disease. Semin Neurol 2007;27:143 50.
Werner CJ, Dogan I, Saß C, et al. Altered resting -state connectivity in Huntington's 
disease. Hum Brain Mapp 2014;35:2582 93.
Wexler NS, Young AB, Tanzi RE, et al. Homozygotes for Huntington's disease. Nature 
1987;326:194 7.
Wild EJ, Boggio R, Langbehn D, et al. Quantification of mutant huntingtin protein in 
cerebrospi[INVESTIGATOR_601335]'s disease patients. J Clin Invest 
2015;125:1979 86.
Wild EJ, Tabrizi SJ. Therapi[INVESTIGATOR_601336]'s disease. Lancet 
Neurol 2017;16:837 47.
Zhang Y, Long JD, Mills JA, et al. Indexing disease p rogression at study entry with 
individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr 
Genet 2011 ;156:75163.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
126/Protocol BN40423 , Version 6Appendix 1a Schedule of A ctivities for Patients Enrolled after Implementation of Protocol 
Version 4
ScreeningaBL Treatment Period EoTbEoT 
for 
ETTbSafety 
Follow -Up 
CallseeETTbSFU
Month 1 3 5 7 9 11 13 15 17 19 21 23 25 25 29
Week 4 to  1 1 5 13 21 29 37 45 53 61 69 77 85 93 101 101 117
Day (W indow) 28 to  21 1 ( 3 (7)dd(7) (7) (56)
Signed informed consentcx
Review of inclusion and 
exclusion criteria x
Demographic data x
Medical histor y and baseline 
conditionsd x xe
Blood sample for CAG repeat 
lengthx
Viral serologyfx
Thyroid panelgx
Vital signshx xex x x x x x x x x x x x x x x
Complete phy sical examination ix xex x x x x x
Neurologic examinationjx xex x x x x x x x x x x x x x x x
ECGkx xex x x x x x x
Hematologylx x x x x x x x x x x x x x x x x x
Chemistrymx x x x x x x x x x x x x x x x x x
Pregnancy testnx xex x x x x x x x x x x x x x x x
Appendix 1a:  Schedule of A ctivities for Patients Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
127/Protocol BN40423 , Version 6ScreeningaBL Treatment Period EoTbEoT 
for 
ETTbSafety 
Follow -Up 
CallseeETTbSFU
Month 1 3 5 7 9 11 13 15 17 19 21 23 25 25 29
Week 4 to  1 1 5 13 21 29 37 45 53 61 69 77 85 93 101 101 117
Day (W indow) 28 to  21 1 ( 3 (7)dd(7) (7) (56)
Local INR and/or PT , aPTT, 
platelet countxx x x x x x x x x x x x x x x x
Urinalysis ox x x x x x x x x x x x x x x x x x
Plasma sample for PK x x x xp x x x x x
Plasma sample for 
immunogenicity testingx x x x x x x x x x x
Plasma sample for biomarkers x x x x x x x x x x x
Blood sample for clinical 
genotypi[INVESTIGATOR_803874]/safety/biomarkersx x x x x x x x x x x x x xyx x
MRIqx x x x x x
HD-DAS x x x x x x x
Independence Scale x x x x x x x x x x x
MoCA x x x x x x x x x x x
C-SSRSrx xex x x x x x x x x x x x x x x
UHDRS FA x x x x x x x x x x
Appendix 1a:  Schedule of A ctivities for Patients Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
128/Protocol BN40423 , Version 6ScreeningaBL Treatment Period EoTbEoT 
for 
ETTbSafety 
Follow -Up 
CallseeETTbSFU
Month 1 3 5 7 9 11 13 15 17 19 21 23 25 25 29
Week 4 to  1 1 5 13 21 29 37 45 53 61 69 77 85 93 101 101 117
Day (W indow) 28 to  21 1 ( 3 (7)dd(7) (7) (56)
TFCsx x x x x x x x x x
TMSs, ccx x x x x x x x x x x
CGI-S x x x x x x x x x x
CGI-C x x x x x x x x x
SDMTsx x x x x x x x x x
SWRsx x x x x x x x x x
AES x x x x x x x x x
SMDD S x x x x x x x x x
NeuroQoL x x x x x x x x x x
EQ-5D-5L (in -clinic) x x x x x x x x x x
PGI-S x x x x x x x x x x
PGI-C x x x x x x x x x
[COMPANY_002] HD mobile app in- clinic 
assessmentsx x x x x x x
[COMPANY_002] HD mobile app remote 
data collectionContinuous remote data collectiontx
Optional exit interview ux x
CRQ: EQ-5D-5L, HUI -self, HUI -
proxy, CrGI -Sx x x x x x x x x x
Appendix 1a:  Schedule of A ctivities for Patients Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
129/Protocol BN40423 , Version 6ScreeningaBL Treatment Period EoTbEoT 
for 
ETTbSafety 
Follow -Up 
CallseeETTbSFU
Month 1 3 5 7 9 11 13 15 17 19 21 23 25 25 29
Week 4 to  1 1 5 13 21 29 37 45 53 61 69 77 85 93 101 101 117
Day (W indow) 28 to  21 1 ( 3 (7)dd(7) (7) (56)
CRQ: AES x x x x x x x x x
CRQ: CrGI -C x x x x x x x x x
Remote data collection of CRQ 
(EQ- 5D-5L, HUI -self, HUI -
proxy, HD- CIAOS, W PAI)Remote data coll ection (see Appendix 4) x
Blood sample for RBR DNA 
(optional)vx
Blood sample for RBR RNA
(optional)v x x x x x
Serum sample for RBR
(optional) vx x x x x
Change in medical information 
since previous visitwx xxxxxxxxxxx x x x x x
Lumbar puncture xx x xxxxxxxxxxx xyxy xy
Study drug administration x xxzxxzxxzxxzxxzxxz
Concomitant medicationsaax x x x x x x x x x x x x x x x x x x x
Adverse events bbx x x x x x x x x x x x x x x x x x x x
ADAanti-drug antibody; AES Apathy Evaluation Scale; BL baseline; CGI-C Clinical Global Impression, Change; CGI -SClinical Global 
Impression, Severity; CrGI -CCompanion -Reported Global Impression, Change; CrGI -SCompanion -Reported Global Impression, Severity;
CRQCompanion -reported questionnaire; CSF cerebrospi[INVESTIGATOR_872]; C SSRS Columbia -Suicide Severity Rating Scale; cUHDRS composite 
Appendix 1a:  Schedule of A ctivities for Patients Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
130/Protocol BN40423 , Version 6Unified Huntington's Disease Rating Scale; DCL diagnostic confidence level; eCRF electronic Case Report Form; EoT end of treatment; EQ -
5D-5LEuroQol 5 -Dimension, 5 -Level Questionnaire; ETT early treatment termination; FA Functional Assessment; HBsAg hepatitis B surface 
antigen; HCV hepatitis C virus; HD Huntington disease; HD -CIAOS Huntington's Disease Companion -Reported Irritability and Angr y Outbursts 
Scale; HD-DASHD Daily Activities Scale; HUI Health Utilities Index; LPlumbar puncture; MoCA Montreal Cognitive Assessment; 
MRImagnetic resonance imaging; Neuro -QolQuality of Life in Neurological Disorders; PGI -CPatient Global Impression, Change; PGI -
SPatient Global Impression, Sever ity; PK pharmacokinetic; Q8W every 8 weeks; RBR Research Biosample Repository; SDMT Symbol 
Digit Modalities Test; SFU safety  follow -up; SMDDS Symptoms of Major Depressive Disorder Scale; S WRStroop W ord Reading; TFC Total 
Functional Capacity Scale; TMS Total Motor Score ; UHDRS Unified Huntington's Disease Rating Scale.
Notes:  All assessments should be performed at the scheduled visit, unless otherwise specified.  On treatment days, all asses sments should be 
performed prior to dos ing, unless otherwise specified.  
aA maxim um of one re -screening will be allowed within 8 weeks of the initial screening failure for patients who fail the initial screening (e.g., as a 
consequence of abnormal laboratory values or general medical status n ot meeting inclusion or exclusion criteria).  If re -screening is required, 
CAG repeat length testin gfrom the initial screening does not need to be repeated (historical values will not be accepted). The screening MRI and 
viral serology from the initial screening , including for other [COMPANY_002] studies, may be acceptable as part of the re -screening assessments, if 
performed within 12 weeks of the baseline visit.  
bPatients who complete the treatment period will return to the clinic for a treatment completion visit at Week 101 (i.e., the EoT visit).  All patients 
enrolled in Study BN40423 who discontinue study treatment prematurely but do not withdraw consent for continued participation in the study 
(including all patients from 22 March 2021 )will follow the ETT visit schedule (see Appendix 1b and Section [IP_ADDRESS] ).Study  visits should be 
planned as per the study schedule, however under exceptional circumstances, atime window of [ADDRESS_1109673] within 56 days of the decision to discontinue the study treatment.
Patients enrolled prior to implementation of Version 4 of the protocol: all patients will be prematurely discontinued from the Study BN40423 and 
will complete their EoT visit for early treatment termination prior to entry into Study BN40955.
cInformed consent must be documented before any study -specific screening procedure is performed and may be obtained more than 28 days 
before initiation of study treatment.
dMedical histor y, including clinically significant diseases, surgeries, HDhistory (including past hospi[INVESTIGATOR_602] [i.e., number, duration, and 
reason]) , over the last [ADDRESS_1109674] on Day  1 or Day 1.
fViral serology: HBsAgand HCV antibo dy(or viral RNA if HCV antibody assay is positive )
gThyroid panel:  thy roid-stimulating hormone and free thyroxine (also known as T4) levels. 
hVital signs include respi[INVESTIGATOR_697], pulse, temperature, and s ystolic and diastolic blood p ressure while the patient is in a seated position after 
resting for approximately 5 minutes.  All data should be recorded on the appropriate eCRF.
Appendix 1a:  Schedule of A ctivities for Patients Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
131/Protocol BN40423 , Version 6iA complete physical examination ,performed at screening and other specified visits, should include an evaluati on of the head, eyes, ears, nose, 
and throat, and the cardiovascular, dermatologic, musculoskeletal, respi[INVESTIGATOR_696], gastrointestinal , and neurologic systems; g enitourinar y 
examinations may  be performed if clinically indicated.   The physi cal examinations should be conducted in the same manner on each occasion to 
ensure comparability to previous examinations. Changes from baseline abnormalities should be recorded in patient notes.  New or worsened 
clinically significant abnormalities (i.e. ,beyond expected variation or normal age -related change) should be recorded as adverse events on the 
Adverse Event eCRF.   Height will be measured atscreening and baseline only.
jA neurologic examination (including fundoscopy) ,perfor med at screening and at every clinical visit, should include assessment of mental status, 
level of conscious ness, cranial nerve function, motor function, sensor y function, reflexes, gait, and coordination.  The neurologic examinations 
should be conducted in the same manner on each o ccasion to ensure comparability to previous examinations.  Neurologic examinations should 
be performed before and after treatment on each dosing day.  At visits when an LP is performed and study treatment is not administer ed, the 
neurological examination should be performed prior to the LP.Weight should also be measured at each visit. Any abnormality identified at 
baseline (Week 1)should be recorded on the General Medical Histor y and Baseline Conditions eCRF.  Changes from baseline abnormalities 
should be recorded in patient notes.  New or worsened clinically significant abnormalities (i.e., beyond expected variation or normal age -related 
change) should be recorded as adverse events on the Adverse Event eCRF.  
kTriplicate ECG are to be performed within approximately 5 minutes of each other, after the patient has been in a supi[INVESTIGATOR_282112] 10 minutes.  ECGs for each patient should be obtained from the same machine whenever possible.  At screening ,baseline 
(Day 1 or Day 1) and other visits , pre-dose ECG should be performed prior to any blood draws and where applicable before the lumbar 
puncture.   For patients in Japan, additional triplicate ECG monitoring will be performed at 2 (± 30 minutes), 4 (± 30 minut es), and 
6(±30minutes) hours following the first administration of study drug (Day 1).
lHematology includes WBC count, RBC count, platelet count, hemoglobin, hematocrit, differential count (neutrophils, eosinophil s, basophils, 
monocy tes, ly mphocy tes).
mSerum chemistry  panel:  includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, potassium, chloride, 
glucose, BUN or urea, creatinine, total protein, albumin, phosphorus, calcium, total and direct bilirubin, ALP, ALT, AST, uric acid, 
gamma -glutam yl transferase , and CPK .
nAll women of childbearing potential will have a serum pregnancy test at screening.  Urine pregnanc y tests will be performed at specified 
subsequent visits.  If aurine pregnanc y test is positive, it must be confirmed by a serum pregnancy test.
oUrinalysis includes dipstick (pH, specific gravity, glucose, protein, ketones, blood) and microscopic examination for all abnormal dipstick results 
(sediment, RBCs, W BCs, casts, cry stals, epi[INVESTIGATOR_159722], bacteria).  
pAt the W eek [ADDRESS_1109675] be available before the patien t can be enrolled in 
the study.  At Weeks 13, 37, 69 , 101 and at the EoT for ETT visit the MRI should be scheduled to occur before the lumbar puncture.  TheMRI 
scan should be performed 7 14 days prior to the lumbar puncture to allow time for re -scanning if the quality of the initial MRI is inadequate. If the 
Appendix 1a:  Schedule of A ctivities for Patients Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
132/Protocol BN40423 , Version 6re-scan cannot be performed prior to the lumbar puncture, then it can be conducted the day after the lumbar puncture, as long as there are no 
post-lumbar puncture contraindication sand it occurs within 2 weeks of the original scan.
rThe C-SSRS will be used to assess eligibility for the study (full version at screening , requiring approximately 20 minutes to administer) and to 
monitor the patients throughout the study at clinic visits (follow -up version, requiring approximately 5 minutes to administer, assuming absence of 
suicidal ideation and no change in clinical status from previous administration).
sThe cUHDRS is a composite motor, cognitive, and global functional clinical outcome measure in patients with HD comprised of t he TFC, the 
TMS, the SDMT, and the SW R scores.
tThe electronic devices for remote data collection will be supplied to patients at screening and must be returned to the clini c in cases where the 
patient does not meet eligibility criteria, at the end of the study, or u pon early termination from the study.  
uOptional exit interviews will be conducted for patients who consent from the selected sites within approximately 1 week after the EoT visit; these 
interviews can be conducted by [CONTACT_803962] -clinic videotaped session .  
vNot applicable for a site that has not been granted approval for RBR sampling.  Performed only for patients at participating sites who have 
provided written informed consent to participate.
wAtthe time of each study drug administration , non -dosing visit ,and safety follow -up telephone calls , an interval medical history should be 
obtained and any changes in medications, any major procedures or hospi[INVESTIGATOR_602], and any physician visits for HD or general medical care 
should be recorded.
Appendix 1a:  Schedule of A ctivities for Patients Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
133/Protocol BN40423 , Version 6xPrior to performing each scheduled lumbar puncture, local laborator y analysis of coagulation factors (INR and/or PT , aPTT) and platelets must 
be conducted and the results reviewed.  Collection for these local lab oratory tests may occur at any time in the 72 hours prior to the lumbar 
puncture.  The lumbar puncture should be performed at approximately the same time at each visit (ideally in the morning betwe en 8:00 a.m. and 
12:00 noon or in the early afternoon betwe en 12:00 noon and 3:00 p.m.) to minimize potential diurnal variation of CSF parameters.  CSF fluid 
(20mL) is to be collected for analyses using a lumbar puncture collection kit.  If there are difficulties in collecting [ADDRESS_1109676]-LP procedure (e.g., air travel, scuba diving, or hot 
air balloons) .  In the case of a failed IT bolus dosing or a failed CSF collection procedure (e.g., due to an inadequate establishment of access to 
the IT space ), a second attempt may  occur up to 7 days after the originally scheduled attempt. For this additional visit, safety and tolerability 
evaluations on the day of LP administration will be performed, i ncluding neurological examination (predose and postdose, or pre -procedure if no 
study treatment is being administered ),vital signs, and a review of adverse events and concomitant medication.  If the second attempt occurs 
more than [ADDRESS_1109677] a ttempt, local laboratory analysis of coagulation factors (INR and/or PT, aPTT) and platelets need to be 
conducted again and results reviewed prior to the LP attempt.
yCSF sample swill be obtained at the Week 101 EoT , Week 101 EoT for ETT, and ETT visit s, but no study drug will be administered.
zPatients in Q16 Warm will receive placebo at these visits.
aaMedication (e.g., prescription drugs, over -the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a 
patient in addition to protocol -mandated treatment from screening to the study completion/ discontinuation visit.
bbAfter informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protoc ol-mandated 
intervention should be reported.  After initiation of study drug, all adverse events will be reported until 5 months af ter the final dose of study drug.  
After this period, all deaths, regardless of cause, should be reported.  In addition, the Sponsor should be notified if the i nvestigator becomes 
aware of any serious adverse event that is believed to be related to prior s tudy drug treatment.  
ccThe DCL will be assessed at screening only (i.e., without the full TMS assessment).  The TMS scale will be assessed (excludin g the DCL) at all 
other timepoints.
ddExcluding MRIs, which have a visit window of  14 to 7 days.
eeDuring the treatment period, a safety follow -up telephone call will be conducted for the months in which no clinic visits are. A safety follow -up 
call will also be conducted approximately 2 months after the W eek 101 visit. Telephone safety follow -up calls will assess any changes to ongoing 
adverse events or occurrence of new adverse events and changes to concomitant medication.  Unscheduled visits can occur based on the 
outcome of this safety follow -up call.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
134/Protocol BN40423 , Version 6Appendix 1b Schedule of Activities for Early Treatment Termination (Applicable to all 
Patients from 22 March 2021)
Visit ETTa FU Week 53aFU Week 69aEoT for ETT
(Week 101)aSafety Follow -
Up Callsb
Month 13 17 25
Window (days)56 days after the decision to 
discontinue study treatment (7) (7) (7)c (7)
Vital signsd x
Complete physical examinatione x
Neurologic examinationf x x
ECGg x x
Hematologyh x x
Chemistryi x x
Pregnancy testj x x
Local INR and/or PT, aPTT, platelet countk x x
Urinalysisl x x
Plasma sample for PK x
Plasma sample for immunogenicity testing x x
Plasma sample for biomarkers x x
CSF sample for safety/biomarkers x x
MRIm x
Independence Scale x x x x
MoCA x x x x
C-SSRSn x x x x
UHDRS FA x x x x
Appendix 1b : Schedule of A ctivities for Early  Treatment Termination (A pplicable to all Patients from 22 March 
2021) (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
135/Protocol BN40423 , Version 6Visit ETTa FU Week 53aFU Week 69aEoT for ETT
(Week 101)aSafety Follow -
Up Callsb
Month 13 17 25
Window (days)56 days after the decision to 
discontinue study treatment (7) (7) (7)c (7)
TFCo x x x x
TMSo x x x x
CGI-S x x x x
CGI-C x x x x
SDMTo x x x x
SWRo x x x x
AES x
SMDDS x
NeuroQoL x x
EQ-5D-5L (in -clinic) x x
PGI-S x x
PGI-C x x
[COMPANY_002] HD mobile app in -clinic assessments x x
[COMPANY_002] HD mobile app remote data collection Continuous remote data collectionp
Optional exit interview x
CRQ: EQ -5D-5L, HUI -self, HUI -proxy, CrGI -S x x
CRQ: AES x
CRQ: CrGI -C x x
Remote data collection of CRQ (EQ -5D-5L, 
HUI -self, HUI -proxy, HD -CIAOS, WPAI)Remote data collection
Appendix 1b : Schedule of A ctivities for Early  Treatment Termination (A pplicable to all Patients from 22 March 
2021) (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
136/Protocol BN40423 , Version 6Visit ETTa FU Week 53aFU Week 69aEoT for ETT
(Week 101)aSafety Follow -
Up Callsb
Month 13 17 25
Window (days)56 days after the decision to 
discontinue study treatment (7) (7) (7)c (7)
Blood sample for RBR RNA (optional)r x
Serum sample for RBR (optional)r x
Change in medical information since previous 
visitsxx x x
Lumbar puncturek xt xt
Concomitant medicationsu x x x x
Adverse eventsv x x x x
AESApathy Evaluation Scale; CGI -CClinical Global Impression, Change; CGI -SClinical Global Impression, Severity; CrGI -
CCompanion -Reported Global Impression, Change; CrGI -SCompanion -Reported Global Impression, Severity; CRQ Companion -reported 
questionnaire; CSF cerebrospi[INVESTIGATOR_872]; CSSRS Columbia -Suicide Severity Rating Scale; cUHDRS composite Unified Huntington's 
Disease Rating Scale; eCRF electronic Case Report Form; EoT end of treatment; EQ -5D-5LEuroQol 5 -Dimension, 5 -Level Questionnaire; 
ETTearly treatment terminat ion; FA Functional Assessment; FUfollow- up; HDHuntington disease; HD -CIAOS Huntington's 
Disease Companion -Reported Irritability and Angry Outbursts Scale; HUIHealth Utilities Index; LP lumbar puncture; MoCA Montreal 
Cognitive Assessment; MRI magnetic resonance imaging; Neuro- QolQuality of Life in Neurological Disorders; PGI -CPatient Global 
Impression, Change; PGI -SPatient Global Impression, Severity; PK pharmacokinetic; RBR Research Biosample Repository; 
SDMT Symbol Digit Modalities Test; SMDDS Symptoms of Major Depressive Disorder Scale; SWR Stroop Word Reading; TFC Total 
Functional Capacity Scale; TMS Total Motor Score; UHDRS Unified Huntington's Disease Rating Scale.
Notes:  Unscheduled safety assessments (MRI, ECG, safety laboratory assessments, vital signs) can be performed if clinically indicated .
aAll patients who discontinue study treatment prematurely but do not withdraw consent for continued participation in the study (this 
includes all patients from 22 March 2021) will attend a minimum of two and up to four in -clinic visits depending on which visits have 
already been completed at the time of study drug discontinuation (see Figure 3).  Patients will complete an ETT visit within 56 days (8 
weeks) of the decision to discontinue study treatment (i.e., 22 March 2021) .  Patients will also return to the clinic for FU study visits at 
Weeks 53 and 69 (if not already completed) for collection of clinical outcome data for the primary and secondary endpoints (see Sec tions 2.1.1 , 
2.1.2 , 2.2 and the table above).  If the ETT visit falls within 30 days of either scheduled visits at Week 53 or Week 69, then only the ETT 
visit should be performed.  Patients will also attend the scheduled EoT for ETT visit at Week 101.  Study visits should be planned as per the 
study schedule, however under exceptional circumstances, a time window of 7 days can be utilized where shown. 
Appendix 1b : Schedule of A ctivities for Early  Treatment Termination (A pplicable to all Patients from 22 March 
2021) (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
137/Protocol BN40423 , Version 6bAfter study treatment discontinuation, a safety follow -up telephone call should be conducted every [ADDRESS_1109678] a visit window of 14 to 7 days .
dVital signs include respi[INVESTIGATOR_697], pulse, temperature, and systolic and diastolic blood pressure while the patient is in a seated position after 
resting for approximately 5 minutes.  All data should be recorded on the appropriate eCRF.
eThe complete physical examination should includ e an evaluation of the head, eyes, ears, nose, and throat, and the cardiovascular, 
dermatologic, musculoskeletal, respi[INVESTIGATOR_696], gastrointestinal, and neurologic systems ; genitourinary examinations may be performed if 
clinically indicated.   Changes from bas eline abnormalities should be recorded in patient notes.  New or worsened clinically significant 
abnormalities (i.e., beyond expected variation or normal age -related change) should be recorded as adverse events on the Adverse Event eCRF.  
fA neurologic examination (including fundoscopy) should include assessment of mental status, level of consciousness, cranial nerve function, 
motor function, sensory function, reflexes, gait, and coordination.  The neurologic examinations should be conducted in the same m anner on 
each occasion to ensure comparability to previous examinations.  At visits when an LP is performed and study treatment is not administered, 
the neurological examination should be performed prior to the LP . Changes from baseline abnormalities should be recorded in patient notes.  
New or worsened clinically significant abnormalities (i.e., beyond expected variation or normal age -related change) should be recorded as 
adverse events on the Adverse Event eCRF.  
gTriplicate ECG are to be performed wit hin approximately 5 minutes of each other, after the patient has been in a supi[INVESTIGATOR_282112] 10 minutes.  ECGs for each patient should be obtained from the same machine whenever possible.  The ECG should be 
performed prior to any blood draw s and before the lumbar puncture.  
hHematology includes WBC count, RBC count, platelet count, hemoglobin, hematocrit, differential count (neutrophils, eosinophil s, basophils, 
monocytes, lymphocytes).
iSerum chemistry panel:  includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, potassium, 
chloride, glucose, BUN or urea, creatinine, total protein, albumin, phosphorus, calcium, total and direct bilirubin, ALP, ALT, AST, uric acid, 
gamma -glutamyl transfera se, and CPK.
jUrine pregnancy tests will be performed at specified visits.  If aurine pregnancy test is positive, it must be confirmed by a serum pregnancy 
test.
Appendix 1b : Schedule of A ctivities for Early  Treatment Termination (A pplicable to all Patients from 22 March 
2021) (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
138/Protocol BN40423 , Version 6kPrior to performing each scheduled lumbar puncture, local laboratory analysis of coagulati on factors (INR and/or PT, aPTT) and platelets 
must be conducted and the results reviewed.  Collection for these local laboratory tests may occur at any time in the 72 hour s prior to the 
lumbar puncture.  The lumbar puncture should be performed at approxim ately the same time at each visit (ideally in the morning between 
8:00 a.m. and 12:00 noon or in the early afternoon between 12:00 noon and 3:00 p.m.) to minimize potential diurnal variation of CSF 
parameters.  CSF fluid (20 mL) is to be collected for anal yses using a lumbar puncture collection kit.  If there are difficulties in collecting 
20mL of CSF fluid, a minimum of [ADDRESS_1109679] -LP procedure (e.g., air travel, scuba diving, or hot air 
balloons) .  In the case of a failed CSF collection procedure (e.g., due to an inadequate establishme nt of access to the IT space), a second 
attempt may occur up to [ADDRESS_1109680] attempt, local laboratory analysis of coagulation factors 
(INR and/or PT, aPTT) and platelets need t o be conducted again and results reviewed prior to the LP attempt.
lUrinalysis includes dipstick (pH, specific gravity, glucose, protein, ketones, blood) and microscopic examination for all abn ormal dipstick 
results (sediment, RBCs, WBCs, casts, crystals, epi[INVESTIGATOR_1663], bacteria).  
mThe MRI should be scheduled to occur before the lumbar puncture.  The MRI scan should be performed 7 [ADDRESS_1109681] -lumbar puncture contraindication sand it 
occurs within 2 weeks of the original scan.
nThe C -SSRS will be used to monitor the patients (follow -up version, requiring approximately 5 minutes to administer, assuming absence of 
suicidal ideation and no change in clinical status from previous administration).
oThe cUHDRS is a composite motor, cognitive, and global functional clinical outcome measure in patients with HD co mprised of the TFC, the 
TMS, the SDMT, and the SWR scores.
pThe electronic devices for remote data collection will be supplied to patients at screening and must be returned to the clini c in cases where the 
patient does not meet eligibility criteria, at th e end of the study, or upon early termination from the study.  
qOptional exit interviews will be conducted for patients who consent from the selected sites within approximately 1 week after the EoT for 
ETT visit; these interviews can be conducted by [CONTACT_803963] -clinic videotaped session.  
rNot applicable for a site that has not been granted approval for RBR sampling.  Performed only for patients at participating sites who have 
provided written informed consent to particip ate.
Appendix 1b : Schedule of A ctivities for Early  Treatment Termination (A pplicable to all Patients from 22 March 
2021) (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
139/Protocol BN40423 , Version 6sAn interval medical history should be obtained at each clinic visit and safety telephone call and any changes in medications, any major 
procedures or hospi[INVESTIGATOR_602], and any physician visits for HD or general medical care should be recorded.
tCSF samples will be obtained at the Week 101 EoT for ETT, and ETT visits but no study drug will be administered.
uMedication (e.g., prescription drugs, over -the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a 
patient in addition to protocol -mandated treatment from screening to the study completion/discontinuation visit.
vAlladverse events will be reported until 5 months after the final dose of study drug.  After this period, all deaths, regardless of cause, should 
be reported.  In addition, the Sponsor should be notified if the investigator becomes aware of any serious adve rse event that is believed to be 
related to prior study drug treatment (see Section 5.6).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
140/Protocol BN40423 , Version 6Appendix 2Clinician -Reported Outcomes for Patients Enrolled after Implementation of Protocol 
Version 4
Assessment Name [CONTACT_601384]. 
Duration Timing
FAUHDRS Functional 
Assessment25 Daily function 15 minBaseline and W eeks5, 21, 37, 53, 
69, 85, and 101 and ETT visits
IS Independence Scale 1 Functional disability 3 minScreening, baseline, and Weeks5, 
21, 37, 53, 69, 85, and 101 and 
ETT visits
TFCTotal Functional 
Capacity Scale5 Overall function 10 minBaseline and W eeks5, 21, 37, 53, 
69, 85, and 101 and ETT visits
TMS Total Motor Score 31 Motor function 15 minDCL only: Screening
TMS without DCL: Baseline and 
Weeks5, 21, 37, 53, 69, 85, and 
101 and ETT visits
C-SSRSColum bia-Suicide 
Severity Scale5Suicidal ideation 
andbehavior20 minfull 
version ; 
5 min follow -up 
versionFull version at screening in clinic ; 
follow -up version at baseline and all 
post-baseline clinic visits 
CGI-SClinical Global 
Impression Severity1Overall severity of 
patient status2minBaseline and W eeks5, 21, 37, 53, 
69, 85, and 101 and ETT visits
CGI-CClinical Global 
Impression Change1Overall change in 
patient status2minWeeks5, 21, 37, 53, 69, 85, and 
101 and ETT visits 
HD-DASHuntington's 
Disease Daily 
Activities Scale 25 Daily function 25 minScreening and Weeks13, 29, 45, 
61, 77, and 93
DCLdiagnostic confidence level.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
141/Protocol BN40423 , Version 6Appendix 3Patient-Reported, Observer -Reported, and Performance Outcomes
and [COMPANY_002] HD Mobile Application for Patients Enrolled after Implementation of Protocol 
Version 4
Assessment Name [CONTACT_601384].
Duration
(min)PRO ,ObsRO , 
PerfO, 
Behavior Timing Location
AESApathy Evaluation 
Scale18 Apathy 10 PRO ObsROBaseline and 
Weeks13, 29, 45, 61, 
77, 93, and 101In-clinic
[COMPANY_002] HD 
mobile app [COMPANY_002] HD mobile app 
with daily Active Test 
and Passive 
MonitoringNATasks (“active test”) that assess 
motor sy mptoms (upper and 
lower body movements, upper 
limb dexterity, voice) and 
non-motor sy mptoms 
(processing speed/voice); 
continuous passive monitoring5Sensor data, 
PRO , PerfODaily at clinic visits 
(Screening, baseline 
and W eeks 5, 53 , and 
101 and ETT visits) [COMPANY_002] HD 
mobile app
CrGI -CCompanion -Reported 
Global Impression, 
Change1 Overall change in patient status 2 ObsROWeeks5, 21, 37, 53, 
69, 85, and 101 and 
ETT visitsIn-clinic on 
electronic 
device
CrGI -SCompanion -Reported 
Global Impression, 
Severity1 Overall severity of patient status 2 ObsROBaseline and W eeks5, 
21, 37, 53, 69, 85, and 
101 and ETT visitsIn-clinic on 
electronic 
device
EQ-5D-5LEuroQol 5 -Dimension , 
5-Level Questionnaire6 Health utilities 5 PRO ObsROBaseline and Weeks 5, 
21, 37, 53, 69, 85, and 
101 and ETT visitsIn-clinic
Weekly[COMPANY_002] HD 
mobile app; 
electronic 
device
Appendix 3 :  Patient -Reported, Observer -Reported, and Performance Outcomes
and [COMPANY_002] HD Mobile A pplication for Patients Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
142/Protocol BN40423 , Version 6Assessment Name [CONTACT_804007].
Duration
(min)PRO ,ObsRO , 
PerfO, 
Behavior Timing Location
HD-SDIHuntington's 
Disease Speaking 
Difficulty Item 1 Speech 1 PRO Weekly[COMPANY_002] HD 
mobile app
HD-CIAOSHuntington's 
Disease Companion -
Reported Irritability 
and Angr y Outbursts 
Scale3Irritability and angry 
outbursts2 ObsRO WeeklyElectronic 
device
HUIHealth Utilities Index 15Health -related quality of 
life10 ObsROBaseline, W eeks5, 21, 37, 
53, 69, 85, and 101 and ETTIn-clinic
WeeklyElectronic 
device
MoCAMontreal Cognitive 
Assessment11 Overall cognitive status 10 PerfOScreening , baseline, 
Weeks5, 21, 37, 53, 69, 85, 
and 101 and ETTIn-clinic
Neuro -Qol 
Cog FuncNeuro -Qol Cognitive 
Function Short Form8 Cognition 5 PROBaseline and W eeks5, 21, 
37, 53, 69, 85, and 101 In-clinic
PGI-CPatient Global 
Impression Change1Overall change in 
patient status2 PROWeeks5, 21, 37, 53, 69, 85, 
and 101 and ETT visitsIn-clinic
PGI-SPatient Global 
Impression Severity1Overall severity of 
patient status2 PROBaseline and W eeks5, 21, 
37, 53, 69, 85, and 101 and 
ETTIn-clinic
Appendix 3 :  Patient -Reported, Observer -Reported, and Performance Outcomes
and [COMPANY_002] HD Mobile A pplication for Patients Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
143/Protocol BN40423 , Version 6Assessment Name [CONTACT_601384].
Duration
(min)PRO ,ObsRO , 
PerfO, 
Behavior Timing Location
SDMT /
eSDMTSymbol Digit 
Modalities TestMax 
number in 
90secondsCognitive 5 PerfOSDMT at baseline and 
Weeks5, 21, 37, 53, 69, 85, 
and 101 and ETT visits In-clinic
eSDMT monthly + at clinic 
visits ( screening, baseline, 
Weeks 5, 53,101, and ETT )[COMPANY_002] HD 
mobile app 
(eSDMT)
SMDDSSymptoms of Major 
Depressive 
Disorder Scale16Depression, anxiety, 
irritability, sleep10 PROBaseline and W eeks13, 29, 
45, 61, 77, 93, and 101 In-clinic
SWR/eSWRStroop Word 
Reading T estMax 
numbers in 
45 sec ondsCognitive 5 PerfOSWR at baseline and 
Weeks5, 21, 37, 53, 69, 85, 
and 101 and ETT visitsIn-clinic
eSW R monthly + at clinic 
visits ( screening, baseline, 
Weeks 5, 53, and 101 and 
ETT)[COMPANY_002] HD 
mobile app 
(eSWR)
WPAIWork Productivity 
and Activity 
Impairment6 Work productivit y 5 PRO ObsRO Baseline and then monthly [COMPANY_002] HD 
mobile app 
and electronic 
device
appapplication; ETT early treatment termination; HD Huntington disease; ObsRO observer -reported outcome; PerfO performance outcome; 
PRO patient -reported outcome.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
144/Protocol BN40423 , Version 6Appendix 4Clinical A ssessments Order and Duration for
Patients Enrolled after Implementation of Protocol Version 4
Table 1 Screening Visit Clinical A ssessments
Block AssessmentsTotal Duration 
(minutes)Site Staff 
Responsible
1Diagnostic Confidence Levela
Huntington's Disease Daily Activities Scale
Independence Scale
MoCA
C-SSRS ~60Qualified 
study 
physician
Break (if needed) ~20-30
2 [COMPANY_002] HD mobile application ~20Qualified 
study 
personnel
C-SSRSColum bia-Suicide Severity Rating Scale; DCL Diagnostic Confidence Level;
HDHuntington disease; MoCA Montreal Cognitive Assessment; TMS Total Motor Score .
aThe DCL will be assessed at screening only (i.e., without the full TMS assessment).  The 
TMS scale will be assessed (excluding the DCL) at all other timepoints.
Appendix 4:  Clinical A ssessments Order and Duration for Patients 
Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
145/Protocol BN40423 , Version 6Table 2 Baseline and Week 101 Clinical A ssessments (for Primary  
Analysis)
Block AssessmentsTotal 
Duration 
(minutes) Site Staff Responsible
1UHDRS Functional Assessment 
Independence Scale
Total Functional Capacity Scale 
Total Motor Score (without Diagnostic 
Confidence Level)
Colum bia-Suicide Severity Rating Scale
Clinical Global Impression Severity 
Clinical Global Impression Change 
(post -baseline visits only)~60 Qualified study phy sician
Break (if needed) ~20[ADDRESS_1109682]
MoCA~20Qualified study 
personnel
Break (if needed) ~10
3aApathy Evaluation Scale (patient and 
companion)
Symptoms of Major Depressive Disorder 
Scale~20Qualified study 
personnel
Break (if needed) ~1020
4aNeuro -Qol Cognition Function Short Form
EuroQol 5 -Dimension, 5 -Level 
Questionnaire ( patientand companion )
Health Utilities Index (companion: self and 
proxy )
Patient/Companion -reported Global 
Impression Severity
Patient /Companion -reported Global 
Impression Change (post -baseline visits 
only)~20Qualified study 
personnel
Break (if needed) ~1020
5 a[COMPANY_002] HD mobile application ~20Qualified study 
personnel
HDHuntington disease; MoCA Montreal Cognitive Assessment; Neuro -QoLQuality of Life in 
Neurological Disorders; UHDRS Unified Huntington's Disease Rating Scale.
aAt the baseline visit and at W eek 101, Blocks 3, 4, and [ADDRESS_1109683] be completed predose at the baseline 
visit.  
Appendix 4:  Clinical A ssessments Order and Duration for Patients 
Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
146/Protocol BN40423 , Version 6Table 3 Follow -Up Clinical A ssessments at Weeks 5, 21, 37, 53, 69, 
and85
Block AssessmentsTotal 
Duration 
(minutes)Site Staff 
Responsible
1UHDRS Functional Assessment 
Independence Scale
Total Functional Capacity Scale 
Total Motor Score (without Diagnostic Confidence Level)
Colum bia-Suicide Severity Rating Scale
Clinical Global Impression Severity 
Clinical Global Impression Change ~60Qualified 
study 
physician
Break (if needed) ~20-[ADDRESS_1109684]
MoCA~20Qualified 
study 
personnel
Break (if needed) ~10
3Neuro -Qol Cognition Function Short Form
EuroQol 5 -Dimension, 5 -Level Questionnaire (patient
and companion )
Health Utilities Index (companion : self and proxy )
Patient/Companion -reported Global Impression Severity
Patient /Companion -reported Global Impression Change ~30Qualified 
study 
personnel
4 [COMPANY_002] HD mobile applicationa~20Qualified 
study 
personnel
MoCA Montreal Cognitive Assessment; Neuro- QoLQuality of Life in Neurological Disorders; 
UHDRS Unified Huntington's Disease Rating Scale
aThese assessments will take place only at Weeks 5 and 53.
Appendix 4:  Clinical A ssessments Order and Duration for Patients 
Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
147/Protocol BN40423 , Version 6Table 4 Follow -Up Clinical A ssessments at Weeks 13, 29, 45, 61, 77, 
and93
Block AssessmentsTotal Duration 
(minutes)Site Staff 
Responsible
1aApathy Evaluation Scale (patient and companion)
Symptoms of Major Depressive Disorder Scale~20Qualified 
study 
personnel
Break (if needed) ~10
2 Huntington's Disease -Daily  Activities Scale ~25Qualified 
study 
physician
aTo be completed prior to safety  assessments.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
148/Protocol BN40423 , Version 6Appendix 5 Guid elines for Order of A ssessments
This guidance is in addition to what is mandated throughout this protocol ,including from
Section 4.5.9 .
Screening Visits: Screening assessments can be performed over several days 
through the 28- day screening period.  Blood sample for CAG repeat testing and the 
MRI scans should be taken as early as possible to enable the results to be available 
in time for randomization.  The electronic clinical outcome assessments ( eCOAs) 
can be done after eligibility has been confirmed for all other parameters, so that 
patients and sites are not spending unnece ssary time on eCOAs before knowing if 
the patient will fulfil lall the other eligibility criteria.
All eCOA blocks should always be done in a sequential order as per Appendix 2, 
Appendix 3, and Appendix 4.  One block cannot be done before the previous block 
is completed (i.e., the blocks should be completed sequentially as Block 1, Block, 2, 
Block 3, Block 4, and Block 5 ).
Within a block, the protocol order should be kept to prevent bias.  All the 
assessments have been ordered by [CONTACT_803964].
eCOA blocks can be split over 2consecutive days.  W hen eCOA blocks are split 
over 2consecutive days, Blocks 1 and 2 should always be completed together on 
the same day.  As such , either Blocks 1 [ADDRESS_1109685] 1 and 2 can be done the day 
before dosing.  
The same methodology should be kept for an individual patient’s eCOA s, to preven t 
intra-patient variability. For example, if the blocks are done all together ,they should 
be performed that way for all visits , but at a minimum for baseline and Week 101 
visits.
The same timings should be kept for each patient’s eCOA sat each visit, but 
especially for D ay 1 and W eek 101 visits .
Blood sampling (all or just coagulation) can be done before Block 1 or after Block 5 
or betwee n blocks ,but only as follows:
oThe eCOAs are separated into 2 consecutive days
oThe blood sampling should be done after Block 2 but should not be done 
before Block 3 on the following day.  
Therefore, blood sampling can occur the day before (before Block 1, after Block 2 ,or 
after Block 5) depending on which eCOAs are done the day before dosing. Alternatively, 
blood sampling can be done before Block 1 on the day of dosing.  Again the same 
methodology should be used for the patient throughout the study but in particularly for 
the D ay 1 and W eek 101 visits.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
149/Protocol BN40423 , Version 6Appendix 6Grading Scale for Adverse Events Relating to 
Laboratory  Abnormalities for A ll Patients
The following grading recommendations for adverse events relating to lab test 
abnormalities are based on the National Cancer Institute Common Terminology Criteria 
for Adverse Events, Version 5.0.
LLNlower limit of normal; ULN upper limit of normal.

Appendix 6 :  Grading Scale for Adverse Events Relating to Laboratory A bnormalities for 
All Patients (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
150/Protocol BN40423 , Version 6LLNlower limit of normal; ULN upper limit of normal.

Appendix 6 :  Grading Scale for Adverse Events Relating to Laboratory A bnormalities for 
All Patients (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
151/Protocol BN40423 , Version 6

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
152/Protocol BN40423 , Version 6Appendix 7[COMPANY_002] HD Mobile Application for Patients Enrolled 
after Implementation of Protocol Version 4:  ActiveTest
The following tasks are part of the "active tests" conducted on the [COMPANY_002] Huntington's Disease 
(HD) mobile application by [CONTACT_102]. 
Daily Questions
Twodaily single -item questions on mood and physical energy will be assessed, asking patients 
about their mood and physical health at the time they are performing the “Active” tests. The 
assessments aim to capture daily mood fluctuations and will be used as a control for the other 
motor and cognitive assessments. 
Cognitive Test (eSDMT)
The Cognitive Test asks participants to match sy mbols with numbers according to a key  as 
quickly and accurately as possible. The key , symbols, numbers are all displayed on a 
smartphone screen. The test assesses visuo -motor integration, and measures visual attention 
and motor speed .  Itis modelled on the pen and paper Sy mbol Digit Modalities Test (SDMT) 
(Smith, 1968) . The SDMT has been shown to be sensitive to sy mptom changes in early HD 
patients (Tabrizi 2012) and is part of the Unified Huntington's Disease Rating Scale ( UHDRS )
assessment (Huntington’s Study Group, 1996).
Word Reading Test (eSWR)
The Word Reading Test asks participants to read aloud color words written in black font on a 
smartphone screen. Their voice will be recorded. The test assesses cognitive processing speed, 
and is modelled on the Stroop W ord Reading (SW R) (Ridley 1935). The "Word Reading "part of 
the S WRTest has been shown to be sensitive to sy mptom changes in patients with early HD 
(Tabrizi 2012) and is part of the UHDRS assessment (Huntington’s Study Group 1996). 
Speeded Tappi[INVESTIGATOR_803875], using the index finger of both the left and right hands. The test assesses 
brady kinesia. Performance will also be impacted by [CONTACT_626958]. It is modelled on 
tappi[INVESTIGATOR_626882] s ymptom changes in early HD (Bechtel et al. 2010; Tabrizi 
etal.2012). A similar finger tappi[INVESTIGATOR_803876] a lso included as part of the UHDRS asses sment 
(Huntington’s Study Group 1996).
Draw aShape Test
The Draw a Shape Test asks participants to trace a series of increasingly complex shapes on the 
smartphone screen. The shapes include lines, a square, a circle, an eight, and a spi[INVESTIGATOR_23585]. This test 
is designed to assess visuomotor coordination and fine motor impairment in early HD patients. It 
is modelled on circle tracing tasks that have been shown to be sensitive to s ymptom changes in 
early HD (Sa y et al. 2011; Tabrizi et al. 2013). 
Chorea Test
The Chorea Test asks participants to hold the smart phone sti ll in their hand with their arm
outstretched, and wear the wrist -worn wearable. As a dual task, participants will also need to 
count backwards aloud. To ensure correct execution, voice will be recorded. The test is 
designed to assess chorea. It draws o n other sensor -based approaches to measure chorea 
(Reilm ann et al. 2010, 2011 ; Kegelmeyer et al. 2017 ). A chorea assessment is also part of the 
UHDRS (Huntington’s Study Group 1996). 
Balance Test
The Balance Test asks participants to stand still while wearing the smartphone and wrist -worn 
wearable. It is an assessment for patients’ static balance function. Sensor -based approaches for 
measuring static balance have been shown to be sensitive to dif ferences in sy mptoms in early 
Appendix 7:  [COMPANY_002] HD Mobile A pplication for Patients Enrolled after Implementation of 
Protocol Version 4:  A ctive Test (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
153/Protocol BN40423 , Version 6HD (Dalton et al. 2013). The test is also part of established scales like the Berg Balance Scale 
(Berg et al. 1992), which are used in HD ( Busse et al. 2009; Rao et al. 2009). The test is 
anchored to the UHDRS assessments for maximal dystonia, maximal chorea ,and tandem 
walking (Huntington Study Group 1996).
U-Turn Test
The U -Turn Test asks participants to walk and turn safely between two points thatare at least 
foursteps apart, while wearing the smartphone and wrist -worn wearable. They  need to make at 
least five turns. The test is designed to assess gait and lower -body  brady kinesia, which are also 
assessed by [CONTACT_626959]. It is modelled on the Timed Up and Go Test, which has been clinically 
validated for the HD population (Busse et al. 2009 ; Rao et al. 2009 ). The test is anc hored to the 
UHDRS gait, brady kinesia body, and ta ndem walking items (Huntington Study Group 1996). 
Walk Test
The Walk Test asks participants walk as fast as is safely possible for [ADDRESS_1109686] is done in a straig ht path with no obstacles (e.g. ,in a park). 
Sensor -based approaches for measuring gait have been shown to be sensitive to differences in 
symptoms in early HD (Dalton et al. 2013). The test is anchored to the UHDRS gait, brady kinesia 
body , and ta ndem wal king items (Huntington Study  Group 1996).
Tasks are automatically scheduled as shown below in Figure [ADDRESS_1109687] on a certain day, scheduled tasks that 
occur less frequently than every second day (i.e., EuroQol 5 -Dimension, 5 Level Questionnaire , 
Work Productivity and Activity Impairment, Huntington's Disease Speaking Difficulty Item , 
2-Minute W alk Test) are rolled over to the next time the act ive test is completed.
References
Bechtel N, Scahill RI, Rosas HD, et al. Tappi[INVESTIGATOR_803877] s ymptomatic Huntington disease. Neurology 2010;75:2150 60.
Berg KO, W ood-Dauphinee SL, W illiam s JI, et al. Measuring balance in the elderly: validation of 
an instrument. Can J Public Health 1992;83(Suppl 2):S7 11.
Busse ME, W iles CM, Rosser AE. Mobility and falls in people with Huntington's disease. J Neurol 
Neurosurg Psychiatr y 2009;80:88 90.
Dalton A, Khalil H, Busse M , et al. Analysis of gait and balance through a single triaxial 
accelerometer in presy mptomatic and sy mptomatic Huntington’s disease. Gait Posture 
2013;37:49 54.
Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. 
Mov Disord 1996;11:136 42.Kegelmey er et al. 2017
Rao AK, Muratori L, Louis ED, et al. Clinical measurement of mobility and balance impairments in 
Huntington's d isease: validity and responsiveness. Gait Posture 2009;29:433 6.
Reilmann R, Bohlen S, Kirsten F, et al. Assessment of involuntary choreatic movements in 
Huntington's disease— toward objective and quantitative measures. Mov Disord 
2011;26:2267 73.
Appendix 7:  [COMPANY_002] HD Mobile A pplication for Patients Enrolled after Implementation of 
Protocol Version 4:  A ctive Test (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
154/Protocol BN40423 , Version 6Reilmann R, Bohlen S, Klopstock T, et al. Graspi[INVESTIGATOR_626884]'s disease - shapi[INVESTIGATOR_626885]. Mov Disord 2010;25:2858 62.
Say MJ, Jones R, Scahill R, et al. Visuomotor integration deficits precede clinical onset in 
Huntington's disease. Neuropsychologia 2011;49:264 70.
Smith A. The sy mbol-digit modalites test: a neurops ychologic test of learning and other cerebral 
disorders. In: Helmuth J, editor. Learning disorders. Seattle: Special Child Publications; 
1968:83 –91.
Stroop JR. Stu dies of interference in serial verbal reactions. J Exp Psychol 1935;18:643 62.
Tabrizi SJ, Reilmann R, Roos RAC, et al. Potential endpoints for clinical trials in premanifest and 
early Huntington's disease in the TRACK -HD study: analy sis of 24 month observational 
data. The Lancet Neurology 2012;11.1:42 53.
Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in 
premanifest and early -stage Huntington's disease in the TRACK -HD study: analysis of 36 -
month observat ional data. Lancet Neurol 2013;12:637 49.
Appendix 7:  [COMPANY_002] HD Mobile A pplication for Patients Enrolled after Implementation of Protocol Version 4:  Active Test (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
155/Protocol BN40423 , Version 6Figure 1 Timing of A ssessments
EQ-5D-5LEuroQol 5-Dimension, 5 Level Questionnaire ; eSDMT electronic Symbol Digit Modalities Test ; HD-SDIHuntington's Disease
Speaking Difficulty Item ; Lleft; PRO patient -reported outcome; R right; WPAI=Work Productivity and Activity Impairment Questionnaire. 

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
156/Protocol BN40423 , Version 6Appendix 8Diagnostic Confidence Level for A ll Patients
The Diagnostic Confidence Level is calculated as shown below (from UHDRS 
Total Motor Score Scale, Item 17):
DIAGNOSIS CONFIDENCE LEVEL
To what degree are you confident that this pe rson meets the operational 
definition of the unequivocal presence of an otherwise unexplained 
extrapyramidal movement disorder
(e. g., chorea, dystonia, bradykinesia, rigidity) in a subject at risk for HD?
0normal (no abnormalities)
1non-specific motor abn ormalities (less than 50% confi dence)
2motor abnormalities that may be signs of HD (50% 89% confi dence)
3motor abnormalities that are like ly signs of HD (90% 98% confi dence)
4motor abnormalities that are unequ ivocal signs of HD ( 99% confidence)
Copy right 1999
Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. 
Mov Disord 1996;11:136 42.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
157/Protocol BN40423 , Version 6Appendix 9Guidance for Neurologic alExamination for 
AllPatients
Perform the neurologic alexamination in the same way every time at screening and at 
every clinic visit.  At dosing visits, perform examination predose and postdose after the 
participant has walked for [ADDRESS_1109688] drug inje ction.
Neurologic alExamination
Mental status (appearance, level of consciousness, behavior, 
speech)
Cranial Nerves II (includin g Visual Acuity and Fundoscopy) XII
Motor examination (bulk, tone, and strength)
Coordination
Abnormal movements
Gait
Reflexes
Sensation (vibration, light touch, pin prick/temperature)
Note:  The neurologic alexamination should be followed at the 
non-dosing clinic visits, end -of-treatment visit, and safety follow -up 
visit.   At visits when a lumbar puncture is performed and study 
treatment is not administered , the neurological examination 
should be performed prior to the lumbar puncture .
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
158/Protocol BN40423 , Version 6Appendix 10Schedule of A ctivities for Patients Enrolled before Implementation of Pr otocol 
Version 4
ScreeningaBL Treatment Period EoTbEoT 
for 
ETT ETTbSFU
Month 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 25 29
Week4 to  1 1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97 101 101 117
Day (W indow )28 to  21 1 (3)dd
Signed informed 
consentcx
Review of inclusion and 
exclusion criteria x
Demographic data x
Medical histor y and 
baseline conditionsdx xe
Blood sample for CAG 
repeat lengthx
Viral serologyfx
Thyroid panelgx
Vital signshx xex x x x x x x x x x x x x x x x x x x x x x x x x x x
Complete phy sical 
examination ix xex x x x x x
Neurologic examinationjx xex x x x x x x x x x x x x x x x x x x x x x x x x x x x
ECGkx xex x x x x x x
Hematologylx x x x x x x x x x x x x x x x x x x x x x x x x x x x x
Appendix 10 : Schedule of A ctivities for Patients Enrolled before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
159/Protocol BN40423 , Version 6ScreeningaBL Treatment Period EoTbEoT 
for 
ETT ETTbSFU
Month 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 25 29
Week4 to  1 1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97 101 101 117
Day (W indow )28 to  21 1 (3)dd
Chemistrymx x x x x x x x x x x x x x x x x x x x x x x x x x x x x
Pregnancy testnx xex x x x x x x x x x x x x x x x x x x x x x x x x x x
Local INR, aPTT, PT
platelet countxx x x x x x x x x x x x x x x x x x x x x x x x x x x x
Urinalysis ox x x x x x x x x x x x x x x x x x x x x x x x x x x x x
Plasma sample for PK x x x xp x x x x x
Plasma sample for 
immunogenicity testingx x x x x x x x x x
Plasma sample for 
biom arkersx x x x x x x x x x
Blood sample for clinical 
genotypi[INVESTIGATOR_803874]/safety/biomarkersx x x x x x x x x x x x x x x x x x x x x x x x x xyx
MRIqx x x x x x
HD-DAS x x x x x x x
Independence Scale x xx x x x x x x x x
MoCA x x x x x x x x x x x
C-SSRSrx xex x x x x x x x x x x x x x x x x x x x x x x x x x x
Appendix 10 : Schedule of A ctivities for Patients Enrolled before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
160/Protocol BN40423 , Version 6ScreeningaBL Treatment Period EoTbEoT 
for 
ETT ETTbSFU
Month 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 25 29
Week4 to  1 1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97 101 101 117
Day (W indow )28 to  21 1 (3)dd
UHDRS FA xx x x x x x x x x
TFCsxx x x x x x x x x
TMSs, ccx xx x x x x x x x x
CGI-S x x x x x x x x x x
CGI-C x x x x x x x x x
SDMTsxx x x x x x x x x
SWRsxx x x x x x x x x
AES x x x x x x x x x
SMDDS x x x x x x x x x
NeuroQoL x x x x x x x x x x
EQ-5D-5L (in -clinic) x x x x x x x x x x
HUI(in-clinic) x x x x x x x x x x
PGI-S x x x x x x x x x x
PGI-C x x x x x x x x x
[COMPANY_002] HD mobile app 
in-clinic assessmentsx x x x x x x x
[COMPANY_002] HD mobile app 
remote data collection Continuous remote data collectiont
Appendix 10 : Schedule of A ctivities for Patients Enrolled before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
161/Protocol BN40423 , Version 6ScreeningaBL Treatment Period EoTbEoT 
for 
ETT ETTbSFU
Month 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 25 29
Week4 to  1 1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97 101 101 117
Day (W indow )28 to  21 1 (3)dd
Optional exit interview ux x
Blood sample for RBR 
DNA (optional)vx
Blood sample for RBR 
RNA (optional)v x x x x x
Serum sample for RBR
(optional) vx x x x x
Change in medical 
information since 
previous visitwxxxxxxxxxxxxxxxxxxxxxxxx x x x x
Lumbar puncture xxxxxxxxxxxxxxxxxxxxxxxxxxxyxy
Study drug 
administrationxxxzxxzxxzxxzxxzxxzxxzxxzxxzxxzxxzxxz
Concomitant 
medicationsaax x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x
Adverse events bbx x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x
ADAanti-drug antibody; AES Apathy Evaluation Scale; BL baseline; CGI-C Clinical Global Impression, Change; CGI -SClinical Global 
Impression, Severity; CSF cerebrospi[INVESTIGATOR_872]; C SSRS Columbia -Suicide Severity Rating Scale; cUHDRS composite Unified Huntington's 
Disease Rating Scale; DCL diagnostic confidence level; eCRF electronic Case Report Form; EoT end of treatment; EQ -5D-5LEuroQol 
5-Dimension, 5 -Level Questionnaire; ETT early treatment termination; FA Functional Assessment; HBsAg hepatitis B surface antigen; 
HCV hepatitis C virus; HD Huntington disease; HD -DASHD Daily Activities Scale; HUI Health Utilities Index; MoCA Montreal Cognitive 
Assessment; MRI magnetic resonance imaging; Neuro -QolQuality of Life in Neurological Disorders; PGI -CPatient Global Impression, 
Appendix 10 : Schedule of A ctivities for Patients Enrolled before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
162/Protocol BN40423 , Version 6Change; PGI -SPatient Global Impression, Severity; PK pharmacokinetic; Q8W every 8 weeks; RBR Research Biosample Repository; 
SDMT Symbol Digit Modalities Test; SFU safety follow -up; SMDDS Symptoms of Major Depressive Disorder Scale; S WRStroop W ord 
Reading; TFC Total Functional Capacity Scale; TMS Total Motor Score; UHDRS Unified Huntington's Disease Rating Scale.
Notes:  All assessme nts should be performed at the scheduled visit, unless otherwise specified.  On treatment days, all assessments should be 
performed prior to dosing, unless otherwise specified.  
aA maxim um of one re -screening will be allowed within 8 weeks of the initial screening failure for patients who fail the initial screening (e.g., as a 
consequence of abnormal laboratory values or general medical status not meeting inclusion or exclusion criteria).  If re -screening is required, 
CAG repeat length testing does not ne ed to be repeated and the screening MRI and viral serology from the initial screening may  be acceptable 
as part of the re -screening assessments, if performed within 12 weeks of the baseline visit.  
bPatients who complete the treatment period will return to the clinic for a treatment completion visit at Week 101 (i.e., the EoT visit).  All patients 
who discontinue study treatment prematurely but do not withdraw consent for continued participation in the study will return to the clinic for study 
visits at W eeks53 and 69 (if not already completed) and at W eek 101 (i.e., the EoT for ETT visit) for collection of at least the data for th e primary  
and secondary endpoints (see Sections 2.1.1 , 2.1.2 , and 2.2).  If the ETT visit falls within 30 days of either sched uled visits at W eek 53 or 
Week 69, then only ETT will be considered.  The ETT visit should be performed 28 days ( 3 day s) after the last dose.  Patients will also attend 
the scheduled EoT for ETT visit at W eek 101 for limited assessments including the col lection of the primary  and secondary endpoints (see 
Sections 2.1.1 , 2.1.2 , and 2.2).  Study visits should be planned as per the study schedule, however under exceptional circumstances, time 
window of [ADDRESS_1109689] be documented before any study -specific screening procedure is performed and may be obtained more than 28 days 
before initiation of study treatment.
dMedical histor y, including clinically significant diseases, surgeries, HDhistory (including past hospi[INVESTIGATOR_602] [i.e., number, duration, and 
reason]) , over the last [ADDRESS_1109690] on Day  1 or Day 1.
fViral serology: HBsAg and HCV antibody
gThyroid panel:  thy roid-stimulating hormone and free thyroxine (also known as T4) levels. 
hVital signs include respi[INVESTIGATOR_697], pul se, temperature, and s ystolic and diastolic blood pressure while the patient is in a seated position after 
resting for approximately [ADDRESS_1109691] abnormalities observed at baseline (Day -1 or Day 1) on the General Medical History and Baseline 
Conditi ons eCRF.  At subsequent visits, record new or worsened clinically significant abnormalities on the Adverse Event eCRF.
iA complete physical examination ,performed at screening and other specified visits, should include an evaluation of the head, eyes, ears, nose, 
and throat, and the cardiovascular, dermatologic, musculoskeletal, respi[INVESTIGATOR_696], gastrointestinal , and neurologic systems ( including fundoscopy ); 
genitourinar y exam inations may be performed if clinically indicated.   The phy sical examinations should be conducted in the same manner on 
each occasion to ensure comparability to previous examinations. Changes from baseline abnormalities should be recorded in patient notes.  
New or worsened clinically signific ant abnormalities (i.e., beyond expected variation or normal age -related change) should be recorded as 
adverse events on the Adverse Event eCRF.   Height will be measu red at screening only.
Appendix 10 : Schedule of A ctivities for Patients Enrolled before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
163/Protocol BN40423 , Version 6jA neurologic examination ,performed at screening and at every clinical visit ,should include assessment of mental status, level of consciousness, 
cranial nerve function, motor function, sensory function, reflexes, and coordination.   The neurologic examinations should be conducted in the 
same manner on each occasion to e nsure comparability to previous examinations. Neurologic examinations should be performed before and 
after treatment on each dosing day.  W eight should also be measured at each visit. An y abnormality identified at baseline should be recorded on 
the Genera l Medical History and Baseline Conditions eCRF.  Changes from baseline abnormalities should be recorded in patient notes.  Ne w or 
worsened clinically significant abnormalities (i.e., beyond expected variation or normal age- related change) should be recorde d as adverse 
events on the Adverse Event eCRF.   
kTriplicate ECG are to be performed after the patient has been in a supi[INVESTIGATOR_73414] 10 minutes.  ECGs for ea ch patient should 
be obtained from the same machine whenever possible.  At scree ning, baseline (Day  1 or Day 1) and other visits, pre -dose ECG should be 
performed prior to any blood draws and where applicable before the lumbar puncture.  
lHematology includes WBC count, RBC count, platelet count, hemoglobin, hematocrit, differential count (neutrophils, eosinophils, basophils, 
monocy tes, ly mphocy tes).
mSerum chemistry  panel:  includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, potassium, chloride, 
glucose, BUN or urea, creatinine, total protein, albumin, phosphorus, calcium, total and direct bilirubin, ALP, ALT, AST, uric acid, 
gamma -glutam yl transferase, and CPK.
nAll women of childbearing potential will have a serum pregnancy test at screening.  Urine pregnanc y tests will be perf ormed at specified 
subsequent visits.  If aurine pregnanc y test is positive, it must be confirmed by a serum pregnancy test.
oUrinalysis includes dipstick (pH, specific gravity, glucose, protein, ketones, blood) and microscopic examination (sediment, RBC s, WBCs, casts, 
crystals, epi[INVESTIGATOR_1663], bacteria).  
pAt the W eek [ADDRESS_1109692] 
4hours after lumbar puncture.
qAt W eeks 13, 37, and 69 and at the EoT visit, the MRI should be scheduled to occur before the lumbar puncture.  It can be scheduled in the day s 
prior to the lumbar puncture (provided it occurs within the visit window).  After patient enrollment, the MRI scan should be per formed 7 [ADDRESS_1109693] be available before the patient can be 
enrolled in the study.
rThe C -SSRS will be used to assess eligibility for the study (full version at baseline, requiring approximately 20 minutes to admini ster) and to 
monitor the patients throughout the study at clinic visits (follow -up version, requiring approximately 5 minutes to administer, assuming absence of 
suicidal ideation and no change in clinical status from previous administration).
sThe cUHDRS is a composite motor, cognitive, and global functional cl inical outcome measure in patients with HD comprised of the TFC, the 
TMS, the SDMT, and the SW R scores.
tThe electronic devices for remote data collection will be supplied to patients at screening and must be returned to the clini c in cases where the 
patient does not meet eligibility criteria, at the end of the study, or upon early termination from the study.  
Appendix 10 : Schedule of A ctivities for Patients Enrolled before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
164/Protocol BN40423 , Version 6uOptional exit interviews will be conducted within approximately 1 week after the EoT visit; these interviews can be conducted by [CONTACT_756].  
vNot applicable for a site that has not been granted approval for RBR sampling.  Performed only for patients at participating s ites who have 
provided written informed consent to participate.
wAt the time of each study drug administration, an interval medical histor y should be obtained and any changes in medications, any major 
procedures or hospi[INVESTIGATOR_602], and any physician visits for HD or general medical care should be recorded.
xPrior to performing each scheduled lumbar puncture, local laborator y analy sis of coagulation factors (INR, aPTT, PT) and platelets must be 
conducted and the results reviewed.  Collection for these local laboratory tests may occur at any time in the 72 hours prior to the lumbar 
puncture.  The lumbar puncture should be perfor med at approximately the same time at each visit (ideally in the morning between 8:00 a.m. and 
12:00 noon or in the early afternoon between 12:00 noon and 3:00 p.m.) to minimize potential diurnal variation of CSF paramet ers.  CSF fluid 
(20mL) is to be col lected for analyses using a lumbar puncture collection kit.  If there are difficulties in collecting [ADDRESS_1109694] conf irm CSF flow is 
present prior to injecting drug at 60 minutes.  A 24G W hitacre (atraumatic) needle should be used.  Depending on institutiona l guidelines, local 
anesthesia should be used for the procedure.  Sedation may  not be used.  Spi[INVESTIGATOR_803878], but is not required.  Ultrasound guidance may be used if attempts at lumbar puncture without imaging are un successful, if it 
is local practice to use ultrasound, or if institutional guidelines dictate use of ultrasound with each lumbar puncture.  Patients will be discouraged 
from resting supi[INVESTIGATOR_803879] a minimum and, if 
feasible, walking briskly.
yThe last CSF sample will be obtained at the W eek 101 EoT visit, but no study drug will be administered.
zPatients in Q8W  arm will receive placebo at these visits.
aaMedication (e.g., prescription drugs, over -the-counter drugs, vaccines, herbal or homeopa thic remedies, nutritional supplements) used by a 
patient in addition to protocol -mandated treatment from screening to the study completion/discontinuation visit.
bbAfter informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protocol -mandated 
intervention should be reported.  After initiation of study drug, all adverse events will be reported until 5 months after the final dose of study drug.  
After this period, all deaths, regardless of cause, sh ould be reported.  In addition, the Sponsor should be notified if the investigator becomes 
aware of any serious adverse event that is believed to be related to prior study drug treatment.  
ccThe DCL will be assessed at screening only (i.e., without the full TMS assessment).  The TMS scale will be assessed (excluding the DCL) at all 
other timepoints.
ddExcluding MRIs, which have a visit window of  14 days .
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
165/Protocol BN40423 , Version 6Appendix 11 Clinician -Reported Outcomes for Patients Enrolled before Implementation of 
Protocol Version 4
Assessment Name [CONTACT_601384]. 
Duration Timing
FAUHDRS Functional 
Assessment25 Daily function 15 minBaseline and W eeks5, 21, 37, 53, 
69, 85, and 101 and ETT visits
IS Independence Scale 1 Functional disability 3 minScreening, baseline, and Weeks5, 
21, 37, 53, 69, 85, and 101 and 
ETT visits
TFCTotal Functional 
Capacity Scale5 Overall function 10 minBaseline and W eeks5, 21, 37, 53, 
69, 85, and 101 and ETT visits
TMS Total Motor Score 31 Motor function 15 minDCL only: Screening
TMS without DCL: Baseline and 
Weeks5, 21, 37, 53, 69, 85, and 
101 and ETT visits
C-SSRSColum bia-Suicide 
Severity Scale5Suicidal ideation 
and behavior20 min full 
version; 
5 min follow -up 
versionFull version at screening in clinic; 
follow -up version at baseline and all 
post-baseline clinic visits 
CGI-SClinical Global 
Impression 
Severity1Overall severity of 
patient status2 minBaseline and W eeks5, 21, 37, 53, 
69, 85, and 101 and ETT visits
CGI-CClinical Global 
Impression 
Change1Overall change in 
patient status2 minWeeks5, 21, 37, 53, 69, 85, and 
101 and ETT visits 
HD-DASHuntington's 
Disease Daily 
Activities Scale 25 Daily function 25 minScreening and Weeks13, 29, 45, 
61, 77, and 93
DCLdiagnostic confidence level.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
166/Protocol BN40423 , Version 6Appendix 12Patient -Reported, Observer -Reported, and Performance Outcomes and [COMPANY_002] HD 
Mobile A pplication for Patients Enrolled before Implementation of Protocol Version 4
Assessment Name [CONTACT_601384].
Duration
(min)PRO, ObsRO, 
PerfO, 
Behavior Timing Location
AESApathy Evaluation 
Scale18 Apathy 10 PRO ObsROBaseline and W eeks13, 
29, 45, 61, 77, 93, and 
101In-clinic
[COMPANY_002] HD 
mobile app [COMPANY_002] HD mobile app 
with daily Active Test 
and Passive 
MonitoringNATasks (“active test”) that assess 
motor sy mptoms (upper and 
lower body movements, upper 
limb dexterity, voice) and 
non-motor sy mptoms 
(processing speed/voice); 
contin uous passive monitoring5Sensor data, 
PRO, PerfODaily at clinic visits 
(Screening, baseline 
and W eeks 25, 49, 73, 
and 101 and ETT visits) [COMPANY_002] HD 
mobile app
CrGI -CCompanion -Reported 
Global Impression, 
Change1 Overall change in patient status 2 ObsROWeeks5, 21, 37, 53, 
69, 85, and 101 and 
ETT visitsIn-clinic on 
electronic 
device
CrGI -SCompanion -Reported 
Global Impression, 
Severity1 Overall severity of patient status 2 ObsROBaseline and W eeks5, 
21, 37, 53, 69, 85, and 
101 and ETT visitsIn-clinic on 
electronic 
device
EQ-5D-5LEuroQol 5 -Dimension, 
5-Level Questionnaire6 Health utilities 5 PRO ObsROBaseline and Weeks 5, 
21, 37, 53, 69, 85, and 
101 and ETT visitsIn-clinic
Weekly[COMPANY_002] HD 
mobile app; 
electronic 
device
Appendix 12 : Patient -Reported, Observer -Reported, and Performance Outcomes and [COMPANY_002] HD Mobile A pplication for Patients Enrolled 
before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
167/Protocol BN40423 , Version 6Assessment NameItem
s ConceptsApprox.
Duration
(min)PRO, ObsRO, 
PerfO, 
Behavior Timing Location
HD-SDIHuntington's 
Disease Speaking 
Difficulty Item 1 Speech 1 PRO Weekly[COMPANY_002] HD 
mobile app
HD-CIAOSHuntington's 
Disease Companion
-Reported Irritability 
and Angr y Outbursts 
Scale3Irritability and angry 
outbursts2 ObsRO WeeklyElectronic 
device
HUIHealth Utilities Index 15Health -related quality of 
life10 ObsROBaseline, W eeks5, 21, 37, 
53, 69, 85, and 101 and ETTIn-clinic
WeeklyElectronic 
device
MoCAMontreal Cognitive 
Assessment11 Overall cognitive status 10 PerfOScreening, baseline, 
Weeks5, 21, 37, 53, 69, 85, 
and 101 and ETTIn-clinic
Neuro -Qol 
Cog FuncNeuro -Qol Cognitive 
Function Short Form8 Cognition 5 PROBaseline and W eeks5, 21, 
37, 53, 69, 85, and 101 In-clinic
PGI-CPatient Global 
Impression Change1Overall change in 
patient status2 PROWeeks5, 21, 37, 53, 69, 85, 
and 101 and ETT visitsIn-clinic
PGI-SPatient Global 
Impression Severity1Overall severity of 
patient status2 PROBaseline and W eeks5, 21, 
37, 53, 69, 85, and 101 and 
ETTIn-clinic
Appendix 12 : Patient -Reported, Observer -Reported, and Performance Outcomes and [COMPANY_002] HD Mobile A pplication for Patients Enrolled 
before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
168/Protocol BN40423 , Version 6Assessment Name [CONTACT_601384].
Duration
(min)PRO, ObsRO, 
PerfO, 
Behavior Timing Location
SDMT/
eSDMTSymbol Digit 
Modalities TestMax 
number in 
90secondsCognitive [ADDRESS_1109695]-SDMT assessment[COMPANY_002] HD 
mobile app 
(eSDMT)
SMDDSSymptoms of Major 
Depressive 
Disorder Scale16Depression, anxiety, 
irritability, sleep10 PROBaseline and W eeks13, 
29, 45, 61, 77, 93, and 101 In-clinic
SWR/eS WRStroop Word 
Reading TestMax 
numbers in 
[ADDRESS_1109696] -SWR 
assessment[COMPANY_002] HD 
mobile app 
(eSWR)
WPAIWork Productivity 
and Activity 
Impairment6 Work productivit y 5 PRO ObsRO Monthly [COMPANY_002] HD 
mobile app 
and electronic 
device
appapplication; ETT early treatment termination; HD Huntington disease; ObsRO observer -reported outcome; PerfO performance outcome; 
PRO patient -reported outcome.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
169/Protocol BN40423 , Version 6Appendix 13Clinical A ssessments Order and Duration for 
Patients Enrolled before Implementation of Protocol Version 4
Table 1 Screening Visit Clinical A ssessments
Block AssessmentsTotal Duration 
(minutes)Site Staff 
Responsible
1Diagnostic Confidence Level
Huntington's Disease Daily Activities Scale
Independence Scale
MoCA
C-SSRS ~60Qualified 
study 
physician
Break (if needed) ~20-30
2 [COMPANY_002] HD mobile application ~20Qualified 
study 
personnel
C-SSRSColum bia-Suicide Severity Rating Scale; HDHuntington disease; MoCA Montreal 
Cognitive Assessment.
Appendix 1 3: Clinical A ssessments Order and Duration for Patients Enrolled before 
Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
170/Protocol BN40423 , Version 6Table 2 Baseline and Week 101 Clinical A ssessments (for Primary  
Analysis)
Block AssessmentsTotal 
Duration 
(minutes) Site Staff Responsible
1UHDRS Functional Assessment 
Independence Scale
Total Functional Capacity Scale 
Total Motor Score (without Diagnostic 
Confidence Level)
Colum bia-Suicide Severity Rating Scale
Clinical Global Impression Severity 
Clinical Global Impression Change 
(post -baseline visits only)~60 Qualified study phy sician
Break (if needed) ~20[ADDRESS_1109697]
MoCA~20Qualified study 
personnel
Break (if needed) ~10
3aApathy Evaluation Scale (patient and 
companion)
Symptoms of Major Depressive Disorder 
Scale~20Qualified study 
personnel
Break (if needed) ~1020
4aNeuro -Qol Cognition Function Short Form
EuroQol 5 -Dimension, 5 -Level 
Questionnaire (patient and companion)
Health Utilities Index (companion: self and 
proxy)
Patient/Companion -reported Global 
Impression Severity
Patient/Companion -reported Global 
Impression Change (post -baseline visits 
only)~20Qualified study 
personnel
Break (if needed) ~1020
5 a[COMPANY_002] HD mobile application ~20Qualified study 
personnel
HDHuntington disease; MoCA Montreal Cognitive Assessment; Neuro -QoLQuality of Life in 
Neurological Disorders; UHDRS Unified Huntington's Disease Rating Scale.
aAt the baseline visit and at week 101, Blocks 3, 4, and [ADDRESS_1109698] be completed predose at the baseline 
visit.  
Appendix 1 3: Clinical A ssessments Order and Duration for Patients Enrolled before 
Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
171/Protocol BN40423 , Version 6Table 3 Follow -Up Clinical A ssessments at Weeks 5, 21, 37, 53, 69, 
and85
Block AssessmentsTotal 
Duration 
(minutes)Site Staff 
Responsible
1UHDRS Functional Assessment 
Independence Scale
Total Functional Capacity Scale 
Total Motor Score (without Diagnostic Confidence Level)
Colum bia-Suicide Severity Rating Scale
Clinical Global Impression Severity 
Clinical Global Impression Change ~60Qualified 
study 
physician
Break (if needed) ~20-[ADDRESS_1109699]
MoCA~20Qualified 
study 
personnel
Break (if needed) ~10
3Neuro -Qol Cognition Function Short Form
EuroQol 5 -Dimension, 5 -Level Questionnaire (patient 
and companion)
Health Utilities Index (companion: self and proxy)
Patient/Companion -reported Global Impression Severity
Patient/Companion -reported Global Impression Change ~30Qualified 
study 
personnel
MoCA Montreal Cognitive Assessment; Neuro- QoLQuality of Life in Neurological Disorders; 
UHDRS Unified Huntington's Disease Rating Scale
Table 4 Follow -Up Clinical A ssessments at Weeks 13, 29, 45, 61, 77, 
and93
Block AssessmentsTotal Duration 
(minutes)Site Staff 
Responsible
1aApathy Evaluation Scale (patient and companion)
Symptoms of Major Depressive Disorder Scale~20Qualified 
study 
personnel
Break (if needed) ~10
2 Huntington's Disease -Daily  Activities Scale ~25Qualified 
study 
physician
aTo be completed prior to safety  assessments.
Appendix 1 3: Clinical A ssessments Order and Duration for Patients Enrolled before 
Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
172/Protocol BN40423 , Version 6Table 5 Digital Monitoring Platform A ssessment Supervised by [CONTACT_803965] 25, 49, 73
Block AssessmentsTotal Duration 
(minutes)Site Staff 
Responsible
1 [COMPANY_002] HD mobile application ~20Qualified 
study 
personnel
HDHuntington disease.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
173/Protocol BN40423 , Version 6Appendix 14 [COMPANY_002] HD Mobile Application for Patients 
Enrolled before Implementation of Protocol Version 4:  Active 
Test
The following tasks are part of the "active tests" conducted on the [COMPANY_002] Huntington's Disease 
(HD) mobile application by [CONTACT_102]. 
Daily Questions
Two daily single -item questions on mood and physical energy will be assessed, asking patien ts 
about their mood and physical health at the time they are performing the “Active” tests. The 
assessments aim to capture daily mood fluctuations and will be used as a control for the other 
motor and cognitive assessments. 
Cognitive Test (eSDMT)
The Cog nitive Test asks participants to match sy mbols with numbers according to a key  as 
quickly and accurately as possible.  The key , symbols, numbers are all displayed on a 
smartphone screen.  The test assesses visuo -motor integration, and measures visual attention 
and motor speed.  It is modelled on the pen and paper Sy mbol Digit Modalities Test (SDMT) 
(Smith, 1968) .  The SDMT has been shown to be sensitive to sy mptom changes in early HD 
patients (Tabrizi 2012) and is part of the Unified Huntington's Disease Ra ting Scale (UHDRS) 
assessment (Huntington’s Study Group, 1996).
Word Reading Test (eSWR)
The Word Reading Test asks participants to read aloud color words written in black font on a 
smartphone screen. Their voice will be recorded.  The test assesses cognitive processing speed, 
and is modelled on the Stroop W ord Reading (SW R) (Ridley 1935).  Th e "Word Reading" part of 
the S WR Test has been shown to be sensitive to sy mptom changes in patients with early HD 
(Tabrizi 2012) and is part of the UHDRS assessment (Huntington’s Study Group 1996). 
Speeded Tappi[INVESTIGATOR_803880], using the index finger of both the left and right hands.  The test assesses 
brady kinesia. Performance will also be impacted by [CONTACT_626958].  It is modelled on 
tappi[INVESTIGATOR_803881] s ymptom changes in early HD (Bechtel et al. 2010; Tabrizi 
etal. 2012). A similar finger tappi[INVESTIGATOR_803882] 
(Huntington’s Study Group 1996).
Draw a Shape Test
The Draw a Shape Test asks part icipants to trace a series of increasingly complex shapes on the 
smartphone screen. The shapes include lines, a square, a circle, an eight, and a spi[INVESTIGATOR_23585].  This test 
is designed to assess visuomotor coordination and fine motor impairment in early HD patient s.  It 
is modelled on circle tracing tasks that have been shown to be sensitive to s ymptom changes in 
early HD (Say et al. 2011; Tabrizi et al. 2013). 
Chorea Test
The Chorea Test asks participants to hold the smartphone still in their hand with their arm
outstretched, and wear the wrist -worn wearable.  As a dual task, participants will also need to 
count backwards aloud.  To ensure correct execution, voice will be recorded.  The test is 
designed to assess chorea.  It draws on other sensor -based approaches to measure chorea 
(Reilm ann et al. 2010, 2011; Kegelmeyer et al. 2017 ). A chorea assessment is also part of the 
UHDRS (Huntington’s Study Group 1996). 
Balance Test
The Balance Test asks participants to stand still while wearing the smartphone and wrist -worn 
wearable.  It is an assessment for patients’ static balance function.  Sensor -based approaches for 
Appendix 14: [COMPANY_002] HD Mobile A pplication for Patients Enrolled before Implementation of 
Protocol Version 4:  Active Test (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
174/Protocol BN40423 , Version 6measuring static balance have been shown to be sensitive to differences in sy mptoms in early 
HD (Dalton et al. 2013).  The test is also part of establis hed scales like the Berg Balance Scale 
(Berg et al. 1992), which are used in HD (Busse et al. 2009; Rao et al. 2009).  The test is 
anchored to the UHDRS assessments for maximal dystonia, maximal chorea, and tandem 
walking (Huntington Study Group 1996).
U-Turn Test
The U -Turn Test asks participants to walk and turn safely between two points that are at least 
foursteps apart, while wearing the smartphone and wrist -worn wearable.  They need to make at 
least five turns.  The test is designed to assess gait an d lower -body  brady kinesia, which are also 
assessed by [CONTACT_626959].  It is modelled on the Timed Up and Go Test, which has been clinically 
validated for the HD population (Busse et al. 2009; Rao et al. 2009).  The test is anchored to the 
UHDRS gait, brady kinesia body, and tandem walking items (Huntington Study Group 1996). 
Walk Test
The Walk Test asks participants walk as fast as is safely possible for [ADDRESS_1109700] is done in a straight path with no obstacles (e.g., in a park).  
Sensor -based approaches for measuring gait have been shown to be sensitive to differences in 
symptoms in early HD (Dalton et al. 2013).  The test is anchored to the UHDRS gait, brady kinesia 
body , and tandem walking items (Huntington Study Grou p 1996).
Tasks are automatically scheduled as shown below in Figure [ADDRESS_1109701] on a certain day, scheduled tasks that 
occur less frequently than every second day (i.e., EuroQol 5- Dimension, 5 Level Questionnaire, 
Work Productivity and Activity Impairment, Huntington's Disease Speaking Difficulty Item, 
2-Minute W alk Test) are rolled over to the next time the active test is completed.
References
Bechtel N, Scahill RI, Rosas HD, et al. Tappi[INVESTIGATOR_803877] s ymptomatic Huntington disease. Neurology 2010;75:2150 60.
Berg KO, W ood-Dauphinee SL, W illiam s JI, et al. Measuring balance in the elderly: v alidation of 
an instrument. Can J Public Health 1992;83(Suppl 2):S7 11.
Busse ME, W iles CM, Rosser AE. Mobility and falls in people with Huntington's disease. J Neurol 
Neurosurg Psychiatr y 2009;80:88 90.
Dalton A, Khalil H, Busse M, et al. Analysis of gait and balance through a single triaxial 
accelerometer in presy mptomatic and sy mptomatic Huntington’s disease. Gait Posture 
2013;37:49 54.
Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. 
Mov Disord 1996;11:136 42.Kegelmey er et al. 2017
Rao AK, Muratori L, Louis ED, et al. Clinical measurement of mobility and balance impairments in 
Huntington's disease: validity and responsiveness. Gait Posture 2009;29:433 6.
Reilmann R, Bohlen S, Kirsten F, et al. Assessment of involuntary choreatic movements in 
Huntington's disease— toward objective and quantitative measures. Mov Disord 
2011;26:2267 73.
Appendix 14: [COMPANY_002] HD Mobile A pplication for Patients Enrolled before Implementation of 
Protocol Version 4:  Active Test (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
175/Protocol BN40423 , Version 6Reilmann R, Bohlen S, Klopstock T, et al. Graspi[INVESTIGATOR_626884]'s disease - shapi[INVESTIGATOR_626885]. Mov Disord 2010;25:2858 62.
Say MJ, Jones R, Scahill R, et al. Visuomotor integration deficits precede clinical onset in 
Huntington's disease. Neuropsychologia 2011;49:264 70.
Smith A. The sy mbol-digit modalites test: a neurops ychologic test of learning and ot her cerebral 
disorders. In: Helmuth J, editor. Learning disorders. Seattle: Special Child Publications; 
1968:83 –91.
Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643 62.
Tabrizi SJ, Reilmann R, Roos RAC, et al. Potential endpoints for clinical trials in premanifest and 
early Huntington's disease in the TRACK -HD study: analy sis of 24 month observational 
data. The Lancet Neurology 2012;11.1:42 53.
Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic prog ression and disease onset in 
premanifest and early -stage Huntington's disease in the TRACK -HD study: analysis of 36 -
month observational data. Lancet Neurol 2013;12:637 49.
Appendix 14: [COMPANY_002] HD Mobile A pplication for Patients Enrolled before Implementation of Protocol Version 4:  Active Test (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
176/Protocol BN40423 , Version 6Figure 1 Timing of A ssessments
EQ-5D-5LEuroQol 5 -Dimension, 5 Level Questionnaire; eSDMT electronic Symbol Digit Modalities Test; HD -SDIHuntington's Disease 
Speaking Difficulty Item; L left; PRO patient -reported outcome; R right; W PAI.1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
PROs
2 Daily Questions (Physica l, Mood) o o o o o o o o o o o o o o o o o o o o o o o o o o o o
EQ-5D-5L o o o o
WPAI o
HD-SDI o o o o
Cognitiv e Tests
eSDMT o
Word reading tes t o
Motor te sts
Speeded tappi[INVESTIGATOR_803883] (L+R) o o o o o o o o o o o o o o o o
Draw shape Test  (L+R) o o o o o o o o o o o o o o o o
Chorea  Test  (L+R) o o o o o o o o o o o o o o o o
Balance Test o o o o o o o o o o o o o o o o
U-Turn Test o o o o o o o o o o o o o o o o
Walkin g
[ADDRESS_1109702] o o o oScre ening, 
Month 6, 12, 18Base line, 
Month 25Timing of  assessments in 4-week rotation ( day)
PROTOCOL A MENDMENT APPROVA L
CONFIDENTIA L
This clinical study is being sponsored globally by F. Hoffmann -La [COMPANY_002] Ltd of Basel, 
Switzerland. However, it may be implemented in individual countries by [CONTACT_26702]'s local affiliates, 
including Genentech, Inc. in the [LOCATION_002].  The information contain ed in this document, especially 
any unpublished data, is the property of F.Hoffmann -La [COMPANY_002] Ltd (or u nder its control) and therefore 
is provided to you in confidence as an investigator, potential investigator, or consultant, for review by 
[CONTACT_10825], your staff , and an applicable Ethics Committee or Institutional Review Board.  It is understood that 
this information will not be disclosed to others without written authorization from [COMPANY_002] except to the 
extent necessary to obtain informed consent from persons to w hom the drug may  be administered.
RO7234292 —F. Hoffmann -La [COMPANY_002] Ltd
Protocol BN40423 , Version 4PROTOCOL
TITLE: A RANDOMIZED, MULTICENTER, DOUBLE -BLIND, 
PLACEBO -CONTROLLED ,PHA SEIII CLINICA L 
STUDY TO EVA LUATE THE EFFICA CY AND 
SAFETY OF INTRA THECA LLY ADMINISTERED 
RO7234292 (RG6042) IN PA TIENTS WITH 
MANIFEST HUNTINGTON'S DISEA SE
PROTOCOL NUMBER: BN40423
VERSION NUMBER: [ADDRESS_1109703] NUMBER: 2018 -002987 -14
IND NUMBER: [ADDRESS_1109704]: RO7234292
MEDICA L MONITOR: , M.D., Ph.D .
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
DATE FINA L: Version 1:  18 September 2018
DATESAMENDED : Version 2 (European Union):  13 December 2018
Version 3 (VHP):  24 January 2019
Version 4:  See electronic date stamp below
 
16-Apr-2019 22:13:46
Title
Approver's Name
[CONTACT_26862] (UTC)

RO7234292 —F. Hoffmann -La [COMPANY_002] Ltd
2/Protocol BN40423 , Version 4PROTOCOL A MENDMENT, VERSION 4:
RATIONA LE
The Study BN40423 protocol has been amended following a 9 -month data review from 
the ongoing open -label extension (OLE) Study BN40697 (ISIS 443139 -CS2).  
Preliminary dataincluding cerebrospi[INVESTIGATOR_872] (CSF) mutant huntingtin (mHTT) protein, 
exploratory fluid biomarkers, and safety/tolerabili tyshow that a 120 mg every -8-week 
(Q8W; every 2 months) dosing regimen of RO7234292 achieves 47% median CSF 
mHTT lowering at trough (i.e., sample taken immediately before the next dose) and the 
120mg every -4-week (Q4W ; monthly) dosing regimen achieves 66% median lowering at 
trough. Both results exceed the 20% 40% target for CSF mHTT lowering at trough and 
steady state based upon efficacy data from nonclinical models, and exceed the result of 
~40% median lowering observed in the completed Phase I/IIa stud y.
Safety and tolerability data for RO7234292 from the Phase II OLE Study BN40697 
suggest that relative to the Q4 W treatment regimen, the Q8 W treatment regimen may be 
more suitable for chronic intrathecal (IT) dosing, as evidenced by [CONTACT_803966]. There have been no acute safety concerns meriting a 
change to the ongoing Study BN40697.  However, given the 9-month CSF mHTT 
results, which suggest a longer than anticipated duration of effect of RO7234292 on CSF 
mHTT lowering , it is not necessary to use Q4 W paradigm to test the existing 
dose rationale in this study.
The existing dose rationale tests a more frequent dosing regimen, which is anticipated to 
maintain trough CSF mHTT reduction of at least ~40% (i.e., Q8 W 120 mg a rm from 
present data), and a less frequent regimen, which is still anticipated to lower mHTT 
acutely, but will allow greater recovery of HTT levels between doses (from present data 
trough CSF mHTT reduction of ~20% is maintained in a 120 -mg Q16W  
paradigm). Thus, this protocol for the 25 -month pi[INVESTIGATOR_127817] (BN40423) has 
been amended to replace the Q4 W arm with an every -16-week (Q16 W; every 4 months) 
arm, while continuing the Q8 W arm and placebo.
Changes to the protocol, along with a rationale f or each change, are summarized below:
The Q4 W dosing regimen has been removed from this study design based on
preliminary data from Study BN40697.  The [ADDRESS_1109705] ~40% (i.e. ,Q8W 120-mgarm from present data) versus a less frequent
dosing regimen that allows for a lower magnitude trough reduction ,which is still
anticipated to lower mHTT acutely, but will allow more recovery of HTT levels
between doses (from present data trough CSF mHTT reduction of ~20% is
maintained in a 120- mg Q16 W parad igm(Sections 1.2, 3.1, 3.3.1, 4.6, and 6).  The
timings of s tudy assessment shave been updated accordingly (Appendix 1).
RO7234292 —F. Hoffmann -La [COMPANY_002] Ltd
3/Protocol BN40423 ,Version 4Treatment regimen descriptions have been updated .  Patients who enrolled in
Study BN40423 before this amendment ( Version 4) will be given the option of
enrolling in the long -term OLE Study BN40955 after a pproval of the OLE study by
[CONTACT_803967] /Investigational Review
Board (Sections 3.1, 3.3.3, and 4.2) .  Those patients will be discontinued from
Study BN40423 at the point of enrollment into Study BN40955 .
Description of study companion requirements has been revised (Section 4.1.1).
Exclusion criteria have been revis ed to further describe drug and/or alcohol abuse
(Sections 4.1.2 and 4.5.2). In addition, clarification has been made for exclusions
for scoliosis and antiretroviral medications (Section 4. 5.5).
Additional details have been provided for administration of study drug by [CONTACT_803968] (Section [IP_ADDRESS]) .  Clarification has also been made that patients should
not perform any activity associated with a change in the ambient air pressure for at
least [ADDRESS_1109706] study drug administration (Section 4.5.5).
Sedation and anti -anxiety medication have been further detailed in the prohibited
therapy section (Section 4.4.2).
A CSF sample for differential cell counts , where feasible, has been added to the
local laboratory samples section (Section 4.5.6).
Preservation of biomarkers samples has been updated from 5 years to 10 years
(Section 4.5.6 ).
Loss of capacity to consent (if legal guardian consent is not possible) has been
added as a possible reason for study treatment discontinuation (Section 4.6.1).
The potential risks section has been updated to include hydrocephalus based upon
observed findings from another intrathecal bolus administered 2’MOE ASO and
changes in CSF protein observed with RO7234292.  Additional updates from the
ongoing Study BN40697 have been made.  The safety monitoring plan and
management guidelines for patients who exp erience adverse events have been
further clarified but principally remain the same (Section 5.1).
The name [CONTACT_3669] [CONTACT_803969]
(Section 5.4.1).
Language has been added to clarify that, after withdrawal of conse nt for
participation in the RBR, remaining RBR samples will be destroyed or will no longer
be linked to the patient (Section [IP_ADDRESS]).
Text has been modified to account for the fact that special situations (i.e., accidental
overdoses and medication errors) are not required to be reported within 24 hours
(Sections [IP_ADDRESS] and 5.4).  Note that serious adverse events associated with
special situations are still required to be reported within 24 hours.
Language has been added to indicate that the study will comply with applicable local,
regional, and national laws (Section 8.1).
RO7234292 —F. Hoffmann -La [COMPANY_002] Ltd
4/Protocol BN40423 ,Version 4Language has been revised to clarify that data posting will not be limited to two
clinical trial registries and to clarify that redacted CSRs are provided only if
requirements of [COMPANY_002]'s global policy on data sharing have been met (Section 9.5) .
Appendices 1 4 and 6 describe study assessments relevant solely to patients
enrolled afterimplementation of Protocol Version 4. Appendices 9 13 describe
study assessments relevant solely to patients enrolled before implementation of
Protocol Version 4.
Guidance for neurological examination has been added as Appendix 8.
This amendment includes cumulative changes to the protocol from Versions 2 (EU) 
and3 (VHP), which were created following comments from the Voluntary Harmonization 
Process (VHP) review.  Protocol Versions 2 and 3 were previously only implemented in 
EU countries, as they were local amendment requests following the European Medicines 
Agency (EMA) review.
Changes brought forwar d from the Version 2 amendment are summarized below:
Additional wording has been added as per Clinical Trial Facilitation Group guidance
to clarify that a vasectomi zed man must undergo a medical assessment of surgical
success before he can be considered surgically sterile (Section 4.1.1).
The inclusion criterion referring to the estimated glomerular filtration rate has been
corrected by [CONTACT_803970] (mL/min) (Section 4.1.1) .
The exclusion criterion regarding current use of antidepressants or benzo diazepi[INVESTIGATOR_803884] 112 weeks to 12 weeks (Section 4.1.2) .
Additional information has been provided in the statistical section around the testing
strategy for the primary endpoint, how missing data will be imputed, clarity around
theuse of historical controls, and details on how the sample size has been
calculated, as requested (Sections 6.2, 6.3, and 6.6).
Changes brought forward from the Version 3 amendment are summarized below:
Clarification has been added to Section 6.12.  An In terim Analysis (IA) will be
performed only after a future protocol amendment outlining a detailed plan of the IA.
Additional minor changes have been made to improve clarity and consistency. 
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
5/Protocol BN40423 , Version 4TABLE OF CONTENTS
PROTOCOL AMENDMENT A CCEPTANCE FORM .......................................... 14
PROTOCOL SYNOPSIS .................................................................................... 15
1. BACKGROUND .......................................................................................... 27
1.1 Background on Huntington's Disease .................................... 27
1.2 Background on RO7234292 .................................................. 28
1.3 Study Rationale and Benefit Risk Assessment ..................... 30
2. OBJECTIVES AND ENDPO INTS ............................................................... 31
2.1 Efficacy Objectives ................................................................ 31
2.1.1 Primary Efficacy Objective ..................................................... 31
2.1.2 Secondary Efficacy Objective ................................................ 31
2.1.3 Exploratory Efficacy Objective ............................................... 32
2.2 Safety Objective .................................................................... 32
2.3 Pharmacokinetic Objectives ................................................... 33
2.4 Immunogenicity Objectives ........ ........................
................... 33
2.5 Biomarker Objectives ............................................................. 33
2.5.1 Primary Biomarker Objective ................................................. 33
2.5.2 Secondary Biomarker Objective ............................................ 33
2.5.3 Exploratory Biomarker Objective ........................................... 34
2.6 Health Status Utility Objective ............................................... 34
3. STUDY DESIGN ......................................................................................... 34
3.1 Description of the Study ................................
......................... 34
3.1.1 Overview of Study Design ..................................................... 34
[IP_ADDRESS] Study Design Overview for Patients Enrolled 
prior to Implementation of Protocol Version 4 ...................... 39
3.1.2 Independent Data Monitoring Committee .............................. 42
3.2 End of Study and Length of Study ......................................... 42
3.3 Rationale for Study Design .................................................... 42
3.3.1 Rationale for RO7234292 Dose and Schedule ...................... 42
3.3.2 Rationale for Patient Population ............................................ 44
3.3.3 Rationale for Control Group ................................................... 45
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
6/Protocol BN40423 , Version 43.3.4 Rationale for Biomarker Assessments ................................... 45
[IP_ADDRESS] Cerebrospi[INVESTIGATOR_116252] ............................................ 45
[IP_ADDRESS] Blood Biomarkers .................................................................. 45
[IP_ADDRESS] Geneti c Testing to Determine CAG Repeat 
Length .................................................................................... 46
[IP_ADDRESS] Clinical Genotypi[INVESTIGATOR_007] ................................................................ 46
[IP_ADDRESS] Magnetic Resonance Imaging ............................................... 46
4. MATERIALS AND METHOD S.................................................................... 47
4.1 Patients.................................................................................. 47
4.1.1 Inclusion Criteria .................................................................... 47
4.1.2 Exclusio n Criteria ................................................................... 49
4.2 Method of Treatment Assignment and Blinding ..................... 51
4.3 Study Treatment and Other Treatments Relevant 
to the Study Design ............................................................... 52
4.3.1 Study Treatment Formulation, Packaging, and 
Handling ................................................................................ 52
[IP_ADDRESS] RO7234292 ........................................................................... 52
[IP_ADDRESS] Placebo .................................................................................. 53
4.3.2 Study Treatment Dosage, Administration, and 
Compliance ............................................................................ 53
[IP_ADDRESS] RO7234292 and Placebo ...................................................... [ADDRESS_1109707] Accountability ................... 53
4.3.4 Continued Access to RO7234292 ......................................... 54
4.4 Concomitant Therapy ............................................................ 55
4.4.1 Permitted Therapy ................................................................ .55
4.4.2 Prohibit ed Therapy ................................................................ 55
4.5 Study Assessments ............................................................... 56
4.5.1 Informed Consent Forms and Screening Log ........................ 56
4.5.2 Medical History, Concomitant Medication, and 
Demographic Data ................................................................ .57
4.5.3 Physical and Neurologic Examinations .................................. 57
4.5.4 Vital Signs .............................................................................. 58
4.5.5 Collection of Cerebrospi[INVESTIGATOR_17106] (Lumbar 
Puncture Procedure) ............................................................. 58
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
7/Protocol BN40423 , Version 44.5.6 Laboratory, Biomarker, and Other Biological 
Samples ................................................................................. 59
4.5.7 Magnetic Resonance Imaging ............................................... 61
4.5.8 Electrocardiograms ................................................................ 61
4.5.9 Patient -Reported, Clinician -Reported, Study 
Observer -Reported ,and Performance Outcomes ................. 62
[IP_ADDRESS] Composite Unified Huntington's Disease Rating 
Scale ...................................................................................... 63
[IP_ADDRESS] Total Fu nctional Capacity Scale ............................................ 63
[IP_ADDRESS] Total Motor Score .................................................................. 63
[IP_ADDRESS] Symbol Digit Modalities Test ................................................. 63
[IP_ADDRESS] Stroop W ord Reading Test .................................................... 63
[IP_ADDRESS] UHDRS Functional Assessment ............................................ 64
[IP_ADDRESS] Independence Scale .............................................................. 64
[IP_ADDRESS] HD D aily Activities Scale ....................................................... 64
[IP_ADDRESS] Clinical Global Impression Severity and Change 
Scales .................................................................................... 64
[IP_ADDRESS] Patient Global Impression Severity and Change 
Scales ................................................................
.................... 64
[IP_ADDRESS] Companion -Reported Global 
Impression Severity and Change Scales .............................. 65
[IP_ADDRESS] Montreal Cognitive Assessment ................................
............ 65
[IP_ADDRESS] Work Productivity and Activity Impairment ............................. 65
[IP_ADDRESS] Apathy Evaluation Scale ........................................................ 66
[IP_ADDRESS] Neuro -
Qol Cognition Function Short Form , 
Version 2............................................................................... 66
[IP_ADDRESS] HDSpeaking Difficulty Item ................................................... 66
[IP_ADDRESS] Symptoms of Major Depressive Disorder Scale .................... 66
[IP_ADDRESS] HD Companion -Reported Irritability and Angry 
Outbursts Scale ..................................................................... 66
[IP_ADDRESS] EuroQol 5 -
Dimension, 5- Level Questionnaire ....................... 67
[IP_ADDRESS] Health Utilities Index Mark 2 and Mark 3 ............................... 67
[IP_ADDRESS] Columbia -Suicide Severity Rating Scale ............................... 67
[IP_ADDRESS] Optional Exit Interviews ......................................................... 68
[IP_ADDRESS] [COMPANY_002] HD Mobile Application:  Remote Testing 
(Smartphone and Wrist-Worn Wearable) ............................... 68
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
8/Protocol BN40423 , Version [IP_ADDRESS] [COMPANY_002] HD Mobile Application:  In -Clinic 
Assessments ......................................................................... 69
4.5.10 Optional Samples for Research Biosample 
Repository ............................................................................. 69
[IP_ADDRESS] Overview of the Research Biosample Repository .................. 69
[IP_ADDRESS] Approval by [CONTACT_33427] .................................................................. 70
[IP_ADDRESS] Sample Collection .................................................................. 70
[IP_ADDRESS] Confidentiality ........................................................................ 71
[IP_ADDRESS] Consent to Participate in the Research 
Biosample Repository ............................................................ 71
[IP_ADDRESS] Withdrawal from the Research Biosample 
Repository ............................................................................. 72
[IP_ADDRESS] Monitoring and Oversight ....................................................... 72
4.6 Treatment, Patient, Study, and Site 
Discontinuation ...................................................................... 72
4.6.1 Study Treatment Discontinuation ........................................... 73
4.6.2 Patient Discontinuation from Study ........................................ 73
4.6.3 Study Discontinuation ............................................................ 74
4.6.4 Site Discontinuation ............................................................... 74
5. ASSESSMENT OF SAFETY ....................................................................... 74
5.1 Safety Pla n............................................................................ 74
5.1.1 Known Risks Associated with Lumbar Puncture .................... 74
[IP_ADDRESS] Post Lumbar Puncture Syndrome ......................................... 75
[IP_ADDRESS] Spi[INVESTIGATOR_626839] .................................................................. 76
[IP_ADDRESS] Meningitis .............................................................................. 76
5.1.2 Potential Risks Associated with RO7234292 ......................... 76
[IP_ADDRESS] Neurologic Changes ............................................................... 76
[IP_ADDRESS] Elevations in CSF WBCs and Protein ................................... 77
[IP_ADDRESS] Thrombocytopenia ................................................................ .77
[IP_ADDRESS] Kidney Effects ........................................................................ 77
[IP_ADDRESS] Liver Effects ........................................................................... 78
[IP_ADDRESS] Hydrocephalus ....................................................................... 78
[IP_ADDRESS] Neuropsychiatric Changes ..................................................... 78
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
9/Protocol BN40423 , Version [IP_ADDRESS] Potential Risk due to Reduction of Target Protein 
HTT........................................................................................ 79
5.1.3 Management of Patients W ho Experience 
Adverse Events ..................................................................... 80
[IP_ADDRESS] Dose Modifications ................................................................ 80
[IP_ADDRESS] Treatment Interruption ........................................................... 80
[IP_ADDRESS] Management Guidelines ........................................................ 80
5.2 Safety Parameters and Definitions ........................................ 82
5.2.1 Adverse Events ..................................................................... 83
5.2.2 Serious Adverse Events (Immediately Reportable 
to the Sponsor) ...................................................................... [ADDRESS_1109708] (Immediately 
Reportable to the Sponsor) .................................................... 84
5.3 Methods and Timing for Capturing and 
Assessing Safety Parameters ................................................ 84
5.3.1 Adverse Event Reporting Period ........................................... 84
5.3.2 Eliciting Adverse Event Information ....................................... 85
5.3.3 Assessment of Severity of Adverse Events ........................... 85
5.3.4 Assessment of Causality of Adverse Events ......................... 86
5.3.5 Procedures for Recording Adverse Events ............................ 86
[IP_ADDRESS] Injection Reactions ................................................................ 86
[IP_ADDRESS] Diagnosis versus Signs and Symptoms ................................ .87
[IP_ADDRESS] Adverse Events That Are Secondary to Other 
Events.................................................................................... 87
[IP_ADDRESS] Persistent or Recurrent Adverse Events ................................ 87
[IP_ADDRESS] Abnormal Laboratory Values ................................................. 88
[IP_ADDRESS] Abnormal Vital Sign Values ................................................... 89
[IP_ADDRESS] Abnormal Liver Function Tests .............................................. 89
[IP_ADDRESS] Deaths ................................................................................... 89
[IP_ADDRESS] Preexisting Medical Conditions .............................................. 90
[IP_ADDRESS] Lack of Efficacy or W orsening of Huntington's 
Disease .................................................................................. 90
[IP_ADDRESS] Hospi[INVESTIGATOR_26589] .......................... 90
[IP_ADDRESS] Reporting Requirements for Cases of Accidenta l 
Overdose or Medication Error ............................................... 91
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
10/Protocol BN40423 , Version [IP_ADDRESS] Patient -Reported or Observer -Reported Outcome 
Data ....................................................................................... 92
[IP_ADDRESS] Safety Biomarker Data ........................................................... [ADDRESS_1109709] ..................... 94
[IP_ADDRESS] Events That Occur prior to Study Drug Initiation .................... 94
[IP_ADDRESS] Events That Occur after Study Drug Initiation ........................ 94
5.4.3 Reporting Requirements for Pregnancies .............................. 94
[IP_ADDRESS] Pregnancies in Female Patients ............................................ 94
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients ................. 95
[IP_ADDRESS] Abortions ............................................................................... 95
[IP_ADDRESS] Congenital Anomalies/Birth Defects ...................................... [ADDRESS_1109710] of Study .......................................... 100
6.5 Summaries of Demographic and Baseline 
Characteristics ..................................................................... 100
6.6 Efficacy Analyses ................................................................ 100
6.6.1 Estimands ............................................................................ 100
6.6.2 Primary Efficacy Analysis .................................................... 102
6.6.3 Secondary Efficacy Analyses .............................................. 102
6.6.4 Subgroup Analyses ............................................................. 103
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
11/Protocol BN40423 , Version 46.6.[ADDRESS_1109711] or Ethics Committee .................. 111
8.4 Confidentiality ...................................................................... 111
8.5 Financial Disclosure ............................................................ 112
9. STUDY DOCUMENTATION, MONIT ORING, AND
ADMINISTRATION ................................................................................... 112
9.1 Study Documentation .......................................................... 112
9.2 Protocol D eviations .............................................................. 112
9.3 Site Inspections ................................................................... 113
9.4 Administrative Structure ....................................................... 113
9.5 Dissemination of Data and Protection of Trade 
Secrets ................................................................................ 113
9.6 Protocol Amendments ......................................................... 114
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
12/Protocol BN40423 , Version 410. REFERENCES ......................................................................................... [ADDRESS_1109712] OF A PPENDICES
Appendix 1 Schedule of Activities for Patients Enrolled after 
Implementation of Protocol Version 4 ...................................... 119
Appendix 2 Clinician -Reported Outcomes for Patients Enrolled after 
Implementation of Protocol Version 4 ...................................... 127
Appendix 3 Patient -Reported, Observer -Reported, and Performance 
Outcomes and [COMPANY_002] HD Mobile Application for Patients 
Enrolled after Implementation of Protocol Version 4................... 128
Appendix 4 Clinical Assessments Order and Duration for Patients 
Enrolled after Implementation of Protocol Version 4 ................ 131
Appendix 5 Grading Scale for Adverse Events Relating to Laboratory 
Abnormalities for All Patients ................................................... 135
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
13/Protocol BN40423 , Version 4Appendix 6 [COMPANY_002] HD Mobile Application for Patients Enrolled after 
Implementation of Protocol Version 4 :  Active Test .................. 138
Appendix 7 Diagnostic Confidence Level for All Patients ........................... 142
Appendix 8 Guidance for Neurological Examination for All Patients ......... 143
Appendix 9 Schedule of Activities for Patients Enrolled before 
Implementation of Protocol Version 4 ...................................... 144
Appendix 10 Clinician -Reported Outcomes for Patients Enrolled before
Implementation of Protocol Version 4 ...................................... 151
Appendix 11 Patient -Reported, Observer -Reported, and Performance 
Outcomes and [COMPANY_002] HD Mobile Application for Patients 
Enrolled before Implementation of Protocol Version 4.............. 152
Appendix 12 Clinical Assessments Order and Duration fo r Patients 
Enrolled before Implementation of Protocol Version 4 .............. 155
Appendix 13 [COMPANY_002] HD Mobile Application for Patients Enrolled before
Implementation of Protocol Version 4:  Active Test ................. 159
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
14/Protocol BN40423 , Version 4PROTOCOL AMENDMENT ACCEPTA NCE FORM
TITLE: A RANDOMIZED, MULTICENTER, DOUBLE -BLIND, 
PLACEBO -CONTROLLED ,PHA SEIII CLINICA L 
STUDY TO EVA LUATE THE EFFICA CY AND 
SAFETY OF INTRA THECA LLY ADMINISTERED 
RO7234292 (RG6042) IN PA TIENTS WITH 
MANIFEST HUNTINGTON'S DISEA SE
PROTOCOL NUMBER: BN40423
VERSION NUMBER: [ADDRESS_1109713] NUMBER: 2018 -002987 -14
IND NUMBER: [ADDRESS_1109714]: RO7234292 
MEDICA L MONITOR: , M.D., Ph.D .
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
I agree to conduct the study  in accordance with the current protocol.
Principal Investigator's Name  (print)
Principal Investigator's Signature [CONTACT_33505].  Please return a copy of 
the signed form as instructed by [CONTACT_27860].

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
15/Protocol BN40423 , Version 4PROTOCOL SYNOPSIS
TITLE:A RANDOMIZED, MULTICENTER, DOUBLE -BLIND, PL ACEBO -
CONTROLLED, PHA SEIII CLINICA L STUDY TO EVA LUATE THE 
EFFIC ACY AND SA FETY OF INTRA THECA LLY A DMINISTERED 
RO7234292 (RG6042) IN PA TIENTS WITH MANIFEST 
HUNTINGTON'S DISEA SE
PROTOCOL NUM BER: BN40423
VERSION NUMBER: [ADDRESS_1109715] NUMBER: 2018- 002987 -14
IND NUMBER: [ADDRESS_1109716]: RO7234292
PHASE: Phase III
INDIC ATION: Huntington's disease
SPONSOR: F. Hoffmann -La [COMPANY_002] Ltd
Objectives and Endpoints
This study will evaluate the efficacy , safety, pharmacokinetic (PK), and biomarker effects of 
RO7234292 compared with placebo in patients with manifest Huntington's disease ( HD).  
Specific objectives and corresponding endpoints for the study are outlined b elow.
Efficacy Objectives
Primary Efficacy  Objecti ve
The primary  efficacy  objective for this study is to evaluate the efficacy of RO7234292 compared 
withplacebo on the basis of the following endpoint:
Change from baseline in the c omposite Unified Hunting ton's Disease Rating Scale
(cUHDRS )score at Week 101
Note:  The primary  efficacy  endpoint for the U.S. Food and Drug Administration (FDA) 
will be c hange from baseline in the Total Functional Capacity (TFC)score at Week 101 
Secondary Efficacy Objective
The secondary efficacy  objective for this study is to evaluate the efficacy of RO7234292 
compared withplacebo on the basis of the following endpoints:  
Change from baseline in scores for the following individual scales at Week 101:
-TFC
-Total Motor Sco re(TMS)
-Symbol Digit Modalities Test (SDMT)
-Stroop Word Reading Test (S WR)
Note:  For the U.S. FDA, the first secondary endpoint will be c hange from baseline in
the cUHDRS score at Week 101 instead of TFC, as TFC will be the primary  endpoint.
Change fro m baseline in the Clinical Global Impression, Severity Scale (CGI -S) score at
Week 101
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
16/Protocol BN40423 , Version 4Proportion of patients with a decrease from baseline of 1 point on the TFC at W eek 101
Proportion of patients with a decline from baseline of 1.2 points on the cUHDRS at Week
101
Proportion of patients with an unchanged or improved score on the Clinical Global
Impression, Change Scale (CGI -C) score from baseline at Week101
Explorator y Efficacy Objective
The exploratory efficacy  objective for this study is to evaluate the efficacy  of RO7234292
compared withplacebo on the basis of the following endpoints:  
Change from baseline in the Apathy Evaluation Scale (AES) score at W eek101
Change from baseline in the Sy mptoms of Major Depressive Disorder Scale (SMDDS)
score at Week101
Change from baseline in the Huntington's Disease Daily Activities Scale (HD -DAS) score at
Week93
Change from baseline in the Patient Global Impression, Severity Scale (PGI -S) score at
Week101
Change from baseline in the Quality of Life in Neuro logical Disorders ( Neuro -Qol) Cognition
Function Short Form at Week 101
Change from baseline in the Huntington's Disease Speaking Difficulty Item Scale (HD -SDI)
score at Week101
Change from baseline in the Huntington's Disease Companion -Reported Irritabil ity and
Angr y Outbursts Scale ( HD-CIAOS) score at Week101
Change from baseline in the in -clinic patient -reported EuroQol 5 -Dimension Questionnaire
(5-level version; EQ -5D-5L) index -score and visual analogue scale (VAS) at W eek 101
Change from baseline in the sensor -based measures collected by [CONTACT_803971] ( app; smartphone and wrist- worn wearable) at Week 101
Safety O bjective
The safety  objective for this study is to evaluate the safety and tolerability of RO72342 92 
compared with placebo on the basis of the following endpoints: 
Incidence and severity of adverse events, with severity determined according to the
Adverse Event Severity Grading Scale
Change from baseline in Montreal Cognitive Assessment (MoCA)
Change from baseline in vital signs
Change from baseline in ECG parameters
Change from baseline in clinical laboratory results
Proportion of patient s with suicidal ideation or behavior , as assessed by [CONTACT_174273] -Suicide
Severity Rating Scale ( C-SSRS ) score at each visit, including detailed focus on any
individual cases identified as having severe ideation or behavior during the study conduct
Pharmacokinetic Objectives
The PKobjective for this study is to characterize the RO7234292 PK profile in plasma and 
trough CSF on the basis of the following endpoint s:
Concentration of RO7234292 in plasma at specified timepoints
Trough concentration of RO7234292 in CSF at specified timepoints
The exploratory pharmacokinetic/pharmacodynamic (PK/PD) objective for this study is to 
evaluate potential relationships between drug exposure and the efficacy and safety of 
RO7234292 on the basis of the following endpoint s:
Relationship between plasma profiles and/or trough CSF concentration s ofPKparameters
for RO7234292 and efficacy endpoints
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
17/Protocol BN40423 , Version 4Relationship between plasma profiles and/or trough CSF concentration s ofPK parameters
for RO7234292 and safety endpoints
Immunogenicity Objectives
The immunogenicity objective for this study is to evaluate the immune response to RO7234292
on the basis of the following endpoint s:
Incidence of anti-drug antibodies ( ADAs )at specified timepoints relative to the prevalence
of ADAs at baseline
Titer and antibody subtype, determined if ADAs are identified
The exploratory immunogenicity objecti ve for this study is to evaluate potential effects of ADAs 
on the basis of the following endpoint:
Relationship between ADA status and efficacy , safety, or PK endpoints
Biomarker Objectives
Primary Biomarker Objective
The primary  biomarker objective for this study is to evaluate the effects of RO7234292 
compared withplacebo on the basis of the following endpoint:
Change from baseline in CSF mHTT protein level at W eek101
Secondary Biomarker Objective
The secondary biomarker objective for this study is to evaluate the effects of RO7234292 
compared withplacebo on the basis of the following endpoints:
Change from baseline in whole and regional brain volumes (caudate, whole brain, and
ventricular), as determined by [CONTACT_803972] e imaging (MRI), at W eek 101
Change from baseline in CSF neurofilament light chain (NfL) protein level at W eek101
Explorator yBiomarker Objective
The exploratory biomarker objective for this study is to identify biomarkers that are predictive of 
response to RO7234292 (i.e., predictive biomarkers), are early surrogates of efficacy, are 
associated with progression to a more severe disease state (i.e., prognostic biomarkers), are 
associated with acquired resistance to RO7234292, are associated with susceptib ility to 
developi[INVESTIGATOR_803856] 
(i.e., safety  biomarkers), can provide evidence of RO7234292 activity (i.e., PDbiomarkers), or 
can increase the knowledge and understanding of disease biology and drug safety, on the basis 
of the following endpoints:
Relationship between biomarkers in blood, plasma, and CSF and efficacy , safety, PK,
immunogenicity, or other biomarke r endpoints
Relationship between imaging biomarkers (e.g., putamen, cortical grey matter, cortical
white matter volumes, resting state functional MRI signal )and efficacy , safety, PK,
immunogenicity, or other biomarker endpoints
Health Status Utility Obje ctive
The exploratory health status utility objective for this study is to evaluate health status utility 
scores of patients treated with RO7234292 on the basis of the following endpoint:
Change from baseline in p atient -and companion -reported EQ -5D-5L Index and VAS scores
at specified timepoints
Change from baseline in companion self -reported and proxy -reported Health Utilities Index
Mark 2 ( HUI2) and Mark 3 (HUI3) scores at specified timepoints
Change from baseline in p atient -and companion -reported WorkProductivity and Activity
Impairment (WPAI) scores at specified timepoints
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
18/Protocol BN40423 , Version 4Study Design
Description of Study
Study BN40423 is a Phase III,randomized, placebo -controlled, double -blind, multic enter clinical 
study to evaluate the efficacy , safety, PK, and biomarker effects ofintrathe cally administered 
RO7234292 in patients with manifest HD. 
Prospective patients will undergo screening assessments during a 4- week screening period.  A 
maximum of one re-screening will be allowed within 8 weeks of the initial screening failure for 
patients who fail the initial screening.
Upon completion of the screening period, eligible patients will be randomly allocated in a 
1:1:1 ratio to receive RO7234292 ever y 8weeks ( Q8W ; RO7234292 Q8W arm), RO7234292 
every 16weeks ( Q16W ; RO7234292 Q16W arm), or placebo Q8W (placebo arm) by [CONTACT_803900].  To maintain the study blind and integrity, patients in the RO7234292 Q16W arm will 
also receive placebo (i.e., alternating doses of active drug and placebo).
During scheduled clinic visits, patients will undergo safety and tolerability evaluations that 
include neurologic examinations, vital signs, ECGs, clinical laboratory tests, MoCA, C -SSRS, 
neuroimaging assessments (neurologic safety sequences), and a review of any adverse events 
including related concomitant medications, as detailed in the sched ule of activities.  
If there is the occurrence of a failed IT bolus dosing procedure due to inadequate 
establishment of access to the IT space, a second dosing attempt may occur up to 7 days after 
the originally scheduled dosing visit.  At this additional visit, safety and tolerability 
evaluations will be performed as described in the schedule of activities.
A telephone safety follow -up call will be conducted for the months in which no clinic visits 
are scheduled to check for any change in patient status ( i.e., adverse events, concomitant 
medications) since the patient’s last visit.  Where deemed appropriate, an unscheduled clinic 
visit should be arranged for safety follow -up; no dosing will occur at these unscheduled visits . 
During the telephone follow -up call, patients will be reminded of their next follow -up visit .  
Patients who complete the treatment period will return to the clinic for an end -of-treatment visit 
at Week 101.  Patients will then be given the option on an individual basis of receiving 
RO7234292 in an OLE study (BN40955) upon completion of Study BN40423, provided they 
meet eligibility criteria and the data from the ongoing RO7234292 program support continued 
development.  Approval of the OLE study must also be granted by [CONTACT_803973] (EC)/Investigational Review Board (IRB).  
All patients enrolled in Study BN40423 who choose to discontinue study treatment prematurely, 
but do not withdraw consent for continued participation in the study, will return to the clinic for 
study visits at W eeks53 and 69 (if not already completed) for collection of at least the data for 
the primary  and secondar y endpoints.  If the early treatment termination visit falls within 30 
days of either scheduled visits at Week53 or Week69, then only the early treatment 
termination visit will be considered.  The early treatment termination visit should be performed 
28 days ( 3 day s) after the last dose.  Patients will also attend the scheduled end -of-treatm ent 
visit at W eek 101. 
An independent Data Monitoring Committee (iDMC) and independent Data Coordinating Center 
(iDCC) will be employed to monitor and evaluate patient safety throughout the study as well as 
to evaluate evidence of early efficacy.  
Study Design Overview for Pa tients Enrolled prior to Implementation of Protocol Version 4
All patients enrolled in Study BN40423 prior to implementation of the Version 4 protocol 
amendment will be prematurely discontinued by [CONTACT_803974] i n the OLE Study BN40955, once approval has been granted by [CONTACT_803975]/IRBs.  Patients will continue to receive treatment in 
Study BN40423 until the OLE study has been approved at their study site.  Patients who 
discontinue tre atment or study prior to Sponsor discontinuation will not be eligible for the 
OLE Study BN40955. 
Patients who choose to enroll in the OLE will complete an end -of-treatment visit in 
Study BN40423, which can also serve as the inclusion visit for Study BN409 55.  All patients 
who are prematurely discontinued by [CONTACT_803976]40955 will additionally undergo a 5 -month postdose safety follow -up visit. 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
19/Protocol BN40423 , Version 4Number of Patients
Approximately [ADDRESS_1109717] meet the following criteria for study entry during screening (some will be 
reassessed at baseline prior to randomization and study drug dosing ):
Signed Informed Consent Form
Age [ADDRESS_1109718] dose administration
Manifest HD diagnosis, defined as a diagnostic confidence level ( DCL)score of 4
Independence Scale (IS) score 70
Genetically confirmed disease by [CONTACT_626896] a CAP score 400 (Zhang et al.
2011), calculated as follows:
CAPAge(CAG repeat length 33.66)
Ability to read the words "red," "blue," and "green" in native language
Ability to walk unassisted without a cane or walker and move about without a wheelchair on
a daily basis as determined at screening and baseline visit
-Long-distance (e.g. ,50meters) use of wheelchairs for convenience ortransfer is
permitted.
Body mass index 16 32 kg/m2; total body weight 40kg
Ability to undergo and tolerate MRI scans (e.g., no claustrophobia, no severe chorea or
other condition that precludes MRI scans or renders scanning intolerable for the patient, no
MRI- incompatible intrauterine devices, metallic dental braces, or other metal implants)
Ability t o tolerate blood draws and lumbar punctures
Estimated glomerular f iltration r ate(eGFR) 60 mL/min (Cockcroft -Gault formula)
Ability and willingness, in the investigator's judgment, to comply with all aspects of the
protocol including completion of interviews and questionnaires for the duration of the study
Ability and willingness, in the investigator's judgment, to carry a smartphone, wear a digital
monitoring device, and complete smartphone -based tasks
Stable medical, ps ychiatric, and neurological statu s for at least 12 weeks prior to screening
and at the time of enrollment
Signed study companion consent for participation ,if a study companion is available, who
fulfills all of the following criteria:
-Age 18 years
-Reliable and competent, in the investigator's judgment
-Sufficiently knowledgeable of the patient's condition to complete study companion
assessments of the patient, and likely to remain sufficiently knowledgeable throughout
the study, in the investigator's judgment
-Able to comment on st udy participant's sy mptoms and functioning experience
Note:  Companions must have no cognitive, behavioral or motor change , in the
opi[INVESTIGATOR_871], that would question the validity of the acquired observer -
reported data .
All effort should be made to retain the study companion; however, should this not be
possible, a study companion can be replaced and new consent obtained.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
20/Protocol BN40423 , Version 4For women of childbearing potentia l:  agreement to remain abstinent (refrain from
heterosexual intercourse) or use contraceptive measures, as defined below:
Women must remain abstinent or use two methods of contraception, including at least 
one method with a failure rate of  1% per year, during the treatment period and for 5 
months after the final dose of study drug. 
A woman is considered to be of childbearing potential if she is postmenarcheal, has 
not reached a postmenopausal state ( 12continuous months of amenorrhea with no 
identified cause other than menopause), and has not undergone surgical sterilization 
(removal of ovaries and/or uterus).  The definition of childbearing potential may be 
adapted for alignment with local guidelines or requirements.
Examples of contracep tive methods with a failure rate of 1%per year include 
bilateral tubal ligation, male sterilization, established proper use of hormonal 
contraceptives that inhibit ovulation, hormone -releasing intrauterine devices, and 
copper intrauterine devices.   A v asectomized man must undergo a medical assessment 
that confirms the success of the surgery before he can be considered surgically sterile.
Hormonal contraceptive methods mu stbe supplemented by a barrier method.
The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and withdrawal 
are not acceptable methods of cont raception.
For men:  agreement to remain abstinent (refrain from heterosexual intercourse) or use a 
condom, and agreement to refrain from donating sperm, as defined below:
With a female partner of childbearing potential or pregnant female partner, men must 
remain abstinent or use a condom during the treatment period and for 5months after 
the final dose of study  drug to avoid exposing the embryo .  Men must refrain from 
donating spe rm during this same period.
The reliability of sexual abstinence should be evaluated in relation to the duration of 
the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence 
(e.g., calendar, ovulation, sy mptothermal, or postovulation methods) and withdrawal 
are not acceptable methods of preventing drug exposure .
Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
History of attempted suicide or suicidal ideation with plan (i.e., active suicidal ideation) that
required hospi[INVESTIGATOR_601316]/or change in level of care within 12 months prior to screening
Current suicidal ideation is demonstrated by [CONTACT_941] C -SSRS per judgment of the 
investigator.  If suicidal ideation is present, a risk assessment should be done by [CONTACT_803904].  Mild passive suicidal i deation (i.e., occasional 
thoughts that life is not worth living or is hard) without history of attempts or 
hospi[INVESTIGATOR_601317] 12 months is generally acceptable for study participation, 
but final decision on participation should be made carefull y and in consultation with an 
appropriately qualified mental health professional. 
Current active ps ychosis, confusional state, or violent behavior
Any serious medical condition or clinically significant laborator y, or vital sign abnormality or
claustroph obia atscreening that, in the investigator's judgment, precludes the patient's safe
participation in and completion of the study
History known to the investigator or presence of an abnormal ECG that is clinically
significant in the investigator's opi[INVESTIGATOR_1649], including complete left bundle branch block, second -
or third -degree atrioventricular heart block, or evidence of prior m yocardial infarction
Clinical diagnosis of chronic migraines
Pregnant or breastfeeding, or intending to become pregnant during the stu dy or within
5months after the final dose of study drug
RO7234292 F. Hoffmann-La [COMPANY_002] Ltd 
22/Protocol BN40423, Version [ADDRESS_1109719] visit occurs.  The end of 
the study is expected to occur a pproximately 117 weeks (29 mont hs) after the last patient is 
enrolled.   
Length of Study 
The total length of the study, fr om screening of the first pati ent to the end of the study, is 
expected to be approximately 4 .5 years.  
Investigational Medicinal Products 
The investigational medicinal prod ucts (IMPs) for this study ar e RO7234292 and RO7234292 
placebo.  
Test Product (Investigational Drug) 
RO7234292 will be supplied by [CONTACT_319071], preservative-free liquid in a 20-mL 
single-use vial containing 10 mL of 6.0 mg/mL RO7234292 drug pr oduct for IT injection.  For a 
120-mg dose (20-mL dosing volume), two vials containing 10 mL o f 6.0 mg/mL RO7234292 will
be pooled by [CONTACT_803977] [ADDRESS_1109720]. For information on the formulation, preparation, and handling o f RO7234292 placebo, refer to 
the pharmacy manual. 
Statistical Methods 
Primary Analysis 
The primary efficacy endpoint is the change from baseline in cU HDRS score at Week 101.  This 
is defined as the attribute "v ariable" of the primary estimand.  
Note:  The primary efficacy endpoi nt for the U.S. FDA will be c hange from baseline in the TFC 
score at Week 101.  TFC will be an alyzed the same way as the cU HDRS. 
The primary efficacy analysis fo r this study will compare each active treatment arm, RO7234292 
Q8W and RO7234292 Q16W , against the placebo arm.  To account for the multiple 
comparison, an appropriate proce dure will be used to maintain the overall two-sided type I error 
at 5% (details will be given in the SAP).  
The analysis of the primary endpoint will be performed by [CONTACT_803978] 
(ANCOVA).  The model will include the corresponding endpoint ba seline score, CAG repeat 
length, baseline CAP score, and  treatment as covariates; the fi nal list of covariates will be 
defined in the SAP.  On the basis of this analysis, least squar es mean for the treatment 
differences at Week 101 and co rresponding 95% CIs will be deriv ed.   
The robustness of the primary method of estimation described ab ove may be explored by 
[CONTACT_803979]. These sens itivity analyses will be describ ed in the SAP. 
Determination of Sample Size   
The planned sample size is adequat e to capture meaningful clini cal decline on both the TFC 
and cUHDRS and was estimated on t he basis of data available fro m non-interventional studies 
(TRACK-HD, COHORT, ENROLL-HD) and a randomized placebo-controlled study (2CARE).  
Based on these data, using the anticipated trial population, a meta-analysis for the change from 
baseline at [ADDRESS_1109721] deviation of 1.78.  A conservative treatment discontinuation 
rate at Week 101 for patients receiving placeb o or active is assumed to be 20% and 15%, 
RO7234292 F. Hoffmann-La [COMPANY_002] Ltd 
23/Protocol BN40423, Version 4  respectively.  Using these assumptions, the si mulation described in the protocol was 
performed to estimate the sample size.   
It was estimated that 220 patient s per arm will provide approxi mately 80% power , at a two-sided 
  0.[ADDRESS_1109722] a 40% slowing of clinical  decline for RO [ADDRESS_1109723] translates into an  expected average decline of 
~0.82 points at 101 weeks for  the RO7234292 arms.  The minimal detectable difference with 
these assumptions is ~0.[ADDRESS_1109724] an interim analysis, along with the rat ionale, specification of the 
endpoint (e.g., clinical and/or b iomarker endpoint), number of patients, and statistical details for 
each analysis, will be introduced via a future protocol amendment , which will be submitted to 
relevant health authorities at least [ADDRESS_1109725] of the interim analysis.  The 
iDMC Charter will document potential recomme ndations the iDMC can make to the Sponsor as 
a result of an interim analysis , and the iDMC Charter will be m ade available to relevant health 
authorities.  
If there is a potential for the study to be stopped for positive efficacy as a result of an interim 
analysis of efficacy data, the type I error rate will be contro lled to ensure statistical validity is 
maintained.  Additional criteria for recommending that the stud y be stopped for positive efficacy 
will be added to a future protocol amendment .   
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
25/Protocol BN40423 , Version 4HRQoL health- related quality of life
HTT huntingtin (gene)
HTT huntingtin (protein)
HUI Health Utilities Index
HUI2 HUI Mark [ADDRESS_1109726]
IND Investigational New Drug (Application)
IRB Institutional Review Board
IS Independence Scale
IT intrathecal
ITT intent -to-treat (population)
IxRS interactive voice or web- based response system 
mHTT mutant huntingtin (protein)
MoCA Montreal Cognitive Assessment
MRI magnetic resonance imaging
NCI National Cancer Institute
NCI CTCAE National Cancer Institute Common Terminology 
Criteria for Adverse Events
Neuro- Qol Quality of Life in Neurological Disorders
NfL neurofilament light chain (protein)
NRS numeric rating scale
NSDR nonstudy drug related (reasons)
ObsRO observer -reported outcome
OLE open -label extension
PD pharmacodynamic
PerfO performance outcome
PGI-C Patient Global Impression Change
PGI-S Patient Global Impression Severity
PK pharmacokinetic
PRO patient -reported outcome
Q4W every 4 weeks
Q8W every 8 weeks
Q16W every 16 weeks
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
26/Protocol BN40423 , Version 4QTc corrected QT interval
RBR Research Biosample Repository
SAP Statistical Analysis Plan
SDMT Symbol Digit Modalities Test
SDR study drug related (reasons)
SMDDS Symptoms of Major Depressive Disorder Scale
SWR Stroop Word Reading
TFC Total Functional Capacity Scale
TMS Total Motor Score
UHDRS Unified Huntington's Disease Rating Scale
VAS visual analog uescale
WES whole exome sequencing
WGS whole genome sequencing
WPAI Work Productivity and Activity Impairment
wtHTT wild-type huntingtin (protein)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
27/Protocol BN40423 , Version 41. BACKGROUND
1.1 BACKGROUND ON HUNTINGTON'S DISEA SE
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused 
by [CONTACT_803908] 1 of the Huntingtin HTT gene on chromosome 4, 
which encodes for a mutant huntingtin (mHTT) protein.  Based upon non clinical and 
clinical evidence, mHTT is considered the primary driver of HD pathophysiology 
(WildandTabrizi 2017 ).  Individuals who carry at least [ADDRESS_1109727] motor onset is 
approximately 10 20 years, with pneumonia, heart failure, or other complications
frequently cited as the cause of death (Sorensen and Fenger 1992 ).  Individuals with 
end-stage disease have complete physical disability and profound body wasting.  
The estimated prevalence of HD in North America, northwestern Europe, and Au stralia 
ranges from 5.96 to 13.17 cases per 100,000 ( Baig et al. 2016 ).  Although genetic 
testing can be used to identify individuals who will develop the disease, the diagnosis of 
HD is clinical through neurologic examination of the motor system.  The cli nical 
diagnosis of HD is made when the patient exhibits " unequivocal presence of an 
otherwise unexplained extrapyramidal movement disorder " (e.g.,chorea, dystonia, 
bradykinesia, rigidity )or "motor onset" (Huntington Study Group 1996 ;
Hogarth etal.2005 ).  Motor onset is typi[INVESTIGATOR_803858] 15 -item motor 
examination of the Unified Huntington's Disease Rating Scale (UHDRS ).  After 
completion of the examination, a certified motor rater assigns a diagnostic confidence 
level (DCL) score.  S cores range from 0 to 4, with 0 representing no impairment and 
4representing unequivocal motor signs of HD ( 99% confidence).  Among the 
considerable clinical phenotypic heterogeneity of the disease, motor onset is one of the 
more robust and consistently -agreed -upon disease features .  Behavioral features, 
including emotional disorders and personality changes, do not have a uniform 
presentation, are epi[INVESTIGATOR_616633], and do not usually progress steadily over time 
(Ross et al. 2014).  
Individuals with H D can be categorized as having either premanifest disease (diagnosed 
prior to motor onset) or manifest disease (diagnosed on the basis of motor onset).  The 
premanifest disease period can be subdivided into presymptomatic and prodromal
periods.  During the presympt omatic period, from birth to young adulthood , individuals 
are not clinically distinguishable from control s.  During the prodromal period, which can 
last many years before threshold clinical motor diagnosis, subtle motor changes and 
variable cognit ive and behavioral changes appear but are not sufficient to make the 
clinical diagnosis of HD. 
Themanifest disease period can be subdivided into five stages based on functional 
capacity ( Ross et al. 2014) .  Stage [ADDRESS_1109728] level of capacit y and is 
characterized by [CONTACT_626902].  
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
28/Protocol BN40423 , Version 4Stage 5 represents severe disability and dependence on full -time care (Shoulson and 
Fahn 1979).  The fiveclinical stages are defined by [CONTACT_803910] (TFC) Scale, with Stage 1 corresponding to TFC scores of 1113, 
Stage 2 to scores of 710, Stage 3 to scores of 36, Stage 4 to scores of 12,and 
Stage 5 to a score of 0 (Shoulson et al. 197 9).  
Currently approved treatments aim to reduce the burden of symptoms, maximize 
function ,and improve the patient 's quality of life (Nance et al. 2011).  Tetrabenazine and 
deutetrabenazine target abnormal involuntary movements (i.e., chorea) associated with 
HD, and these symptomatic therapie s have a challenging benefit risk profile.  These 
drugs have been linked to many significant adverse events, including parkinsonism, 
akathisia, sedation, and depression and suicidal thoughts.  T hey are contraindicated in 
patients who are actively suicidal and in patients with untreated or inadequately treated 
depression.  Additionally, they may prolong the corrected QT interval (QTc) , and caution 
is advised when used in combination with other drugs or medical conditions that 
potentially prolong the QTc.
Other medications are utilized in HD to address particular symptoms, such as 
antidepressants (for depression, agitation, irritability), anticonvulsants (for irritability, 
impulsive behavior), anxiolytics (for anxiety), cognitive -enhancing agents (for cogniti ve 
disturbances) ,and neuroleptics (for chorea) (Paulson and Albin 2011).  
To date, there are no approved treatments able to slow or stop the clinical progression
ofHD.  
1.2 BACKGROUND ON RO7234292
Neuropathological abnormalities in HD appear to be the cons equence of a toxic 
gain offunction of the mHTT protein ( Wexler et al. 1987; W alker2007; 
Moumné etal.2013).  Therefore, a therapy that reduces synthesis of the toxic mHTT
protein should directly target the primary disease mechanism.  As the genetic origin of 
HD is localized to just one gene, inhibiting the expression of this HTT gene is a 
promising therapeutic option (Stanek et al. 2013) .
RO7234292 ( RG6042 ) was originally developed by [CONTACT_81801], Inc. and was 
formerlyknown as ISIS443139 and IONIS -HTTRx .  This antisense oligonucleotide (ASO)
is being developed to reduce the synthesis of all forms of the HTT protein by [CONTACT_626904] -type and the mutant alleles and directing its catalytic 
degradation through the action of ribonuclease H1, an endogenous enzyme present in 
most mammalian cells (Crooke and Bennett 1996; Cerritelli and Crouch 2009), including 
cells of interest in the CNS (e.g. ,neurons and neuroglia).  Reduction of theHTT gene 
mRNA, which in turn limits translation of the wild-type and mutant huntingtin protein,
could potentially inhibit all downstream toxic effects and lead to a sustained reversal in 
HD symptoms.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
29/Protocol BN40423 , Version 4Pharmacology data support selective targeting of HTT mRNA transcripts from both 
alleles as a potentially safe and effective mechanism for the tr eatment of HD .  Using 
ASOs targeting human HTT mRNA in rodents and non -human primates, s ignificant 
reduction of mutant HTT mRNA transcripts , wild -type HTT mRNA transcripts ,and mH TT
protein has been achieved throughout most brain regions (Kordasiewicz et al. 2012).  
Furthermore , transient delivery of these ASOs in transgenic mouse models of HD
delayed disease progression andmediated a sustained reversal of disease phenotype 
that persisted longer than HTT mRNA knockdown ( Kordasiewicz et al. 2012; Stanek et 
al. 2013 ).  
Nonclinical proof -of-concept studies with ASOs targeting mutant HTT have been 
conducted in three models of HD, including YAC128 mice expressing the full -length 
mutant human HTT transgene with a 128 CAG repeat expansion, bacterial artificial 
chromosome (BAC)HDmice expressing the full -length mutant human HTT genomic 
sequence with 97 CAG/CAA repeats, and R6/2 mice expressing exon 1 of the mutant 
human HTT gene with 110135CAG repeats.  These studies demonstrate that ASOs 
targeting human HTT mRNA improve motor function and protect against human HTT
transgene expression in YAC128 mice; i mprove motor function, hypoactivity ,and stress 
response in BACHD mice ; and p reserve striatal volume and increase survival in R6/2 
mice.
Thepharmacokinetics and toxicity of intrathecal (IT) administration of RO7234292 , an 
ASO that targets human HTT mRNA, were assessed in cynomolgus monkeys for 
13weeks (biweekly for the first month and then monthly ther eafter) at dose levels up to 
50mg/dose (5bolus administrations, for a total dose o f 250 mg) and chronically for 
9months, up to 35 mg/dose ([ADDRESS_1109729] rations for a total dose of 
350mg).  The drug was safe and well tolerated in these studies.
In a first -in-human, Phase I/IIa dou ble-blind, placebo -controlled, dose -escalation study 
(Clinicaltrials.gov Identifier [STUDY_ID_REMOVED]) (ISIS 443139 -CS1) four doses of RO7234292 
(ranging from 10 mg to 120 mg) were welltolerated and achieved significant 
dose- dependent lowering of cerebrospi[INVESTIGATOR_872] ( CSF) mHTT protein when administered 
intrathecally every 4 weeks (Q4 W; monthly ) to [ADDRESS_1109730] HD .  
Exploratory analyses identified a relationship between lowering of mHTT protein and 
improvement in some clinical measures.  Taken together, these data support further 
clinical testing to demonstrate definitive clinical benefit of mHTT protein reduction in the 
CNS. The data from this study also supported the initiation of Study ISIS 443139 -CS2 
(Study BN40697; Clinicaltrials.gov Ident ifier [STUDY_ID_REMOVED]) , a Phase II open -label 
extension (OLE) study for patients who participated in Study ISIS 443139 -CS1.  
Nine- month clinical data from the ongoing, 15 -month, Phase II OLE 
Study BN40697 including CSF mHTT protein, exploratory fluid biomarkers, and 
safety/tolerability data are available for reporting.  All individuals in Study BN40967 
have reached the 9 -month timepoint of the planned 15 -month study, and several 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
30/Protocol BN40423 , Version 4individuals have now received RO7234292 for ov er 1 year on both regimens.  
Study BN40697 will be continued until its anticipated completion by [CONTACT_466] 2019.    
Preliminary data show that a 120 mg every -8-week (Q8W; every 2 months) dosing 
regimen of RO7234292 achieves 47% median CSF mHTT lowering at trough 
(i.e., sample taken immediately before the next dose) and the 120 mg Q4W dosing 
regimen achieves 66% median lowering at trough.  Both results exceed the 20% 40% 
target for CSF mHTT lowering at trough and steady state based upon efficacy data from 
nonclinical models, and exceed the result of approximately 40% median lowering 
observed in the completed Phase I/IIa study. 
Further details on nonclinical and clinical studies can be found in the RO7234292
Investigator's Brochure .
1.3 STUDY RA TIONA LE A ND BENEF ITRISK A SSESSMENT
Presently, there are no therapi[INVESTIGATOR_626842], 
which is relentless until patients experience premature death.  The ASO RO7234292 is 
designed to target the cause of HD and offers the potential to meet this unmet medical 
need.  
To date, nonclinical and clinical data support further investigation of RO7234292 in 
patients with manifest HD.  Building on the completed Phase I/IIa study and the ongoing 
Phase II OLE study, this Phase III, double- blind , placebo -controlled study (BN40423) will 
collect longer -term clinical efficacy and safety data to definitively evaluate the benefit 
and potential risks of RO7234292 when administered by [CONTACT_626905] Q8W or every 
16weeks ( Q16W; every 4 months ) over a 25-month (2- year) period to patients with 
manifest HD.   
Review of safety and tolerability 9 -month data for RO7234292 from the Phase II OLE 
suggests that, relative to the Q4W treatment regimen, the Q8W treatment regimen may 
be more suitable for chronic I T dosing, as evidenced by [CONTACT_803980].  This is supported by [CONTACT_803913], 
decreased proportion of patients with moderate adverse events, and fewer adverse events 
considered possibly relat ed to study drug in the Q8W regimen compared to the Q4W 
regimen (for details see the RO7234292 Investigator’s Brochure).
There have been no acute safety concerns meriting a change to the ongoing Phase II 
OLE study protocol (BN40697).  However, given the 9-month CSF mHTT results, 
which suggest a longer than anticipated duration of effect of RO7234292 on CSF 
mHTT lowering, it is not necessary to use a Q4W paradigm to test the dose rationale.   
As a result, the results from OLE Study BN40697 justify a change in Study BN40423 
to explore less frequent dosing regimens by [CONTACT_626908] Q8W RO7234292 and 
placebo arms, and replacing the Q4W arm with a Q16W arm.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
31/Protocol BN40423 , Version 4The existing dose rationale tests a mo re frequent dosing regimen (i.e ., 120 mg Q8W), 
which from present datais anticipated to maintain trough CSF mHT T reduction of at 
least ~40%, and a less frequent regimen (i.e., 120 mg Q16W), which is still anticipated 
to lower mHTT acutely, but will allow greater recovery of HTT levels between doses.  
From present data, trough CSF mHTT reduction of ~20% is maintained in a 120 -mg 
Q16W paradigm.   
The known potential risks associated with RO7234292 and additional risks related to 
lumbar punctures a re elaborated , along with mitigation measures, in Section 5.1.Taking 
into account the measures to minimize risk to patients participating in this study, the 
potential risks identified for IT administration of RO7234292 are ju stified by [CONTACT_803981].
2. OBJECTIVES A ND ENDPO INTS
This study will evaluate the efficacy, safety, pharmacokinetic (PK), and biomarker effects
of RO7234292 compared with placebo in patients with manifest HD.  Specific objectives 
and corresponding endpoints for the study are outlined below.
2.1 EFFICA CY OBJECTIVES
2.1.1 Primary  Efficacy  Objective
The primary efficacy objective for this study is to evaluate the efficacy of RO7234292
compared withplacebo on the basis of the following endpoint:
Change from baseline in the composite Unified Huntington's Disease Rating Scale
(cUHDRS
)score at Week 101
Note:  The primary efficacy endpoint for the U.S. Food and Drug Administration 
(FDA) will be c hange from baseline in the TFC score at Week 101.
2.1.2 Secondary  Efficacy Objective
The secondary efficacy objective for this study is to evaluate the efficacy of RO7234292 
compared withplacebo on the basis of the following endpoints:  
Change from baseline in scores for the following individual scales at Week 101:
-TFC
-Total Motor Score (TMS)
-Symbol Digit Modalities Test (SDMT)
-Stroop Word Reading (SW R)Test
Note:  For the U.S. FDA, the first secondary endpoint will be c hange from
baseline in the cUHDRS score at Week 101 instead of TFC, as TFC will be the
primary endpoint.
Change from baseline in the Clinical Global Impression, Severity Scale (CGI -S)
score at Week 101
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
32/Protocol BN40423 , Version 4Proportion of patients with a decrease from baseline of 1 point on the TFC at 
Week101
Proportion of patients with a decline from baseline of 1.2 points on the cUHDRS at 
Week 101
Proportion of patients with an unchanged or improved score on the Clinical Global 
Impression, Change Scale (CGI -C) score from baseline at Week101
2.1.3 Exploratory  Efficacy  Objecti ve
The exploratory efficacy objective for this study is to evaluate the efficacy of RO7234292
compared withplacebo on the basis of the following endpoints:  
Change from baseline in the Apathy Evaluation Scale (AES) score at W eek101
Change from baseline in the Symptoms of Major Depressive Disorder Scale 
(SMDDS) score at W eek101
Change from baseline in the Huntington's Disease Daily Activities Scale (HD -DAS) 
score at Week93
Change from baseline in the Patient Global Impression, Severity Scale (PGI -S) 
score at Week101
Change from baseline in the Quality of Life in Neurological Disorders ( Neuro -Qol) 
Cognition Function Short Form at Week101
Change from baseline in the Huntington's Disease Speaking Difficulty Item Scale 
(HD-SDI) score at Week101
Change fro m baseline in the Huntington's Disease Companion -Reported Irritability 
and Angry Outbursts Scale ( HD-CIAOS) score at W eek101
Change from baseline in the in -clinic patient -reported EuroQol 5 -Dimension 
Questionnaire (5 -level version; EQ -5D-5L) index -score a nd visual analogue scale 
(VAS) at Week 101
Change from baseline in the sensor -based measures collected by [CONTACT_626913] (app; smartphone and wrist -worn wearable) at Week 101
2.2 SAFETY OBJECTIVE
The safety objective for this study is to evaluate the safety and tolerability of RO7234292 
compared with placebo on the basis of the following endpoints: 
Incidence and severity of adverse events, with severity determined according to the 
Adverse Event Severity Grading Scale (see Table 4 )
Change from baseline in Montreal Cognitive Assessment (MoCA)
Change from baseline in vital signs 
Change from baseline in ECG parameters
Change from baseline in clinical laboratory results
Proportion of patient s with suicidal ideation or behavior , as assessed by 
[CONTACT_174273] -Suicide Severity Rating Scale ( C-SSRS) score at each visit, including 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
33/Protocol BN40423 , Version 4detailed focus on any individual cases identified as having severe ideation or 
behavior during the study conduct
2.3 PHA RMA COKINETIC OBJE CTIVE S
The PKobjective for this study is to characterize the RO72 [ZIP_CODE] PK profile in plasma 
and trough CSF on the basis of the following endpoint s:
Concentration of RO7234292 in plasma at specified timepoints
Trough concentration of RO7234292 in CSF at specified timepoints
The exploratory pharmacokinetic/pharmacodynamic (PK/PD) objective for this study is to 
evaluate potential relationships between drug exposure and the efficacy and safety of 
RO7234292 on the basis of the following endpoint s:
Relationship between plasma profiles and/or trough CSF concentrations of
PKparameters for RO7234292 and efficacy endpoints
Relationship between pla sma profiles and/or trough CSF concentrations of PK
parameters for RO7234292 and safety endpoints
2.4 IMMUNOGENICITY OBJEC TIVE S
The immunogenicity objective for this study is to evaluate the immune response to 
RO7234292 on the basis of the following endpoint s:
Incidence of anti-drug antibodies ( ADAs )at specified timepoints relative to the
prevalence of ADAs at baseline
Titer and antibody subtype, determined if ADAs are identified
The exploratory immunogenicity objective for this study is to evaluate potential effects of 
ADAs on the basis of the following endpoint:
Relationship between ADA status and efficacy, safety, or PK endpoints
2.5 BIOMA RKER OBJECTIVE S
2.5.1 Primary  Biomarker Objective
The primary biomarker objective for this study is to evaluate the effects of RO7234292 
compared withplacebo on the basis of the following endpoint:
Change from baseline in CSF mHTT protein level at Week101
2.5.2 Secondary  Biomarker Objective
The secondary biomarker objective for this study is to evaluate the ef fects of 
RO7234292 compared withplacebo on the basis of the following endpoints:
Change from baseline in whole and regional brain volumes (caudate, whole brain,
and ventricular), as determined by [CONTACT_803899] (MRI), at
Week101
Change from baseline in CSF neurofilament light chain (NfL) protein level at
Week101
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
34/Protocol BN40423 , Version 42.5.3 Exploratory  Biomarker Objective
The exploratory biomarker objective for this study is to identify biomarkers that are 
predictive of response to RO7234292 (i.e., predictive biomarkers), are early surrogates 
of efficacy, are associated with progression to a more severe disease state 
(i.e., prognostic biomarkers), are associated with acquired resistance to RO7234292 , are 
associated with susceptibility to developi[INVESTIGATOR_803859] (i.e., safety biomarkers), can provide evidence 
of RO7234292 activity (i.e., PDbiomarkers), or can increase the knowledge and 
understanding of disease biology and drug safety, on the ba sis of the following 
endpoint s:
Relationship between biomarkers in blood, plasma, and CSF (listed in Section 4.5.6 )
and efficacy, safety, PK, immunogenicity, or other biomarker endpoints
Relationship between imaging biomarkers (e.g., putamen, cortical grey matter, 
cortical white matter volumes, resting state functional MRI signal ) (see Section 4.5.7 ) 
and efficacy, safety, PK, immunogenicity, or other biomarker endpoints
2.6 HEA LTH STA TUS UTILIT Y OBJECTIVE
The exploratory health status utility objective for this study is to evaluate health status 
utility scores of patients treated with RO7234292 on the basis of the following endpoint:
Change from baseline in p atient -and companion -reported EQ -5D-5L Index and 
VAS scores at specified timepoints 
Change from baseline in companion self -reported and p roxy-reported Health Utilities 
Index Mark 2 ( HUI2) and Mark 3 (HUI3) scores at specified timepoints
Change from baseline in p atient -and companion -reported Work Productivity and 
Activity Impairment (WPAI) scores at specified timepoints 
3. STUDY DESIGN
3.[ADDRESS_1109731] HD. 
Prospective patients will undergo screening assessments during a 4 -week screening 
period.  A maximum of one re-screening will be allowed within 8 weeks of the initial 
screening failure for patients who fail the initial screening (see Section 4.5.1 ). 
Upon completion of the screening period, eligible patients will be randomly allocated in a 
1:1:1 ratio to receive RO7234292 Q8W (RO7234292 Q8W arm), RO7234292 Q16W
(RO7234292 Q16W arm), or placebo Q8W (placebo arm) by [CONTACT_626918], as described 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
35/Protocol BN40423 , Version 4in Table 1.  To ma intain the study blind and integrity, patients in the RO7234292 Q16W
arm will also receive placebo (i.e., alternating doses of active drug and placebo).
Table 1Treatment Regimens after Implementation of Protocol Version 4
Arm Treatment Regimen
RO7234292 Q8W arm RO7234292 loading dose:  120 mg at Days 1 and 29 (2 doses)
RO7234292:  120 mg Q8W from Week 13 to Week 93 (11 doses)
RO7234292 Q16W arm RO7234292 loading dose:  120 mg at Days 1 and 29 (2 doses)
RO7234292:  120 mg Q16W from Week 21 to Week 85 (5 doses)
Placebo:  Q16W from Week 13 to Week 93 (6 doses)
Placebo arm Placebo:  at Days 1 and 29 (2 doses) and Q8W from Week 13 to 
Week 93 (11 doses)
Q8W every 8 weeks; Q16W every 16 weeks.
During scheduled clinic visits, patients will undergo safety and tolerability evaluations
that include neurologic examinations, vital signs, ECGs, clinical laboratory tests, MoCA, 
C-SSRS, neuroimaging assessments (neurologic safety sequences), and a review of
anyadverse events including related concomitant medications, as detailed in Appendix 1.
If there is the occurrence of a failed IT bolus dosing procedure due to inadequate 
establi shment of access to the IT space, a second dosing attempt may occur up to 7 days 
after the originally scheduled dosing visit.  At this additional visit, safety and 
tolerability evaluations will be performed as described in Appendix 1.
A telephone safety follow -up call will be conducted for the months in which no clinic 
visits are scheduled to check for any change in patient status (i.e., advers e events, 
concomitant medications) since the patient’s last visit.  Where deemed appropriate, an 
unscheduled clinic visit should be arranged for safety follow -up; no dosing will occur at 
these unscheduled visits.  During the telephone follow -up call, patients will be 
reminded of their next follow -up visit.
Patients who complete the treatment period will return to the clinic for an 
end-of-treatment visit at W eek 101.  Patients will then be given the option on an 
individual basis of receiving RO7234292 i n an OLE study (BN40955) upon completion of 
Study BN40423, provided they meet eligibility criteria and the data from the ongoing 
RO7234292 program support continued development . Approval of the OLE study must 
also be granted by [CONTACT_803982]
(EC)/Investigational Review Board (IRB).  
All patients enrolled in Study BN40423 who choose to discontinue study treatment 
prematurely ,but do not withdraw consent for continued participation in the study ,will
return to the cli nic for study visits at W eeks53 and 69 (if not already completed) for 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
36/Protocol BN40423 , Version 4collection of at least the data for the primary and secondary endpoints (see 
Sections 2.1.1, 2.1.2, and
 2.2).  If the early treatment termination visit falls within 30 
days of either scheduled visits at Week 53 or Week 69, then only the early treatment 
termination visit will be considered.  The early treatment termination visit should be 
performed 28 days (7 days) after the last dose.  Patients will also attend the scheduled 
end-o f-treatment visit at Week 101.   
An independent Data Monitoring Committee (iDMC) and independent Data Coordinating 
Center (iDCC) will be employed to monitor and evaluate patient safety throughout the 
study as well as to evaluate evidence of early efficacy (see Section 3.1.2).  
The Sponsor may choose to conduct one or more interim analyses during the study 
(further details are given in Section 6.12).
Figure
 1 and Figure
 2 present the study schema and overview of the dosing schedule  
respectively, for patients enrolled in Study BN40423 after implementation of Protocol 
Version 4.  A schedule of activities is provided in
 Appendix 1.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
38/Protocol BN40423 , Version 4Figure 2Dosing Schema for Patients Enrolled after Implementation of Protocol Version 4
EoTend of treatment; Q8W every 8 weeks ; Q16W every 16 weeks .
Notes:  Red, solid arrows indicate study drug administration, while black, dotted arrows indicate placebo administration.  Pa tients in the 
RO7234292 Q8 W arm will receive a loading dose of RO7234292 on Days 1 and 29 (loading period), foll owed by [CONTACT_803914] Q8W. Patients 
in the RO7234292 Q16W arm will receive a loading dose of RO7234292 on Days 1 and 29 (loading period), followed by [CONTACT_642643] Q8W doses 
of placebo and active study drug.

RO7234292F. Hoffmann-L a [COMPANY_002] Ltd  
39/Protocol BN40423, Version [IP_ADDRESS] Study Design Over view for Patients Enrolled prior to 
Implementation of Protocol Version 4
All patients enrolled in Study BN40423 prior to implementation of the Version 4 
protocol amendment will be prematurely discontinued by [CONTACT_803983]40955, once approval has been 
granted by [CONTACT_803984]/IRBs.  Patients will continue to 
receive treatment in Study BN40423 until the OLE study has been approved at their 
study site.  Patients who disc ontinue treatment or study prior to Sponsor 
discontinuation will not be eligible for the OLE Study BN40955. 
Patients who choose to enroll in the OLE will complete an end -of-treatment visit in 
Study BN40423, which can also serve as the inclusion visit for Study BN40955.  All 
patients who are prematurely discontinued by [CONTACT_803985]40955 will additionally undergo a 5 -month postdose safety follow -up visit. 
Table 2presents the treatment regimen for all patients before implementation of the 
Version 4 protocol.
Table 2Treatment Regimens prior to Implementation of Protocol 
Version 4
Arm Treatment Regimen
RO7234292 Q4W arm RO7234292:  120 mg Q4W from Week 1 to Week 97 (25 doses)
RO7234292 Q8W arm RO7234292 loading dose:  120 mg at Days 1 and 29 (2 doses)
Placebo:  Q8W from Week 9 to Week 97 (12 doses)
RO7234292:  120 mg Q8W from Week 13 to Week 93 (11 doses)
Placebo arm Placebo:  Q4W from Week 1 to Week 97 (25 doses)
Q4W every 4 weeks; Q8W every 8 weeks.
Figure 3and Figure 4present study schema and overviews of the dosing schedule, 
respectively.  A schedule of activities is provided in Appendix 9, with additional 
assessments described in Appendix 10, Appendix 11, Appendix 12, and Appendix 13.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
41/Protocol BN40423 , Version 4Figure 4Dosing Schema for Patients Enrolled prior to Implementation of Protocol Version 4
EoTend of treatment; Q4W every 4 weeks; Q8W every 8 weeks.
Notes:  Red, solid arrows indicate study drug administration, while black, dotted arrows indicate placebo administration.  Pa tients in the 
RO7234292 Q8W arm will receive a loading dose of RO7234292 on Days 1 and 29 (loading period), followed by [CONTACT_803918]. 

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
42/Protocol BN40423 , Version 43.1.[ADDRESS_1109732], and abnormalities from neuroimaging assessme nts;vital signs; ECG
assessments ; laboratory parameters; and any other relevant safety information will be 
reviewed on a regular basis by [CONTACT_803919].   This information may 
also include MRI data and exploratory CSF biomarkers, for exam ple NfL and Tau.
These reviews will occur approximately every 6 months or at the discretion of the iDMC. 
The iDMC will also undertake evaluation of any interim analys is. Specific operational 
details ,such as the committee's composition, frequency and timing of meetings, and 
members' roles and responsibilities ,will be detailed in an iDMC Charter.
3.[ADDRESS_1109733] visit occurs.  The 
end of the study is expected to occ ur approximately 117 weeks (29 months) after the last 
patient is enrolled.  
The total length of the study, from screening of the first patient to the end of the study, is 
expected to be approximately 4 .5years . 
In addition, the Sponsor may decide to term inate the study at any time.
3.3 RATIONA LE FOR STUDY DESIGN
3.3.1 Rationale for RO7234292 Dose and Schedule
The magnitude and duration of mHTT protein lowering that is required for clinical 
efficacy is unknown.  Specifically, it is unknown whether acute mHTT protein lowering 
alone with full recovery of protein levels between dosing will be sufficient for clinical 
efficacy, or whether more sustained suppression of protein levels will be required for 
clinical efficacy.  Data from transgenic animal models sugges t that brain tissue lowering 
of mHTT protein in the range of 30% 60% is associated with beneficial effects on the 
disease phenotype, which corresponds to a trough CSF lowering range of 2 0%40%
based on a non- human primate PK/PD model.  
Because of this unc ertainty, two active dosing regimens and a placebo arm will be used 
in this study:  RO7234292 Q8W (RO7234292 Q8W arm), RO7234292 Q16W
(RO7234292 Q16W arm), and placebo Q8W (placebo arm) by [CONTACT_626918].  To maintain 
the study blind and integrity, patients in the RO7234292 Q16W arm will also receive 
placebo (i.e., alternating doses of active drug and placebo).
The 120 -mg dose has been chosen for the Q8W dosing group based on the following:
In the chronic toxicology study in cynomolgus monkeys, the no -observ ed-adverse-
effect level was determined to beat least 35 mg/dose (the highest dose tested) .  
Conservatively correcting for differences in CSF volume between cynomolgus 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
43/Protocol BN40423 , Version 4monkeys ( 15 mL) and humans ( 150 mL) with a scaling factor of 10, the human 
equivalent dose corresponds to 350 mg, representing a 3 -fold safety margin to the 
proposed 120 -mg clinical dose.  
Both the 90 -mg and 120 -mg RO7234292 Q4 W groups in the Phase I/IIa study 
(ISIS 443139 -CS1) resulted in a median CSF mHTT protein reduction of 
approximately 40%, with individual cases reaching approximately 60% reduction at 
trough, well above the described preclinical threshold for efficacy.  The 120 -mg dose 
group exhibited a more consistent decline compared with the 90 -mg dose group. 
In the same Phase I/ IIa study, 120 mg of RO7234292 administered intrathecally 
Q4W for four doses was safe and well tolerated compared with placebo.  See 
additional details in the RO7234292 Investigator's Brochure. 
In approximately 70% of patients (23 of 34 patients) assigned to receive 
RO7234292 in the Phase I/IIa study , CSF mHTT protein was declining at the last 
trough measurement (either Day 113 or 141), suggesting sustained reduction of 
CSF mHTT protein up to 2 months postdose (last timepoint assessed). 
In the 120 -mg RO7234292 group in the Phase I/IIa study, CSF mHTT protein levels 
were reduced by [CONTACT_2669] 35% in all five cases for which a Day 141 sample was 
collected (i.e., [ADDRESS_1109734] dose ), in line with the observed Q8W OLE 
data. 
 Data from the ongoing Ph ase II OLE Study BN40697 (ISIS 443139 -CS2) showed 
that 120- mg doses administered in Q4W and Q8W regimens achieved 66% and 47% 
median reductions of CSF mHTT from baseline at trough, respectively, after 9 
months.  Both results exceed the 20% 40% target for C SF mHTT lowering at 
trough and steady state based upon efficacy data from nonclinical models, and 
exceed the result of approximately 40% median lowering observed in the completed 
Phase I/IIa study.  The observed effects on CSF mHTT lowering in the OLE afte r 
administration of three or four doses of 120 mg were also approximately 40%, 
consistent with results from the Phase I/IIa study (ISIS 443139- CS1).
 Review of safety and tolerability data for RO7234292 from the Phase II OLE 
suggest that relative to the Q4W treatment regimen, the Q8W treatment regimen 
may be more suitable for chronic IT dosing.  This is supported by [CONTACT_803920], decreased proportion of patients with moderate 
adverse events, and fewer adverse events considered possibly related to study drug 
in the Q8W regimen compared to the Q4W regimen (for details see the RO7234292 
Investigator’s Brochure).
The 120 -mg dose has been chosen for the Q16W dosing group based on the following: 
 The nonclinical PK/PD model predicted the observed Q8W 9 -month reductions (for 
details see the RO7234292 Investigator’s Brochure).  From this same model, a 
Q16W regimen is predicted to result in median CSF HTT trough lowering of 20%, 
within the range of the 20% 40% target for CSF mHT T lowering at trough and 
steady state. 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
44/Protocol BN40423 , Version 4 Acute lowering in this same model in the 120 -mg Q16W regimen is 20% CSF 
mHTT reduction, above observed threshold for efficacy based upon nonclinical 
models. 
 Maintenance of trough lowering is not a necessary feature of this less frequent arm 
to test the primary hypothesis.   The hypothesis of this 120 -mg Q16W arm (acute 
lowering, followed by [CONTACT_626921]) is supported by 
[CONTACT_803986] -mediated lowering of HTT protein i s 
associated with sustained phenotypic benefit in the BACHD model ( Kordas iewicz 
et al. 2012).  Efficacy in this model is sustained for 6 months even after a complete 
recovery of target mRNA and protein. 
Testing the less frequent regimen is of high intere st to mitigate potential unknown 
long-term complications associated with a more frequent IT dosing of [ADDRESS_1109735] 
concentrations when administered systemically (Schoch and Miller 2017).  Therefore, 
the IT drug delivery method will be used in this trial, as presently no alternatives exist.  
A 25-month (2 -year) study treatment length has been chosen because the 
signal -to-noise characteristics of the primary endpoint cUHDRS (T FC for U.S. FDA) as 
investigated in prospective observational cohort studies and in placebo groups of prior 
clinical trials suggest that this length is optimal for trial efficacy .  A treatment duration of 
25 months will also enable demonstration of sustain ed, durable benefit on slowing
clinical progression as presumed to be achiev able with RO7234292 (which is proposed 
to be administered as a chronic treatment to slow clinical progression).  S tudies with a 
shorter treatment duration, such as 18 months, would require a dramatically larger 
sample size (i.e., 50%) under the 30% slowing of clinical progression assumption .This 
would result in a potential risk of signal dilution due to inherent variability of a larger 
number of sites and clinical raters, resultin g in a potential increased risk of type II error.  
In summary, a [ADDRESS_1109736] the hypoth esis of clinical efficacy ,as a function of 
more versus less frequent dosing, while mitigating theoretical risks of long -term IT 
dosing of 120 mg and of non -allele specific lowering of HTT.  The 25- month duration is 
also considered appropriate for providin g evidence of the benefit risk profile of
RO7234292 and longer -term tolerability of IT administration.
3.3.[ADDRESS_1109737] HD ( DCL score of 4[i.e., motor abnormalities 99% likely to be 
due to HD] ) who are ambulatory without assistance, verbal, and possess a CAGAge 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
45/Protocol BN40423 , Version 4Product (CAP) score of 400(Zhang et al. 2011; see Section 4.1.1 ) and an 
Independence Scale (IS) score of [ADDRESS_1109738] disease where disabi lity might be more plausibly 
reversed or slowed in response to a therapeutic intervention compared with patients with 
more advanced disease (Penney et al. 1990).   This definition also corresponds to the 
patients most commonly recruited at present for clini cal trials aiming to slow clinical 
progression.  Such cohorts are known to have a longitudinal decline in clinical measures 
(Paulsen et al. 2014) over a timeframe appropriate for clinical trials .
3.3.3 Rationale for Control Group
Patients will be randomly alloc ated to receive active treatment (RO7234292 Q8W or 
Q16W) or placebo in this double -blind study because there are no disease -modifying 
standard -of-care treatments for patients with HD.  The placebo arm will be compared 
with the RO7234292 treatment arms to e nable a robust assessment of the primary 
endpoint and the benefit -risk profile.  As each patient completes the study or is 
prematurely discontinued by [CONTACT_14547] a consequence of the changes to the study 
through Protocol Version 4, they will be given t he option of receiving RO7234292 in an 
OLE study (BN40955), provided they meet eligibility criteria and the data from the 
ongoing RO7234292 program support continued development.  Approval of 
Study BN40955 must also be granted by [CONTACT_803922]/IRB.   
3.3.4 Rationale for Biomarker A ssessments
[IP_ADDRESS] Cerebrospi[INVESTIGATOR_803885] C NS.  A toxic gain -of-function mechanism of mHTT
protein is widely considered to be the primary driver of disease pathophysiology in HD 
(WildandTabrizi 2017 ).  mHTT protein in human CSF is associated with disease stage 
and severity and with biomarkers of neuronal damage, including CSF NfL and CSF tau 
levels ( Wildet al. 2015).  NfL levels in CSF predict progressive MRI measures of brain 
atrophy, as well as progressive clinical decline in patients ( Wildand Tabrizi 2017 ).  
Longitudinal analysis of mHTT, NfL , and other biomarkers related to HD, 
neurodegeneration, and inflammation in CSF may extend the current understanding of 
HD pathophysiology and progression and provide further data on how these putatively 
prognostic and potentially predictive biomarkers wi ll respond to disease- modifying 
treatment.
[IP_ADDRESS] Blood Biomarkers
NfL levels in blood correlate with NfL levels in CSF and could serve as prognostic blood 
biomarkers of disease onset and progression in HD ( Wildand Tabrizi 2017 ;
Johnson etal.2018 ).  Longitudinal analysis of NfL and other biomarkers related to HD, 
neurodegeneration, and inflammation in blood may facilitate understanding of HD 
pathophysiology and progression.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
46/Protocol BN40423 , Version [IP_ADDRESS] Genetic Testing to Determine CA G Repeat Length
HD is caused by [CONTACT_803923] 1 of the HTT gene located on chromosome 4,
resulting in a polyglutamine (CAG) expansion in the huntingtin protein.  Above 35 CAG 
repeats, the age of HD onset is inversely correlated with the length of the expansion 
(Duyao et al. 1993).  CAG repeat length will be determined by [CONTACT_803924] .  
[IP_ADDRESS] Clinical Genoty pi[INVESTIGATOR_601322], it only 
accounts for approximately 50% of the variance.  Identification of other genetic modifiers
of disease severity and disease progression in HD could provide important insights, as 
has been recently shown in the Genetic Modifiers of Huntington's Disease Consortium 
(2015 ), where relatively common single nucleotide polymorphisms in the HD population
were found to be associated with either an accelerated or delayed age of motor onset.  
Ablood sample will be collected to detect individual single nucleotide polymorphism s to 
explore, for example, their influence on progression rates, age of onset, disea se severity, 
or response to treatment.  
[IP_ADDRESS] Magnetic Resonance Imaging
MRI is a non -invasive method to assess structure and function of the human brain and 
can provide insights into pathophysiological mechanisms of neurologic and 
neuropsychiatric disease. Several MRI techniques have shown sensitivity to detect 
abnormal structure and function within brains of individuals suffering from HD.   Structural 
MRI will be used to assess brain volume, diffusion -weighted MRI will be used to examine 
structural brain conne ctivity , and resting -state f unctional MRI will be employed to identify 
functional connectivity. All of the measure s will be assessed at the whole- brain and
regional level s. The acquisition parameters of each sequence, structure, and length of 
each MRI se
ssion and image processing algorithms will be outlined in a separate MRI 
manual.
Structural Magnetic Resonance Imaging
Numerous structural MRI studies have demonstrated wide -spread brain atrophy ,
including whole -brain, caudate, and ventricular changes in patients with premanifest and 
manifest HD ( Douaud et al. 2006; Harrington et al. 2016 ).  Brain volume correlates with 
cognitive function (Peinemann et al. 2005 ).  Further, whole- brain, caudate, and 
ventricular volumes can predict and track progressive clinical decline in patients with HD 
and can also be associate dwith molecular biomarkers of neurodegeneration, 
such asNfL (Tabrizi etal. 2012 ). 
Diffusion Magnetic Resonance Imagi ng
Widespread changes in basal ganglia cortical structural connectivity have also been 
observed in patients with HD ( Novak et al. 2015), including associations between 
striatum -sensorimotor cortex connections and UHDRS motor scale and TMS
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
47/Protocol BN40423 , Version 4(Bohanna et al. 2 011), suggesting that the clinical phenotype in manifest HD may be a 
result of altered structural connectivity.
Resting -State Functional Magnetic Resonance Imaging
Resting- state functional MRI studies have generated evidence for functional connectivity 
alterations and their correlation to several clinical and cognitive measures in patients 
with HD ( Werneretal.2014 ; Dogan et al. 2015 ; Liuetal.2016 ; Espi[INVESTIGATOR_601323].2018 ), 
implying that disrupted functional integrity of distinct brain networks may underlie clinical 
progression in HD.
4. MATERI ALS AND METHOD S
4.[ADDRESS_1109739] meet the following criteria for study entry during screening (some will be 
reassessed at baseline prior to randomization and study drug dosing ):
Signed Informed Consent Form
Age [ADDRESS_1109740] dose administration
Manifest HD diagnosis, defined as a DCL score of 4 (see Appendix 7)
Independence Scale (IS) score 70 
Genetically confirmed disease by [CONTACT_626896] a CAP score 400 (Zhang 
et al. 2 011), calculated as follows:
CAPAge(CAG repeat length 33.66)
Ability to read the words "red," "blue," and "green" in native language
Ability to walk unassisted without a cane or walker and move about without a 
wheelchair on a daily basis as determined at screening and baseline visit
-Long-distance (e.g. ,50meters) use of wheelchairs for convenience or
transfer ispermitted.
Body mass index 16 32 kg/m2; total body weight 40kg
Ability to undergo and tolerate MRI scans (e.g., no claustrophobia, no severe chorea 
or other condition that precludes MRI scans or renders scanning intolerable for the 
patient, no MRI -incompatible intrauterine devices, metallic dental braces, or other 
metal implants)
Ability to tolerate blood draws and lum bar punctures
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
48/Protocol BN40423 , Version 4Estimated glomerular filtration rate(eGFR) 60 mL/min (Cockcroft -Gault formula)
Ability and willingness, in the investigator's judgment, to comply with all aspects of 
the protocol including completion of interviews and questionnaires for th e duration of 
the study 
Ability and willingness, in the investigator's judgment, to carry a smartphone, wear a 
digital monitoring device, and complete smartphone -based tasks
Stable medical, psychiatric, and neurological status for at least 12 weeks prior to 
screening and at the time of enrollment
Signed study companion consent for participation ,if a study companion is available ,
who fulfills all of the following criteria:
-Age 18 years
-Reliable and competent, in the investigator's judgment
-Sufficiently knowledgeable of the patient's condition to complete study 
companion assessments of the patient, and likely to remain sufficiently 
knowledgeable throughout the study, in the investigator's judgment
-Able to comment on study participant's symptoms and functi oning experience, 
as required per Appendix 1
Note:  Companions must have no cognitive, behavioral or motor change , in the 
opi[INVESTIGATOR_871], t hat would question the validity of the acquired 
observer -reported data.
All effort should be made to retain the study companion; however, should this 
not be possible, a study companion can be replaced and new consent obtained.
For women of childbearing potential:  agreement to remain abstinent (refrain from 
heterosexual intercourse) or use contraceptive measures, as defined below:
Women must remain abstinent or use twomethods of contraception, including 
at least one method with a failure rate of 1% per year, during the treatment 
period and for 5 months after the final dose of study drug. 
A woman is considered to be of childbearing potential if she is postmenarcheal, 
has not reached a postmenopausal state ( 12continuous months of 
amenorrhea with no identified cause other than menopause), and has not 
undergone surgical sterilization (removal of ovaries and/or uterus).   The 
definition of childbearing potential may be adapted for alignment with local 
guidelines or requirements.
Examples of contraceptive methods with a failure rate of 1%per year include 
bilateral tubal ligation, male sterilization, established proper use of hormonal 
contraceptives that inhibit ovulation, hormone -releasing intrauterine devices, 
and copper intrauterine devices.   A vasect omized man must undergo a medical 
assessment that confirms the success of the surgery before he can be considered 
surgically sterile. 
Hormonal contraceptive methods must be supplemented by a barrier method.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
49/Protocol BN40423 , Version 4The reliability of sexual abstinence should be e valuated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and withdrawal are not acceptable methods of contrace ption.
For men:  agreement to remain abstinent (refrain from heterosexual intercourse) or 
use a condom, and agreement to refrain from donating sperm, as defined below:
With a female partner of childbearing potential or pregnant female partner, men 
must re main abstinent or use a condom during the treatment period and for 
5months after the final dose of study drug to avoid exposing the embryo.  Men 
must refrain from donating sperm during this same period.
The reliability of sexual abstinence should be evaluated in relation to the 
duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation 
methods) and w ithdrawal are not acceptable methods of preventing drug 
exposure .
4.1.2 Exclusion Criteria
Patients who meet any of the following criteria will be excluded from study entry:
History of attempted suicide or suicidal ideation with plan (i.e., active suicidal 
ideation) that required hospi[INVESTIGATOR_601316]/or change in level of care within 12 months 
prior to screening
Current suicidal ideation is demonstrated by [CONTACT_941] C -SSRS per judgment of the 
investigator.  If suicidal ideation is present, a risk assessment should be done 
by [CONTACT_601341].  Mild passive suicidal ideation 
(i.e., occasional thoughts that life is not worth living or is hard) without history of 
attempts or hospi[INVESTIGATOR_601317] 12 months is generally acceptable for 
study participation, but final decision on participation should be made carefully 
and in consultation with an appropriately qualified mental health professional. 
Current active psychosis, confusional state, or violent behavior
Any serious medical condition or clinically significant laboratory, or vital sign 
abnormality or claustrophobia at screening that, in the investigator's judgment,
precludes the patient's safe participation in and completion of the study
History known to the investigator or presence of an abnormal ECG that is clinically 
significant in the investigator 's opi[INVESTIGATOR_1649], including complete left bundle branch block, 
second- or third- degree atrioventricular heart block, or evidence of prior myocardial 
infarction
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
50/Protocol BN40423 , Version 4Clinical diagnosis of chronic migraines
Pregnant or breastfeeding, or intending to become pregnant during the study or 
within [ADDRESS_1109741] prior to initiation of 
study drug.   
Presence of an implanted shunt for the drainage of CSF or an implanted CNS 
catheter
Positive for hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg)
at screening
Known HIV infection
Current or previous use of an antisense oligonucleotide (including small interfering 
RNA)
Current or previous use of anti -psychotics presc ribed for a primary independent 
psychotic disorder (i.e., schizophrenia, schizoaffective disorder, bipolar disorder 
type I, severe with psychotic features), cholinesterase inhibitors, memantine, 
amantadine, or riluzole within [ADDRESS_1109742] udy treatment
Current use of antipsychotics for motor symptoms or mood stabilization 
(i.e., irritability or aggressive behavior) and/or tetrabenazine, valbenazine, or 
deutetrabenazine at a dose that has not been stable for at least 12 weeks prior to 
screen ing or is anticipated to change between screening and treatment initiation
Current use of supplements (e.g., coenzyme Q10, vitamins, creatine) at a dose that 
has not been stable for at least 6 weeks prior to screening or is anticipated to 
change during the study
Current use of an a ntidepressant or benzodiazepi[INVESTIGATOR_16717] a dose that has not been 
stable for at least 12weeks prior to screening or is anticipated to change between 
screening and treatment initiation
Treatment with investigational therapy within 4 weeks or 5 drug-elimination half -lives 
prior to screening, whichever is longer
Antiplatelet or anticoagulant therapy within 14 days prior to screening or anticipated 
use during the study, including, but not limited to, aspi[INVESTIGATOR_248] ( unless 81mg/day ), 
clopi[INVESTIGATOR_51153] l, dipyridamole, warfarin, dabigatran, rivaroxaban, and api[INVESTIGATOR_3822]
History of bleeding diathesis or coagulopathy
Platelet count less than the lower limit of normal   
Platelet counts between 125,000 and 150,000 mm3are permissible as long as 
the investigator confirms there is no evidence of current bleeding diathesis or 
coagulopathy.  
History of gene therapy, cell transplantation, or any experimental brain surgery
Concurrent or planned participation in any interven tional clinical study, including 
explicit pharmacological and non -pharmacological interventions
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
51/Protocol BN40423 , Version 4Observational studies (e.g., ENROLL -HD prospective study) are acceptable. 
Drug (i.e., cannabis, opi[INVESTIGATOR_2480], stimulant, hallucinogen, designer) and/or alcohol abuse
or psychological or physiological dependency within 12 months prior to screening, 
as per the investigator's judgment
Abuse is defined as a maladaptive pattern of use that leads to failure to fulfill 
major work or social obligations or use in situations wh ere it leads to physical 
danger or legal problems, and may be the focus of clinical attention.  
Poor peripheral venous access
Scoliosis or spi[INVESTIGATOR_803886]7234292 up 
the neuraxis
 Aninfection requiring oral or IV antibiotics within 14 days prior to screening
Antiretroviral medications , including antiretroviral medication taken as prophylaxis
Malignancy within 5 years prior to screening, except basal or squamous cell
carcinoma of the skin or carcinoma in situ of the cervix that has been successfully 
treated
Preexisting structural brain lesion (e.g., tumor, arterio -venous malformation) as 
assessed by a centrally read MRI scan during the scr eening period
4.[ADDRESS_1109743] after the entire cohort has been discontinued from 
Study BN40423.  Patients will receive either the Q8W regimen or Q16W regimen in 
Study BN40955.  These patients wil l not be included in the primary analysis for Study 
BN40423.
Patients enrolled after implementation of Protocol Version 4 will be randomly allocated 
to receive 120 mg of RO7234292 Q8W , 120 mg of RO7234292 Q16W , or placebo Q8W .  
An independent interactive v oice or web- based response system (IxRS) provider will 
conduct randomization and hold the treatment assignment code.
Study site personnel and patients will be blinded to treatment assignment during the 
study.  The Sponsor and its agents will also be blinded to treatment assignment, with the 
exception of individuals who require access to patient treatment assignments to fulfill 
their job roles during theclinical trial. These roles include the unblinding group, clinical 
supply chain managers, sample handling staff, operational assay group personnel, IxRS 
service provider, iDMC members, and iDCC members.
While PK and ADA samples must be collected from patients assigned to the placebo 
arm to maintain the bl inding of treatment assignment, PK and ADA assay results for 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
52/Protocol BN40423 , Version 4these patients are generally not needed for the safe conduct or proper interpretation of 
this study.  Laboratories responsible for performing study drug PK and ADA assays will 
be unblinded to pat ient treatment assignment in order to identify appropriate samples for 
analysis .  PK samples from patients assigned to the placebo arm will not be analyzed for 
study drug PK concentration except by [CONTACT_32236] (e.g., to evaluate a possible error in 
dosing).  B aseline ADA samples will be analyzed for all patients.  Post -baseline ADA 
samples from patients assigned to the placebo arm will not be analyzed for ADAs except 
by [CONTACT_32236].
If unblinding is necessary for a medical emergency (e.g., in the case of a serious 
adverse event for which patient management might be affected by [CONTACT_123514]), the investigator will be able to break the treatment code by 
[CONTACT_123517].  The investigator is not required to contact [CONTACT_123516]; however, the treatment code should not be broken 
except in emergency situations.
If the investigator wishes to know the identity of the study drug for any reason other than 
a medical emergency, he or she should contact [CONTACT_803987].  The 
investigator should document and provide an explanation for any non -emergency 
unblinding.  If the Medical Monitor agrees to patient unblinding, t he investigator will be 
able to break the treatment code by [CONTACT_123517].
As per health authority reporting requirements, the Sponsor's Drug Safety representative 
will break the treatment code for all serious, unexpected suspected adverse reactions 
(see Section 5.7) that are considered by [CONTACT_123518].  The patient may continue to receive treatment .  The investigator, patient, 
and Sponsor personnel will remain blinded to treatment assig nment, with the exception 
of the Drug Safety representative and personnel who must have access to patient 
treatment assignments to fulfill their roles (as defined above).
4.3 STUDY TRE ATMENT A ND OTHER TRE ATMENTS REL EVANT 
TO THE STUDY DESIGN
The investigational medicinal products (IMPs) for this study are RO7234292 and 
RO7234292 placebo. 
4.3.1 Study Treatment Formulation, Packaging, and Handling
[IP_ADDRESS] RO7234292
RO7234292 will be supplied by [CONTACT_319071], preservative -free liquid in a 
20-mL single -use vial containing 10 mL of 6.0 mg/mL RO7234292 drug product for
ITinjection. For a 120- mg dose (20 -mL dosing volume), two vials containing 10 mL of
6.0mg/mL RO7234292 will be pooled by [CONTACT_803988] 20 mL of study d rug.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
53/Protocol BN40423 , Version 4For information on the formulation, preparation, and handling of RO7234292, refer to the 
pharmacy manual.
[IP_ADDRESS] Placebo
RO7234292 placebo will be supplied by [CONTACT_14547] a sterile, preservative -free liquid 
in a 20-mL single -use vial containing [ADDRESS_1109744].
For information on the formulation, preparation, and handling of RO7234292 placebo, 
refer to the pharmacy manual.
4.3.2 Study Treatment Dosage, A dministration, and Compliance
The treatment regimens are summarized in Section 3.1.
Any dose modification should be noted on the Study Drug Administration electronic 
Case Report Form (eCRF) .  Cases of accidental overdose or medication error, along
with any associated adverse events, should be reported as described in Section [IP_ADDRESS]
Guidelines for treatment interruption or discontinuation for patients who experience 
adverse events are provided in Section 5.1.3 .
[IP_ADDRESS] RO7234292 and Placebo
Each dose of RO7234292 (120 mg) and placebo will be administered as a single 
ITbolus injection of [ADDRESS_1109745] A ccountability
All IMPs required for completion of this study (RO7234292 or placebo ) will be provided 
by [CONTACT_1034].  The study site will acknowledge receipt of IMPs supplied by [CONTACT_429], using the IxRS to confirm the shipment condition and content.  Any damaged 
shipments will be replaced.
IMPs will either be disposed of at the study site accor ding to the study site's institutional 
standard operating procedure or be returned to the Sponsor with the appropriate 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
54/Protocol BN40423 , Version 4documentation.  The site's method of destroying Sponsor -supplied IMPs must be agreed 
to by [CONTACT_1034].  The site must obtain written aut horization from the Sponsor before 
any Sponsor -supplied IMP is destroyed, and IMP destruction must be documented on 
the appropriate form.
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by 
[CONTACT_803989].
4.3.4 Continued A ccess to RO7234292
The Sponsor will offer continued access to [COMPANY_002] IMP (RO7234292 ) free of charge to 
eligible patients in accordance with the [COMPANY_002] Global Policy on Continued Access to 
Investigational Medicinal Product , as outlined below.
A patient will be eligible to receive [COMPANY_002] IMP (RO7234292) after completing the study if 
allof the following conditions are met:
The patient has a life- threatening or severe medical condition and requires 
continued [COMPANY_002] IMP t reatment for his or her well -being
There are no appropriate alternative treatments available to the patient
The patient and his or her doctor comply with and satisfy any legal or regulatory 
requirements that apply to them
A patient will notbe eligible to receive [COMPANY_002] IMP (RO7234292 ) after completing the 
study if anyof the following conditions are met:
The [COMPANY_002] IMP is commercially marketed in the patient's country and is reasonably 
accessible to the patient (e.g., is covered by [CONTACT_11581] t's insurance or wouldn't 
otherwise create a financial hardship for the patient)
The Sponsor has discontinued development of the IMP or data suggest that the IMP 
is not effective for HD
The Sponsor has reasonable safety concerns regarding the IMP as treatment for 
HD
Provision of the [COMPANY_002] IMP is not permitted under the laws and regulations of the 
patient's country
The [COMPANY_002] Global Policy on Continued Access to Investigational Medicinal Product is 
available at the following web site:
http://www.roche. com/policy_continued_access_to_investigational_medicines.pdf
Patients may be eligible to receive RO7234292 as part of an OLE study (BN40955) , as 
described in Section 3.1.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
55/Protocol BN40423 , Version 44.4 CONCOMITA NT THERA PY
Concomitant HD therapy should constitute the optimal supportive care for the individual 
according to the investigator's own best clinical judgment.   Concomitant therapy consists 
of any medication (e.g., prescriptio n drugs, over -the-counter drugs, vaccines, herbal or 
homeopathic remedies, nutritional supplements) used by a patient in addition to 
protocol -mandated treatment from screening to the end -of-treatment visit for patients 
who enter OLE Study BN40955 or the sa fety follow -up visit for patients who do not enroll 
in the OLE study .  Allsuch medications should be reported to the investigator and 
recorded on the Concomitant Medications eCRF.
4.4.1 Permitted Therapy  
Patients are permitted to use the following therapi[INVESTIGATOR_014] d uring the study:
Contraceptive agents
Supplements (e.g., coenzyme Q10, vitamins, creatine) if the dose has been stable 
for at least 6 weeks prior to screening and the dose is not anticipated to change 
during the study
Antipsychotics only if prescribed for motor symptoms or for mood stabilization (i.e., 
irritability or aggressiveness) and/or tetrabenazine/deutetrabenazine/valbenazine if 
the dose has been stable for at least 12 weeks prior to screening and the dose is 
not anticipated to change between screening and the start of study treatment 
If clinically indicated, dose changes or medication stoppi[INVESTIGATOR_803862].
Antidepressant or benzodiazepi[INVESTIGATOR_803863] 12 weeks 
prior to s creening and the dose is not anticipated to change between screening and 
the start of study treatment 
If clinically indicated, dose changes or medication stoppi[INVESTIGATOR_803887].
Anti-epi[INVESTIGATOR_803864], pain, restless legs, or insomnia
Aspi[INVESTIGATOR_110247] 81 mg/day
Local anesthesia for the lumbar puncture procedure , depending on institutional 
guidelines   
Sedation may not be used for lumbar puncture.
4.4.2 Prohibited Therapy
Use of the following concomitant therapi[INVESTIGATOR_204721]:
Experimental agents or marketed HD agents at experimental doses that are being 
tested for the treatment of HD, including, but not li mited to, cholinesterase inhibitors, 
memantine, amantadine, and riluzole  
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
56/Protocol BN40423 , Version 4Antiplatelet or anticoagulant therapy, including, but not limited to, aspi[INVESTIGATOR_248] (unless
81mg/day ), clopi[INVESTIGATOR_7745], dipyridamole, warfarin, dabigatran, rivaroxaban, and
api[INVESTIGATOR_3822]
Sedati on for lumbar puncture or IT bolus procedures in the study
Depending on institutional guidelines, local anesthesia is permissible for the 
lumbar puncture procedure
Use of anti -anxiety medication is discouraged during scheduled MRI scans in the
study. Anti-anxiety medication used to prevent movement disorder to allow
successful MRI scan is not permitted in this study, as movement disorder too
severe to scan under drug -free conditions is an overall study exclusionary criterion.
4.5 STUDY ASSESSMENTS 
The schedule of activities to be performed during the study is provided in Appendix 1.  
All activities should be performed and documented for each patient.  
Patients will be closely monitored for safety and tolerability throughout the study.  
Patients should be assessed for toxicity prior to each dose; dosing will occur only if the 
clinical assessment and local laboratory test values are a cceptable.
4.5.[ADDRESS_1109746] be obtained before 
performing any study -related procedures (including screening evaluations).  Informed 
Consent Forms for patients and study co mpanions (if available) will be maintained at the 
study site , regardless of whether the patient is subsequently enrolled .  If a patient's 
capacity to consent is in question, the investigator should consult an appropriately 
qualified colleague who will inde pendently assess capacity.  This additional assessment 
should also be documented.  If the patient’s capacity is confirmed, the investigator may 
proceed with signing of the Informed Consent Form.
All screening evaluations must be completed and reviewed to c onfirm that patients meet 
eligibility criteria before enrollment.  The investigator will maintain a screening log to 
record details of all patients screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
A maximum of one re-screening will be allowed within 8 weeks of the initial screening 
failure for patients who fail the initial screening (e.g., as a consequence of abnormal 
laboratory values or general medical status not meeting inclusion or exclusion criteria).  
If re-screening is required, CAG repeat length testing does not need to be repeated 
(historical values will not be accepted) and the screening MRI and viral serology from the 
initial screening , including f rom other [COMPANY_002] studies, may be acceptable as part of the 
re-screening assessments if performed within 12 weeks of the baseline visit.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
57/Protocol BN40423 , Version 44.5.2 Medical History , Concomitant Medication, and Demographic 
Data
Medical history, including clinically significant diseases, surgeries, HDhistory (including 
past hospi[INVESTIGATOR_602] [i .e., number, duration, and reason] )over the last 2 years , 
reproductive status, smoking history , and use of alcohol and drugs of abuse will be 
recorded at baseline.  Alcohol and/or drug abuse is defined as a maladaptive pattern of 
use that leads to failure to fulfill major work or social obligations or use in situations 
where it leads to physical danger or legal problems, and may be the focus of clinical 
attention.  Da ily use of any drug (i.e., cannabinoid, opi[INVESTIGATOR_2480], stimulant, hallucinogen, 
designer) or daily alcohol use that meets criteria for either abuse or psychological or 
physiological dependence is not permitted and is exclusionary.  Occasional use that 
does not me et the criteria for abuse is permissible in this study.  
In addition, all medications (e.g .,prescription drugs, over -the-counter drugs, vaccines, 
herbal or homeopathic remedies, nutritional supplements) used by [CONTACT_803928] -of-treatment visit for patients who enter OLE Study BN40955 or the 
safety follow -up visit for patients who do not enroll in the OLE study will be recorded.  At 
the time of each study drug administration and telephone safety follow -up calls , an
interval medical history should be obtained and any changes in medications and any 
physician visits for HD or general medical care should be recorded.
Demographic data will include age, sex, self -reported race/ethnicity , and education level 
based on the International Standard Classification of Education scale .  Demographic
data and social status data ( e.g., relationship to patient and employment status) will also 
be collected for the study companion. Race/ethnicity is recorded because of the 
potential contribution of this variable to differences in observed pharmacokinetics, 
pharmacodynamics, toxicity, and/or response to treatment. 
A unique HD i dentification number (HDID) will be collected from patients who already 
have an HDID.  For patients without an HDID, the number will be created via a web 
portal (see Section 8.4).
4.5.3 Physical and Neurologic Examinations
A complete physical examination, performed at screening and other specified visits (see 
Appendix 1), should include an evaluation of the head, eyes, ear s, nose, and throat, and 
the cardiovascular, dermatologic, musculoskeletal, respi[INVESTIGATOR_696], gastrointestinal, and 
neurologic systems (including fundoscopy); genitourinary examinations may be 
performed if clinically indicated.  The physical examinations should be conducted in the 
same manner on each occasion to ensure comparability to previous examinations.  
Height will be measured at baseline only.
A neurologic examination, performed at screening and at every clinical visit, should 
include assessment of mental status, level of consciousness, cranial nerve function, 
motor function, sensory function, reflexes, gait, and coordination (see Appendix 8).  The
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
58/Protocol BN40423 , Version 4neurologic examination should be conducted in the same manner on each occasion to 
ensure comparability to previous examinations.  Neurologic examinations should be 
performed before and after treatment on each dosing day.  W eight should also be 
measur ed at each visit .
Any abnormality identified at baseline (Week 1) should be recorded on the General 
Medical History and Baseline Conditions eCRF.  Changes from baseline abnormalities 
should be recorded in patient notes.  New or worsened clinically signific ant abnormalities 
(i.e., beyond expected variation or normal age -related change) should be recorded as 
adverse events on the Adverse Event eCRF.  
4.5.4 Vital Signs
Vital signs will include measurements of respi[INVESTIGATOR_697], pulse, temperature, and 
systolic and d iastolic blood pressure while the patient is in a seated position after resting 
for approximately 5 minutes.  All data should be recorded on the appropriate eCRF.
4.5.5 Collection of Cerebrospi[INVESTIGATOR_17106] (Lumbar Puncture Procedure)
Within 72 hours prior to perfor ming each scheduled lumbar puncture, local laboratory 
analysis of coagulation factors (INR and/or PT , aPTT) and platelets must be conducted 
and the results reviewed.  The lumbar puncture should be performed at approximately 
the same time at each visit (ide ally in the morning between 8:00 a.m. and 12:00 noon or 
in the early afternoon between 12:00 noon and 3:00 p.m.) to minimize potential diurnal 
variation of CSF parameters.  CSF fluid (20 mL) is to be collected for analyses using a 
lumbar puncture collectio n kit.  If there are difficulties in collecting [ADDRESS_1109747] lumbar puncture syndrome.  
Depending on institutional guidelines, local anesthesia should be used for the procedure.  
Sedation may not be used.  Spi[INVESTIGATOR_803888], but ultrasound is not required.  Ultrasound guidance 
may be used if attempts at lumbar puncture without imaging are unsuccessful, if it is 
local practice to use ultrasound, or if institutional guidelines dictate use of ultrasound 
with each lumbar puncture.  For details on the lumbar puncture and IT bolus dosing 
procedure, please refer to the LP procedure and CSF collection guidelines manual and 
instructional v ideo.
Administration will occur via a lumbar puncture using a needle inserted into the 
L3/L4 space, although placement at a different level (either in the space above or the 
space below) is allowed if patient anatomy or clinical judgment dictates.   The lef t lateral 
position is mandatory in the first instance for the procedure, unless patient -specific 
factors require use of the upright, sitting position.  Whichever position is used, once 
access is established to the IT space, the entire IT bolus procedure sh ould be completed 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
59/Protocol BN40423 , Version 4in the same position, to limit the risk of the needle losing position while the spi[INVESTIGATOR_803889].
Patients will be discouraged from resting supi[INVESTIGATOR_803867] a minimum and, 
if feasible, walking briskly for approximately [ADDRESS_1109748] 
72hours postdose (e.g., air travel, scuba d iving, or hot air balloons).
Lumbar punctures will be performed as specified in the schedule of activities (see 
Appendix 1), with the last CSF sample obtained at the Week 101 end- of-treatment visit.  
No study drug will be administered at that visit.
4.5.6 Laboratory , Biomarker, and Other Biological Samples
Samples for the following laboratory tests will be sent to the study site's local laboratory 
for analysis:
Coagulation:  INR and/or PT , aPTT, and platelet count
Urine pregnancy test
Urine pregnancy tests will be performed for women of childbearing potential at 
specif ied visits.  If aurine pregnancy test is positive, it must be confirmed by a 
serum pregnancy test (analyzed at a central laboratory).
CSF for safety:  cell count (including RBCs and WBCs), glucose, and protein
 CSF sample for differential cell counts (abs olute or percentage), where feasible
The following samples will be sent to a central laboratory:
Hematology:  WBC count, RBC count, platelet count, hemoglobin, hematocrit, and
differential count (neutrophils, eosinophils, basophils, monocytes, lymphocytes )
Serum chemistry panel:  bicarbonate or total carbon dioxide (if considered standard
of care for the region), sodium, potassium, chloride, glucose, BUN or urea,
creatinine, total protein, albumin, phosphorus, calcium, total and direct bilirubin, ALP,
ALT, AST, uric acid, gamma- glutamyl transferase, and CPK
Thyroid panel:  thyroid -stimulating hormone and free thyroxine (also known as T4)
levels
Viral serology:  HBsAg and HCV antibody
Serum pregnancy test
Serum pregnancy tests will be performed for women of childbearing potential at 
screening .  At subsequent visits , it will be performed to confirm a positive urine 
pregnancy test (if applicable).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
60/Protocol BN40423 , Version 4Urinalysis, including dipstick (pH, specific gravity, glucose, protein, ketones, blood)
and microscopic examinatio nfor all abnormal dipstick results (sediment, RBCs,
WBCs, casts, crystals, epi[INVESTIGATOR_1663], bacteria)
CSF and blood (plasma) samples for PK analyses and metabolite identification
Blood (plasma) samples for immunogenicity analyses
Blood sample fordetermination of CAG repeat length in HTT for patient eligibility
CSF samples for analysis of mHTT and NfL levels to evaluate the effects of
RO7234292 compared withplacebo (primary and secondary biomarker endpoints)
Blood, plasma ,and CSF samples for exploratory research on biomarkers and
biomarker assay development
Exploratory biomarker research may include, but will not be limited to, total HTT protein, 
tau, and other proteins related to HD, neurode generation, and inflammation.  Research 
may involve extraction of DNA and analysis of mutations, single nucleotide 
polymorphisms, and other genetic variations.  Resear ch will not be aimed at
distinguish inggermline mutations from somatic mutations .  
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.
Unless the patient gives specific consent for his or her leftover samples to be stored for 
optional exploratory research (see Section 4.5.10 ), biological samples will be destroyed 
when the final Clinical Study Report has been completed, with the following exception s:
Blood, plasma, and CSF samples collected for biomarker research and biomarker
assay development will be destroyed no later than 10years after the final Clinical
Study Report has been completed .
Blood (p lasma ) and CSF samples collected for PK or immunogenicity analysis may
be needed for additional immunogenicity characterization and for PK or
immunogenicity assay development and validation
; therefore, these samples will be
destroyed no later than 5years after the final Clinical Study Report has been
completed .
When a patient withdraws from the study, samples collected prior to the date of 
withdrawal may still be analyzed, unless the patient specifically requests that the 
samples be destroyed or local laws require dest ruction of the samples.  However, if 
samples have been tested prior to withdrawal, results from those tests will remain as 
part of the overall research data. 
Data arising from sample analysis , including data on mutations, will be subject to the 
confidenti ality standards described in Section 8.4.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analy ses will generally not be provided to study investigators or 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
61/Protocol BN40423 , Version 4patients unless required by [CONTACT_2371] .  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication.
4.5.[ADDRESS_1109749] 
thecapability to perform a resting -state functional MRI or diffusion -weighted 
MRI. Forthese cases ,the Medical Monitor should be consulted; approval to continue 
without these scans would be required.
The MRI should be performed using a 3- Tesla (3T) magnet.  The acquisition parameters 
of each sequence, structure, and length of each MRI session, as well as image 
processing algorithms, will be outlined in a separate MRI manual.   MRI scans will be 
managed by a central laboratory to monitor and ensure the integrity and quality of the 
acquired data.  The screening MRI will be evaluated by [CONTACT_803929].  Lo cal neuroradiologists will still be responsible for assessing 
MRI-related ongoing safety monitoring. During central review, the Sponsor and/or site 
staff will be notified of any unexpected findings requir ingclinical follow -up.  
MRI should take place as early as possible within the screening window but may take 
place at any time during screening.  The MRI safety and efficacy screening scan will 
need to pass the central laboratory image QC and the results must be available before 
the patient can be enrolled in the study.   
After patient enrollment at specified timepoints, the MRI must be scheduled to occur 
before the lumbar puncture (see Appendix 1).  The MRI scan should be performed 
714days prior to the lumbar puncture to allow time for re -scanning if the quality of 
the initial MRI is inadequate.
4.5.8 Electrocardiograms
Triplicate ECG recording will be obtained at specified timepoints , within approximately 
5minutes of each other , as outlined in the schedule of activities (see Appendix 1), and 
may be obtained at unscheduled timepoints as clinically indicated.
The ECG recordings must be performed using a standard high -quality, high -fidelity 
digital electrocardiograph machine equipped with computer -based interval 
measurements.  Lead placeme nt should be as consistent as possible.  ECG recording 
must be performed after the patient has been resting in a supi[INVESTIGATOR_21683] 
10minutes.  All ECGs are to be obtained prior to other invasive procedures scheduled at 
that same time (e.g., blood draws) and should not be obtained within 30 minutes after 
any meal.  Circumstances that may induce changes in heart rate, including 
environmental distractions (e.g., television, radio, conversation) should be avoided 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
62/Protocol BN40423 , Version 4during the pre -ECG resting period and during ECG recording. All data should be 
recorded on the appropriate eCRF.
The ECG recordings may be electronically transferred to a central vendor.  The
investigator must review, sign, and date all ECG tracings.  Paper copi[INVESTIGATOR_626856]'s permanent study file at the site.  
4.5.9 Patient -Reported, Clinician -Reported, Study  
Observer -Reported, and Performance Outcomes
Patient -reported outcome (PRO) , clinician -reported outcome ( ClinRO ), 
observer -reported outcome (ObsRO), and performance outcome (PerfO) data will be
collected in the clinic to document the change from baseline over time .  Additionally, 
PRO, ObsRO, and PerfO data will be collected remotel y.  The instruments , translated 
into the local language as appropriate, will be completed in their entirety at specified 
timepoints during the study.  To ensure instrument validity and that data standards meet 
health authority requirements, instruments wil l be self -administered or administered by a 
trained rater (as appropriate) .  In-clinic data should be collected prior to the performance 
of the lumbar puncture procedure .
Patients , clinicians, and study companions (if participating) will use an electronic device 
to capture outcome data during clinic visits , and scoring of ClinRO and PerfO measures 
will be supervised during acquisition and entry into a tablet to ensure instructions are 
given and appropriately followed.  Paper must not be used to capture clinical outcome 
data, unless it is for performance outcome measures (e.g., SDMT and MoCA). 
Performance measure outcomes must be completed in ink and not pencil.
Patients will use a smartphone andwrist-worn wea rable to capture outcome data 
remotely and at specif ied visits (see Section [IP_ADDRESS] ).  Study companions will use an 
electronic device to capture data remotely and at specified visits.  The electronic device s
and/or instructions for completing the questionnaires electronically will be provided to 
patients and study companions by [CONTACT_6624].  Study companion device data will be 
transmitted to a centralized database maintained by [CONTACT_40893].  The 
patient device data will be transmitted to a centralized database maintained by [CONTACT_429].  The data will be available for access by [CONTACT_108897].  If the 
device is lost, a replacement will be sent.  All devices are en crypted and password 
protected.  SeeAppendix 1for the schedule of activities, and Appendix 3and 
Appendix 4for a summary of timing and duration of each PRO, ClinRO, ObsRO, and 
PerfO assessment. Appendix 5shows the order and approximate timing of 
assessments at each clinic visit. Appendix 9through Appendix 13 show relevant 
information for patients who enrolled in Study BN40423 before implementation of 
Protocol Version 4.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
63/Protocol BN40423 , Version [IP_ADDRESS] Composite Unified Huntington's Disease Rating Scale
The cUHDRS is a composite motor, cognitive, and global functional clinical outcome 
measure in patients with HD comprised of an equally weighted su m of Z scores of the 
TFC, the TMS, the SDMT, and the S WR scores from the UHDRS (Huntington Study 
Group 1996). It is a multidomain measure of clinical decline that tracks underlying 
progressive brain changes and is related to changes in daily functional ab ility 
(Schobel et al. 2017).  
[IP_ADDRESS] Total Functional Capacity  Scale 
The TFC is a validated measure of global patient function in HD.   The TFC represents 
the investigator's assessment of the patient's capacity to perform a range of activities of 
basic daily li ving, including working, chores, managing finances, eating, dressing, and 
bathing.  The 5 -item assessment is based on a brief interview with the patient and the 
study companion (if available).  The TFC score ranges from 0 to 13, with a higher score 
represe nting better functioning.  A 1-point change in TFC score is a clinically meaningful 
change in patient function (e.g., a 1 -point decline may indicate the loss of ability to work 
in a normal capacity) (Huntington Study Group 1996).  The TFC takes approximately 
10minutes to administer and will be completed at clinic visits .  
[IP_ADDRESS] Total Motor Score
The TMS is a holistic measure of motor function in HD that is linked to both functional 
capacity based on the TFC score, independence, and driving status 
(Beglinger etal.2012; Schobel et al. 2017).  
The TMS score is the sum of the individual motor ratings obtained from administration of 
the 31 -item motor assessment portion of the UHDRS by [CONTACT_093].  The score 
ranges from 0 to 124, with a higher score represent ing more severe impairment.  The 
TMS takes approximately 15 minutes to administer and will be completed at clinic visits.
[IP_ADDRESS] Symbol Digit Modalities Test
The SDMT is used to assess attention, visuoperceptual processing, working memory, 
and psychomotor speed. It has been shown to have strong reliability and validity 
(Smith 1982 ).  The patient pairs abstract symbols with specific numbers according to a 
translation key.  The test measures the number of items correctly paired (maximum 
of110 correct pairs) in 90 seconds.  The SDMT will be administered at clinic visits and 
can be completed in less than 5 minutes.  It will also be administered at specified 
timepoints indicated in Appendix 6on the [COMPANY_002] HD mobile app (via electronic SDMT).
[IP_ADDRESS] Stroop Word Reading Test 
The S WR Test is a measure of attention, processing, and psychomotor speed and 
depends upon quick verbal motor output.  Patients are presented with a page of color 
names (i.e., "BLUE," "RED," or "GREEN") printed in black ink and are asked to read 
aloud as many words as possible within a given amount of time (in 45 seconds).  The 
number of words read correctly is counted, with a higher score indicating better cognitive 
performance.  It will also be administered at specified timepoints indicated in 
Appendix 6 on the [COMPANY_002]  HD mobile app (via electronic SWR).    
[IP_ADDRESS] UHDRS Functional Assessment
The UHDRS Functional Assessment is a checklist of 25 common daily tasks.  The 
investigator indicates if the patient can perform the task by [CONTACT_91959] a score of 1 to all "yes" 
replies.  The checklist is then summed, and scores can range from 0 (inability to do any 
task) to 25 (ability to do all tasks on the checklist).  The UHDRS FA can be completed in 
15 minutes.  
[IP_ADDRESS] Independence Scale
A patient's IS score is a measure of disease progres
sion in functional disability and will 
be completed to evaluate a patient's degree of independence at screening and at 
specified timepoints.  It
 is a subscale of the UHDRS. The scale consists of 19 discrete 
levels ranging from 10 to 100 (by 5), in which a score of 100 indicates no special care is 
needed and a score of 10 indic
ates the patients is fed by [CONTACT_803930]. 
[IP_ADDRESS] HD Daily Activ
ities Scale
The HD-D AS assesses patients' daily function.  Following a semi-structured interview 
with the patient and/or study companion, the patient's ability level to perform daily tasks 
such as eating or using a telephone will be recorded.  Each item is scored on a 4-p oint 
Likert-t ype scale, where [ADDRESS_1109750].
[IP_ADDRESS]
 Clinical Global Impression Severity and Change Scales
The CGI-S  is a single-i tem measure of current global severity and is c
ompleted by [CONTACT_626929].  The CGI-S  is assessed using an 11-point numeric 
rating scale (NRS), where higher scores indicate greater severity.  The CGI-S  can be 
completed in approximately 2 minutes.
The CGI-C  is a single
-item measure of change in global status (since starting the study) 
and is completed by [CONTACT_803990].  The CGI
-C has seven 
response options:  "very much worse," "much worse," "minimally worse," "no change," 
"minimally improved," "much improved," and "very much improved."  The CGI-C  can be 
completed in approximately 2 minutes.  To assess the relevance of this change, a 
follow-up question with dichotomous response options ("yes" or "no") asks if the change 
has had a meaningful impact on the patient’s well
-being.
[IP_ADDRESS] Patient Global Impression Severity  and Change Scales
The PGI-S  is a single-i tem measure of current global severity and is completed by [CONTACT_803932].  The PGI
-S can be completed in approximately 2 minutes.  
The PGI-S  is assessed using an 11-p oint NRS, where higher scores indic
ate greater 
severity.  
RO7234292F. Hoffmann-L a [COMPANY_002] Ltd
64/Protocol BN
[ZIP_CODE], Version 4
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
65/Protocol BN40423 , Version 4The PGI -C is a single- item measure of change in global status (since starting the study) 
and is completed by [CONTACT_803933] -baseline visits.  The PGI -C has seven 
response options:  "very much worse," "much worse," "minimall y worse," "no change," 
"minimally improved," "much improved," and "very much improved." To assess the 
relevance of this change, a follow -up question with dichotomous response options ("yes" 
or "no") asks if the change has had a meaningful impact on the pat ient's well -being.  The 
PGI-C can be completed in approximately 2minutes.
[IP_ADDRESS] Companion -Reported Global Impression Severity and Change 
Scales
The Companion -Reported Global Impression Severity ( CrGI -S) is a single -item measure 
of current global severity and i s completed by [CONTACT_283769] (about the patient) at 
specified clinic visits.  The CrGI -Scan be completed in approximately 2minutes.  The 
CrGI -S is assessed using an 11 -point NRS, where higher scores indicate greater 
severity.  
The Companion -Reported Glo bal Impression Change ( CrGI -C) is a single
-item measure 
of change in global status (since starting the study) and is completed by [CONTACT_283769] 
(about the patient) at specified post -baseline visits.  The CrGI -C has seven response 
options:  "very much worse," "much worse," "minimally worse," "no change," "minimally 
improved," "much improved," and "very much improved." To assess the relevance of this 
change, a follow -up question with dichotomous response options ("yes" or "no") asks if 
the change has had a meaningful impact on the patient's well -being.  The CrGI -C can be 
completed in approximately 2minutes.  
[IP_ADDRESS] Montreal Cognitive Assessment
The MoCA is a patient -completed assessment used to detect cognitive impairment.  It 
contains a series of basic assessments , including attention and visuospatial tasks.  The 
total score ranges from 0 30, where lower scores indicate greater impairment.  It will be 
used in this study to characterize patients at screening and longitudinally to assess 
cognitive status at regular i ntervals throughout the study.  It takes approximately 
10minutes to administer.
[IP_ADDRESS] Work Productivity and A ctivity Impairment
The W PAI contains [ADDRESS_1109751] of disease on employment status 
(yes/no), hours missed due to disease, hours missed du e to other reasons, hours 
worked, and impact on productivity and on daily activities (both using an 11- point NRS, 
where higher scores indicate greater impact).  The W PAI takes approximately 5 minutes 
to complete.  The WPAI will be completed by [CONTACT_102] (about him/herself) and by [CONTACT_803934] (if available, about him/herself).  It will be completed at specified 
timepoints remotely by [CONTACT_803991] (if available) on an electronic device.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
66/Protocol BN40423 , Version [IP_ADDRESS] Apathy Evaluation Scale 
The AES is an 18 -item assessment of apathy, including overt behavior, cognitive 
aspects of motivation, and emotional responsivity.  Each item is scored on a 4 -point 
Likert scale, from 1 ("Not at all") to 4 ("A lot").  A total score is create d by [CONTACT_10621] 
18 items (scores range from 18 to 72; 3 items are reverse scored), with higher scores 
indicating greater apathy.  The AES takes approximately 10 minutes to complete and will 
be completed by [CONTACT_803992] (if available) at specified clinic visits.
[IP_ADDRESS] Neuro -Qol Cognition Function Short Form, Version 2
The Neuro -Qol Cognition Function Short Form contains 8 items (including "trouble 
concentrating" and difficulty "learning new tasks or instructions"), each assessed using a 
5-point Likert scale, where lower scores indicate greater difficulty (4 items) or greater
frequency (4 items).  The raw sum score is converted to a T -score distribution
(mean 50, standard deviation 10).  The Neuro -QolCognition Function Short Form
takes approximately 5 minutes to complete and will be completed by [CONTACT_803993].
[IP_ADDRESS] HDSpeaking Difficulty Item
The HD -SDI includes a single question assessing difficulty speaking over the past 
7days. It is assessed using a 5- point Likert scale, where higher scores indicate a 
greater frequency of difficulty.  The HD -SDI can be completed in less than 1 minute and 
will be completed at specified timepoints remotely by [CONTACT_803938].
[IP_ADDRESS] Symptoms of Major Depressive Disorder Scale 
The SMDDS is a newly developed, valid, and reliable self -report assessment of 
depression ( McCarrier et al. 2016 ).  It contains [ADDRESS_1109752] urbance.  Each item is assessed on a 5 -point 
Likert scale, from "Not at all" to "Extremely" (9 items) and from "Never" to "Always" 
(7items).  Item scores from 15 of the items (the least severe of the two eating items is 
not included) are summed to create a 060 score, where higher scores indicate more 
severe depressive symptomatology.  The SMDDS takes approximately 10 minutes to 
complete and will be completed by [CONTACT_803939].
The patient should be referred for immediate psychiatr ic evaluation in any event of 
suspected active suicidal intent, significant suicidal behavior, or clinical finding 
suggesting that the patient is dangerous to himself or herself.
[IP_ADDRESS] HD Companion -Reported Irritability  and Angry Outbursts Scale 
The HD -CIAOS is a study companion -reported assessment of the patient's irritability and 
angry outbursts over the past 7 days and will be completed at specified timepoints 
remotely by [CONTACT_283769] (if available) on an electronic device .  It consists of three 
items: frequ ency of irritable behavior (6 -point Likert scale: "Not at all" to "Always"), 
frequency of angry outbursts (number of occurrences), and severity of the worst outburst 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
67/Protocol BN40423 , Version 4(4-point Likert scale "Mild" to "Very severe").  The HD -CIAOS takes about 2 minutes to 
complete.
[IP_ADDRESS] EuroQol 5 -Dimension , 5-Level Questionnaire
The EQ-5D-5L is a validated self -report health status questionnaire used to calculate a 
health status utility score for use in health economic analyses ( EuroQol Group 1990 ; 
Brooks 1996 ; Herdman et al. 2011 ;Janssen et al. 2013 ).  There are two components to 
the EQ -5D-5L:  a 5-item health state profi le that assesses mobility, self -care, usual 
activities, pain/discomfort, and anxiety/depression, as well as a VAS that measures 
health state.  Published weighting systems allow for creation of a single composite score 
of the patient's health status (Index score) from the 5-item scores (i.e., does not include 
the VAS).  The EQ -5D-5L takes approximately 5minutes to complete.  The Index score 
will be used in this study for informing pharmacoeconomic evaluations. The VAS score 
will be used to assess health -related quality of life ( HRQoL) . The EQ -5D-5L will be 
completed both by [CONTACT_102] (about him/her self) and by [CONTACT_601370]
(ifavailable, about him/herself )at baseline and at specified post -baseline clinic visits on 
anelectronic device.  In addition, it will be completed remotely at specified timepoints by 
[CONTACT_803994] .
[IP_ADDRESS] Health Utilities Index Mark 2 and Mark 3
The HUIis a multi -attribute system of health status (Feeny et al. 1995).  The HUI2 and 
HUI3 questionnaire (commonly referred to as HUI2/3) contains 15 items with Likert -type 
response options.  From these items, two scores can be produced:  HUI2 (7 items) and 
HUI3 (8 items).  Both scores are health utility indexes, where 0 death, and 1 perfect 
health.
The HUI2/3 will be completed by [CONTACT_283769], both about him/herself and as a proxy 
report of the patient’s HRQoL.  The H UI2/3 will be completed at specified timepoints at 
clinic visits and remotely on an electronic device.
[IP_ADDRESS] Columbia- Suicide Severity Rating Scale
The C -SSRS is a structured tool to assess suicidal ideation and behavior.  
Four constructs are measured:  severity of ideation, intensity of ideation, behavior, and 
lethality of actual suicide attempts.  Binary (yes/no) data are collected for 10 categories, 
and composite endpoints based on the categories are followed over time to monitor 
patient safety ( Posner et al. 2011).  It maps to the Columbia -Classification Algorithm for 
Suicide Assessment and meets the criteria listed in the U.S. FDA draft guidance for 
assessment of suicidality in clinical trials ( FDA 2012 ).  The C -SSRS will be used to 
assess eligibility for the study (full version at baseline, requiring approximately 20 
minutes to administer) and to monitor the patients throughout the study at clini c visits 
(follow -up version, requiring approximately 5 minutes to administer, assuming absence 
of suicidal ideation and no change in clinical status from previous administration).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
68/Protocol BN40423 , Version 4The patient should be referred for immediate psychiatric evaluation in any e vent of 
suspected active suicidal intent, significant suicidal behavior, or clinical finding 
suggesting that the patient is dangerous to himself or herself.
[IP_ADDRESS] Optional Exit Interviews
Optional exit interviews will be conducted witha subset of patients (up t o60patients ) at 
select sites within approximately 1 week after the end -of-treatment visit.  The 
semi -structured interviews will be conducted by [CONTACT_803995] .  The interviews will enable patients to provide details about 
changes they observe in their symptoms, as well as any impacts on daily life.
Interviews will be transcribed verbatim ,and themes emerging from these transcripts will 
be interpreted in relation to changes in patients' clinical outcome assessment scores . All 
participants in this optional study interview will be asked which arm they thought they 
were assigned to (120 mg Q8W , 120 mg Q16W , or placebo).  Of note, patients, staff,
and the Sponsor will remain blind to patient treatment assignment during the study, as 
outlined in Section 4.2.
Additional consent for this optional portion of the study will be included in the relevant 
Informed Consent Form.
[IP_ADDRESS] [COMPANY_002] HD Mobile A pplication:  Remote Testing (Smartphone 
and Wrist -Worn Wearable)
Smartphones and wrist -worn wearables have high -quality sensors that enable the 
remote, non -invasive, frequent ,and preci se measurement of motor and non -motor 
symptoms (Maetzl er et al. 2013; Andrzejewski et al. 2016; Adams et al. 2017; Lipsmeier 
et al. 2018) .  Each patient will receive a preconfigured smartphone and wrist -worn 
wearable with installed software for the [COMPANY_002] HD mobile app assessments.  The 
devices and software wi ll monitor motor symptoms, non -motor symptoms, and activities 
associated with routine daily living throughout the course of the study.  Additional details 
are available in the [COMPANY_002] HD mobile app (Smartphone) manual.
Patients will be provided with devices and trained on their use during screening.  
Patients will also have in -clinic assessments of the digital platform that are supervised 
as indicated in Appendix 6.  Outside of the clinic, patients will be instructed to conduct
an "active test" every day at approximately the same time (ideally in the morning, after 
breakfast).  The active test consists of a short, preconfigured schedule of tasks that 
assess motor symptoms (upper and lower body movements, upper limb dexterity, voice) 
and non- motor symptoms (processing speed, voice).  Testing will usually last 
approximately 5 minutes in total on a typi[INVESTIGATOR_626857].  Not all tests are daily.  
Additional information on the tasks and schedule is specified in Appendix 6.  
For "passive monitoring," pati ents will be instructed to carry the smartphone in a manner 
convenient to them (e.g., in a pocket or in a Sponsor -provided pouch) and wear the 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
69/Protocol BN40423 , Version 4wrist-worn wearable throughout the day as they go about their daily routines.  
Companions (where available) will receive their own independent electronic device at 
screening, which is different from the patient smartphone.  
Patients will be encouraged to adhere to the daily schedule of tasks as much as possible; 
however, patients will not be excluded from the study for poor adherence, nor will 
missing a daily test be considered a protocol deviation. 
Device sensor data will be recorded continuously, throughout the active tests and 
passive monitoring.  Sound will only be recorded during selected active test tasks.  Da ta 
will be encrypted and uploaded to secure servers when the smartphone is connected 
toWi-Fi.  Patients will be asked to charge the devices overnight.  If patients have a W i-Fi 
network at home, they will be encouraged to connect their smartphone to enable data 
transfer.  If no W i-Fi network is available, the sensor data will be transferred during clinic 
visits or after the devices have been returned.
[COMPANY_002] HD mobile app "baseline" data will consist of all data collected prior to and 
including the baseline visit (up to 28 days).  Baseline data will be collected for at least 
the 7 days up to and including Day 1. 
[IP_ADDRESS] [COMPANY_002] HD Mobile A pplication:  In -Clinic Assessments
Patients will be instructed to bring the smartphone and wearable to every clinic visit to 
check adherence and technical status of the devices.  At specified clinic visits, patients 
will be asked to conduct the "active tes t" tasks under the supervision of trained site staff , 
as shown in Appendix 6.  
The smartphone and wearable must be returned to the clinic in cases where the patient 
does not meet eligibility criteria, at the end of the study, or upon early termination from 
the study .  Atthe time of study completion or early termination, patients will be asked to 
complete a pen -and-paper satisfaction survey about their experience using the 
smartphone and wrist -worn wearable.
4.5.10 Optional Samples for Research Biosample Repository
[IP_ADDRESS] Overview of the Research Biosample Repository
The Research Biosample Repository (RBR) is a centrally administered group of facilities 
used for the long- term storage of human biological specimens, including body fluids, 
solid tissues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides).  The 
collection, storage, and analysis of RBR samples will facilitate the rational design of new 
pharmaceutical agents and the development of diagnostic tests, which may allow for 
individualized drug therapy for patients in the future.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
70/Protocol BN40423 , Version 4Samples for the RBR will be collected from patients who give specific consent to 
participate in this optional research.  RBR samples will be used to achieve the following 
objectives:
To study the association of biomarkers with efficacy or disea se progression
To identify safety biomarkers that are associated with susceptibility to developi[INVESTIGATOR_123407]
To increase knowledge and understanding of disease biology and drug safety
To study drug response, including drug effects and the processes of drug absorption 
and disposition
To develop biomarker or diagnostic assays and establish the performance 
characteristics of these assays
[IP_ADDRESS] Approval by [CONTACT_803996], storage, and analysis of RBR samples is contingent upon the review and 
approval of the exploratory research and the RBR portion of the Informed Consent Form 
by [CONTACT_25733]'s IRB/EC and, if applicable, an appropriate regulatory body.  I f a site has not 
been granted approval for RBR sampling, this section of the protocol (Section 4.5.10)
will not be applicable at that site.
[IP_ADDRESS] Sample Collection
The following samples will be stored in the RBR and used for research purposes, 
including, but not limited to, research on biomarkers related to RO7234292, the HTT 
protein, HD or other diseases , or drug safety:
Blood and serum samples collected at baseline and at W eeks 37, 69, and 101
Leftover blood, plasma, and CSF samples and any derivatives thereof (e.g .,proteins, 
peptides )
The above samples may be sent to one or more laboratories for analysis of germline or 
somatic mutations via whole genom e sequencing (W GS), whole exome sequencing 
(WES), or other genomic analysis methods.  Genomics is in creasingly informing 
researcher s'understanding of disease pathobiology.  W GS and W ES provide a 
comprehensive characterization of the genome and exome, resp ectively, and, along with 
clinical data collected in this study, may increase the opportunity for developi[INVESTIGATOR_397988] a drug or d evelop adverse events.
Data generated from RBR samples will be analyzed in the context of this study but will 
also be explored in aggregate with data from other studies.  The availability of a larger 
dataset will assist in identification and characterizati on of important biomarkers and 
pathways to support future drug development.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
71/Protocol BN40423 , Version 4For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.  
RBR samples are to be stored until they are no longer needed or until they are 
exhausted.  However, the RBR storage period will be in accordance with the 
IRB/EC -approved Informed Consent Form and applicable laws (e.g., health authority 
requirements).
[IP_ADDRESS] Confidentiality
RBR samples and associated data will be labeled with a unique patien t identification 
number.
Patient medical information associated with RBR samples is confidential and may be 
disclosed to third parties only as permitted by [CONTACT_25734] (or separate 
authorization for use and disclosure of personal health infor mation) signed by [CONTACT_102], 
unless permitted or required by [CONTACT_2371].
Given the complexity and exploratory nature of the analyses of RBR samples, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless requir ed by [CONTACT_2371].  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication.
Data generated from RBR samples must be available for inspection upon request by 
[CONTACT_803997], and Sponsor monitors, 
representatives, and collaborators, as appropriate.
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of the RBR data will become and remain the exclusive and unburdened property 
of the Sponsor, except where agreed otherwise.
[IP_ADDRESS] Consent to Participate in the Research Biosample Repository
The Informed Consent Form will contain a separate section that addresses participation 
in the RBR.  The investigator or autho rized designee will explain to each patient the 
objectives, methods, and potential hazards of participation in the RBR.  Patients will be 
told that they are free to refuse to participate and may withdraw their consent at any time 
and for any reason during the storage period.  A separate, specific signature [CONTACT_20030] a patient's agreement to provide optional RBR samples.  Patients 
who decline to participate will not provide a separate signature.
The investigator should document whether or not the patient has given consent to 
participate and (if applicable) the date(s) of consent, by [CONTACT_76990].
In the event of an RBR participant's death or loss of competence, the participant's 
samples and data w ill continue to be used as part of the RBR research.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
72/Protocol BN40423 , Version [IP_ADDRESS] Withdrawal from the Research Biosample Repository
Patients who give consent to provide RBR samples have the right to withdraw their 
consent at any time for any reason.  After withdrawal of consent, any r emaining 
samples will be destroyed or will no longer be linked to the patient.  However, if RBR 
samples have been tested prior to withdrawal of consent, results from those tests will
remain as part of the overall research data.  If a patient wishes to with draw consent to 
the testing of his or her RBR samples during the study , the investigator must inform the 
Medical Monitor in writing of the patient's wishes through use of the appropriate RBR 
Subject W ithdrawal Form and must enter the date of withdrawal on the RBR Research 
Sample W ithdrawal of Informed Consent eCRF.  
Ifa patient wishes to withdraw consent to the testing of his or her RBR samples after 
closure of the site, the investigator must inform the Sponsor by [CONTACT_803998]:
global_rcr -[EMAIL_1377]
A patient's withdrawal from this study does not, by [CONTACT_5071], constitute withdrawal of consent 
for testing of RBR samples.  Likewise, a patient's withdrawal of consent for testing of 
RBR samples does not constitute withdrawal from this study.
[IP_ADDRESS] Monitoring and Oversight
RBR samples will be tracked in a manner consistent with Good Clinical Practice by a 
quality -controlled, auditable, and appropriately validated laboratory information 
managemen t system, to ensure compliance with data confidentiality as well as 
adherence to authorized use of samples as specified in this protocol and in the Informed 
Consent Form.  Sponsor monitors and auditors will have direct access to appropriate 
parts of record s relating to patient participation in the RBR for the purposes of verifying 
the data provided to the Sponsor.  The site will permit monitoring, audits, IRB/EC review, 
and health authority inspections by [CONTACT_123544].
4.6 TREA TMENT, PA TIENT, STUDY, AND SITE DISC ONTINUA TION
Due to the Sponsor’s decision to discontinue the [ADDRESS_1109753] this with a 120 -mg Q16W dosing regimen in Protocol Version 4, all patients 
who enrolled prior to implementation of Protocol Version 4 will be prematurely 
discontinued from the study by [CONTACT_803943] -of-treatment 
visit prior to entry into Study BN40955. 
An excessive rate of withdrawals (either study treatment discont inuation or withdrawal 
from the study) can render the study results non -interpretable.  Therefore, all efforts 
should be taken to motivate patients to comply with all study -specific procedures and to 
be followed until the end of the 101 -week, placebo -contr olled treatment period. 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
73/Protocol BN40423 , Version 4Investigators should explore all possible options to contact [CONTACT_803999], especially 
end-of-treatment visits.  The site must document all attempts to try to contact [CONTACT_804000]'s medical records and source do cuments.
4.6.[ADDRESS_1109754] permanently discontinue study treatment if they experience any of the 
following:
Any medical condition that the investigator or Sponsor determines may jeopardize 
the patient's safety if he or she continues to receive study treatment
Investigator or Sponsor determination that treatment discontinuation is in the best 
interest of the patient
Pregnancy
 Loss of capacity to consent, if legal guardian consent is not possible
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF.  Patients who discontinue study treatment prematurely will not be
replaced.
All patients who discontinue study treatment prematurely but do not withdraw consent for 
continued participa tion in the study will return to the clinic for study visits at W eeks 53 
and 69 (if not already completed) for collection of at least the data for the primary and 
secondary endpoints (see Sections 2.1.1 , 2.1.2 , and 2.2).  If the early treatment
termination visit falls within [ADDRESS_1109755] the right to voluntarily withdraw from the study at any time for any reason.  
In addition, the investigator has the right to withdraw a patient from the study at any time.  
Reasons for withdrawal from the study may include, but are not limited to, the following:
Patient withdrawal of consent
Study termination or site closure
Every effort should be made to obtain information on patients who withdraw from the 
study but have not withdrawn consent.  The primary reason for withdrawal from the 
study should be documented on the appropriate eCRF.  If a patient requests to be 
withdrawn from the study, this request must be documented in t he source documents 
and signed by [CONTACT_093].  Patients who withdraw from the study will not be
replaced.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
74/Protocol BN40423 , Version 44.6.3 Study Discontinuation
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following:
The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to patients
Patient enrollment is unsatisfactory
The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.  
4.6.4 Site Discontinuation
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following:
Excessiv ely slow recruitment
Poor protocol adherence
Inaccurate or incomplete data recording
Non-compliance with the International Council for Harmonisation (ICH) guideline for 
Good Clinical Practice
No study activity (i.e., all patients have completed the study a nd all obligations have 
been fulfilled)
5. ASSESSMENT OF SA FETY
5.[ADDRESS_1109756] udies.  The known safety risks for the lumbar puncture procedure and 
RO7234292 are outlined below in Sections 5.1.1 and 5.1.2 , respectively .  Please refer to 
the RO7234292 Investigator's Brochure for a complete summary of safety information.
Several measures will be taken to ensure the safety of patients participating in this study , 
including the eligibility criteria .  Patients will undergo safety monitoring during the study, 
including assessment of the incidence and severity of adverse events .  Guidelines for 
managing adverse events, including cri teria for treatment interruption or discontinuation, 
are provided below .
5.1.[ADDRESS_1109757]lumbar puncture syndrome, spi[INVESTIGATOR_626858], and meningitis (see 
Sections [IP_ADDRESS] through [IP_ADDRESS] ) are potential risks associated with lumbar puncture. 
In the complet edPhase I/IIa study, the most commonly reported adverse event s across 
all treatment groups (RO7234292, n 34; placebo, n 12) were procedural pain (54% of 
patients ) and post lumbar puncture syndrome (37% of patients ).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
75/Protocol BN40423 , Version 4In the ongoing Phase II OLE Study BN40967 (9 -month data), potential post lumbar 
puncture adverse events (including procedural pain, post lumbar puncture syndrome, 
post-procedural discomfort, headache, and migraine) occurring within 72 hours of drug 
adminis tration were summarized per cohort.  For the Q4W cohort (n 23), 28 events 
were reported in 13 (56%) of patients; for the Q8W cohort (n 23),27 events were 
reported in 12 (52.2%) patients. 
Many of the complications associated with lumbar puncture can be av oided by [CONTACT_803944] a 24G atraumatic needle with a stylet, adherence to procedural 
guidelines (see lumbar puncture manual and instructional video), and careful 
assessment of th e patient, including neurologic examination with fundoscopy both prior
to and post lumbar puncture procedure.  Lumbar puncture should be avoided when a 
contraindication is present.
CSF leakage is more likely with larger bore needles.  To minimize this risk,a 
24G atraumatic needle will be used.  Training for use of the 24G atraumatic needle in 
this study will be provided prior to initiation of lumbar puncture, as will a review of 
extension tubing use and the need to gently aspi[INVESTIGATOR_626861].  If 
headache with characteristics of low -pressure syndrome is present after the procedure
and persists despi[INVESTIGATOR_31740] -of-care treatment , a blood patch should be considered .  
Formation of a subarachnoid epi[INVESTIGATOR_626863] (i.e. ,when a skin plug is introduced into the 
arachnoid space )can be avoided by [CONTACT_2363] a needle with stylet, which is mandatory.  
Rarely ,brain herniation can occur in the setting of lumbar puncture and increased 
intracranial pressure.  
There are specific contraindications to performing lumbar puncture.  T hese include 
unstable cardiorespi[INVESTIGATOR_82219], where positioning patient for lumbar puncture may not 
be tolerated, signs of cerebral herniation or incipi[INVESTIGATOR_626864], signs of 
increased intracranial pressure, or focal neurological findings on e xamination.  In those 
patients, lumbar puncture (and IT treatment administration) should not be performed and 
appropriate diagnostic work -up should be initiated.  On a case -by-case basis and 
following discussion with the Medical Monitor, such pa tients may be able to resume 
treatment.  P revious lumbar surgery is an exclusion criterion for this study.    
In the setting of H D, for the purposes of lumbar puncture and ITbolus injection of
RO7234292 , moderate to severe truncal chorea may also be prohibitive.  
[IP_ADDRESS] PostLumbar Puncture Sy ndrome
RO7234292 will be delivered directly to the CNS by [CONTACT_803945].  
Postlumbar puncture syndrome (e.g., headaches, nausea, vomiting, infection, 
hemorrhage, nerve irritation pain) can occur with IT administration .  Experience to date 
with post lumbar puncture syndrome, as reported in the completed Phase I/IIa study, 
includes headache, which occurred after 10% of procedures and was transient and mild 
in the vast majority of patients.   In the ongoing Phase II OLE St udy BN40967 (9 -month 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
76/Protocol BN40423 , Version 4data), [ADDRESS_1109758] lumbar puncture syndrome were reported in the Q4W cohort 
(17.4%) and 3 in the Q8W cohort (13.0%).  All these events were rated as mild and 
resolved without treatment with the exception of 1 event in the Q4W coho rt that 
required treatment (mild and resolved). 
Patients should walk post lumbar procedure, to assist drug distribution (see 
Section [IP_ADDRESS] ); however, if a patient develops a headache after the lumbar puncture 
with characteristic features, which makes walking intolerable, the patient should be 
encouraged to first sit down and if the headache persists then lie in a comfortable 
position, which is most likely in the supi[INVESTIGATOR_803890].  Supportive treatment may include rehydration, consumption of caffeinated 
drinks, simple analgesics, opi[INVESTIGATOR_2438] , and antiemetics.  If these conservative measures fail, 
more specific measures may be indicated.
[IP_ADDRESS] Spi[INVESTIGATOR_626866]lumbar puncture spi[INVESTIGATOR_626867] a very rare but important potential risk that 
can present as persistent back pain, radicular pain, new sensory or motor symptoms, 
sphincter disturbance, or meningism.  Prompt MRI scanning should be performed if 
suspi[INVESTIGATOR_626868].  Patients with susceptibility to bleeding, patients 
with coagulopathy, and patient sreceiving anticoagulant therapy are at an increased risk 
of spi[INVESTIGATOR_626869] (see Section 4.1.2 ).  
Management of spi[INVESTIGATOR_803891].
[IP_ADDRESS] Meningitis
Meningitis is a rare potential risk of lumbar puncture.  Patients may present with 
headache, meningism, photophobia, neck stiffness, and pyrexia.  Guidelines for 
management of patients with suspect ed meningitis are provided in Table [ADDRESS_1109759] been consider ed in relation to clinical data 
available as of 30 January 2019, including the completed Phase I/IIa study and ongoing 
Phase II OLE study (9 -month datacut).  
[IP_ADDRESS] Neurologic Changes
In cynomolgus monkeys, acute, transient deficits in lower spi[INVESTIGATOR_154531] (patellar 
reflex in particular) were typi[INVESTIGATOR_218206] 2 to 8 hours following dosing, in the 13 -
week and the chronic toxicity studies.  The transient changes in patellar reflex were 
observed in all treatment groups, including controls, with a slightly higher incidence in 
the high -dose groups.  These findings were fully reversible within 24 hours following 
dosing.  No other treatment -related changes in general sensory and motor function 
parameters nor changes in the cerebral reflexes were observed.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
77/Protocol BN40423 , Version 4In the Phase I/IIa MAD study (ISIS 443139 -CS1), no adverse trends in neurological 
examinations were detected and only a few drug -related neurological adverse events 
were observed in 2 patients.  See the RO7234292 Investigator’s Brochure for more 
information.
Following LP administration and post -LP mobilization, neurologic examinations should 
beconducted .  In addition, patients should be observed in clinic for any complications 
or complaints post -LP and intrathecal bolus injection of RO7234292.
[IP_ADDRESS] Elevations in CSF WBCs and Protein
Mild elevations in CSF W BCs have been observed during the Phase I/IIa, 
dose- escalation study (Study ISIS 443139 -CS1) and its respective OLE study 
(Study ISIS 443139 -CS2 [Study BN40697]) at various timepoints that are sometimes 
associated with changes in CSF protein without signs of inflammation .  The majority of 
patients have counts under [ADDRESS_1109760] generally 
been asymptomatic.  One case with elevations in CSF W BCs and CSF protein 
presented with ankle hyporeflexia after the seventh dose of 120 mg monthly with 
enhancement of the cauda equina noted on MRI of the spi[INVESTIGATOR_050] , with no other clinical 
sequelae noted .  
The CSF W BC elevations were also observed in the chronic non- human primate study 
with slight increases over time.  Increases were mild, and there was no apparent dose 
dependency.
[IP_ADDRESS] Thrombocytopenia
Reductions in pla telet count have been observed after systemic administration of some 
2'-MOE chimeric ASOs to clinical trial subjects.  However, no clinically significant 
reductions in platelet counts have been observed in clinical studies for RO7234292 to 
date.  Inone13-week and one 9-month IT toxicity studies of RO7234292 in the 
cynomolgus monkey, there were no effects on hematology or coagulation parameters.
No clinically significant reduction in platelet counts was observed in the completed 
RO7234292 Phase I/IIa study . In the ongoing phase II OLE study (BN40697), no 
events of thrombocytopenia have been reported to date (9 -month data).
Platelet counts will be monitored at each study visit prior to lumbar puncture.  See 
Table 3for patient stoppi[INVESTIGATOR_626871].
[IP_ADDRESS] Kidney  Effects
Reductions in renal function have been observed after administration of some 2' -MOE 
containing chimeric ASOs to clinical trial subjects.  In the [ADDRESS_1109761] article related 
histologic findings in the visceral organs or effects on clinical chemistries.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
78/Protocol BN40423 , Version 4No clinically significant reduction in kidney function was observed in the completed 
RO7234292 Phase l/IIa study. In the ongoing P hase II OLE study (BN40697) ,one case 
of moderate proteinuria considered related to the study drug has been reported in the 
Q4W cohort (resolved without any intervention );no other clinically significant kidney 
abnormality has been observed.
Kidney function will be monitored at each study visit.  Guidelines for management of 
patients who develop decreased renal function are provided in Table 3.
[IP_ADDRESS] Liver Effects
Elevations in liver enzymes have been observed after administration of some 2' -MOE 
chimeric ASOs to clinical trial subjects. However, no clinically significant elevation in liv er 
enzymes was observed in the clinical studies for RO7234292 to date.
In the 13- week and 9 -month toxicity studies of RO7234292 in cynomolgus monkeys, 
there were no drug related histologic findings in the visceral organs, including the liver, 
or effects on clinical chemistry test levels. No clinically significant elevations in liver 
enzymes were observed in the completed RO7234292 Phase I/IIa study. In the ongoing 
Phase II OLE study (BN40697), liver enzyme adverse events were reported in 
2patients in the Q 4W cohort (one moderate event of gamma -glutamyltransferase 
increase, ongoing, and one mild hepatic enzyme increase which resolved without any 
intervention and were considered not related to RO7234292 by [CONTACT_093]).  No 
other clinically significant h epatic abnormality has been observed.
Liver enzymes will be monitored at each study visit.  Guidelines for management of 
patients who develop decreased liver function are provided in Table 3 .
[IP_ADDRESS] Hydrocephalus
Hydrocephalus is included as a warning in the labelling of one marketed 
IT-administered 2' -MOE chimeric ASO.  No hydrocephalus was observed in the 
completed RO7234292 Phase I/IIa MAD study (ISIS 443139 -CS2) and the ongoing 
Phase II OLE study (BN40697) to date.
[IP_ADDRESS] Neuropsy chiatric Changes
RO7234292 is directly administered to the CNS , with limited clinical experience.
Nonclinical studies in animals did not show any adverse effects o n the CNS.  Though a 
single case of completed suicide has occurred in the ongoing Phase II OLE study 
(BN40697), when weighing all available details of the case, the investigator has 
concluded that this event was not related to RO7234292.  Patients should be closely 
monitored for signs and symptoms of neuropsychiatric changes in addition to routine 
monitoring with the Columbia -Suicide Severity Rating Scale (C -SSRS) and the 
Montreal Cognitive Assessment battery.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
79/Protocol BN40423 , Version [IP_ADDRESS] Potential Risk due to Reduction of Target Protein HTT
By [CONTACT_626940], RO7234292 lowers levels of both 
mHTT protein and normal wild -type huntingtin (wtHTT) protein in all patients, regardless 
of genetic variations.  The ASO modality provides partial, transient, reversible ,and 
titratable HTT lowering.  Partial HTT lowering is safe and well tolerated in normal rodents 
and non- human primates, as shown in multiple studies using ASOs and non -reversible 
approaches. Furthermore, no safety signals of concern emerged during the rec ent 
Phase I/IIa study of RO7234292 in adults with HD (see RO7234292 Inve stigator's 
Brochure ), in which partial lowering was achieved.
Transgenic mice expressing human mHTT develop progressive HD -like phenotypes that 
recapi[INVESTIGATOR_626872].  ASO -mediated mHTT lowering provides 
therapeutic benefits and often r estores normal functioning in transgenic and fully 
humanized animal models of HD, with generally similar results regardless of whether 
wtHTT is also lowered. Moreover, no detrimental effects of partial wtHTT lowering in 
animal models have been reported in multiple studies using ASOs and non -reversible 
approaches.
Still, the c urrent understanding of the diverse cellular functions of HTT suggests potential 
theoretical risks associated with reducing total HTT levels in people with HD. More than 
two decades o f research findings implicate HTT in a wide array of cellular functions, 
including microtubule- based transport, F- actin -based trafficking, Rab -based trafficking, 
brain- derived neurotrophic factor transport, ciliogenesis, transcription, chromatin 
modificati on, post -transcriptional gene- expression regulation, neurogenesis, 
synaptogenesis, synaptic plasticity, signaling pathways, cell stress responses, cell 
survival, selective macro -autophagy and DNA damage repair, as detailed in a recent 
review article (Liu a ndZeitlin 2017).
Although functional HTT (mutant or wild-type) is es sential for embryogenesis, 
near-complete genetic ablation of HTT has little or no reported neurological effect in 
normal adult animals. However, complete ablat ion of wtHTT protein expression 
throughout life results in a worsening motor phenotype and, in male transgenic mice, 
age-dependent emergence of brain atrophy and decreased testicular size (Van 
Raamsdonk et al. 2005).  In contrast, decreases in mHTT protein expression ameliorate 
disease, and increases in mHTT protein exacerbate disease in animal models of HD, 
regardless of concomitant changes in wtHTT protein levels.
No clinically significant new neurologic events were observed in the completed 
Phase l/IIastudy.   As a precaution, a full neurologic examination will be conducted at 
each study visit (on dosing days before and after dosing), and additional monitoring of 
cognition will be conducted throughout the study using the MoCA .
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
80/Protocol BN40423 , Version 45.1.3 Management of Patients Who Experience A dverse Eve nts
[IP_ADDRESS] Dose Modifications
No dose modifications are permitted in this study, whether by [CONTACT_626941] (i.e., all 
participants will receive 20 mL of study drug per injection on a Q8W basis).
[IP_ADDRESS] Treatment Interruption
Study drug may be temporarily suspended in patients who experience toxicity 
considered to be related to study drug.  If study drug has been withheld for 60days
because of signs of persistent drug -induced toxicity or if the scheduled dose has been 
missed, the investigator should consult the Medical Monitor to determine if 
discontinuation from study drug is warranted.   Study drug may be suspended for 
reasons other than toxicity (e.g., surgical procedures) with Medical Monito r approval.  
The investigator and the Medical Monitor will determine the acceptable length of 
treatment interruption.
[IP_ADDRESS] Management Guidelines
Guidelines for management of specific adverse events are outlined in Table 3.  
Additional guidelines are provided in the subsections below.
Initial clinical laboratory tests with results meeting criteria for withholding study drug must 
be repeated on new specimens as soon as possible , and results must be available prior 
to administering the next dose of study drug. In general, patients who do not reach the 
stoppi[INVESTIGATOR_626873] ;however ,the investig ator and Sponsor should confer 
as to whether additional close monitoring of the patient is indicated.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
81/Protocol BN40423 , Version 4Table 3Guidelines for Management of Patients Who Experience A dverse 
Events
Event Action to Be Taken
Elevations in CSF WBC 
count or proteins or 
suspected meningitis, 
radiculitis, arachnoiditis , or 
other acute neurologic 
symptomsWithhold study drug if diagnosis of meningitis, radiculitis,
arachnoiditis , or acute neurologic symptoms is suspected and 
initiate appropriate diagnostic work -up as indicated. 
Clinical signs a nd sy mptoms (e.g., headache, stiff neck, fever) 
plus confirmatory WBC count are required for diagnosis of 
suspected meningitis, and clinical signs and s ymptoms are 
required for diagnosis of radiculitis ,arachnoiditis , or acute 
neurologic symptoms .  Isolate d low -level (e.g., 5 50 W BC 
count) elevations in CSF W BC count without clinical s ymptoms 
does not meet criteria for diagnosis of suspected meningitis.  
The Medical Monitor should be consulted in all cases where 
WBC count CSF elevations above 10 are presen t, or a change 
from baseline in CSF proteins greater than twice baseline or 
where there is uncertainty to discuss next steps of patient 
managem ent in the study.
If diagnosis of suspected meningitis, radiculitis, arachnoiditis , or 
other acute neurologic sym ptoms is refuted, the study drug may 
be resumed after consultation with the Medical Monitor.
In the event meningitis, radiculitis, arachnoiditis , or acute
neurologic symptom diagnosis is confirmed, standard -of-care 
therapi[INVESTIGATOR_803892].
Thrombocy topenia Ifplatelet count is 100,000/mm3:
oMonitor platelet count weekly
If platelet count is 75,000/mm3and 50,000/mm3in the 
absence of major bleeding or clinically relevant non -major 
bleeding :
oWithhold study  drug until the platelet count has recovered 
to 100,000/mm3.  
oThe suitability of the patient for continued dosing and 
frequency of monitoring should be discussed with the 
Medical Monitor . 
If platelet count is 50,000/mm3:
oPermanently discontinue study drug . 
oMonitor platelet count s daily until two successive values 
show improvement .  Then monitor ever y 2[ADDRESS_1109762] of care should be considered for 
patients whose platelet count is 25,000/mm3.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
82/Protocol BN40423 , Version 4Table 3 Guidelines for Management of Patients Who Experience A dverse 
Events (cont.)
Decreased renal function Withhold study  drug in the event of a persistent (2 weeks) 
decrease in eGFR or CrCl or increase in creatinine, as defined
below:
o eGFR (using Cockcroft -Gault) or CrCl 60mL/min
o Creatinine level increase of 2.0 above baseline
Study drug may be resumed when follow -up test results show
that the patient no longer meets the dose interruption criteria.
Elevated liver enzy mes ALT or AST is 3ULN:
o Monitor weekly until ALT and AST return to 1.2ULN.
o Further investigation into the liver enzy me elevations may
include hepatitis serologies and other diagnostic tests at
the discretion of the investigator in consultation with the
Medical Monitor.
Withhold study drug i n the event ofliver enzy mes that meet the
following criteria without an alternative explanation (as
discussed with the Medical Monitor):
o ALT or AST 5ULN
o ALT or AST 3ULN, combined with total
bilirubin 2ULN or INR 1.[ADDRESS_1109763] 3ULN coinciding with new appearance of
fatigue, nausea, vomiting, right upper quadrant pain or
tenderness, fever, rash , and/ or concomitant eosinophilia.
o Discontinue study drug permanently if levels do not return
to baseline after 30 days.
CrClcreatinine clearance; CSF cerebrospi[INVESTIGATOR_872]; eGFR estim ated glomerular filtration rate; 
ULNupper limit of normal.
5.[ADDRESS_1109764], performing 
protocol -specified safety laboratory assessments, measuring protocol -specified vital 
signs, and conducting other protocol -specified tests that are deemed critical to the safety 
evaluation of the study.
Certain types of events require immediate reporting to the Sponsor, as outlined in 
Section 5.4.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
83/Protocol BN40423 , Version 45.2.[ADDRESS_1109765], regardless of causal attribution.  An adverse event can 
therefore be any of the following:
Any unfavorable and unintended sign (including an abnormal laboratory finding),
symptom, or disease temporally associated with the use of a medicinal product,
whether or not considered related to the medicinal product
Any new disease or exacerbation of an existing disease (a worsening in the
character, frequency, or severity of a known condition) (see Sections [IP_ADDRESS] and
[IP_ADDRESS] for more information)
Recurrence of an intermittent medical condition (e.g., headache) not present at
baseline
Any deterioration in a laboratory value or other clinical test (e.g., ECG, X -ray) that is
associated with symptoms or leads to a change in study treatment or concomitant
treatment or discontinuation from study drug
Adverse events that are related to a protocol -mandated intervention, including those
that occur prior to assignment of study treatment (e.g., screening invasive
procedures such as biopsies)
5.2.2 Serious A dverse Events (Immediately  Reportable to the 
Sponsor)
A serious adverse event is any adverse event that meets any of the following criteria:
Is fatal (i.e., the adverse event actually causes or leads to death)
Is life threatening (i.e., the adverse event, in the view of the investigator, places the
patient at immediate risk of death)
This does not include any adverse event that, had it occurred in a more severe 
form or was allowed to continue, might have caused death.
Requires or prolongs inpatient hospi[INVESTIGATOR_059] (see Section [IP_ADDRESS])
Results in persistent or significant disability/incapacity (i.e., the adverse event
results in substantial disruption of the patient's ability to conduc t normal life
functions)
Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to
study drug
Is a significant medical event in the investigator's judgment (e.g., may jeopardize the
patient or may require medical/surgical intervention to prevent one of the outcomes
listed above)
The terms "severe" and "serious" are notsynonymous.  Severity refers to the intensity of 
an adverse event (e.g., rated as mild, moderate, or severe, or according to National 
Cancer Institute Common Termi nology Criteria for Adverse Events [NCI CTCAE]; see
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
84/Protocol BN40423 , Version 4Section 5.3.3 ); the event itself may be of relatively minor medical significance (such as 
severe headache without any further findings).
Severity and seriousness need to be independently assessed for each adverse event 
recorded on the eCRF.
Serious adverse events are required to be reported by [CONTACT_25741] (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for 
reporting instructions).
5.2.[ADDRESS_1109766] (Immediately  Reportable to 
the Sponsor)
Adverse events of special interest are required to be reported by [CONTACT_33473] (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 for reporting instructions).  Adverse events of special interest for this study 
are as follows:
Cases of potential drug- induced liver injury that include an elevated ALT or AST in
combination with either an elevated bilirubin or clinical jaundice, as defined by [CONTACT_25742]'s
Law (see Section [IP_ADDRESS] )
Suspected transmission of an infectious agent by [CONTACT_1758] d rug, as defined below :
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non -pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a patient exposed to a medicinal product.  This term applies only
when a contamination of the study drug is suspected.
5.3 METHODS A ND TIMING F OR CA PTURING A ND ASSESSING 
SAFETYPARAMETERS
The investigator is responsible for ensuring that all adverse events (see Section 5.2.1 for 
definition) are recorded on the Adverse Event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Sections 5.45.6.
For each adverse event recorded on the Adverse Event eCRF, the investigator will make 
an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see 
Section 5.3.3 ), and causality (see Section 5.3.4 ).  
5.3.[ADDRESS_1109767].  All 
adverse events, whether reported by [CONTACT_25743], will be 
recorded in the patient's medical record and on the Adverse Event eCRF.
After informed consent has been obtained but prior to initiation of study drug , only 
serious adverse events caused by a protocol -mandated intervention (e.g., invasive 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
85/Protocol BN40423 , Version 4procedures such as biopsies, discontinuation of medications) should be reported 
(see Section 5.4.2 for instructions for reporting serious adverse events).
After initiation of study drug, all adverse events will be reported until [ADDRESS_1109768] dose in the OLE study 
(BN40955), at which time reporting will occur per the new study requirements .
Instructions for reporting adverse events that occur after the adverse event reporting 
period are provided i n Section 5.6.
5.3.2 Eliciting A dverse Ev ent Information
A consistent methodology of non -directive questioning should be adopted for eliciting 
adverse event information at all patient evaluation timepoints.  Examples of non -directive 
questions include the following:
"How have you felt since your last clinic visi t?"
"Have you had any new or changed health problems since you were last here?" 
5.3.3 Assessment of Severity  of A dverse Events
The adverse event severity grading scale indicated in Table 4 will be used for assessing 
adverse event severity.  Laboratory values determined as an adverse event should be 
graded as per Appendix 5, which is based on the NCI CTCAE ( v5.0).
Table 4Adverse Event Severity Grading Scale
Severity Description
Mild Discomfort noticed, but no disruption of normal daily activity
Moderate Discomfort sufficient to reduce or affect normal daily activity
Severe Incapacitating with inability to work or to perform normal daily activity
Note:  Regardless of severity, some events may  also meet seriousness criteria.  
Refer to definition of a serious adverse event (see Section 5.2.2 ).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
86/Protocol BN40423 , Version 45.3.4 Assessment of Causality  of Adverse Events
Investigators should use their knowledge of the patient, the circumstances surrounding 
the event, and an evaluation of any potential alternative causes to determine whether an 
adverse event is considered to be related to the study drug, indicating "yes" or "no" 
accordingly.  The following guidance should be taken into consideration (see also
Table 5 ):
Temporal relationship of event onset to the initiation of study drug
Course of the event, with special consideration of the effects of dose red uction, 
discontinuation of study drug, or reintroduction of study drug (as applicable)
Known association of the event with the study drug or with similar treatments
Known association of the event with the disease under study
Presence of risk factors in the patient or use of concomitant medications known to 
increase the occurrence of the event
Presence of non -treatment -related factors that are known to be associated with the 
occurrence of the event
Table 5Causal A ttribution Guidance
Is the adverse event suspected to be caused by [CONTACT_25745], evidence, 
science -based rationales, and clinical judgment?
YES There is a plausible temporal relationship between the onset of the adverse event and 
administration of the study drug, and the adverse event cannot be readily explained by 
[CONTACT_102]'s clinical state, intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the 
adverse event follows a known pattern of response to the study drug; and/or the 
adverse event abates or resolves upon discontinuation of the study drug or dose 
reduction and, if applicable, reappears upon re -challenge.
NO An adverse event will be considered related, unless it fulfills the criteria specified below .  
Evidence exists that the adverse event has an etiology other than the study drug 
(e.g., preexisting medical condition, underlying disease, intercurrent illness, 
orconcomitant medication); and/or the adverse event has no plausible temporal 
relationship to administration of the study drug (e.g., cancer diagnosed 2 days after 
firstdose of study drug).
5.3.[ADDRESS_1109769] medical terminology/concepts when recording adverse 
events on the Adverse Event eCRF .  Avoid colloquialisms and abbreviations.
Only one adverse event term should be recorded in the event field on the Adverse Event 
eCRF.
[IP_ADDRESS] Injection Reactions
Adverse events that occur during or within 24 hours after study drug administration 
should be captur ed as individual signs and symptoms on the Adverse Event eCRF 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
87/Protocol BN40423 , Version 4rather than an overall diagnosis (e.g., record dyspnea and hypotension as separate 
events rather than a diagnosis of IT bolus -related reaction or anaphylactic reaction.
[IP_ADDRESS] Diagnosis versus Signs an d Sy mptoms
For adverse events other than injectio nreactions (see Section [IP_ADDRESS] ), a diagnosis (if
known) should be recorded on the Adverse Event eCRF rather than individual signs and 
symptoms (e.g., record only liver failure or hepatitis rather than jaundice, asterixis, and 
elevated transaminases).  However, if a constellation of signs and/or symptoms cannot 
be medically characterized as a single diagnosis or syndrome at the time of reporting, 
each individual event should be recorded on the Adverse Event eCRF.  If a diagnosis is 
subsequently established, all previously reported adverse events based on signs and 
symptoms should be nullified and replaced by [CONTACT_335578], with a starting date that corresponds to the starting date of the first 
symptom of the eventual diagnosis.
[IP_ADDRESS] Adverse Events That A re Secondary  to Other Events
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by [CONTACT_5252], with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event 
that is separated in time from the i nitiating event should be recorded as an independent 
event on the Adverse Event eCRF.  For example:
If vomiting results in mild dehydration with no additional treatment in a healthy adult,
only vomiting should be reported on the eCRF.
If vomiting results i n severe dehydration, both events should be reported separately
on the eCRF.
If a severe gastrointestinal hemorrhage leads to renal failure, both events should be
reported separately on the eCRF.
If dizziness leads to a fall and consequent fracture, all th ree events should be
reported separately on the eCRF.
If neutropenia is accompanied by [CONTACT_25747], both events should be reported
separately on the eCRF.
All adverse events should be recorded separately on the Adverse Event eCRF if it is 
unclear as to whether the events are associated.
[IP_ADDRESS] Persistent or Recurrent A dverse Events
A persistent adverse event is one that extends continuously, without resolution, between 
patient evaluation timepoints.  Such events should only be recorded o nce on the 
Adverse Event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the event is first reported.  If a persistent adverse event becomes 
more severe, the most extreme severity should also be recorded on the Ad verse Event 
eCRF.  If the event becomes serious, it should be reported to the Sponsor immediately 
(i.e., no more than 24 hours after learning that the event became serious; see 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
88/Protocol BN40423 , Version 4Section 5.4.2 for reporting instructions).  The Adverse Event eCRF should be updated 
by[CONTACT_25748] "non -serious" to "serious," providing the date that the event 
became serious, and completing all data fields related to serious adverse events.
A recurrent adverse event is one that resolves between patient evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the Adverse Event eCRF.
[IP_ADDRESS] Abnormal Laborat ory Values
Not every laboratory abnormality qualifies as an adverse event.  A laboratory test result 
must be reported as an adverse event if it meets any of the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy
Is clinically significant in the investigator's judgmen t 
It is the investigator's responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., ALP and bilirubin 5 ULN associated with cholestasis), only the diagnosis 
(i.e., cholestasis) should be recorded on the Adverse Event eCRF.
If a clinically significant laboratory abnormalit y is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the Adverse Event eCRF, along with a 
descriptor indicating whether the test result is above or below the normal range 
(e.g., "elevated potassium," as opposed to "abnormal potassium").  If the laboratory 
abnormality can be characterized by a precise clinical term per standard definitions, the 
clinical term should be recorded as the adverse event.  For example, an elevated serum 
potassium level of 7.0 mEq/L should be recorded as "hyperkalemia."
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section [IP_ADDRESS] for 
details on recording persistent adverse events).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
89/Protocol BN40423 , Version [IP_ADDRESS] Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event if it meets any of the following criteria:
Is accompanied by [CONTACT_4659]
Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)
Results in a medical intervention or a change in concomitant therapy
Isclinically significant in the investigator's judgment 
It is the investigator's responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classi fied as an adverse event.
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high blood pressure), only the diagnosis (i.e., hypertension) should be recorded on 
the Adverse Event eCRF.
Observations of the same clinically significant vital sign abnormality from visit to visit 
should only be recorded once on the Adverse Event eCRF (see Section [IP_ADDRESS] for 
details on recording persistent adverse events).
[IP_ADDRESS] Abnormal Liver Function Tests
The finding of an elevated ALT or AST ( 3ULN) in combination with either an elevated 
total bilirubin ( 2ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as 
defined by [CONTACT_25742]'s Law).  Therefore, investigators must report as an adverse event the 
occurrence of either of the following:
Treatment -emergent ALT or AST 3ULN in combination with total bilirubin 
2ULN
Treatment -emergent ALT or AST 3ULN in combination with clinical jaundice
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the Adverse Event eCRF (see Section [IP_ADDRESS]) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event), either as a serious adverse event or an adverse event of special interest (see 
Section 5.4.2 ).
[IP_ADDRESS] Deaths
All deaths that occur during the protocol -specified adverse event reporting period (see 
Section 5.3.1 ), regardless of relationship to study drug, must be recorded on the 
Adverse Event eCRF and immediately reported to the Sponsor (see Section 5.4.2 ).This 
includes death attributed to progression of HD .
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
90/Protocol BN40423 , Version 4Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the Adverse Event eCRF.  Generally, only one such event should be 
reported.  If the cause of death is unknown and cannot be ascertained at the time of 
reporting, "unexplained death" should be recorded on the Adverse Event eCRF.  If the 
cause of death later becomes available (e.g., after autopsy), "unexplained death" should
be replaced by [CONTACT_25749].  The term "sudden death" should not be 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death").
If the death is attributed solely to progression of HD, "Huntington's disease progr ession" 
should be recorded on the Adverse Event eCRF.   
Deaths that occur after the adverse event reporting period should be rep orted as 
described in Section 5.6.
[IP_ADDRESS] Preexisting Medical Conditions
A preexisting medical condition is one that is present at the screening visit for this study.  
Such conditions should be recorded on the General Medical History and Baseline 
Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  W hen 
recording such events on the Adverse Event eCRF, it is important to convey the concept 
that the preexisting co ndition has changed by [CONTACT_9672] 
(e.g., "more frequent headaches").
[IP_ADDRESS] Lack of Efficacy  or Worsening of Huntington's Disease
Events that are clearly consistent with the expected pattern of progression of the 
underlying disease should notbe recorded as adverse events.  These data will be 
captured as efficacy assessment data only.  If there is any uncertainty as to whether an 
event is due to disease progression, it should be reported as an adverse event.
[IP_ADDRESS] Hospi[INVESTIGATOR_803893] (i.e., inpatient admission to a hospi[INVESTIGATOR_307]) 
or prolonged hospi[INVESTIGATOR_25676] a serious adverse 
event (per the definition of serious adverse event in Section 5.2.2 ), except as outlined 
below.  
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
91/Protocol BN40423 , Version 4An event that leads to hospi[INVESTIGATOR_26664] a serious adverse event:
Hospi[INVESTIGATOR_25678]
Planned hospi[INVESTIGATOR_33402]
Hospi[INVESTIGATOR_272] a preexisting condition, provided that all of the following criteria 
are met:
The hospi[INVESTIGATOR_33403] .
The patient has not experienced an adverse event .
An event that leads to hospi[INVESTIGATOR_33405] a serious adverse event, but should be reported as an adverse event 
instead:
Hospi[INVESTIGATOR_25682]
[IP_ADDRESS] Reporting Requirem ents for Cases of Accidental Overdose or 
Medication Error
Accidental overdose and medication error (hereafter collectively referred to as "special
situations"), are defined as follows:
Accidental overdose:  accidental administration of a drug in a quantity that is higher 
than the assigned dose
Medication error:  accidental deviation in the administration of a drug 
In some cases, a medication error may be intercepted prior to administration of 
the drug.
Special situations are not in themselves adverse even ts, but may result in adverse 
events.  Each adverse event associated with a special situation should be recorded 
separately on the Adverse Event eCRF.  If the associated adverse event fulfills 
seriousness criteria, the event should be reported to the Sponsor immediately 
(i.e., nomore than 24 hours after learning of the event; see Section 5.4.2 ).  For 
RO7234292 or placebo, adverse events associated with special situations should be 
recorded as described below for each situation:
Accidental overdose:  Enter the adverse event term.  Check the "Accidental 
overdose" and "Medication error" boxes.
Medication error that does not qualify as an overdose:  Enter t he adverse event term.  
Check the "Medication error" box.
Medication error that qualifies as an overdose:  Enter the adverse event term.  
Check the "Accidental overdose" and "Medication error" boxes.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
92/Protocol BN40423 , Version 4In addition, all special situations associated with RO7234292 or placebo, regardless of 
whether they result in an adverse event, should be recorded on the Adverse Event 
eCRF as described below:
Accidental overdose:  Enter the drug name [INVESTIGATOR_1238] "accidental overdose" as the event
term.  Check the "Accidental overdose" and "Medication error" boxes.
Medication error that does not qualify as an overdose:  Enter the name [CONTACT_804008] a description of the error (e.g., wrong dose administered, wrong
dosing schedule, incorrect route of administration, wrong drug, expi[INVESTIGATOR_803894]) as the event term.  Check the "Medication error" box.
Medication error that qualifies as an overdos e:  Enter the drug name [INVESTIGATOR_1238] "accidental
overdose" as the event term.  Check the "Accidental overdose" and "Medication
error" boxes.  Enter a description of the error in the additional case details.
Intercepted medication error:  Enter the drug name [INVESTIGATOR_1238] "intercepted medication
error" as the event term.  Check the "Medication error" box.  Enter a description of
the error in the additional case details.
As an example, an accidental overdose that resulted in a headache would require two
entries on the Adverse Event eCRF, one entry to report the accidental overdose and 
one entry to report the headache.  The "Accidental overdose" and "Medication error" 
boxes would need to be checked on both eCRF pages.
[IP_ADDRESS] Patient -Reported or Observer -Reported Outcome Data
Adverse e vent reports will not be derived by [CONTACT_803947] ,ObsRO ,or digital 
wearable device (HD mobile app) data, and safety analyses will not be performed using 
PRO or ObsRO or digital wearable device data.  Sites are not expected to review the 
PRO or Obs ROor digital wearable device data for adverse events.
[IP_ADDRESS] Safety  Biomarker Data
Adverse event reports will not be derived from safety biomarker data by [CONTACT_1034], 
and safety biomarker data will not be included in the formal safety analyses for this study.  
In addition, safety biomarker data will not inform decisions on patient management.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
93/Protocol BN40423 , Version 45.[ADDRESS_1109770] report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than [ADDRESS_1109771] udy drug:
Serious adverse events (defined in Section 5.2.2 ; see Section 5.4.2 for details on
reporting requirements)
Adverse events of special interest (defined in Section 5.2.3 ; see Section 5.4.2 for
details on reporting requirements)
Pregnancies (see Section 5.4.3 for details on reporting requirements)
The investigator must report new significant follow -up information for these events to the 
Sponsor immediately (i.e., no more than 24 hours after becoming aware of the 
information).  New significant information includes the following:
New signs or symptoms or a change in the diagnosis
Significant new diagnostic test results
Change in causality based on new information
Change in the event's outcome, including recovery
Additional narrative information on the clinical course of the event
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC.
5.4.[ADDRESS_1109772] Information for All Sites
Medical Monitor: , M.D., Ph.D .
Telephone No.:
Mobile Telephone No.:
To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will
access the [COMPANY_002] Medical Emergency List, escalate emergency medical calls, provide 
medical translation service (if necessary), connect the investigator with a [COMPANY_002] Medical 
Responsible (listed above and/or on the [COMPANY_002] Medical Emergency List), and track a ll 
calls.  The Emergency Medical Call Center Help Desk will be available [ADDRESS_1109773] information, will be distributed to all investigato rs. 

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
94/Protocol BN40423 , Version 45.4.[ADDRESS_1109774]
[IP_ADDRESS] Events That Occur prior to Study  Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol -mandated intervention should be reported.  
The paper Clinical Trial Serious Adverse Event/Adverse Event of Special Interest 
Reporting Form provided to investigators should be completed and submitted to the 
Sponsor or its designee immediatel y (i.e., no more than 24 hours after learning of the 
event), either by [CONTACT_249177].
[IP_ADDRESS] Events That Occur after Study  Drug Initiation
After initiation of study drug, serious adverse events and adverse events of special 
interest will be reported until [ADDRESS_1109775] all case details that can be gathered immediately (i.e., within 24 hours 
after learning of the event) on the Adverse Event eCRF and submit the report via the 
electronic data capture (EDC) system.  A report will be generated and sent to [COMPANY_002] 
Safety Risk Management by [CONTACT_27950].
In the event that the EDC system is unavailable, the paper Clinical Trial Serious Adverse 
Event/Adverse Event of Special Interest Reporting Form provided to investigators should 
be completed and submitted to the Sponsor or its designee immediately (i.e., no more 
than 24 hours after learning of the event), either by [CONTACT_123565].  Once the 
EDC system is available, all information will need to be entered and submitted via the 
EDC system.  
Instructions for reporting serious adverse events that occur 5 months after the final 
dose of study treatment are provided in Section 5.6.
5.4.3 Reporting Requirements for Pregnancies
[IP_ADDRESS] Pregnancies in Female Patients
Female patients of childbearing potential will be instructed to immediately inform the 
investigator if they become pregnant during the study or within 5 months after the final
dose of study drug .  A paper Clinical Trial Pregnancy Reporting Form should be 
completed and submitted to the Sponsor or its designee immediately (i.e., no more than 
24 hours after learning of the pregnancy), either by [CONTACT_804001].  Pregnancy 
should not be recorded on the Adverse Event eCRF .  The investigator should 
discontinue study drug and counsel the patient, discussing the risks of the pregnancy 
and the possible effects on the fetus.  Monitoring of the patient should continue until 
conclusion of the pregnancy.  Any serious adverse events associated with the 
pregnancy (e.g., an event in the fetus, an event in the mother during or after the 
pregnancy, or a congenital anomaly/birth defect in the child) should be reported on the 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
95/Protocol BN40423 , Version 4Adverse Event eCRF.  In addition, the investigator will submit a Clinical Trial Pregnancy 
Reporting Form when updated information on the course and outcome of the pregnancy 
becomes available.  
[IP_ADDRESS] Pregnancies in Female Partners of Male Patients
Male patients will be instructed through the Informed Consent Form to immediately 
inform the investigator if their partner becomes pregnant during the study or within 
5months after the final dose of study drug after the final dose of study drug.  A paper 
Clinical Trial Pregnancy Reporting Form should be completed and submitted to the 
Sponsor or its designee immediately (i.e., no more than 24 hours after learning of the 
pregnancy), either by [CONTACT_804002].  Attempts should be made to collect and 
report details of the course and outcome of any pregnancy in the partner of a male 
patient exposed to study drug.  When permitted by [CONTACT_779], the pregnant partner would 
need to sign an Authorization for Use and Disclosure of Pregnancy Health Information to 
allow for follow -up on her pregnancy.  If the authorization has been signed, the 
investigator should submit a Clinical Trial Pregnancy Reporting Form when updated 
information o n the course and outcome of the pregnancy becomes available.  An 
investigator who is contact[CONTACT_40883], to 
support an informed decision in cooperation with the treating physician and/or 
obstetrician.
[IP_ADDRESS] Abortions
Aspontaneous abortion should be classified as a serious adverse event (as the Sponsor 
considers abortions to be medically significant), recorded on the Adverse Event eCRF, 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event; see Section 5.4.2 ).  
If a therapeutic or elective abortion was performed because of an underlying maternal or 
embryofetal toxicity, the toxicity should be classified as a serious adverse event, 
recorded on th e Adverse Event eCRF, and reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2 ).A therapeutic or 
elective abortion performed for reasons other than an underlying maternal or 
embryofetal toxicity is not considered an adverse event.
All abortions should be reported as pregnancy outcomes on the paper Clinical Trial 
Pregnancy Repo rting Form.
[IP_ADDRESS] Congenital A nomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female patient exposed to study 
drug or the female partner of a male patient exposed to study drug should be classified 
as a serious adverse event, reco rded on the Adverse Event eCRF, and reported to the 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
96/Protocol BN40423 , Version 4Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 ).
5.[ADDRESS_1109776] to 
follow -up, or the patient withdraws consent.  Every effort should be made to follow all 
serious adverse events considered to be related to study drug or trial -related procedures 
until a final outcome can be reported.
During the study period, resolution of adverse events (with dates) should be documented 
on the Adverse Event eCRF and in the patient's medical record to facilitate source data 
verification.
All pregnancies reported during the study should be followed until pregnancy outcome.
5.5.[ADDRESS_1109777], and pregnancies, the 
Sponsor or a designee may follow up by [CONTACT_756], fax, email, and/or a monitoring visit 
to obtain additional case details and outcome information (e.g., from hospi[INVESTIGATOR_803895], consultant reports, autopsy reports) in order to perform an independent 
medical assessment of the reported case.
5.6 ADVERSE EVENTS THA T OCCUR AFTER THE A DVERSE 
EVENT REPORTING PERI OD
The Sponsor should be notified if the investigator becomes a ware of any serious 
adverse event that occurs after the end of the adverse event reporting period (defined as 
greater than 5 months after the final dose of study drug), if the event is believed to be 
related to prior study drug treatment.  These events sho uld be reported through use of 
the Adverse Event eCRF.  However, if the EDC system is not available, the investigator 
should report these events directly to the Sponsor or its designee, either by [CONTACT_736493]/Adverse Event of 
Special Interest Reporting Form using the fax number or email address provided to 
investigators.
5.[ADDRESS_1109778] experience to identify and expeditiously 
communicate possible new safety findings to investigators, IRBs, ECs, and applicable 
health author ities based on applicable legislation.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
97/Protocol BN40423 , Version 4To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events using the following reference documen t:
RO7234292 Investigator's Brochure
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will a lso be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by [CONTACT_25753].
6. STATISTICA L CONSIDER ATIONS AND ANAL YSIS PLAN
All patients enrolled prior to Version 4 of the protocol will not be included for any 
efficacy analysis.  The safety data collected for these patients up to and including the 
end of treatment visit in Protocol BN40423 will be analyzed separately.  
The pri mary efficacy analysis will be conducted at the end of the study (see Section 3.2).  
Treatment assignments will be unblinded to the S ponsor at the end of the study after the 
data have been cleaned andverified and the database has been locked.
Details of the planned statistical analyses mentioned below will be fully specified in a 
separate Statistical Analysis Plan ( SAP) , which will be finalized prior to the locking and 
unblinding of the study database.
Unless otherwise specified, all the p- values considered in Section 6are two -sided.
6.1 ANAL YSIS POPULA TIONS
The intent -to-treat (ITT) population will consist of all patients enrolled after 
implementation of Protocol Version [ADDRESS_1109779] of all patients who enroll after 
implementation of Version 4 of the protocol and also receive any study treatment.  The 
safety population will be the primary population for all safety analys es.  For the 
purpose of all safety analyses, it will be assessed whether patients rece ived a treatment 
different from the one they were randomized to at any time during the course of the 
study.  In case the number and duration of such “treatment switches” warrants it, the 
safety population may be redefined by [CONTACT_804003] s to the treatment 
actually received, as opposed to which treatment they were randomized to.
The PK population will include all randomized patients who received at least one dose, 
and had sufficient sampling to permit PK evaluation.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
99/Protocol BN40423 , Version 42.Generate change from baseline values in TFC at Week 49 and Week 101 for
Nplacebo patients according to the following bivariate normal distribution:
where y_wk49 and y_wk101 is t he change from baseline in TFC, respectively, at 
Week 49 and Week 101, is the assumed true change at those two timepoints, 
and ∑ is the variance -covariance matrix.  Subsequently:
set to missing both values at Week 49 and Week 101 for 10% of the
Nplacebo patients
set to missing only the value at Week 101 for additional 10% of the
Nplacebo patients
Given how missing data will be imputed, it is not relevant to differentiate 
missing data into SDR versus NSDR reasons for placebo patients.
3.Apply multiple imputations and derive [ADDRESS_1109780] to compare active versus placebo at Week 101 for each completed
dataset and pool the result (Rubin 1987) to derive an estimate of the treatment
effect, including a p- value.
Across the 500,000 simulations, the power achieved, with the N patients per arm was 
calculated by [CONTACT_803950] p -value (in above Step 4) was below 5% 
by 500,000.  The above procedure was repeated by [CONTACT_803951] N until the 
calculated power was close to 80%.
It was estimated that 220 patients per arm will provide approximately 80% power, at a 
two-sided  0.[ADDRESS_1109781] a 40% slowing of clinical decline for RO7234292 as 
compared with placebo at [ADDRESS_1109782] translates into an expected 
average decline of ~0.82 points at 101 weeks for the RO7234292 arms.  The minimal 
detectable difference with these assumptions is ~0.[ADDRESS_1109783] MENT 
A hierarchical approach will be used for multiple adjustments that accounts for 
comparisons of two active dosing regimens (RO7234292 Q8W and RO7234292 Q16W) 
versus placebo, as well as multiple endpoints (the primary and secondary endpoints).  

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
100/Protocol BN40423 , Version 4The primary e ndpoint will be tested for RO7234292 Q8W against placebo at alpha level 
5% and, if significant, then RO7234292 Q16W against placebo. 
Secondary endpoints will be tested for each active treatment versus placebo.  Within 
each testing chain (RO7234292 Q8W and RO7234292 Q16W), the endpoint will be 
tested only if the preceding endpoint is significant at the divided alpha level.  Details of
the order for secondary endpoints and the split of alpha will be detailed in the SAP. 
6.[ADDRESS_1109784] OF STUDY
The num bersof patients who enroll in the study , discontinue from the study , and
complete the study will be summarized overall and by [CONTACT_2939].  Reasons for 
premature study withdrawal will be listed and summarized.  Enrollment and major 
protocol deviations w ill be listed and evaluated for their potential effects on the 
interpretation of study results.
6.5 SUMMA RIES OF DEMOGRA PHIC AND BA SELINE 
CHA RACTERISTICS
Demographic and baseline characteristics (including age, sex, CAG repeat length, CAP, 
HD stage, education) will be summarized using means, standard deviations, medians, 
and ranges for continuous variables and proportions for categorical variables, as 
appropriate.  Summaries will be presented overall and by [CONTACT_1570].
6.6 EFFICA CY ANAL YSES
To ensure the treatment groups under comparison are concurrent and that treatment 
regimens are comparable across the entire dosing period of the 25 -month study, for all 
efficacy analyses, patients enrolled prior to implementation of Protocol Version 4 will 
not be included an d will be offered the option to enroll into Study BN40955 before 
reaching the primary endpoint assessment in the current study.    
6.6.1 Estimands
Following the very recent estimand framework outlined in the ICH -E9 draft addendum
(FDA 2017) , the attributes of the estimand for the primary endpoint are defined as 
follows:
Population: ITT population (see Section 6.1)
Variable:   Change from baseline in cUHDRS score at Week 101  
–Note: cUHDRS scale will be replaced by [CONTACT_803952] .
Intercurrent events (ICEs) : 
–Treatment discontinued for study drug related reasons (e.g., treatment -related 
adverse event or lack of efficacy):
After treatment discontinuation, t he actual off -treatment values will be 
used in the analysis. 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
101/Protocol BN40423 , Version 4–Treatment discontinued for NSDR reasons (e.g., lost to follow -up):
After treatment discontinuation, imputed hypothetical values as if patient s 
had contin ued receiving study drug will be used in the analysis. In this 
instance, any data collected after treatment discontinuation will not be 
included in the analysis. 
Population level summary:   Difference in mean change from baseline at Week 101
between each active arm and the placebo arm
The primary estimand is a combination of a treatment -policy strategy and a hypothetical 
strategy (FDA 2017) to account for the different assumptions for each type of ICE. 
The Sponsor will emphasize to investigators the importance of collecting data for the 
primary endpoint through Week 101 , even if patients discontinue study drug but do not 
withdraw study consent, as well as the importance of providing detail ed reasons for 
treatment discontinuation . The primary estimator ,described by [CONTACT_803953] 6.6.2 , will be applied on the dataset produced afte r multiple imputation of any 
missing value.  In principle,
 missing data as well as off -treatment data from patients who discontinued
treatment for NSDR reasons will be imputed from patients with available data
from the same treatment arm collected while on treatment
 missing data from patients who discontinued treatment for SDR reasons will be
imputed from:
- patients with available data from the placebo arm collected either while on
treatment or off treatment and
- patients with available data from the same tr eatment arm collected while off
treatment
Multiple imputation of missing data values will be performed as follows:
1.Imputation step:   Missing data values will be imputed "m" times leading to "m"
complete datasets.
2.Analysis step:   Each of the resulting "m" datasets will be analyzed using the
statistical model described in Section 6.6.2, which will provide an estimate of
treatment difference.
3.Pooling step:   The results from the "m" datasets will be combined (Rubin 1987)
leading to an overall estimate of the treatment effect and associated 95% confidence
intervals and p -values.
Full details of the algorithm for multiple imput ation (e.g., which reference population to 
use for each missing data pattern ,number of imputed datasets, method for imputation , 
etc.) will be provided in the SAP.
A supplementary estimand may be considered (and will be defined in the SAP). 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
102/Protocol BN40423 , Version 46.6.2 Primary  Effica cy Analysis
The primary efficacy endpoint is the change from baseline in cUHDRS score at 
Week101.  This is defined as the attribute "variable" of the primary estimand in Section 
6.6.1 .
Note: The primary efficacy endpoint for the U.S. FDA will be change from baseline in 
the TFC score at W eek 101. TFC will be analy zed the same way as the cUHDRS.
The primary efficacy analysis for this study will compare each active treatment arm, 
RO7234292 Q8W and RO7234292 Q16W , against the placebo arm.  
To account for the multiple comparison, an appropriate procedure will be used to 
maintain the overall two- sided type I error at 5% (details will be given i n the SAP). 
The analysis of the primary endpoint will be performed by [CONTACT_803954] (ANCOVA ).  The model will include the corresponding endpoint baseline 
score, CAG repeat length, baseline CAP score (defined in Section 4.1.1 ), and treatment 
as covariates .  On the basis of this analysis, least squares mean for the treatment 
differences at Week101 and corresponding 95% CIs will be der ived.  
The robustness of the primary method of estimation described above may be explored 
by [CONTACT_803955]. These sensitivity analyses will be described in the S AP.
6.6.3 Secondary  Efficacy Analy ses
The secondary efficacy endpoints are identified in Section 2.1.2 .
Similar hypotheses as for the primary efficacy endpoint will be tested for the secondary 
continuous efficacy endpoints. 
Categorical endpoints, such as CGI -C and the proportion of progressors, will be 
analyzed by [CONTACT_803956] (categorical), CAG 
repeat length, and CAP score as covariates .   
Methods for controlling type I error in the testing of the secondary endpoints will be 
described in t he SAP. 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
103/Protocol BN40423 , Version 46.6.4 Subgroup A nalyses
The results of selected efficacy variables will be summarized within subgroups using 
descriptive statistics.  The following variables will be used to define subgroups:
Sex (male vs. female)
Age at baseline (45 vs. 45years )
CAGrepeat length (43 vs. 43)
Stage at baseline (I, II, III)
–Stage III will be considered only if there are enough patients.
Additional exploratory analyses of efficacy results may be performed using an ANCOVA 
model, similar to the primary analysis, ba sed on change from baseline for the variable of 
interest, with baseline score (not for analysis by [CONTACT_803957]), CAP score, CAG repeat 
length (not for analysis by [CONTACT_803958]), treatment, subgroup, and treatment -by-
subgroup interaction as covariat es.
6.6.5 Exploratory  Efficacy  Analysis
The exploratory efficacy endpoints are identified in Section 2.1.3 .
The exploratory endpoints will be summarized usi ng tables, listings, and graphs, as 
appropriate.  Additional statistical modeling may be considered (e.g., ANCOVA, logistic 
regression).
6.6.[ADDRESS_1109785] to important 
baseline characteristics (e.g., gender, CAG, age, IS, International Standard 
Classification of Education ).  The objective for use and exact algorithm for selecting 
historical controls will be specified in the SAP.  If implemented, the actual selection will 
be made before database lock and unblinding of treatment allocation and will be
documented and stored i n the Sponsor's database.   
Whether the Sponsor will decide to use those the historical controls, the exact algorithm 
for borrowing and for deriving an overall treatment effect will be described in the SAP 
before unblinding.
Additionally, given that some of the patients who will be enrolled in this study may have 
been part of ENROLL -HD, the Sponsor may explore a within -patient comparison for the 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
104/Protocol BN40423 , Version 4rate of decline in cUHDRS or TFC score, beforetreatment with RO7234292 (prior to 
randomization, using ENROLL -HDregistry data) and after treatment with RO7234292
(after randomization, using study data), for patients who were randomized to the active 
arm and had follow -up in ENROLL- HD of at least 1 year's duration prior to randomization 
into this study.
6.7 SAFETY ANAL YSES
The safety population (see Section 6.1) will be the primary population for all analyses of 
safety data.  Incorrect treatment assig nments (patients who received a treatment 
different than their planned randomized treatment) will be summarized and the impact on 
the safety assessment will be discussed.
For all safety analyses, patients enrolled prior to implementation of the Version 4 of the 
protocol will be summarized separately.
All verbatim adverse event terms will be mapped to MedDRA thesaurus terms.  The 
adverse event severity grading scale indicated in Table 4 will be used for assessing 
adverse event severity.  Laboratory values determined as an adverse event should be 
graded as per Appendix 5, which is based on the NCI CTCAE (v5.0).
All safety data , including adverse events, laboratory tests, CSSR- S,MoCA, ECG, and 
vital signs will be reported in individual listings and summarized by [CONTACT_626898]. For continuous variables, both the original 
value as well as the change from baseline will be reported. 
The incidence of adverse events will be summarized on the basis of body systems a nd 
dictionary preferred terms. The incidence of adverse events by [CONTACT_804004]. 
The iDMC will review safety data throughout the study. Analyses required for the iDMC 
data review will be performed as described in the iDMC Charter.
6.8 PHA RMA COKINETIC ANAL YSES
For all patients in the PK population (Section 6.1),CSF and plasma concentrations of 
RO7234292 will be presented descriptively, including arithmetic and geometric means, 
median, range, standard deviations, and coefficients of variation.   Nonlinear 
mixed -effects modeling will be used to analyze the concentration time data for
RO7234292 in CSF and plasma following IT administration .A covariate analysis will be 
conducted to evaluate the effect of covariates such as body weight, age ,and sex on 
RO7234292 exposure.   
Population and in dividual estimates of primary PK parameters (e.g., clearance, 
distribution volume) and secondary PK parameters (e.g.,area under the plasma 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
105/Protocol BN40423 , Version 4concentration time curve, average trough plasma concentration) will be computed and 
used to explore exposure- respons e relationship on primary and key secondary
endpoints, as well as safety measures.  The data from this study may be pooled with 
data from other studies conducted with RO7234292 to support the population PK/PD 
modeling .
Details of this mixed- effects modelin g and exploration of exposure -response analysis 
and results will be described and reported in a document separat efrom the Clinical 
Study Report.
6.[ADDRESS_1109786] one ADA 
assessment.  Patients will be grouped according to treatment received or, if no treatment 
is received prior to study discontinuation, according to treatment assigned.
The numbers and proportions of ADA -positive patients and ADA -negative patients at 
baseline (baseline prevalence) will be summarized by [CONTACT_1570]. For those who 
are ADA -positive, titers will be estimated as well as antibody subtype .  In addition, t he 
numbers and proportions of ADA -positive patients and ADA -negative patients at 
baseline (baseline prevalence) and after drug administration (post -baseline incidence) 
will be summarized for patients on active treatment only. When determining 
post-baseline incidence, patients are considered to be ADA positive if they are ADA 
negative or have missing data at baseline but develop an ADA response following study 
drug exposure (treatment -induced ADA response), or if they are ADA positive at 
baseline and the titer of one or more post -baseline samples is at least is at least 4 -fold 
greater than the titer of the baseline sample (treatment -enhanced ADA response).  
Patients are considered to be ADA negative if they are ADA negative or have missing 
data at baseline and all post -baseline samples are negative, or if they are ADA positive 
at baseline b ut do not have any post -baseline samples with a titer that is at least 4-fold 
greater than the titer of the baseline sample (treatment unaffected). 
The relationship between ADA status and safety, efficacy, PK, and biomarker endpoints 
will be analyzed and reported via descriptive statistics.
6.[ADDRESS_1109787] s model repeat measurem entmodel will be used to model the change in 
each primary and secondary biomarker endpoint, adjusting for the baseline endpoint, 
CAG repeat length, CAP score, treatment, visit, and treatment -by-visit interaction (the 
final list of covariates and details o f the model will be specified in the SAP).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
106/Protocol BN40423 , Version 46.[ADDRESS_1109788] an interim analysis, along with the rationale, specification of the 
endpoint (e.g., cl inical and/or biomarker endpoint), number of patients, and statistical 
details for each analysis, will be introduced via a future protocol amendment , which will 
be submitted to relevant health authorities at least [ADDRESS_1109789] data clarification from the sites, which the sites 
will resolve electronically in the EDC system.
The Spo nsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.  Central laboratory data electronic data 
from clinic visits (see Section 7.3)and electronic data obtained from the [COMPANY_002] HD 
mobile app (see Section 7.4) will be sent directly to the Sponsor, using the Sponsor's 
standard procedures to handle and process the electronic transfer of these data.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
107/Protocol BN40423 , Version 4eCRFs and correction documentation will be maintained in the EDC system's audit trail.  
System backups for data stored by [CONTACT_40892]'s standard procedures.
7.[ADDRESS_1109790] that is attributable, secure, and accurate, 
in compliance with U.S. FDA regulations for electronic records (21 CFR Part 11).  The 
data will be transmitted to a centralized database maintained by [CONTACT_307191].
Theelectronic data will be available for view access only, via a secure vendor web portal. 
Only identified and trained users may view the data, and their actions will become part of 
the audit trail.  T heSponsor will have view access only.  System backups for data stored 
by [CONTACT_430762]'s standard procedures.
Once the study is complete, the data, audit trail, and trial and syste m documentation will 
be archived.  The investigator will receive patient data for the site in both human -and 
machine- readable formats on an archival -quality compact disc that must be kept with the 
study records as source data.  Acknowledgement of receipt of the compact disc is 
required.  In addition, the Sponsor will receive all data in a machine -readable format on a 
compact disc.
7.4 ELECTRONIC DA TA OBTA INED BY [CONTACT_626950] L 
MONITORING PLA TFORM
During "active tests" and "passive monitoring," the smartp hone and wrist -worn wearable 
record movement and location data.  Data on the technical status and connectivity of the 
devices is also recorded.  Patients can choose to pause location data recording.  
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
108/Protocol BN40423 , Version 4Nopatient identifiable information is stored on the dev ices.  For selected "active test" 
tasks, touch and sound is also recorded.  Video is not recorded.
[COMPANY_002] HD mobile app (smartphone and wrist -worn wearable) sensor data are encrypted 
and uploaded to secure servers whenever the smart phone is connected to Wi-Fi . All 
sensor data will be managed by [CONTACT_626951].  This includes, but is not limited, to the analysis of 
sensor data together with protocol -specified assessments and activities as sociated with 
routine daily living.   The data will not be analyzed for efficacy until study end, unless they 
are chosen to be a part of a pre -specified interim analysis along with other clinical and/or 
biomarker endpoints.
7.5 SOURCE DA TA DOCUMENT ATION
Study m onitors will perform ongoing source data verification and review to confirm that 
critical protocol data (i.e., source data) entered into the eCRFs by [CONTACT_77038], complete, and verifiable from source documents. 
Source documents (paper or electronic) are those in which patient data are recorded 
and documented for the first time.  They include, but are not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, PROs , evaluation checklists, 
pharmacy di spensing records, recorded data from automated instruments, copi[INVESTIGATOR_70069], 
microfiche, photographic negatives, microfilm or magnetic media, X -rays, patient files, 
and records k ept at pharmacies, laboratories, and medico -technical departments 
involved in a clinical trial.
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protoco l data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliter ated or destroyed and must be retained per 
the policy for retention of records described in Section 7.7.
To facilitate source data verification and review, the investigators and institutions must 
provide the Sponsor direct access to applicable source documents and reports for 
trial-related monitoring, Sponsor audits, and IRB/EC review.  The study site must also 
allow inspection by [CONTACT_804005].
7.6 USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into a study site's computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with health 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
109/Protocol BN40423 , Version 4authority requirements pertaining to computerized systems used in clinical research.  An 
acceptable computerized data collection system allows preservation of the original entry 
of data.  If original data are m odified, the system should maintain a viewable audit trail 
that shows the original data as well as the reason for the change, name [CONTACT_33508], and date of the change.
7.[ADDRESS_1109791] of this study and the distribution of 
IMP, including eCRFs, electronic or paper PRO, ClinRO, ObsRO (if applicable), and 
PerfO data (if applicable ), Informed Consent Forms, laboratory test results, and 
medication inventory records, must be retained by [CONTACT_079] [INVESTIGATOR_8178] [ADDRESS_1109792] to local regulations.  
No records may be disposed of without the written approval of the Sponsor.  W ritten 
notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another location.
[COMPANY_002] will retain study data for 25 years after the final Clinical Study Report has been 
completed or for the length of time required by [CONTACT_109851], whichever is longer.
8. ETHICA L CONSIDERA TIONS
8.1 COMPLIA NCE WITH LA WSAND REGULATIONS
This study will be conducted in full conformance with the ICH E6 guideline for Good 
Clinical Practice and the principles of the Declaration of Helsinki, or the applicable laws 
and regulations of the country in which the research is conducted, whichever aff ords the 
greater protection to the individual.  The study will comply with the requirements of the 
ICH E2A guideline (Clinical Safety Data Management:  Definitions and Standards for 
Expedited Reporting).  Studies conducted in the [LOCATION_002] or under a U .S. 
Investigational New Drug (IND) Application will comply with U.S. FDA regulations and 
applicable local, state, and federal laws.  Studies conducted in the European Union or 
European Economic Area will comply with the E.U. Clinical Trial Directive (2001/ 20/EC ) 
and applicable local, regional, and national laws.
8.2 INFORMED CONSENT
The Sponsor's sample Informed Consent Form (and ancillary sample Informed Consent 
Forms) will be provided to each site.  If applicable, it will be provided in a certified 
translatio n of the local language.  The Sponsor or its designee must review and approve 
any proposed deviations from the Sponsor's sample Informed Consent Forms or any 
alternate consent forms proposed by [CONTACT_779] (collectively, the "Consent Forms") before 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
110/Protocol BN40423 , Version 4IRB/EC sub mission.  The final IRB/EC approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes according to local requirements.
If applicable, the Informed Consent Form will contain separate sections for any optional 
procedures.   The investigator or authorized designee will explain to each patient the 
objectives, methods, and potential risks associated with each optional procedure.  
Patients will be told that they are free to refuse to participate and may withdraw their 
consent a t any time for any reason.  A separate, specific signature [CONTACT_33509] a patient's agreement to participate in optional procedures.  Patients who 
decline to participate will not provide a separate signature.
The Consent Forms must be signe d and dated by [CONTACT_514909].  If a study companion will participate, he/she must also sign 
and date a consent form prior to participation in the study.  The case history or clinical 
records for each patient shall document the informed consent process and that written 
informed consent was obtained prior to participation in the study.
The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the patient 
to participate.  The final revised IRB/EC -approved Consent Forms must be provided to 
the Sponsor for health authority submission purposes.
Patients must be re -consented to the most current version of the Consent Forms (or to a 
significant new information/findings addendum in accordance with applicable laws and 
IRB/EC policy) during their participation in the study.  For any updated or revised 
Consent Forms, the case history or clinical records for each patient shall do cument the 
informed consent process and that written informed consent was obtained using the 
updated/revised Consent Forms for continued participation in the study.   If the patient 
should lose capacity to consent during the study (i.e., after enrollment), as judged by [CONTACT_1275], a legally authorized representative may sign on behalf of the patient.
A copy of each signed Consent Form must be provided to the patient or the patient's 
legally authorized representative.  All signed and dated Consent Forms must remain in 
each patient's study file or in the site file and must be available for verification by [CONTACT_33483].
For sites in the [LOCATION_002], each Consent Form may also include patient authorization 
to allow use and disclosure of pers onal health information in compliance with the U.S. 
Health Insurance Portability and Accountability Act (HIPAA) of 1996.  If the site utilizes a 
separate Authorization Form for patient authorization for use and disclosure of personal 
health information und er the HIPAA regulations, the review, approval, and other 
processes outlined above apply except that IRB review and approval may not be 
required per study site policies.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
111/Protocol BN40423 , Version 48.[ADDRESS_1109793] be submitted to the IRB/EC by [CONTACT_9532] [INVESTIGATOR_25684]/EC before the study is initiated.  
Inaddition, any patient recruitment m aterials must be approved by [CONTACT_1201]/EC. 
The Principal Investigator [INVESTIGATOR_25685]/EC annually or more frequently in accordance with the requirements, 
policies, and procedures establish ed by [CONTACT_1201]/EC.  Investigators are also responsible 
for promptly informing the IRB/EC of any protocol amendments (see Section 9.6).
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety reports 
or other safe ty-related communications from the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by [CONTACT_11577]/EC, and 
archived in the site's study file. 
8.[ADDRESS_1109794] parties only as permitted by [CONTACT_25734] (or separate 
authorization for use and disclosure of pe rsonal health information) signed by [CONTACT_102], 
unless permitted or required by [CONTACT_2371].
Medical information may be given to a patient's personal physician or other appropriate 
medical personnel responsible for the patient's welfare, for treatment purposes.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
patients unless required by [CONTACT_2371].  The aggregate results of any conducted research will 
be available in accordance with the effective Sponsor policy on study data publication 
(see Section 9.5).
Data generated by [CONTACT_25757], Sponsor monitors, 
representatives, and collaborators, and the IRB/EC for each study site, as appropriate.
Study data may be submitted to government or other health research databases or 
shared with researchers, government agencies, companies, or other groups that are not 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
112/Protocol BN40423 , Version 4participating in this study.  These data may be combined with or linked to other data and 
used for research purposes, to advance science and public health, or for analysis, 
development, and commercialization of products to treat and diagnose disease. Linking 
of data will be facilitated by [CONTACT_601379] (see Section 4.5.2 ).The HDID is a unique 
coded identifier for persons participating in studies in HD.  This HDID will stay the same 
for a person throughout all trials.  The use of the unique identifier will assure that people 
are only enr olled once in large observational studies like Enroll -HD, REGISTRY, 
COHORT, PREDICT, and TRACK -HD and will also allow approved comparison and 
combination of data between studies.  The HDID is a 9-digit number created by a secure 
one-way algorithm, based on unchanging information (date of birth, birth name, place of 
birth and mother’s maiden name). The identifying data are used for the split second 
needed by [CONTACT_804006] i n the study database. For patients without a 
pre-existing HDID number in the source notes, the investigator should store the original 
data and the newly generated HDID in the patient’s source documents and in the 
investigator file.   The HDID can be genera ted within the web portals of the observational 
studies or in the specially defined portal for the HDID generation under: 
https://hdid.enroll -hd.org. Inaddition, redacted clinical study reports and other summary 
reports will be provided upon request.
8.5 FINANCIAL DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appro priate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study (see definition of end of 
study in Section 3.2).
9. STUDY DOCUMENTATION, MONITORING, A ND 
ADMINISTRA TION
9.[ADDRESS_1109795] of 
the study to be fully documented, including, but not limited to, the protocol, protocol 
amendments, Informed Consent Forms, and documentation of IRB/EC and 
governmental approval.  In addition, at the end of the study, the investigator will receive 
the patient data, inclu ding an audit trail containing a complete record of all changes to 
data.
9.[ADDRESS_1109796] on patient safety and 
data integrity to the Sponsor and to the IRB/EC in accordance with established IRB /EC 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
113/Protocol BN40423 , Version 4policies and procedures.  The Sponsor will review all protocol deviations and assess 
whether any represent a serious breach of Good Clinical Practice guidelines and require 
reporting to health authorities.  As per the Sponsor's standard operating proce dures, 
prospective requests to deviate from the protocol, including requests to waive protocol 
eligibility criteria, are not allowed.
9.3 SITE INSPECTIONS
Site visits will be conducted by [CONTACT_26833] , patients' medical records, and eCRFs.  The investigator will 
permit national and local health authorities; Sponsor monitors, representatives, and 
collaborators; and the IRBs/ECs to inspect facilities and records relevant to this study.
9.4 ADMINISTRA TIVE STR UCTURE
This trial will be sponsored and managed by F. Hoffmann -La [COMPANY_002] Ltd.  The Sponsor 
will provide clinical operations management, data management, and medical monitoring.
Approximately 90sites globally will participate to enroll approximately 660 patients after 
implementation of Version 4 of the protocol .  Enrollment will occur through an IxRS.   
Central facilities will be used for certain study assessments throughout the study 
(e.g., specified laboratory tests, biomarker and PK analyses), as specified in 
Section 4.5.6 .  Accredited local laboratories will be used for routine monitoring ; local 
laboratory ranges will be collected.
An iDMC will be employed to monitor and evaluate patient safety throughout the study.  
9.5 DISSEMINA TION OF DA TA AN D PROTECTION OF TRA DE 
SECRETS
Regardless of the outcome of a trial, the Sponsor is dedicated to ope nly providing 
information on the trial to healthcare professionals and to the public, at scientific 
congresses, in clinical trial registries, and in peer -reviewed journals. The Sponsor will 
comply with all requirements for publication of study results.  S tudy data may be shared 
with others who are not participating in this study (see Section 8.4for details) and 
redacted Clinical Study Reports and other summary reports will be made available upon 
request, provided the requirements of [COMPANY_002]'s global policy on data sharing have been 
met.  For more information, refer to the [COMPANY_002] Global Policy on Sharing of Clinical Trials
Data at the following web site:
www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.pdf
The results of this study may be published or presented at scientific congresses.  For all 
clinical trials in patients involving an IMP for which a marketing auth orization application 
has been filed or approved in any country, the Sponsor aims to submit a journal 
manuscript reporting primary clinical trial results within 6 months after the availability of 
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
114/Protocol BN40423 , Version 4the respective Clinical Study Report.  In addition, for all clinical trials in patients involving 
an IMP for which a marketing authorization application has been filed or approved in any 
country, the Sponsor aims to publish results from analyses of additional endpoints and 
exploratory data that are clinically meaningful and statistically sound.
The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior 
to submission for publication or presentation.  This allows the Sponsor to protect 
proprietary information and to provide comments b ased on information from other 
studies that may not yet be available to the investigator.
In accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter trials only in their entirety and not as ind ividual center 
data.  In this case, a coordinating investigator [INVESTIGATOR_12992].
Authorship will be determined by [CONTACT_14346].  Any form al publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by [CONTACT_26834].
Any inventions and resulting patents, improvements, and/or know -how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.
9.6 PROTOCOL A MENDMENTS
Any protocol amendments will be prepared by [CONTACT_13099] r.  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to patients or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact [CONTACT_3031]).
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
115/Protocol BN40423 , Version 410. REFERENCES
Andrzejewski KL, Dowling AV, Stamler D, et al. Wearable sensors in Huntington disease:
a pi[INVESTIGATOR_799]. J Huntington's Dis 2016; 5.2:199 206.
Adams JL, Dinesh K, Xiong M,et al. Multiple wearable sensors in parkinson and 
Huntington disease individuals: a pi[INVESTIGATOR_626876]. Digit 
Biomark 2017:1:52 63
Baig SS, Strong M, Quarrell OW . The global prevalence ofHuntington's disease: a 
systematic review and discussion . Neurodegener Dis Manag 2016;6:331 43.
Beglinger LJ, Prest L, Mills JA, et al. Clinical predictors of driving status in Hun tington's 
disease. Mov Disord 2012;27:1146 52.
Bohanna I, Georgiou -Karistianis N, Sritharan A, et al. Diffusion tensor imaging in 
Huntington's disease reveals distinct patterns of white matter degeneration 
associated with motor cognitive deficits. Brain Im aging Behav 2011;5:171 80.
Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53 72.
Cerritelli SM, Crouch RJ. Ribonuclease H: the enzymes in eukaryotes. FEBS J 
2009;276:1494 505.
Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Annu Rev 
Pharmacol Toxicol 1996;36:107 29.
Dogan I, Eickhoff CR, Fox PT, et al. Functional connectivity modeling of consistent 
cortico -striatal degeneration in Huntington's disease. Neuroimage Clin 
2015;7:640 52.
Douaud G, Gau ra V, Ribeiro MJ, et al. Distribution of grey matter atrophy in Huntington's 
disease patients: a combined ROI -based and voxel -based morphometric study. 
Neuroimage 2006;32:1562 75.
Duyao M, Ambrose C, Myers R, et al. Trinucleotide repeat length instability and age of 
onset in Huntington's disease. Nat Genet 1993;4:387 92.
Espi[INVESTIGATOR_601333], Turner JA, Vergara VM, et al. Whole-brain connectivity in a large study of 
Huntington's disease gene mutation carriers and healthy controls . Brain Connect 
2018 ;8:166 78. 
EuroQol Group. EuroQol a new facility for the measurement of health- related quality of 
life. Health Policy 1990;16:199 208.
[FDA] Food and Drug Administration.  Guidance for industry: suicidal ideation and 
behavior: prospective assessment of occurrence in clinical trials [resource on the 
Internet] 2012 [cited 28 February 2018]. Available from: 
https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/guidances/uc
m315156.htm.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
116/Protocol BN40423 , Version 4[FDA] Food and Drug Administration. E9(R1) statistical principles for clinical trials: 
addendum: estimands and sensitivity analysis in clinical trials. [resource on the 
Internet] 2017 [cited [ADDRESS_1109797] 2018]. Available from: 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/UCM582738.pdf .
Feeny D, Furlong W, Boyle M, et al. Multi -attribute health status classification systems . 
Health utilities index. Pharmacoeconomics 1995;7:490 502.
Genetic Modifiers of Huntington's Disease Consortium. Identification of genetic factors 
that modify clinical onset of Huntington's disease. Cell 2015;162:516 26.
Harrington DL, Long JD, Durgerian S, et al. Cross -sectional and longitudinal multimodal 
structural imaging in prodromal Huntington's disease. Mov Disord 
2016;31:1664 75.
Herdman M, Gudex C, Lloyd A, et al. De velopment and preliminary testing of the new 
five-level version of EQ -5D (EQ -5D-5L). Qual Life Res 2011;20:1727 36.
Hogarth P, Kayson E, Kieburtz K, et al. Interrater agreement in the assessment of motor 
manifestations of Huntington's disease. Mov Disord 2005;20:293 7.
Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and 
consistency. Mov Disord 1996 ;11:136 42.
Janssen MF, Pi[INVESTIGATOR_19370], Golicki D, et al. Measurement properties of the EQ -5D-5L 
compared to the EQ -5D-3L across eight patient groups: a multi -country study. 
Qual Life Res 2013;22:1717 27.
Johnson EB, By[CONTACT_597684], Gregory S, et al. Neurofilament light protein in blood predicts 
regional atrophy in Huntington disease. Neurology 2018;90:e717 23.
Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of 
Huntington's disease by [CONTACT_626957]. Neuron 
2012;74:1031 44.
Lipsmeier F, Taylor KI, Kilchenmann T, et al. Evaluation of smartphone- based ts ting to 
generate exploratory outcome measures in a phase 1 Parkinson' s disease clinical 
trial. Mov Disord 2018. doi : 10.1002/mds.[ZIP_CODE]. Epub ahead of print.
Liu JP, Zeitlin SO. Is huntingtin dispensable in the adult brain? J Huntingtons 
Dis2017;6:1 17.
Liu W , Yang J, Chen K, et al. Resting -state fMRI reveals potential neural correlates of 
impaired cognition in Huntington's disease. Parkinsonism Relat Disord
2016;27:41 6.
Maet zler W , Domingos J, Srulijes K, et al. Quantitative wearable sensors for object ive 
assessment of Parkinson's disease. Mov Disord 2013;28:1628 37.

RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
117/Protocol BN40423 , Version 4McCarrier KP, Deal LS, Abraham L, et al. Patient -centered research to support the 
development of the Symptoms of Major Depressive Disorder Scale (SMDDS): 
initial qualitative research. Patient 2016;9:117 34.
Moumné L, Betuing S, Caboche J. Multiple aspects of gene dysregulation in 
Huntington's disease. Front Neurol 2013;4:127.
Nance M, Paulsen JS, Rosenblatt A, et al. A physician's guide to the management of 
Huntington's disease, 3rdedition. Huntington's Disease Society of America, 2011. 
Novak MJ, Seunarine KK, Gibbard CR, et al. Basal ganglia -cortical structural 
connectivity in Huntington's disease. Hum Brain Mapp 2015;36:1728 40.
Paulsen JS, Long JD, Ross CA, et al. Prediction of manifest Huntington's disease with 
clinical and imaging measures: a prospective observational study. 
Lancet Neurol 2014;13:1193 201.
Paulson HL, Albin RL. Huntington’s disease: clinical features and routes to therapy. In: 
Lo DC, Hughes RE, editors. Neurobiology of Huntington's disease: applications to 
drug discovery. Boca Raton (FL): CRC Press/Taylor & Francis; 2011: Chapter 1.
Peinemann A, Schuller S, Pohl C, et al. Executive dysfunction in early stages of 
Huntington's disease is associated with striatal and insula r atrophy: a 
neuropsychological and voxel -based morphometric study. J Neurol Sci 
2005;239:11 9.
Penney JB, Young AB, Shoulson I, et al. Huntington’s disease in Venezuela: 7 years of 
follow -up on symptomatic and asymptomatic individuals.  Movement Disorders
1990;5:93 9.
Posner K, Brown GK, Stanley B, et al. The Columbia -Suicide Severity Rating Scale: 
initial validity and internal consistency findings from three multisite studies with 
adolescents and adults. Am J Psychiatry 2011;168:1266 77.
Ross CA, Pantelya t A, Kogan J, et al. Determinants of functional disability in 
Huntington's disease: role of cognitive and motor dysfunction. Mov Disord 
2014;29:1351 8.
Rubin DB. Multiple Imputation for Nonresponse in Surveys. [LOCATION_001]: John Wiley 
and Sons. 1987.
Schobel SA, Palermo G, Auinger P, et al. Motor, cognitive, and functional declines 
contribute to a single progressive factor in early HD.
Neurology 2017 ;89:2495 2502.
Schoch KM, Miller TM. Antisense oligonucleotides: translation from mouse models to 
human neurodegenerative diseases. Neuron 2017;94:1056 70.
Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. 
Neurology 1979;29:1 3.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
118/Protocol BN40423 , Version 4Smith, A. Symbol Digit Modalities Test (SDMT). Manual (rev.). Los Angeles: Western 
Psychological Services, 1982.
Sorensen SA, Fenger K. Causes of death in patients with Huntington's disease and in 
unaffected first degree relatives. J Med Genet 1992;29:911 4.
Stanek LM, Yang W, Angus S, et al. Antisense oligonucleotide -mediated correction of 
transcriptional dysregul ation is correlated with behavioral benefits in the YAC128 
mouse model of Huntington's disease. J Huntingtons Dis 2013;2:217 28.
Tabrizi SJ, Reilmann R, Roos RAC, et al. Potential endpoints for clinical trials in 
premanifest and early Huntington's disease in the TRACK -HD study: analysis of 
24month observational data. Lancet Neurol 2012;11:42 53.
Van Raamsdonk JM, Pearson J, Rogers DA, et al. Loss of wild -type huntingtin 
influences motor dysfunction and survival in the YAC128 mouse model of 
Huntington disease. Hum Mol Genet 2005;14:1379 92.
Walker FO. Huntington's disease. Semin Neurol 2007;27:143 50.
Werner CJ, Dogan I, Saß C, et al. Altered resting -state connectivity in Huntington's 
disease. Hum Brain Mapp 2014;35:2582 93.
Wexler NS, Young AB, Tanzi RE, et al. Homozygotes for Huntington's disease. Nature 
1987;326:194 7.
Wild EJ, Boggio R, Langbehn D, et al. Quantification of mutant huntingtin protein in 
cerebrospi[INVESTIGATOR_601335]'s disease patients. J Clin Invest 
2015;125:1979 86.
Wild EJ, Tabrizi SJ. Therapi[INVESTIGATOR_601336]'s disease. Lancet 
Neurol 2017;16:837 47.
Zhang Y, Long JD, Mills JA, et al. Indexing disease p rogression at study entry with 
individuals at-risk for Huntington dis ease. Am J M ed Genet B Neuropsychiatr 
Genet 2011 ;156:75163.
RO7234292 F. Hoffmann-La [COMPANY_002] Ltd 
119/Protocol BN40423, Version 4 Appendix 1  
Schedule of Activities for Patients Enroll ed after Implementation of Protocol Version 4  
Screening a BL Treatment Period EoT b EoT 
for 
ETT Safety 
Follow-
Up 
Calls eeETT b S F U  
Month 1 3 5 7 9 11 13 15 17 19 21 23 25 25  2 9  
Week 4 to 1 1 5 13 21 29 37 45 53 61 69 77 85 93 101 101 117 
Day (Window) 28 to 2 1 1 ( ( 7) dd( 7) ( 7) 
Signed informed consent c x  
Review of inclusion and 
exclusion criteria  x  
Demographic data x  
Medical history and baseline 
conditions d x xe 
Blood sample for CAG repeat 
length x  
Viral serology f x  
Thyroid panel g x  
Vital signs hx xe x  x  x  x  x  x  x  x  x  x  x  x  x  x  x  
Complete physical examination i x  xe  x   x   x x x x 
Neurologic examination j x xe x  x  x  x  x  x  x  x  x  x  x  x  x  x  x  x  
ECG kx xe x x x x x x x 
Hematology l x x x x x x x x x x x x x x x x x 
Appendix 1:Schedule of Activities for Patient s
 Enrolled after Implementation of Protocol Version 4 (cont.)  
RO7234292 F. Hoffmann-La [COMPANY_002] Ltd 
120/Protocol BN40423, Version 4  Screening a BL Treatment Period EoT b EoT 
for 
ETT Safety 
Follow-
Up 
Calls eeETT b S F U  
Month 1 3 5 7 9 11 13 15 17 19 21 23 25 25  2 9  
Week 4 to 1 1 5 13 21 29 37 45 53 61 69 77 85 93 101 101 117 
Day (Window) 28 to 2 1 1 ( ( 7) dd( 7) ( 7) 
Chemistry m x x x x x x x x x x x x x x x x x 
Pregnancy test nx xe x x x x x x x x x x x x x x x 
Local INR  and/or PT , aPTT, 
platelet count x x x x x x x x x x x x x x x x x 
Urinalysis o x  x  x  x  x  x  x  x  x  x  x  x  x  x  x  x x 
Plasma sample for PK   x  x  x  x p  x x x x x 
Plasma sample for 
immunogenicity testing x x x x x x x x x x 
Plasma sample for biomarkers x x x x x x x x x x 
Blood sample for clinical genotypi[INVESTIGATOR_007]   x
e 
CSF sample for PK/safety/biomarkers x x x x x x x x x x x x x x
y x 
MRI q x x x x x x 
HD-DAS x x x x x x x 
Independence Scale x x x x x x x x x x x 
MoCA x x x x x x x x x x x 
C-SSRS rx xe x  x  x  x  x  x  x  x  x  x  x  x  x  x  x  
Appendix 1:Schedule of Activities for Patient s
 Enrolled after Implementation of Protocol Version 4 (cont.)  
RO7234292 F. Hoffmann-La [COMPANY_002] Ltd 
121/Protocol BN40423, Version 4  Screening a BL Treatment Period EoT b EoT 
for 
ETT Safety 
Follow-
Up 
Calls eeETT b S F U  
Month 1 3 5 7 9 11 13 15 17 19 21 23 25 25  2 9  
Week 4 to 1 1 5 13 21 29 37 45 53 61 69 77 85 93 101 101 117 
Day (Window) 28 to 2 1 1 ( ( 7) dd( 7) ( 7) 
UHDRS FA x x x x x x x x x x 
TFC s x x x x x x x  x  x  x  
TMS s, cc x x x x x x x x  x  x  x  
CGI-S x x x x x x x x x x 
CGI-C x x x x x x x x x 
SDMT s x x x x x x x  x  x  x  
SWR s x x x x x x x  x  x  x  
AES x x x x x x x x x 
SMDDS x x x x x x x x x 
NeuroQoL x x x x x x x x x x 
EQ-5D-5L (in-clinic) x x x x x x x x x x 
PGI-S x x x x x x x x x x 
PGI-C x x x x x x x x x 
[COMPANY_002] HD mobile app in-clinic 
assessments x x x  x  x  x  x 
[COMPANY_002] HD mobile app remote 
data collection Continuous remote data collection t 
Optional exit interview u x x 
Appendix 1:Schedule of Activities for Patient s
 Enrolled after Implementation of Protocol Version 4 (cont.)  
RO7234292 F. Hoffmann-La [COMPANY_002] Ltd 
122/Protocol BN40423, Version 4  Screening a BL Treatment Period EoT b EoT 
for 
ETT Safety 
Follow-
Up 
Calls eeETT b S F U  
Month 1 3 5 7 9 11 13 15 17 19 21 23 25 25  2 9  
Week 4 to 1 1 5 13 21 29 37 45 53 61 69 77 85 93 101 101 117 
Day (Window) 28 to 2 1 1 ( ( 7) dd( 7) ( 7) 
CRQ: EQ-5D-5L, HUI-self, 
HUI-proxy, CrGI-S   x x  x  x  x  x  x x x x 
CRQ: AES   x x  x  x  x  x  x x x 
CRQ: CrGI-C x  x  x  x  x  x x x x 
Remote data collection of CRQ (EQ-5D-5L, HUI-self, HUI-proxy, HD-CIAOS, WPAI) Remote data collection (see Appendix 4 ) 
Blood sample for RBR DNA (optional)
 v  x  
Blood sample for RBR RNA 
(optional) v x x x x x 
Serum sample for RBR(optional) 
v   x x x x x 
Change in medical information 
since previous visit w x x x x x x x x x x x x x x x x x 
Lumbar puncture x x x x x x x x x x x x x x x y x y 
Study drug administration  x x x zx x zx x zx x zx x zx x z
Concomitant medications aa x  x  x  x  x  x  x  x  x  x  x  x  x  x  x  x  x  x x x 
Adverse events bb x  x  x  x  x  x  x  x  x  x  x  x  x  x  x  x  x  x x x 
Appendix 1:Schedule of A ctivities for Patients Enrolled after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
126/Protocol BN40423 , Version 4bbAfter informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a proto col-mandated 
intervention should be reported.  After initiation of study drug, all adverse events will be reported until 5 months a fter the final dose of study drug.  
After this period, all deaths, regardless of cause, should be reported.  In addition, the Sponsor should be notified if the i nvestigator becomes 
aware of any serious adverse event that is believed to be related to prior study  drug treatment.  
ccThe DCL will be assessed at screening only (i.e., without the full TMS assessment).  The TMS scale will be assessed (excludin g the DCL) at all 
other timepoints.
ddExcluding MRIs, which have a visit window of  14 to 7 days .
eeTelephone safety follow -up calls will assess any changes to ongoing adverse events or occurrence of new adverse events and changes to 
concomitant medication.  Unscheduled visits can occur based on the outcome of this safety follow -up call.
Appendix 3:Patient -Reported, Observer -Reported, and Performance Outcomes and [COMPANY_002] HD Mobile A pplication for Patients Enrolled 
after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
129/Protocol BN40423 , Version 4Assessment Name [CONTACT_804007].
Duration
(min)PRO ,ObsRO , 
PerfO, 
Behavior Timing Location
HD-SDIHuntington's 
Disease Speaking 
Difficulty Item 1 Speech 1 PRO Weekly[COMPANY_002] HD 
mobile app
HD-CIAOSHuntington's 
Disease Companion -
Reported Irritability 
and Angr y Outbursts 
Scale3Irritability and angry 
outbursts2 ObsRO WeeklyElectronic 
device
HUIHealth Utilities Index 15Health -related quality of 
life10 ObsROBaseline, W eeks5, 21, 37, 
53, 69, 85, and 101 and ETTIn-clinic
WeeklyElectronic 
device
MoCAMontreal Cognitive 
Assessment11 Overall cognitive status 10 PerfOScreening , baseline, 
Weeks5, 21, 37, 53, 69, 85, 
and 101 and ETTIn-clinic
Neuro -Qol 
Cog FuncNeuro -Qol Cognitive 
Function Short Form8 Cognition 5 PROBaseline and W eeks5, 21, 
37, 53, 69, 85, and 101 In-clinic
PGI-CPatient Global 
Impression Change1Overall change in 
patient status2 PROWeeks5, 21, 37, 53, 69, 85, 
and 101 and ETT visitsIn-clinic
PGI-SPatient Global 
Impression Severity1Overall severity of 
patient status2 PROBaseline and W eeks5, 21, 
37, 53, 69, 85, and 101 and 
ETTIn-clinic
Appendix 3:Patient -Reported, Observer -Reported, and Performance Outcomes and [COMPANY_002] HD Mobile A pplication for Patients Enrolled 
after Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
130/Protocol BN40423 , Version 4Assessment Name [CONTACT_601384].
Duration
(min)PRO ,ObsRO , 
PerfO, 
Behavior Timing Location
SDMT /
eSDMTSymbol Digit 
Modalities TestMax 
number in 
90secondsCognitive 5 PerfOSDMT at baseline and 
Weeks 5, 21, 37, 53, 69, 85, 
and 101 and ETT visits In-clinic
eSDMT monthly + at clinic 
visits ( screening, baseline, 
Weeks 5, 53,101, and ETT )[COMPANY_002] HD 
mobile app 
(eSDMT)
SMDDSSymptoms of Major 
Depressive 
Disorder Scale16Depression, anxiety, 
irritability, sleep10 PROBaseline and W eeks13, 29, 
45, 61, 77, 93, and 101 In-clinic
SWR/eSWRStroop Word 
Reading T estMax 
numbers in 
45 sec ondsCognitive 5 PerfOSWR at baseline and 
Weeks 5, 21, 37, 53, 69, 85, 
and 101 and ETT visitsIn-clinic
eSW R monthly + at clinic 
visits ( screening, baseline, 
Weeks 5, 53, and 101 and 
ETT)[COMPANY_002] HD 
mobile app 
(eSWR)
WPAIWork Productivity 
and Activity 
Impairment6 Work productivit y 5 PRO ObsRO Baseline and then monthly [COMPANY_002] HD
mobile app
and electronic 
device
appapplication; ETT early treatment termination; HD Huntington disease; ObsRO observer -reported outcome; PerfO performance outcome; 
PRO patient -reported outcome.
RO7234292F. Hoffmann-L a [COMPANY_002] Ltd  
131/Protocol BN40423, Version 4Appendix 4Clinical A ssessments Order and Duration for
Patients Enrolled after Implementation of Protocol Version 4
Table 1 Screening Visit Clinical A ssessments
Block AssessmentsTotal Duration 
(minutes)Site Staff 
Responsible
1Diagnostic Confidence Level
Huntington's Disease Daily Activities Scale
Independence Scale
MoCA
C-SSRS~60Qualified 
study 
physician
Break (if needed) ~20-30
2 [COMPANY_002] HD mobile application ~20Qualified 
study 
personnel
C-SSRColumbia -Suicide Severity Rating Scale; HDHuntington disease; MoCA Montreal
Cognitive Assessment.
Appendix 4:Clinical A ssessments Order and Duration for Patients Enrolled after 
Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
132/Protocol BN40423 , Version 4Table 2 Baseline and Week 101 Clinical A ssessments (for Primary  
Analysis)
Block AssessmentsTotal 
Duration 
(minutes) Site Staff Responsible
1UHDRS Functional Assessment 
Independence Scale
Total Functional Capacity Scale 
Total Motor Score (without Diagnostic 
Confidence Level)
Colum bia-Suicide Severity Rating Scale
Clinical Global Impression Severity 
Clinical Global Impression Change 
(post -baseline visits only)~60 Qualified study phy sician
Break (if needed) ~20[ADDRESS_1109798]
MoCA~20Qualified study 
personnel
Break (if needed) ~10
3aApathy Evaluation Scale (patient and 
companion)
Symptoms of Major Depressive Disorder 
Scale~20Qualified study 
personnel
Break (if needed) ~1020
4aNeuro -Qol Cognition Function Short Form
EuroQol 5 -Dimension, 5 -Level 
Questionnaire ( patientand companion )
Health Utilities Index (companion: self and 
proxy )
Patient/Companion -reported Global 
Impression Severity
Patient /Companion -reported Global 
Impression Change (post -baseline visits 
only)~20Qualified study 
personnel
Break (if needed) ~1020
5 a[COMPANY_002] HD mobile application ~20Qualified study 
personnel
HDHuntington disease; MoCA Montreal Cognitive Assessment; Neuro -QoLQuality of Life in 
Neurological Disorders; UHDRS Unified Huntington's Disease Rating Scale.
aAt the baseline visit and at week 101, Blocks 3, 4, and [ADDRESS_1109799] be completed predose at the baseline 
visit.  
Appendix 4:Clinical A ssessments Order and Duration for Patients Enrolled after 
Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
133/Protocol BN40423 , Version 4Table 3 Follow -Up Clinical A ssessments at Weeks 5, 21, 37, 53, 69, 
and85
Block AssessmentsTotal 
Duration 
(minutes)Site Staff 
Responsible
1UHDRS Functional Assessment 
Independence Scale
Total Functional Capacity Scale 
Total Motor Score (without Diagnostic Confidence Level)
Colum bia-Suicide Severity Rating Scale
Clinical Global Impression Severity 
Clinical Global Impression Change ~60Qualified 
study 
physician
Break (if needed) ~20-[ADDRESS_1109800]
MoCA~20Qualified 
study 
personnel
Break (if needed) ~10
3Neuro -Qol Cognition Function Short Form
EuroQol 5 -Dimension, 5 -Level Questionnaire (patient
and companion )
Health Utilities Index (companion : self and proxy )
Patient/Companion -reported Global Impression Severity
Patient /Companion -reported Global Impression Change ~30Qualified 
study 
personnel
4 [COMPANY_002] HD mobile applicationa ~20Qualified 
study 
personnel
MoCA Montreal Cognitive Assessment; Neuro- QoLQuality of Life in Neurological Disorders; 
UHDRS Unified Huntington's Disease Rating Scale
a These assessments will take place only at Weeks 5 and 53.
Appendix 4:Clinical A ssessments Order and Duration for Patients Enrolled after 
Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
134/Protocol BN40423 , Version 4Table 4 Follow -Up Clinical A ssessments at Weeks 13, 29, 45, 61, 77, 
and93
Block AssessmentsTotal Duration 
(minutes)Site Staff 
Responsible
1aApathy Evaluation Scale (patient and companion)
Symptoms of Major Depressive Disorder Scale~20Qualified 
study 
personnel
Break (if needed) ~10
2 Huntington's Disease -Daily  Activities Scale ~25Qualified 
study 
physician
aTo be completed prior to safety  assessments.
Appendix 5:Grading Scale for A dverse Events Relating to Laboratory A bnormalities for 
All Patients ( cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
136/Protocol BN40423 , Version 4LLNlower limit of normal; ULN upper limit of normal.

Appendix 5:Grading Scale for A dverse Events Relating to Laboratory A bnormalities for 
All Patients ( cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
137/Protocol BN40423 , Version 4

Appendix 6 [COMPANY_002] HD Mobile Application for Patients Enrolled 
after Implementation of Protocol Version 4:  Active Test
The following tasks are part of the "active tests" conducted on the [COMPANY_002] Huntington's Disease 
(HD) mobile application by [CONTACT_102]. 
Daily Questions
Tw
o daily single-i tem questions 
on mood and physical energy will be assessed, asking patients 
about their mood and physical health at the time they are performing the “Active” tests. The 
assessments aim to capture daily mood fluctuations and will be used as a control for the other 
motor and cognitive assessments. 
Cognitive Test (eSDMT)
The Cognitiv
e Test a sks participants to match symb
ols with numbers according to a key as 
quickly and accurately as possible. The key, symbols, numbers are all displayed on a 
smartphone screen.
 The test assesses visuo-m otor integration, and measures visual attention 
and mot
or speed.  It is modelled on the pen and paper Sy
mbol Digit Modalities Test (SDMT) 
(Smith, 1968). The SDMT has been shown to be sensitive to symptom changes in early HD 
patients (Tabrizi 2012) and is part of the Unified Huntington's Disease Rating Scale (UHDRS)
 
assessment (Huntington’s Study Group, 1996).
Word Reading Test (eSWR)
The Word Reading Test asks participants to read aloud color words written in black font on a 
sm
artphone screen. Their voice will be recorded. The test assesses cognitive processing speed, 
and is modelled on the Stroop Word Reading (SWR) (Ridley 1935). The "Word Reading" part of 
the S
WR Test has been shown to be sensitive to symptom changes in patients with early HD 
(Tabrizi 2012) and is part of the UHDRS assessment (Huntington’s Study Group 1996). 
Speeded Tappi[INVESTIGATOR_803875], using the index
 finger of both the left and right hands. The test assesses 
bradykinesia. Performance will also be impacted by [CONTACT_626958].
 It is modelled on 
tappi[INVESTIGATOR_626882] s ymptom changes in early HD (Bechtel et al. 2010; Tabrizi 
et al. 2012). A similar finger tappi[INVESTIGATOR_803896] 
(Huntington’s Study Group 1996).
Draw a Shape Test
The Draw a Shape Test asks participants to trace a series of increasingly complex shapes on the 
smartphone screen. The shapes include lines, a square, a circle, an eight, and
 a spi[INVESTIGATOR_23585]. This test 
is designed to assess visuomotor coordination and fine motor impairment in early HD patients. It 
is modelled on circle tracing tasks that have been shown to be sensitive to s
ymptom changes in 
early HD (Say et al. 2011; Tabrizi et al. 2013). 
Chorea Test
The Chorea Test asks participants to hold the smartphone s
till in their hand with their arm  
outstretched, and wear the wrist-w orn wearable.
 As a dual task, participants will also need to 
count backwards  aloud. To ensure correct execution, voice will be recorded. The test is 
designed to assess chorea.
 It draws on other sensor-b ased approaches to measure chorea 
(
Reilmann et al. 2010, 2011
; Kegelmeyer e t al. 2017). A chorea assessment is also part of the 
UHDRS (Huntington’s Study Group 1996). 
Balance Test
The Balance Test asks participants to stand still while wearing the smartphone and wrist-w orn 
wearable. It is an assessment for patients’ static balance function.
 Sensor-b ased approaches for 
RO7234292F. Hoffmann
-La [COMPANY_002] Ltd
138/Protocol BN40423, Version 4
Appendix 6:[COMPANY_002] HD Mobile A pplication for P atients Enrolled after Implementation of 
Protocol Version 4 : Active Test (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
139/Protocol BN40423 , Version 4measuring static balance have been shown to be sensitive to differences in sy mptoms in early 
HD (Dalton et al. 2013). The test is also part of established scales like the Berg Balance Scale 
(Berg et al. 1992), which are used in HD ( Busse et al. 2009; Rao et al. 2009). The test is 
anchored to the UHDRS assessments for maximal dystonia, maximal chorea ,and tandem 
walking (Huntington Study Group 1996).
U-Turn Test
The U -Turn Test asks participants to walk and turn safely between two points thatare at least
foursteps apart , while wearing the smartphone and wrist -worn wearable. They  need to make at
least five turns. The test is designed to assess gait and lower -body  brady kinesia, which are also
assessed by [CONTACT_626959]. It is modelled on the Timed Up and Go Test, which has been clinically
validated for the HD population (Busse et al. 2009 ; Rao et al. 2009 ). The test is anchored to the
UHDRS gait, brady kinesia body, and ta ndem walking items (Huntington Study Group 1996).
Walk Test
The Walk Test asks participants walk as fast as is safely possible for [ADDRESS_1109801] is done in a straight path with no obstacles (e.g. ,in a park). 
Sensor -based approaches for measuring gait have been shown to be sensitive to differences in 
symptoms in ear ly HD (Dalton et al. 2013). The test is anchored to the UHDRS gait, brady kinesia 
body , and ta ndem walking items (Huntington Study  Group 1996).
Tasks are automatically scheduled as shown below in Figure [ADDRESS_1109802] on a certain day, scheduled tasks that 
occur less frequently than every second day (i.e., EuroQol 5 -Dimension, 5 Level Questionnaire , 
Work Productivity and Activity Impairment, Huntington 's Disease Speaking Difficulty Item , 
2-Minute W alk Test) are rolled over to the next time the active test is completed.
References
Bechtel N, Scahill RI, Rosas HD, et al. Tappi[INVESTIGATOR_803877] s ymptomatic Huntington disease. Neurology 2010;75:2150 60.
Berg KO, W ood-Dauphinee SL, W illiam s JI, et al. Measuring balance in the elderly: validation of 
an instrument. Can J Public Health 1992;83(Suppl 2):S7 11.
Busse ME, W iles CM, Rosser AE. Mobility and falls in people with Huntington's disease. J Neurol 
Neurosurg Psychiatr y 2009;80:88 90.
Dalton A, Khalil H, Busse M, et al. Analysis of gait and balance through a single triaxial 
accelerometer in presy mptomatic and sy mptomatic Huntington’s disease. Gait Posture 
2013;37:49 54.
Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. 
Mov Disord 1996;11:136 42.Kegelmey er et al. 2017
Rao AK, Muratori L, Louis ED, et al. Clinical measurement of mobility and balance impairments in 
Huntington's d isease: validity and responsiveness. Gait Posture 2009;29:433 6.
Reilmann R, Bohlen S, Kirsten F, et al. Assessment of involuntary choreatic movements in 
Huntington's disease— toward objective and quantitative measures. Mov Disord 
2011;26:2267 73.
Appendix 6:[COMPANY_002] HD Mobile A pplication for P atients Enrolled after Implementation of 
Protocol Version 4 : Active Test (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
140/Protocol BN40423 , Version 4Reilmann R, Bohlen S, Klopstock T, et al. Graspi[INVESTIGATOR_626884]'s disease - shapi[INVESTIGATOR_626885]. Mov Disord 2010;25:2858 62.
Say MJ, Jones R, Scahill R, et al. Visuomotor integration deficits precede clinical onset in 
Huntington's disease. Neuropsychologia 2011;49:264 70.
Smith A. The sy mbol-digit modalites test: a neurops ychologic test of learning and other cerebral 
disorders. In: Helmuth J, editor. Learning dis orders. Seattle: Special Child Publications; 
1968:83 –91.
Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935; 18:643 62.
Tabrizi SJ, Reilmann R, Roos RAC, et al. Potential endpoints for clinical trials in premanifest and 
early Huntington's disease in the TRACK -HD study: analy sis of 24 month observational 
data. The Lancet Neurology 2012;11.1:42 53.
Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in 
premanifest and early -stage Huntingt on's disease in the TRACK -HD study: analysis of 36 -
month observational data. Lancet Neurol 2013;12:637 49.
RO7234292F. Hoffmann-L a [COMPANY_002] Ltd  
142/Protocol BN40423, Version 4Appendix 7Diagnostic Confidence Level for All Patients
The Diagnostic Confidence Level is calculated as shown below (from UHDRS 
Total Motor Score Scale, Item 17):
DIAGNOSIS CONFIDENCE LEVEL
To what degree are you confident that this pe rson meets the operational 
definition of the unequivocal presence of an otherwise unexplained 
extrapyramidal movement disorder
(e. g., chorea, dystonia, bradykinesia, rigidity) in a subject at risk for HD?
0normal (no abnormalities)
1non-specific motor abn ormalities (less than 50% confi dence)
2motor abnormalities that may be signs of HD (50% 89% confi dence)
3motor abnormalities that are like ly signs of HD (90% 98% confi dence)
4motor abnormalities that are unequ ivocal signs of HD ( 99% con fidence)
Copy right 1999
Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. 
Mov Disord 1996;11:136 42.
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
143/Protocol BN40423 , Version 4Appendix 8Guidance for Neurologic alExamination for 
AllPatients
Perform the neurologic alexamination in the same way every time at screening and at 
every clinic visit.  At dosing visits, perform examination predose and postdose after the 
participant has walked for [ADDRESS_1109803] drug injection.
Neurologic alExamination
 Mental status (appearance, level of consciousness, behavior,
speech)
 Cranial Nerves II (including Vision and Fundoscopy) XII
 Motor examination (bulk, tone, and strength)
 Coordination
 Abnormal movements
 Gait
 Reflexes
 Sensation (vibration, light touch, pin prick/temperature)
Note:  The neurologic al examination should be followed at the 
non-dosing clinic visits, end -of-treatment visit, and safety 
follow -up visit.
RO7234292F. Hoffmann-L a [COMPANY_002] Ltd  
144/Protocol BN40423, Version 4Appendix 9Schedule of Activities for Patients Enrolled before Implementation of Protocol 
Version 4
ScreeningaBL Treatment Period EoTbEoT 
for 
ETT ETTbSFU
Month 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 25 29
Week4 to  1 1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97 101 101 117
Day (Window )28 to  21 1 (3)dd
Signed informed 
consentcx
Review of inclusion and 
exclusion criteria x
Demographic data x
Medical histor y and 
baseline conditionsd x xe
Blood sample for CAG 
repeat lengthx
Viral serologyfx
Thyroid panelgx
Vital signshx xex x x x x x x x x x x x x x x x x x x x x x x x x x x
Complete phy sical 
examination ix xex x x x x x
Neurologic examinationjx xex x x x x x x x x x x x x x x x x x x x x x x x x x x x
Appendix 9: Schedule of Assessments for Patients Enrolled before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
145/Protocol BN40423 , Version 4ScreeningaBL Treatment Period EoTbEoT 
for 
ETT ETTbSFU
Month 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 25 29
Week4 to  1 1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97 101 101 117
Day (Window )28 to  21 1 (3)dd
ECGkx xex x x x x x x
Hematologylx x x x x x x x x x x x x x x x x x x x x x x x x x x x x
Chemistrymx x x x x x x x x x x x x x x x x x x x x x x x x x x x x
Pregnancy testnx xex x x x x x x x x x x x x x x x x x x x x x x x x x x
Local INR, aPTT, PT
platelet countxx x x x x x x x x x x x x x x x x x x x x x x x x x x x
Urinalysis ox x x x x x x x x x x x x x x x x x x x x x x x x x x x x
Plasma sample for PK x x x xp x x x x x
Plasma sample for 
immunogenicity testingx x x x x x x x x x
Plasma sample for 
biom arkersx x x x x x x x x x
Blood sample for clinical 
genotypi[INVESTIGATOR_803874]/safety/biomarkersx x x x x x x x x x x x x x x x x x x x x x x x x xyx
MRIqx x x x x x
HD-DAS x x x x x x x
Independence Scale x xx x x x x x x x x
MoCA x x x x x x x x x x x
Appendix 9: Schedule of Assessments for Patients Enrolled before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
146/Protocol BN40423 , Version 4ScreeningaBL Treatment Period EoTbEoT 
for 
ETT ETTbSFU
Month 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 25 29
Week4 to  1 1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97 101 101 117
Day (Window )28 to  21 1 (3)dd
C-SSRSrx xex x x x x x x x x x x x x x x x x x x x x x x x x x x
UHDRS FA xx x x x x x x x x
TFCsxx x x x x x x x x
TMSs, ccx xx x x x x x x x x
CGI-S x x x x x x x x x x
CGI-C x x x x x x x x x
SDMTsxx x x x x x x x x
SWRsxx x x x x x x x x
AES x x x x x x x x x
SMDDS x x x x x x x x x
NeuroQoL x x x x x x x x x x
EQ-5D-5L (in -clinic) x x x x x x x x x x
HUI(in-clinic) x x x x x x x x x x
PGI-S x x x x x x x x x x
PGI-C x x x x x x x x x
[COMPANY_002] HD mobile app 
in-clinic assessmentsx x x x x x x x
[COMPANY_002] HD mobile app 
remote data collection Continuous remote data collectiont
Appendix 9: Schedule of Assessments for Patients Enrolled before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
147/Protocol BN40423 , Version 4ScreeningaBL Treatment Period EoTbEoT 
for 
ETT ETTbSFU
Month 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 25 29
Week4 to  1 1 5 9 13 17 21 25 29 33 37 41 45 49 53 57 61 65 69 73 77 81 85 89 93 97 101 101 117
Day (Window )28 to  21 1 (3)dd
Optional exit interview ux x
Blood sample for RBR 
DNA (optional)vx
Blood sample for RBR 
RNA (optional)vx x x x x
Serum sample for RBR
(optional) vx x x x x
Change in medical 
information since 
previous visitwxxxxxxxxxxxxxxxxxxxxxxxx x x x x
Lumbar puncture xxxxxxxxxxxxxxxxxxxxxxxxxxxyxy
Study drug 
administrationxxxzxxzxxzxxzxxzxxzxxzxxzxxzxxzxxzxxz
Concomitant 
medicationsaax x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x
Adverse events bbx x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x
ADAanti-drug antibody; AES Apathy Evaluation Scale; BL baseline; CGI-C Clinical Global Impression, Change; CGI -SClinical Global 
Impression, Severity; CSF cerebrospi[INVESTIGATOR_872]; C SSRS Columbia -Suicide Severity Rating Scale; cUHDRS composite Unified Huntington's 
Disease Rating Scale; DCL diagnostic confidence level; eCRF electronic Case Report Form; EoT end of treatment; EQ -5D-5LEuroQol 
5-Dimension, 5 -Level Questionnaire; ETT early treatment termination; FA Functional Assessment; HBsAg hepatitis B surface antigen;
HCV hepatitis C virus; HD Huntington disease; HD -DASHD Daily Activities Scale; HUI Health Utilities Index; MoCA Montreal Cognitive
Assessment; MRI magnetic resonance imaging; Neuro- QolQuality of Life in Neurological Disorders; PGI -CPatient Global Impression,
Appendix 9: Schedule of Assessments for Patients Enrolled before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
148/Protocol BN40423 , Version 4Change; PGI -SPatient Global Impression, Severity; PK pharmacokinetic; Q8W every 8 weeks; RBR Research Biosample Repository; 
SDMT Symbol Digit Modalities Test; SFU safety follow -up; SMDDS Symptoms of Major Depressive Disorder Scale; S WRStroop W ord 
Reading; TFC Total Functional Capacity Scale; TMS Total Motor Score; UHDRS Unified Huntington's Disease Rating Scale.
Note s:  All assessments should be performed at the scheduled visit, unless otherwise specified.  On treatment days, all assessmen ts should be 
performed prior to dosing, unless otherwise specified.  
aA maxim um of one re -screening will be allowed within 8 week s of the initial screening failure for patients who fail the initial screening (e.g., as a 
consequence of abnormal laboratory values or general medical status not meeting inclusion or exclusion criteria).  If re -screening is required, 
CAG repeat length tes ting does not need to be repeated and the screening MRI and viral serology from the initial screening may  be acceptable 
as part of the re -screening assessments, if performed within 12 weeks of the baseline visit.  
bPatients who complete the treatment period will return to the clinic for a treatment completion visit at Week 101 (i.e., the EoT visit).  All patients 
who discontinue study treatment prematurely but do not withdraw consent for continued participation in the study will return to the clinic for study 
visits at W eeks53 and 69 (if not already completed) and at W eek 101 (i.e., the EoT for ETT visit) for collection of at least the data for th e primary  
and secondary endpoints (see Sections 2.1.1 , 2.1.2 , and 2.2).  If the ETT visit falls within 30 days of either scheduled visits at W eek 53 o r 
Week 69, then only ETT will be considered.  The ETT visit should be performed 28 days ( 3 day s) after the last dose.  Patients will also attend 
the scheduled EoT for ETT visit at W eek 101 for limited assessments including the collection of the primary  and secondary endpoints (see 
Sections 2.1.1 , 2.1.2 , and 2.2).  Study visits should be planned as per the study schedule, however under exceptional circumstances, time 
window of [ADDRESS_1109804] be documented before an y study -specific screening procedure is performed and may be obtained more than 28 days 
before initiation of study treatment.
dMedical history, including clinically significant diseases, surgeries, HDhistory (including past hospi[INVESTIGATOR_602] [i.e., number , duration, and reason]) , 
over the last [ADDRESS_1109805] on Day  1 or Day 1.
fViral serology: HBsAg and HCV antibody
gThyroid panel:  thy roid-stimulating hormone and free thyroxine (also known as T4) levels. 
hVital signs include respi[INVESTIGATOR_697], pulse, temperature, and s ystolic and diastolic blood pressure while the patient is in a seated position after 
resting for approximate ly [ADDRESS_1109806] abnormalities observed at baseline (Day - 1 or Day 1) on the General Medical History and Baseline 
Conditions eCRF.  At subsequent visits, record new or worsened clinically significant abnormalities on the Adverse Event eCRF .
iA comple te physical examination ,performed at screening and other specified visits, should include an evaluation of the head, eyes, ears, nose, 
and throat, and the cardiovascular, dermatologic, musculoskeletal, respi[INVESTIGATOR_696], gastrointestinal , and neurologic systems (including fundoscopy ); 
genitourinar y exam inations may be performed if clinically indicated.   The phy sical examinations should be conducted in the same manner on 
each occasion to ensure comparability to previous examinations. Changes from baseline abnor malities should be recorded in patient notes.  
New or worsened clinically significant abnormalities (i.e., beyond expected variation or normal age -related change) should be recorded as 
adverse events on the Adverse Event eCRF.   Height will be measured at b aseline only.
Appendix 9: Schedule of Assessments for Patients Enrolled before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
149/Protocol BN40423 , Version 4jA neurologic examination ,performed at screening and at every clinical visit, should include assessment of mental status, level of consciousness, 
cranial nerve function, motor function, sensory function, reflexes, and coordination.   The neu rologic examinations should be conducted in the 
same manner on each occasion to ensure comparability to previous examinations. Neurologic examinations should be performed before and 
after treatment on each dosing day.  Weight should also be measured at ea ch visit. Any abnormality identified at baseline should be recorded on 
the General Medical History and Baseline Conditions eCRF.  Changes from baseline abnormalities should be recorded in patient notes.  New or 
worsened clinically significant abnormalities (i.e., beyond expected variation or normal age- related change) should be recorded as adverse 
events on the Adverse Event eCRF.   
kTriplicate ECG are to be performed after the patient has been in a supi[INVESTIGATOR_73414] 10 minutes.  ECGs for e ach patient should 
be obtained from the same machine whenever possible.  At screening, baseline (Day 1 or Day 1) and other visits, pre -dose ECG should be 
performed prior to any blood draws and where applicable before the lumbar puncture.  
lHematology in cludes WBC count, RBC count, platelet count, hemoglobin, hematocrit, differential count (neutrophils, eosinophils, basophils,
monocy tes, ly mphocy tes).
mSerum chemistry  panel:  includes bicarbonate or total carbon dioxide (if considered standard of care for the region), sodium, potassium, chloride, 
glucose, BUN or urea, creatinine, total protein, albumin, phosphorus, calcium, total and direct bilirubin, ALP, ALT, AST, uric acid, 
gamma -glutam yl transferase, and CPK.
nAll women of childbearing potential wi ll have a serum pregnancy test at screening.  Urine pregnanc y tests will be performed at specified 
subsequent visits.  If aurine pregnanc y test is positive, it must be confirmed by a serum pregnancy test.
oUrinalysis includes dipstick (pH, specific gravi ty, glucose, protein, ketones, blood) and microscopic examination (sediment, RBCs, W BCs, casts,
crystals, epi[INVESTIGATOR_1663], bacteria).
pAt the W eek [ADDRESS_1109807] 
4hours after lumbar puncture.
qAt W eeks 13, 37, and 69 and at the EoT visit, the MRI should be scheduled to occur before the lumbar puncture.  It can be sch eduled in the day s 
prior to the lumbar puncture (provided it occurs within the visit window).  After patient enrollment, the MRI scan should be performed 7 [ADDRESS_1109808] be available before the patient can be 
enrolled in the study.
rThe C -SSRS will be used to assess eligibility for the study (full version at baseline, requiring approximate ly 20 minutes to administer) and to 
monitor the patients throughout the study at clinic visits (follow -up version, requiring approximately 5 minutes to administer, assuming absence of 
suicidal ideation and no change in clinical status from previous adminis tration).
sThe cUHDRS is a composite motor, cognitive, and global functional clinical outcome measure in patients with HD comprised of t he TFC, the 
TMS, the SDMT, and the SW R scores.
tThe electronic devices for remote data collection will be supplied to patients at screening and must be returned to the clinic in cases where the 
patient does not meet eligibility criteria, at the end of the study, or upon early termination from the study.  
Appendix 9: Schedule of Assessments for Patients Enrolled before Implementation of Protocol Version 4 (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
150/Protocol BN40423 , Version 4uOptional exit interviews will be conducted within approximately 1 week after the EoT visit; these interviews can be conducted by [CONTACT_756].
vNot applicable for a site that has not been granted approval for RBR sampling.  Performed only for patients at participating sites who have 
provided written informed consent to participate.
wAt the time of each study drug administration, an interval medical histor y should be obtained and any changes in medications, any major 
procedures or hospi[INVESTIGATOR_602], and any physician visits for HD or general medical care should be recorde d.
xPrior to performing each scheduled lumbar puncture, local laborator y analysis of coagulation factors (INR, aPTT, PT) and plat elets must be 
conducted and the results reviewed.  Collection for these local laboratory tests may occur at any time in the 72 hours prior to the lumbar 
puncture.  The lumbar puncture should be performed at approximately the same time at each visit (ideally in the morning betwe en 8:00 a.m. and 
12:00 noon or in the early afternoon between 12:00 noon and 3:00 p.m.) to minimize pote ntial diurnal variation of CSF parameters.  CSF fluid 
(20mL) is to be collected for analyses using a lumbar puncture collection kit.  If there are difficulties in collecting [ADDRESS_1109809] confirm CSF flow is 
present prior to injecting drug at 60 minutes.  A 24G W hitacre (atraumatic) needle should be used.  Depending on institutiona l guidelines, local 
anesthesia should be used for the procedure.  Sedation may  not be used.  Spi[INVESTIGATOR_803878], but is not required.  Ultrasound guidance may be used if attempts at lumbar puncture without imaging are un successful, if it 
is local practice to use ultrasound, or if institutional guidelines dictate use of ultrasound with each lumbar puncture.  Pat ients will be discouraged 
from resting supi[INVESTIGATOR_803897] a minimum and, if 
feasible, walking briskly.
yThe last CSF sample will be obtained at the W eek 101 EoT visit, but no study drug will be administered.
zPatients in Q8W  arm will receive placebo at these visits.
aaMedication (e.g., prescription drugs, over -the-counter drugs, vaccines, herbal or homeopathic remedies, nutritional supplements) used by a 
patient in addition to protocol -mandated treatment from screening to the study completion/discontinuation visit.
bbAfter informed consent has been obtained but prior to initiation of study drug, only serious adverse events caused by a protoc ol-mandated 
intervention should be reported.  After initiation of study drug, all adverse events will be reported until 5 months af ter the final dose of study drug.  
After this period, all deaths, regardless of cause, should be reported.  In addition, the Sponsor should be notified if the i nvestigator becomes 
aware of any serious adverse event that is believed to be related to prior s tudy drug treatment.  
ccThe DCL will be assessed at screening only (i.e., without the full TMS assessment).  The TMS scale will be assessed (excludin g the DCL) at all 
other timepoints.
ddExcluding MRIs, which have a visit window of  14 days .
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
151/Protocol BN40423 , Version 4Appendix 10Clinician- Reported Outcomes for Patients Enrolled before Implementation of 
Protocol Version 4
Assessment Name [CONTACT_601384]. 
Duration Timing
FAUHDRS Functional 
Assessment25 Daily function 15 minBaseline and W eeks5, 21, 37, 53, 
69, 85, and 101 and ETT visits
IS Independence Scale 1 Functional disability 3 minScreening, baseline, and Weeks5, 
21, 37, 53, 69, 85, and 101 and 
ETT visits
TFCTotal Functional 
Capacity Scale5 Overall function 10 minBaseline and W eeks5, 21, 37, 53, 
69, 85, and 101 and ETT visits
TMS Total Motor Score 31 Motor function 15 minDCL only: Screening
TMS without DCL: Baseline and 
Weeks5, 21, 37, 53, 69, 85, and 
101 and ETT visits
C-SSRSColum bia-Suicide 
Severity Scale5Suicidal ideation 
and behavior20 min full 
version; 
5 min follow -up 
versionFull version at screening in clinic; 
follow -up version at baseline and all 
post-baseline clinic visits 
CGI-SClinical Global 
Impression 
Severity1Overall severity of 
patient status2 minBaseline and W eeks5, 21, 37, 53, 
69, 85, and 101 and ETT visits
CGI-CClinical Global 
Impression 
Change1Overall change in 
patient status2 minWeeks5, 21, 37, 53, 69, 85, and 
101 and ETT visits 
HD-DASHuntington's 
Disease Daily 
Activities Scale 25 Daily function 25 minScreening and Weeks13, 29, 45, 
61, 77, and 93
DCLdiagnostic confidence level.
Appendix 11: Patient -Reported, Observer -Reported, and Performance Outcomes and [COMPANY_002] HD Mobile Application for Patients 
Enrolled before Implementation of Protocol Version 4(cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
153/Protocol BN40423 , Version 4Assessment NameItem
s ConceptsApprox.
Duration
(min)PRO, ObsRO, 
PerfO, 
Behavior Timing Location
HD-SDIHuntington's 
Disease Speaking 
Difficulty Item 1 Speech 1 PRO Weekly[COMPANY_002] HD 
mobile app
HD-CIAOSHuntington's 
Disease Companion
-Reported Irritability
and Angr y Outbursts 
Scale3Irritability and angry 
outbursts2 ObsRO WeeklyElectronic 
device
HUIHealth Utilities Index 15Health -related quality of 
life10 ObsROBaseline, W eeks5, 21, 37, 
53, 69, 85, and 101 and ETTIn-clinic
WeeklyElectronic 
device
MoCAMontreal Cognitive 
Assessment11 Overall cognitive status 10 PerfOScreening, baseline, 
Weeks5, 21, 37, 53, 69, 85, 
and 101 and ETTIn-clinic
Neuro -Qol 
Cog FuncNeuro -Qol Cognitive 
Function Short Form8 Cognition 5 PROBaseline and W eeks5, 21, 
37, 53, 69, 85, and 101 In-clinic
PGI-CPatient Global 
Impression Change1Overall change in 
patient status2 PROWeeks5, 21, 37, 53, 69, 85, 
and 101 and ETT visitsIn-clinic
PGI-SPatient Global 
Impression Severity1Overall severity of 
patient status2 PROBaseline and W eeks5, 21, 
37, 53, 69, 85, and 101 and 
ETTIn-clinic
Appendix 11: Patient -Reported, Observer -Reported, and Performance Outcomes and [COMPANY_002] HD Mobile Application for Patients 
Enrolled before Implementation of Protocol Version 4(cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
154/Protocol BN40423 , Version 4Assessment Name [CONTACT_601384].
Duration
(min)PRO, ObsRO, 
PerfO, 
Behavior Timing Location
SDMT/
eSDMTSymbol Digit 
Modalities TestMax 
number in 
90secondsCognitive [ADDRESS_1109810]-SDMT assessment[COMPANY_002] HD 
mobile app 
(eSDMT)
SMDDSSymptoms of Major 
Depressive 
Disorder Scale16Depression, anxiety, 
irritability, sleep10 PROBaseline and W eeks13, 
29, 45, 61, 77, 93, and 101 In-clinic
SWR/eS WRStroop Word 
Reading TestMax 
numbers in 
[ADDRESS_1109811] -SWR 
assessment[COMPANY_002] HD 
mobile app 
(eSWR)
WPAIWork Productivity 
and Activity 
Impairment6 Work productivit y 5 PRO ObsRO Monthly [COMPANY_002] HD 
mobile app 
and electronic 
device
appapplication; ETT early treatment termination; HD Huntington disease; ObsRO observer -reported outcome; PerfO performance outcome; 
PRO patient -reported outcome.
RO7234292F. Hoffmann-L a [COMPANY_002] Ltd  
155/Protocol BN40423, Version 4Appendix 12Clinical Assessments Order and Duration for 
Patients Enrolled before Implementation of Protocol Version 4
Table 1 Screening Visit Clinical A ssessments
Block AssessmentsTotal Duration 
(minutes)Site Staff 
Responsible
1Diagnostic Confidence Level
Huntington's Disease Daily Activities Scale
Independence Scale
MoCA
C-SSRS~60Qualified 
study 
physician
Break (if needed) ~20-30
2 [COMPANY_002] HD mobile application ~20Qualified 
study 
personnel
C-SSRColumbia -Suicide Severity Rating Scale; HDHuntington disease; MoCA Montreal
Cognitive Assessment.
Appendix 1 2:Clinical Assessments Order and Duration for Patients Enrolled before 
Implementation of Protocol Version 4(cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
156/Protocol BN40423 , Version 4Table 2 Baseline and Week 101 Clinical A ssessments (for Primary  
Analysis)
Block AssessmentsTotal 
Duration 
(minutes) Site Staff Responsible
1UHDRS Functional Assessment 
Independence Scale
Total Functional Capacity Scale 
Total Motor Score (without Diagnostic 
Confidence Level)
Colum bia-Suicide Severity Rating Scale
Clinical Global Impression Severity 
Clinical Global Impression Change 
(post -baseline visits only)~60 Qualified study phy sician
Break (if needed) ~20[ADDRESS_1109812]
MoCA~20Qualified study 
personnel
Break (if needed) ~10
3aApathy Evaluation Scale (patient and 
companion)
Symptoms of Major Depressive Disorder 
Scale~20Qualified study  
personnel
Break (if needed) ~1020
4aNeuro -Qol Cognition Function Short Form
EuroQol 5 -Dimension, 5 -Level 
Questionnaire (patient and companion)
Health Utilities Index (companion: self and 
proxy)
Patient/Companion -reported Global 
Impression Severity
Patient/Companion -reported Global 
Impression Change (post -baseline visits 
only)~20Qualified study 
personnel
Break (if needed) ~1020
5 a[COMPANY_002] HD mobile application ~20Qualified study 
personnel
HDHuntington disease; MoCA Montreal Cognitive Assessment; Neuro -QoLQuality of Life in 
Neurological Disorders; UHDRS Unified Huntington's Disease Rating Scale.
aAt the baseline visit and at week 101, Blocks 3, 4, and [ADDRESS_1109813] be completed predose at the baseline 
visit.  
Appendix 1 2:Clinical Assessments Order and Duration for Patients Enrolled before 
Implementation of Protocol Version 4(cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
157/Protocol BN40423 , Version 4Table 3 Follow -Up Clinical A ssessments at Weeks 5, 21, 37, 53, 69, 
and85
Block AssessmentsTotal 
Duration 
(minutes)Site Staff 
Responsible
1UHDRS Functional Assessment 
Independence Scale
Total Functional Capacity Scale 
Total Motor Score (without Diagnostic Confidence Level)
Colum bia-Suicide Severity Rating Scale
Clinical Global Impression Severity 
Clinical Global Impression Change ~60Qualified 
study 
physician
Break (if needed) ~20-[ADDRESS_1109814]
MoCA~20Qualified 
study 
personnel
Break (if needed) ~10
3Neuro -Qol Cognition Function Short Form
EuroQol 5 -Dimension, 5 -Level Questionnaire (patient 
and companion)
Health Utilities Index (companion: self and proxy)
Patient/Companion -reported Global Impression Severity
Patient/Companion -reported Global Impression Change ~30Qualified 
study 
personnel
MoCA Montreal Cognitive Assessment; Neuro- QoLQuality of Life in Neurological Disorders; 
UHDRS Unified Huntington's Disease Rating Scale
Table 4 Follow -Up Clinical A ssessments at Weeks 13, 29, 45, 61, 77, 
and93
Block AssessmentsTotal Duration 
(minutes)Site Staff 
Responsible
1aApathy Evaluation Scale (patient and companion)
Symptoms of Major Depressive Disorder Scale~20Qualified 
study 
personnel
Break (if needed) ~10
2 Huntington's Disease -Daily  Activities Scale ~25Qualified 
study 
physician
aTo be completed prior to safety  assessments.
Appendix 1 2:Clinical Assessments Order and Duration for Patients Enrolled before 
Implementation of Protocol Version 4(cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
158/Protocol BN40423 , Version 4Table 5 Digital Monitoring Platform A ssessment Supervised by [CONTACT_803965] 25, 49, 73
Block AssessmentsTotal Duration 
(minutes)Site Staff 
Responsible
1 [COMPANY_002] HD mobile application ~20Qualified 
study 
personnel
HDHuntington disease.
Appendix 13 [COMPANY_002] HD Mobile Application for Patients 
Enrolled before Implementation of Protocol Version 4:  Active 
Test
The following tasks are part of the "active tests" conducted on the [COMPANY_002] Huntington's Disease 
(HD) mobile application by [CONTACT_102]. 
Daily Questions
Two daily single-i tem questions on mood and physical energy will be assessed, asking patients 
about their mood and physical health at the time they
 are performing the “Active” tests. The 
assessments aim to capture daily mood fluctuations and will be used as a control for the other 
mo
tor and cognitive assessments. 
Cognitive Test (eSDMT)
The Cognitive Test
 asks participants to match symb
ols with numbers according to a key as 
quickly and accurately as possible.  The key, symbols, numbers are all displayed on a 
smartphone screen.  The test assesses visuo-m otor integration, and measures visual attention 
and motor speed.  It is modelled on the pen and paper Sy
mbol Digit Modalities Test (SDMT) 
(
Smith, 1968).  The SDMT has been shown to be sensitive to symptom changes in early HD 
patients (Tabrizi 2012) and is part of the Unified Huntington's Disease Rating Scale (UHDRS) 
assessment (Huntington’s Study Group, 1996).
Word Reading Test (eSWR)
The Word Reading Test asks participants to read aloud color words written in black font on a 
smartphone s
creen. Their voice will be recorded.  The test assesses cognitive processing speed, 
and is modelled on the Stroop Word Reading (SWR) (Ridley 1935).  The "Wo
rd Reading" part of 
the SWR Test has been shown to be sensitive to symptom changes in patients with early HD 
(Tabrizi 2012) and is part of the UHDRS assessment (Huntington’s Study Group 1996). 
Speeded Tappi[INVESTIGATOR_803898], using the index finger of both the left and right hands.  The test assesses 
bradykinesia. Performanc
e will also be impacted by [CONTACT_626958].  It is modelled on 
tappi[INVESTIGATOR_626882] s ymptom changes in early HD (Bechtel et al. 2010; Tabrizi 
et al. 2012). A similar finger tappi[INVESTIGATOR_803882] 
(Huntington’s Study
 Group 1996).
Draw a Shape Test
The Draw a Shape Test asks participants to trace a series of increasingly complex shapes on the 
smartphone screen. The shapes include lines, a square, a circle, an eight, and a spi[INVESTIGATOR_23585].  This
 test 
is designed to assess visuomotor coordination and fine motor impairment in early HD patients.  It 
is modelled on circle tracing tasks that have been shown to be sensitive to sym
ptom changes in 
early HD (Say et al. 2011; Tabrizi et al. 2013). 
Chorea Test
The Chorea Test asks participants to hold the smartphone still in their hand with their arm  
outstretched, and wear the wrist-w orn wearable.  As a dual task, participants will also need to 
count backwards aloud.  To ensure correct execution, voice will be recorded.  The test is 
designed to assess chorea.  It draws o
n other sensor-b ased approaches to measure chorea 
(Reilmann et al. 2010, 2011;
 Kegelmeyer et al. 2017). A chorea assessment is also part of the 
UHDRS (Huntington’s Study Group 1996). 
RO7234292F. Hoffmann-L a [COMPANY_002] Ltd
159/Protocol BN40423, Version 4
Appendix 1 3:[COMPANY_002] HD Mobile Application for Patients Enrolled before 
Implementation of Protocol Version 4: Active Test (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
160/Protocol BN40423 , Version 4Balance Test
The Balance Test asks participants to stand still while wearing the smartphone and wrist -worn 
wearable.  It is an assessment for patients’ static balance function.  Sensor -based approaches for 
measuring static balance have been shown to be sensitive to differences in sy mptoms in early 
HD (Dalton et al. 2013).  Th e test is also part of established scales like the Berg Balance Scale 
(Berg et al. 1992), which are used in HD (Busse et al. 2009; Rao et al. 2009).  The test is 
anchored to the UHDRS assessments for maximal dystonia, maximal chorea, and tandem 
walking (Hu ntington Study Group 1996).
U-Turn Test
The U -Turn Test asks participants to walk and turn safely between two points that are at least
foursteps apart, while wearing the smartphone and wrist -worn wearable.  They need to make at
least five turns.  The tes t is designed to assess gait and lower -body  brady kinesia, which are also
assessed by [CONTACT_626959].  It is modelled on the Timed Up and Go Test, which has been clinically
validated for the HD population (Busse et al. 2009; Rao et al. 2009).  The test is anchor ed to the
UHDRS gait, brady kinesia body, and tandem walking items (Huntington Study Group 1996).
Walk Test
The Walk Test asks participants walk as fast as is safely possible for [ADDRESS_1109815] is done in a straight path with no obstacles (e.g., in a park).  
Sensor -based approaches for measuring gait have been shown to be sensitive to differences in 
symptoms in early HD (Dalton et al. 2013).  The test is anchored to the UHDRS gait, brady kinesia 
body , and tandem walkin g items (Huntington Study Group 1996).
Tasks are automatically scheduled as shown below in Figure [ADDRESS_1109816] on a certain day, scheduled tasks that 
occur less frequently than every second day (i.e., EuroQol 5- Dimension, 5 Level Questionnaire, 
Work Productivity and Ac tivity Impairment, Huntington's Disease Speaking Difficulty Item, 
2-Minute W alk Test) are rolled over to the next time the active test is completed.
References
Bechtel N, Scahill RI, Rosas HD, et al. Tappi[INVESTIGATOR_803877] s ymptomatic Huntington disease. Neurology 2010;75:2150 60.
Berg KO, W ood-Dauphinee SL, W illiam s JI, et al. Measuring balance in the elderly: validation of 
an instrument. Can J Public Health 1992;83(Suppl 2):S7 11.
Busse ME, W iles CM, Rosser AE. Mobility and falls in people with Huntington's disease. J Neurol 
Neurosurg Psychiatr y 2009;80:88 90.
Dalton A, Khalil H, Busse M, et al. Analysis of gait and balance through a single triaxial 
accelerometer in presy mptomatic and sy mptomatic Huntington’ s disease. Gait Posture 
2013;37:49 54.
Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. 
Mov Disord 1996;11:136 42.Kegelmey er et al. 2017
Rao AK, Muratori L, Louis ED, et al. Clinical measurement of mobility and balance impairments in 
Huntington's disease: validity and responsiveness. Gait Posture 2009;29:433 6.
Appendix 1 3:[COMPANY_002] HD Mobile Application for Patients Enrolled before 
Implementation of Protocol Version 4: Active Test (cont.)
RO7234292 F.Hoffmann -La [COMPANY_002] Ltd
161/Protocol BN40423 , Version 4Reilmann R, Bohlen S, Kirsten F, et al. Assessment of involuntary choreatic movements in 
Huntington's disease— toward objective and quantitative measures. Mov Disord 
2011;26:2267 73.
Reilmann R, Bohlen S, Klopstock T, et al. Graspi[INVESTIGATOR_626884]'s disease - shapi[INVESTIGATOR_626885]. Mov Disord 2010;25:2858 62.
Say MJ, Jones R, Scahill R, et al. Visuomotor integration deficits precede clinical onset in 
Huntington's disease. Neuropsychologia 2011;49:264 70.
Smith A. The sy mbol-digit modalites test: a neurops ychologic test of learning and other cerebral 
disorders. In: Helmuth J, editor. Learning dis orders. Seattle: Special Child Publications; 
1968:83 –91.
Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935;18:643 62.
Tabrizi SJ, Reilmann R, Roos RAC, et al. Potential endpoints for clinical trials in premanifest and 
early Huntington's disease in the TRACK -HD study: analy sis of 24 month observational 
data. The Lancet Neurology 2012;11.1:42 53.
Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in 
premanifest and early -stage Huntingt on's disease in the TRACK -HD study: analysis of 36 -
month observational data. Lancet Neurol 2013;12:637 49.